



Jla ckvmb Awa`Bi

gnvLvjx

XvKv-1212

(www.dgda.gov.bd)

i|cKí (Vision)t mK#ji Rb" gvbmuú b I wbi#c` Jla wbiðZ Ki#Z Avgi m#Pó|



eWIK cWZ#e`b-2016

(Z_` AwaKvi AvBb, 2009 tgvZ#eK cKwkZ)

Dc†`óv

†gRi †Rbv†ij †gvt †gv[¯]vīdRý ingvb
gnvcīiPvjK, JIa ckvmb Aīa`Bi

mᄁúv`bv cīiI`

†gvt iᄁûj Avīgb, cīiPvjK (PjīZ`vīqZ), JIa ckvmb Aīa`Bi
†gvt b†ij Bmjvg, DccīiPvjK, JIa ckvmb Aīa`Bi
†gvt BqvnBqv, mnKvix cīiPvjK, JIa ckvmb Aīa`Bi
Gm, Gg, mveixbv BqvQīgb, JIa ZĖveavqK, JIa ckvmb Aīa`Bi
gībi Dīīb Avn†g`, JIa ZĖveavqK, JIa ckvmb Aīa`Bi
†gvt AvBqv†nv†mb, mnKvix cīiPvjK, JIa ckvmb Aīa`Bi

mᄁúv`K
m`m"
m`m"
m`m"
m`m"
m`m" mīPe

mn†hīMZvq

JIa ckvmb Aīa`B†ii KgKZv I KgPvixē,

c"Q`

†gvt AvīZKž ingvb, Aīdm mnKvix Kvg KīᄁúDUvi gýŷīiK,
JIa ckvmb Aīa`Bi

ckvkKvj

†g, 2017

gýŷ

evsjv†`k mīKvīi gýŷvjg, †ZRMu, XvKv-1208|

ingvb

gnvciiPvjK
Jla ckymb Aia`Bi |



ciipvjK (Pt `vt)

Jla ckymb Aia`Bi

~v~ I ciievi Kj`vY gšYvjg

MYcRiZšx evsj#`k miKvi

máúv`Kxq

miKvi, ~vqZkwmZ, msieae× ms~v Ges miKvi ev iet`kx A\_vq#b mō ev ciipvjZ iefb temiKvi ms~vi KgKv#Ui ~"QZv I Reven`nZv ciZōvi gva`g mKymb iB#ōZKi#Yi Rb" miKvi Z~ AiaKvi AvBb cYqb K#i#Q| AvBb tgrv#eK Z~ ciIqv RbM#Yi AiaKvi| RbM#Yi ÁvZi# ~-c#Yv~Z Z~ cKv#ki Aifcvtq Jla ckymb Aia`Bi ciZeQi ewIK ciZe`b cKvK K#i ~v#K| GiB aivewnKZvq 2016 mv#j Jla ckymb KZK máúv`Z KgKv#Ui ciZe`b cYqb I cKvK Kiv n#`Q| mg#qi mv#_ mv#_ #`ki Jla iKí iet`Z.n#`Q| ~t bikashman e shilp ebg krmvrbman oshutai evRvi iBqš#Y Jla ckymbi KgKv#Ui ciiaI ciIbqZ e#x c#`Q| GKibōZv, AvšiiKZv, c#Póv, KgZrciZv I K#Wi cik#gi gva`g Jla ckymbi KgKZv I KgPvixMY G iekij KgKv#Ui ciipvjBv K#i Avm#Qb, iemZ eQ#i máúv`Z KgKv#Ui ciZdijZ n#`Q| Jla ckymb KZK. iemZ GK eQ#i máúv`Z mKj KgKv#Ui Z~v~ cKwKZ ciZe`b Ašfy Kiv n#`Q| GQvovI G ciZe`b máúv`Rb PvUvi, Z~ c`vbKvix KgKZv#i ZvjKv, 2016-2017 A\_eQ#ii ev#RU, gibe máú` Dbqb ielqK কার্যক্রম, ফার্মাকোভিজিলাস সংক্রান্ত কার্যক্রম, জাতীয় শুদ্ধাচার কৌশল, ইনোভেশন সংক্রান্ত কার্যক্রম, তথ্য প্রযুক্তির ব্যবহার, Jla ckymb Aia`B#ii máúv`ZK A#RZ mvdj", Aia`B#ii m#ve×Zv I bim#bi Dcvq Ges fiel`r ciikiv mibtek Kiv n#`Q| প্রতিবেদনের পরিশিষ্ট হিসেবে ঊষধ প্রশাসন অধিদপ্তরে বিভিন্ন কার্যক্রমের আবেদনের সাথে দাখিলযোগ্য প্রয়োজনীয় কাগজপত্রাদির তালিকা, কর্মকর্তাদের জব ডেসক্রিপশন, স্বপ্রণোদিত Z~ cKv#ki iB#`iKv, RvZiq Jlab#Z-2016, Over The Counter (OTC) Jlai ZvjKv, AZ`vek`Kxq Jlai ZvjKv, iefb Jlai t~ivcDvUK KvmmfiEK cYvZ tKvWi ZvjKv, Jla রপ্তানিকৃত দেশের তালিকা, অধিদপ্তরের অধীন জেলা কার্যালয়সমূহের ঠিকানা ও বিভিন্ন কার্যক্রমের ফি-Gi ZvjKv mibtek Kiv n#`Q| Jla ckymbi gv chv#qi KgKZvMY, b`vkbvj K#Uvj j`ve#iUix, XvKv, tmUvj Wm tUv÷s j`ve#iUix, PEmg ciZ gv#mi máúv`Z KgKv#Ui ciZe`b (nvW I mdUKic) Jla ckymb Aia`B#i tciY K#i ~v#K, D³ ciZe`b#i Kic Aia`B#ii Z~ tKv#I msijY Kiv nq| GQvovI carb Kvhj#qi iefb kvLv KZK máúv`Z KgKv#Ui WvUvDciE(cI`i Kic) iBqigZ Z~ tKv#I tciY Kiv nq| Aia`B#ii ckymb I nmve kvLv nZ msMpxZ Z~v~ I Z~`Kv#I msijY Kiv nq| Z~`Kv#I msijY Z~v~ nZ 2016 mv#ji iefb Z~v~ G ciZe`b mibtekZ n#`Q| Jla ckymbi KgKZv-KgPvixMY KZK #ciZ/mieivnKZ.Z#`i fiE#ZB ciZe`bU cYqb Kiv n#`Q| Zv#`i mn#hwmZv Qvov G Z~mgx ciZe`bU cYqb Kiv mae nZv bv| msikó mKj KgKZv I KgPvixK ciZe`b cYqb mnvqZv c`v#bi Rb" ab`ev` Ávcb KivQ| Aia`B#ii gnvciiPvjK ciZe`bU cYqb I cKv#ki ielq ~`K iB#`kbv ~`tq#Qb, civgk ~`tq#Qb, Drmyn I tciYv h#tq#Qb| ciZe`b cYqb I cKv#k gnvciiPvjK g#nv`qi AvšiiK mn#hwmZv Ges civg#ki Rb" KZÁZv cKik KivQ| ciZe`bU c`Q` GtK#Qb A#dm mnKvix Kig K#múDUvi g#v#iK tgrt AvvZKz ingvb, Jla ckymbi Aaxb iefb Kvhjg Ges Aia`B#ii iefb kvLv nZ eQi e`vcx c#B Z~v~ A#Z h#Zi mv# Jla ZÈveavqK Gm,Gg, mveixbv BqvQigb Z~`Kv#I msijY K#i#Qb| D³ Z~v~ ciZe`b mibtek Kiv n#`Q| G ewIK ciZe`b cYqb#i mv#_ msikó mevB#K AvšiiK ab`ev` Ávcb KivQ| ciZe`bU iBq#v#e cYqb AvšiiKZv I c#Póvi NvUiz iQj bv, ZviciI á#š t~`K th#ZB c#i| RbMY I mKj ÷`vK#niv#i`i MVbg#K mgr#jvPbv I civgk cZ`vkv KivQ| f#á#š iPiYZ n#j AvMigx eQi, #jv#Z Avil i#i#c ciZe`b cYqb mae n#e|

tgrt i:új Awgb

ciipvjK (PjiZ`vqZ)

Jla ckymb Aia`Bi |

t mPxcÎ t

1	f#gKv	1
2	Jla ckymb Aia`B#i i cUf#g I cZôv	1
3	Jla ckymb Aia`B#i i Ab#g`Z I KgiZ Rbe#j i Z_`v`	1
4	Jla ckymb Aia`B#i i †jv#Mv	2
5	Jla ckymb Aia`B#i i Kvhvejx	2
6	mmU#Rb PvUvi	3
7	ঔষধ প্রশাসন অধিদপ্তরের সিদ্ধান্ত গ্রহণের প্রক্রিয়া	5
8	dvskbvj †i, †jUui A_#iU	7
9	Jla ckymb Aia`Bi KZK.Rvbgvix, 2016 n#Z W#m#i, 2016 chš m#úv`Z Kvhvejx	7
9.1	Jla Drcv`#bi Ab#g`Z cK#í i ZvjKv	7
9.2	Jla Drcv`bKvix cZôv#bi jvB#mY bevgb	7
9.3	Jla Drcv`bKvix cZôv#bi bZb Drcv`b jvB#mY c`vb	7
9.4	2016 mv#j mvgvqK evZjKZ.Jl#ai ZvjKv	7
9.5	2016 mv#j †iR#÷kb evZjKZ.Jl#ai ZvjKv	8
9.6	jvB#mY evZjKZ.Jla Drcv`bKvix cZôv#bi ZvjKv	11
9.7	W`vk teW #f#EK AbjvBb #i#c#Us #m#÷g	13
9.8	#gvU L#iv I cvBKvix Wm jvB#mYi msL`v	13
9.9	2012 n#Z 2016 mvj chš L#iv Wm jvB#mY bevg#bi Z#bvgjK c#imsL`vb	13
9.10	2012 n#Z 2016 mvj chš c#i`kbKZ.dv#gmx i c#imsL`vb	14
9.11	2012 n#Z 2016 mvj chš c#i`kbKZ.Jla c`ZKvix KvILvbi Z#bvgjK c#imsL`vb	14
9.12	Wm †KvU, g`wR#÷U †KvU I #gveBj †KvU `v#qiKZ.gvgjvi #eeiY	15
9.13	2012 n#Z 2016 mvj chš `v#qiKZ.gvgjvi Z#bvgjK c#imsL`vb	16
9.14	2012 n#Z 2016 mvj chš cixYv I #e#kl#Yi #big#E Wm †U#÷s j`ve#iUix#Z †c#iZ Jl#ai bgvvi Z#bvgjK c#imsL`vb	18
9.15	2012 n#Z 2016 mvj chš ivR` Av`v#qi Z#bvgjK c#imsL`vb	18
9.16	ন্যাশনাল কন্ট্রোল ল্যাবরেটরী, ঢাকা কর্তৃক প্রাপ্ত নমুনা এবং পরীক্ষা ও বিশ্লেষণ সংক্রান্ত #eeiYx	19
9.17	2012 n#Z 2016 mvj chš b`vkbvj K#Uvj j`ve#iUix, XvKv KZK cvB bgbv Ges cixYv I #e#klY Gi Z#bvgjK c#imsL`vb	20
9.18	সেন্ট্রাল ড্রাগ টেস্টিং ল্যাবরেটরী, চট্টগ্রাম কর্তৃক প্রাপ্ত নমুনা পরীক্ষা ও বিশ্লেষণ সংক্রান্ত বিবরণী	20
10	Z_` A#Kvi AvBb Ab#gq# mieivnKZ.Z#_`i #eeiYx	21
11	evsjv#`#ki Jla iB#vb	25
12	ঔষধ প্রশাসন অধিদপ্তরের মানব সম্পদ উন্নয়ন কার্যক্রম	26

13	<i>Jl#ai #bivcĖ (Safety) I dvgv#K#f#Rj"vY t evsjv#`k #cyvcU</i>	33
14	বার্ষিক কর্মসম্পাদন সংক্রান্ত সমঝোতা স্মারক	39
15	<i>evsjv#`k #g#W#Kj #WfvBm #bqšY</i>	40
16	<i>#mev c#Z mn#RKiY</i>	40
17	<i>RvZxq i#v#Pvi #Kškj</i>	41
18	<i>MYibv#</i>	43
19	<i>RvZxq Jlab#Z-2016</i>	44
20	<i>#UKmB Dbqb Af#ó (SDG)</i>	47
21	Antibiotic Resistance	47
22	<i>g#Wj dv#gmx I g#Wj #g#W#mb kc</i>	48
23	Digital Expo-2016	49
24	<i>Jla ck#mb A#a`B#i i cavb Kv#vj#qi bZ# feb D#0#ab</i>	50
25	<i>B#bv#fkb #Ug</i>	51
26	<i>Z_` chy# i e`envi</i>	51
27	<i>Jla ck#mb A#a`B#i i 2010 n#Z 2016 mvj chš A#RZ mvdj"</i>	52
28	<i>Jla ck#mb A#a`B#i i mxgve#Zvmg# I #bim#bi Dcvq</i>	55
29	<i>f#el`r c#iKíb#</i>	57
30	<i>Dcmsnvi</i>	57

t c_w i_w kó t

ciiikó-Kt	ঔষধ প্রশাসন অধিদপ্তরে বিভিন্ন কার্যক্রমের আবেদনের সাথে দাখিলযোগ্য প্রয়োজনীয় KvMRcÎv`i ZvjjKv	59
ciiikó-Lt	Jla ckvmb Awa`B†ii 2016-2017 A_eQ†ii ev†RU	72
ciiikó-Mt	Jlধ প্রশাসন অধিদপ্তরের কর্মকর্তাদের দায়িত্ব (জব ডেসক্রিপশন)	74
ciiikó-Nt	Jla ckvmb Awa`B†ii KgKZv†`i bvg, Kvhvjq i bvg l c`ex	77
ciiikó-Ot	Z_`c`vbKvix KgKZv†`i ZvjjKv	81
ciiikó-Pt	mc†Yv`Z Z_`cKv†ki v†b†`vKv	83
ciiikó-Qt	AZ`vek`Kxq JI†ai ZvjjKv (A`v†jvc`v_K)	87
ciiikó-Rt	AZ`vek`Kxq Avq†v`K JI†ai ZvjjKv	97
ciiikó-St	AZ`vek`Kxq BDvbv K JI†ai ZvjjKv	98
ciiikó-Tt	AZ`vek`Kxq tnviglc`v_K JI†ai ZvjjKv	103
ciiikó-Ut	e`e`vcÎvnx b JI†ai ZvjjKv (A`v†jvc`v_K)	107
ciiikó-Vt	e`e`vcÎvnx b Avq†v`K JI†ai ZvjjKv	108
ciiikó-Wt	e`e`vcÎvnx b JI†ai ZvjjKv (BDvbv)	109
ciiikó-Xt	Jla iBvixKZ.†`†ki ZvjjKv	112
ciiikó-Yt	ASSIGNED CODE AGAINST THERAPEUTIC CLASS OF DRUG	113
ciiikó-Zt	Jla ckvmb Awa`B†ii AvIZvaxb †Rjv Kv hvjq l cixÿvMvimg†ni vKvibv	115
ciiikó-_t	ঔষধ প্রশাসন অধিদপ্তরের বিভিন্ন কার্যক্রমের নির্ধারিত ফি	118

1| fīgKv̄t

Jla ckymb Awa`Bi t`tki Jla w̄bqšYi GKgV̄l mīKw̄i c̄iZôv̄b| Jla ckymb Awa`Bi Rv̄Zxq Jla w̄bqšYKv̄ix KZçȳ w̄n̄m̄te Awf̄w̄Z|G c̄iZôv̄bi ḡj j̄ȳ" gvb̄m̄ú̄b, w̄bivc` I Kv̄hKi Jla Drcv̄`b, আমদানী, বিক্রয়, weZiY Ges JĪai t̄h̄s̄<sup>3</sup> K e`envi w̄b̄iðZ Kiv̄|Jla w̄bqšYi t̄ȳt̄i W̄m Ḡv̄±-1940, W̄m īj̄m-1945, t̄ēj̄j W̄m īȳm-1946, W̄m (K̄p̄Uvj) Āw̄b̄v̄Y-1982 I B̄n̄vi Ḡv̄t̄ḡŪḡU Ges Rv̄Zxq Jla b̄w̄Z-2016 Ges mīKvi KZK. w̄ēfb mḡt̄q c`È w̄b̄t̄`kb̄v̄ Ab̄ȳiY Kiv̄ nq|

ঔষধ প্রশাসনের অন্যতম কার্যক্রম h_v-Jla Drcv̄`b Kv̄iLv̄vi bZ̄ȳ cK̄i ḡj̄v̄qb I Ab̄ȳḡv̄`b, Jla c̄-Z̄ȳZi Rb̄" jv̄B̄m̄Ȳ প্রদান ও নবায়ন, খুচরা ও পাইকারী ঔষধ বিক্রয় লাইসেন্স প্রদান ও নবায়ন, ঔষধের রেজিস্ট্রেশন প্রদান ও নবায়ন, JĪai ḡj̄" w̄baviY I ḡj̄" mb` c`vb, JĪai K̄v̄Pḡvj I t̄ḡvoK m̄vḡM̄x Avḡ`v̄b̄xi Rb̄" eK̄ij̄÷ Ab̄ȳḡv̄`b, Jla Avḡ`v̄b̄xi t̄ȳt̄i B̄t̄ÛÈ Ab̄ȳḡv̄`b, Avḡ`v̄b̄xiKZ. w̄Zix Jla I JĪai K̄v̄Pḡvj̄i Q̄voc̄i c`vb, Jla iB̄w̄bi Rb̄" jv̄B̄m̄Ȳ, Certificate of Pharmaceutical Product (CPP)/Free Sale Certificate (FSC) I Good Manufacturing Practice (GMP) m̄w̄Ūd̄t̄KU c`v̄bi Rb̄" c̄t̄qv̄R̄b̄q W̄K̄ḡU, ck̄m̄t̄bi Rb̄" eiv̄iKZ. ēr̄m̄iK ēv̄t̄j̄t̄, বিগত বৎসরে সম্পাদিত কার্যক্রমের বিবরণ, ck̄m̄t̄bi R̄bēt̄ji Z\_`w̄" Āš̄f̄ȳ K̄i c̄iZ̄e`b̄U cȲqb Kiv̄ n̄t̄q̄Q|

IĪjai gZ R̄xeb īȳv̄Kv̄ix cY` e`env̄t̄i t̄ȳt̄i m̄s̄iKó t̄ck̄v̄R̄x̄ Ges R̄b̄MȲ h̄v̄t̄Z m̄iVK̄ w̄m̄x̄v̄š̄ M̄nȲ Kīt̄Z c̄v̄t̄i, IĪx̄ Ges IĪjai w̄bqšȲ e`e`v̄ m̄ú̄t̄K mḡ`K āviȲv̄ t̄c̄t̄Z c̄v̄t̄i, t̄`tk̄ Drc̄w̄`Z, Avḡ`v̄b̄xiKZ. I ēv̄R̄iR̄v̄ZKZ. IĪjai D̄ci ḡib̄ȳt̄i āviȲv̄ ú̄ónq, Āv̄`v̄ c̄iZiðZ n̄q t̄m̄ R̄b̄" Jla w̄bqšYKv̄ix c̄iZôv̄b m̄ú̄t̄K Ges Jla সংক্রান্ত Z\_`w̄" ḡvb̄ȳt̄i w̄b̄KU m̄n̄R̄j̄f" n̄l̄qv̄ c̄t̄qv̄R̄b̄| Z_` c̄v̄l̄qv̄ R̄b̄M̄t̄Yi Āv̄B̄m̄Z Āw̄K̄vi, t̄m̄ j̄t̄ȳ`B̄ w̄ēMZ ēQi, j̄vi ḡt̄Zv̄BJla ckymb Awa`B̄t̄i i 2016 m̄v̄t̄j̄ m̄ú̄w̄`Z KḡK̄v̄t̄Ûi c̄iZ̄e`b̄ c̄K̄v̄t̄ki D̄t̄`v̄M̄ M̄p̄x̄Z nq|

2|Jla ckymb Awa`B̄t̄i cUf̄ḡ I c̄iZôv̄t

1971 m̄v̄t̄ji c̄ē Jla ckymb w̄Qj c̄w̄K̄`vb̄ t̄K̄`x̄q mīK̄vi c̄iP̄w̄j̄Z GK̄U`Bi| 1971 m̄v̄t̄ji c̄i ḠŪ m̄v̄`n̄ I R̄b̄ms̄L̄`v̄ w̄bqšȲ ḡš̄Ȳv̄j̄t̄qi GK̄Ū m̄sh̄ȳ বিভাগ হিসেবে কার্যক্রম চালাচ্ছিল। ১৯৭৪ m̄v̄t̄j̄ m̄v̄`n̄ I c̄īēvi K̄j̄v̄Ȳ ḡš̄Ȳv̄j̄t̄qi Āax̄b̄ Jla ckymb GK̄Ū Āvj̄v̄`v̄ c̄īi`B̄t̄i c̄īiȲZ nq| m̄ēt̄k̄l̄ 2010 m̄v̄t̄j̄ Jla ckymb c̄īi`B̄t̄iK̄ Awa`B̄t̄i D̄b̄x̄Z Kiv̄ nq| Jla ckymb Awa`Bi MȲc̄R̄v̄Z̄š̄ ēis̄j̄v̄t̄`k̄ mīK̄v̄t̄i m̄v̄`n̄ I c̄īēvi K̄j̄v̄Ȳ ḡš̄Ȳv̄j̄t̄qi Āax̄b̄ t̄`tk̄i IĪjai GK̄ḡV̄l j̄v̄B̄m̄Ȳs̄ I w̄bqšYKv̄ix KZçȳ| Jla ckymbc̄P̄w̄j̄Z Jla Āv̄B̄b̄ c̄t̄qv̄M̄ K̄i Jla নিয়ন্ত্রণ সংক্রান্ত সকল কর্মকাণ্ড পরিচালনা K̄i _v̄t̄K|

Jla ckymb Awa`B̄t̄i i AM̄t̄b̄v̄m̄t̄ḡ t̄ḡv̄U 370Ū c` īt̄q̄Q. t̄m̄M̄ȳj̄vi ḡt̄a` 118Ū c\_ḡ t̄k̄Ȳxi c`, 25Ū w̄ðZ̄x̄q t̄k̄Ȳxi c`, 115Ū ZZ̄x̄q t̄k̄Ȳxi c` Ges 112Ū PZ̄z̄ t̄k̄Ȳxi c` īt̄q̄Q| ḡn̄v̄c̄w̄iP̄v̄j̄K Jla ckymb Awa`B̄t̄i i c̄ar̄b̄ Ges j̄v̄B̄m̄Ȳs̄ KZçȳ (W̄m̄M̄) w̄n̄m̄t̄ē ȳḡZ̄iv̄c̄iB̄| Jla ckymb Awa`B̄t̄i i c̄ar̄b̄ K̄v̄h̄v̄j̄q ḡn̄v̄L̄v̄j̄x̄, X̄v̄K̄v̄q Āēw̄`Z̄ I t̄R̄j̄v̄ c̄h̄v̄t̄q̄ Ḡi Āax̄b̄ 55Ū K̄v̄h̄v̄j̄q īt̄q̄Q|Jla ckymb Awa`B̄t̄i i Āv̄ĪZ̄v̄f̄ȳb̄v̄k̄b̄v̄j̄ W̄m̄ K̄p̄Ūvj̄ j̄`v̄ēt̄iŪix̄, ḡn̄v̄L̄v̄j̄x̄, X̄v̄K̄v̄ Ges t̄m̄Ūvj̄ W̄m̄ t̄Ūw̄÷s̄ j̄`v̄ēt̄iŪix̄, P̄ĒM̄v̄t̄ḡ`ȳ t̄Ūw̄÷s̄ j̄`v̄ēt̄iŪix̄ īt̄q̄Q|

3|Jla ckymb Awa`B̄t̄i i Ab̄ȳḡv̄`Z̄ I KḡiZ̄ R̄bēt̄ji Z_`w̄" t

Jla ckymb Awa`B̄t̄i i AēK̄v̄w̄t̄ḡv̄t̄Z̄ t̄ḡv̄U R̄bēj̄ 370|

eZ̄ḡv̄t̄b̄ KḡiZ̄ KḡK̄Z̄v̄, KḡP̄v̄ix̄ I kb̄" c̄t̄`i Z\_`w̄" w̄b̄ḡīc̄t̄

t̄k̄Ȳx̄	Ab̄ȳḡv̄`Z̄ c`	KḡiZ̄	kb̄" c`
1g	118	95	23
2q	25	15	10
3q	115	76	39
4_	112 (57+Āv̄DŪ t̄m̄v̄ims̄ 55)	97	15
t̄ḡv̄U	370	283	87

b'vkbvj WwM K#Uvj j've#iUix (NCL), gnLvJx, XvKvi Rbe#ji cimsL'vbt

†kYx	Abjg'Z c`	KgiZ	KgiZ (mshy)	kb` c`
1g	09	03	06	06
2q	05	03	05	02
3q	29	23	13	06
4_	17	13	05	04
†gvU	60	42	29	18

4| Jla ckymb Aia`B#ii †jv#Mv

2016 mv#j Jla ckymb Aia`B#ii †jv#Mv ceZY Kiv n#q#Q| evsjv#`#ki RvZxq cZvKvi mv#_mv`k`†i#L cZxK A#_†jv#MvUi is bevpb Kiv n#q#Q| †jv#MvUi gvSLv#b AvZik KuPi bx#P K'vcmy, mviA I meR cvZvQie i#q#Q, hv Øviv cZxK A#_mKj c#ZiJla I tgnWK'vj WfvBmibqSYeSv#bv n#q#Q|



WpIt Jla ckymb Aia`B#ii †jv#Mv

5| Jla ckymb Aia`B#ii Kivhejx t

eZgv#b †`#k 266U A'v#jvc'w\_K Jla c`ZKvix c#Zôvb cvq 20,406 †KvU UvKvi Jla I JI#ai KuPvgj %Zix K#i| GQvov †`#k 267U BDbvbx I 207U Avq#K Ges 79 U tnviglc'w\_K I 32U nvevj Jla Drcv`bKvix c#Zôvb cvq 850 †KvU UvKvi Jla Drcv`b K#i\_v#K| †`#k 123680U লাইসেন্সধারী ঔষধ বিক্রয়ের dv#gmX i#q#Q| বিধি মোতাবেক এসব ঔষধ প্রস্তুতকারী ও বিক্রয়কারী প্রতিষ্ঠানের যাবতীয় কর্মকাণ্ড নিয়ন্ত্রণ ও gubUis Gi`wqZJla ckymb Aia`Bi cvjb K#i_v#K|

D#jL#hvm` Kv#ক্রমঃ

- 1| Jla Drcv`b KviLvbn`nvc#bi bZy cKí Abjg'v`b|
- 2| Drcv`#bi Rb`cPijZ A'v#jvc'w_K JI#ai †i#m#ic Abjg'v`b|
- 3| AvBGbGb ZvjKvf³ c#`i bgy cixy I we#kIY|
- 4| bZy A'v#jvc'w_K Jla Drcv`b jvB#mY BmY|
- 5| A'v#jvc'w_K Jla Drcv`b jvB#mY c`Ašfy³/†iR#÷kb|
- 6| A'v#jvc'w_K JI#ai tgvOKmvgMx Abjg'v`b|
- 7| †`#k Drcv`Z I gj`wbq#ŠZ ZvjKvf<sup>3</sup> A'v#jvc'w\_K JI#ai m#ev"PLPiv gj`baviY/gj`wbqšÎY ZvjKv e#nfZ JI#ai f'vU c`v#biwbq#ŠE wb#`kK gj`mb`c`vb|
- 8| Jla Drcv`#bi wbq#ŠE Avg`vbxKZ.KuPvgj/c`wKs g'v#Uuiqij-GieK#j ÷ Abjg'v`b|
- 9| A'v#jvc'w_K Jla Drcv`b jvB#mY bevqb|
- 10| A'v#jvc'w_K Jla Drcv`b jvB#mYi g#jKvbn`c#ieZb/nvbiš i|
- 11| Avg`vbi wbq#ŠE we#`kx JI#ai †iR#÷kbc`vb|
- 12| Avg`vbxKZ.JI#ai Bb#WÈ/cvdigv Bbf#qmAbjg'v`b|
- 13| Avg`vbxKZ.KuPvgj/c`ZyKZ.JI#ai QvocÎ c`vb|

14| Avg`vbxKZ.Jl'ai mtey"P Lpiv gf" baviY/cytbaviY|
 15| BDbvbx/Avgte`K/nvej Jl'ai iimic Abtg`b|
 16| bZp BDbvbx/Avgte`K/nvej Jla Drcv`b jvBtmY BmKiY|
 17| BDbvbx/Avgte`K/nvej Jl'ai tgvokmvgMx Abtg`b|
 18| BDbvbx/Avgte`K/nvej Jl'ai Abtg`Z iimic-Gi bgp cixyv ItekiY|
 19| BDbvbx/Avgte`K/nvej Jla Drcv`b jvBtmY c` Ašfy`/iR÷kb|
 20| BDbvbx/Avgte`K/nvej Jla Drcv`b jvBtmY bevgb|
 21| e"³ gviKvbnab Jla Drcv`b jvBtmYi gviKvbn n`ššii cewbtg`b|
 22| BDbvbx/Avgte`K/nvej Jla Drcv`b KviLvbv`nbnšš Abtg`b|
 23| BDbvbx/Avgte`K/nvej Jla Drcv`bKvix cizôvbi bvg cieZb|
 24| BDbvbx/Avgte`K/nvej Jla Drcv`b jvBtmYi gviKvbn cieZb|
 25| tnvglc`v\_K Jl'ai iimic Abtg`b|
 26| bZp tnvglc`v\_K Jla Drcv`b jvBtmY Bm|
 27| tnvglc`v\_KJl'ai Abtg`Z iimic Gi bgp cixyv ItekiY|
 28| tnvglc`v\_K Jl'ai tgvok mvgMx Abtg`b|
 29| tnvglc`v\_K Jla Drcv`b jvBtmY c` Ašfy`/iR÷kb|
 30| tnvglc`v\_K Jla Drcv`b jvBtmY bevgb|
 31| tnvglc`v\_K Jla Drcv`b jvBtmYi gviKvbn n`Zššii cewbtg`b|
 32| tnvglc`v\_K Jla Drcv`b KviLvbv`nbnšš Abtg`b|
 33| tnvglc`v\_K Jla Drcv`bKvix cizôvbi bvg cieZb Abtg`b |
 34| tnvglc`v\_K Jla Drcv`b jvBtmYi gviKvbn cieZb|
 35| tnvglc`v\_KKupigj Avg`vbx i eKij ÷ Abtg`b|
 36| nvejKupigj Avg`vbx i eKij ÷ Abtg`b|
 37| tnvglc`v\_K Jla Avg`vbx i Abtg`b|
 38| Jla iBvbi Abtg`b (CPP, FSC, Form-10A IGMP mb` BmKiY)|
 39| bZp Lpiv A`jvc`v_K/Avgte`K/BDbvbx/tnvglc`v_K Wm jvBtmY c`vb|
 40| bZp cvBKvix A`jvc`v_K/Avgte`K/BDbvbx/tnvglc`v_K Wm jvBtmY c`vb|
 41| ফার্মাকোভিজিলেস সংক্রান্ত কার্যক্রম ciiPjbi|
 42| Jla ckvmbi KgKvU ciiPjbiq Digital (Automation)cxiZi cqm|
 43| Jl'ai Lpiv I cvBKvix t`vKvbn Wc`v Ges Jla c`ZKvix cizôvb bvgigZ ci`kb|
 44| cixyv ItekiYi i bvgE`Jl'ai bgp Dššjb|
 45| Jla AvBb jnBkvix`i iei`x Wm tKvU, g`vR÷U tKvU I tgvBj tKvU gvgjv`vqi|

6|U#Rb Puvi t

1. fkb I gkb

ickí (Vision)tmKtji Rb" gvbmaúb I ibivc` Jla ibiðZ KiZ Avgiv m#Pó|

Afjy" (Mission)t ibivc`, KvKi I gvb-maúb Jla ibiðZ Kivi gva`g gvbe I c`v` myy`
 Kiv|

2. cizkz tmevgr (bvMiK tmev) t

ক্রমিক নং	tmev	tmev MnYKvix	máun`bi mgqmxgv (qs máu`c`ve cniBi ci)
1.	Jl'ai bZk KviLvbv`vc`bi cKí c`Zve gf`vqb Kiv	vib`qvmKvix	120 Kg i`em
2.	Re I ARe Jla c`ZKiY jvBtmY c`vb	Jla Drcv`bKvix cizôvb	120 Kg i`em
3.	Re I ARe Jla c`ZKiY jvBtmY bevgb	Jla Drcv`bKvix cizôvb	90 Kg i`em
4.	BDbvbx, Avgte`K, tnvglc`v_K I nvej Jla Drcv`b jvBtmY c`vb	Jla Drcv`bKvix cizôvb	120 Kg i`em
5.	BDbvbx, Avgte`K, tnvglc`v_K I nvej Jla Drcv`b jvBtmY bevgb	Jla Drcv`bKvix cizôvb	60 Kg i`em
ক্রমিক নং	tmev	tmev MnYKvix	máun`bi mgqmxgv (qs máu`c`ve cniBi ci)

6.	Jl#ai tiumic Abjg`b ,cPijZ Jla (ie`gib Jla)	Jla Drcv`bKvix cizôib	90 Kg i`em
7.	bZb Jl#ai tiumic Abjg`b	Jla Drcv`bKvix I Avg`vbKvix cizôib	120 Kg i`em
8.	Jl#ai KUpvj I tgvOK`e`v Avg`vbi eKij÷i ceibjg`b c`vb	Jla Drcv`bKvix cizôib	30 Kg i`em
9.	Abjg`Z tiumici bgp cixÿvi Rb` cixÿvMti tciYi e`e`v MnY	Jla Drcv`bKvix cizôib	07 Kg i`em
10.	tj#ej, KvUb I BbmU Abjg`b Kiv	Jla Drcv`bKvix cizôib	20 Kg i`em
11.	Jla c`ZKiYi jvBtmY bZb Jla iBeÜb	Jla Drcv`bKvix cizôib	60 Kg i`em
12.	Avg`vbKZ.Jla, Jl#ai KUpvj I c`vKs tgUuiqvj Kv÷gm KZcYi iBKU ntZ Qvo Kivi cZ`vqb cÎ c`vb	Jla Avg`vbKvIK I Drcv`bKvix cizôib	05 Kg i`em
13.	Jl#ai mteP Lpiv iBt`kK gf` Abjg`b Kiv	Jla Avg`vbKvIK I Drcv`bKvix cizôib	30 Kg i`em
14.	Jla Avg`vbi t iRt÷kb c`vb	Jla Avg`vbKvIK	90 Kg i`em
15.	Jla Avg`vbi t iRt÷kb beiqb	Jla Avg`vbKvIK	60 Kg i`em
16.	Jla iBvbi jvBtmY c`vb	Jla Drcv`bKvix cizôib	15 Kg i`em
17.	ie`k ntZ Jla Avg`vbi ceibjg`b c`vb	Jla Avg`vbKvIK	40 Kg i`em
18.	ie`k Jla iBvbi CPP/FSC c`vb	Jla Drcv`bKvix cizôib	07 Kg i`em
19.	GMP mb` c`vb	Jla Drcv`bKvix cizôib	90 Kg i`em
20.	Jl#ai iEavb Abjg`b	Jla Drcv`bKvix cizôib	30 Kg i`em
21.	পাইকারী ঔষধ বিক্রয়ের লাইসেন্স প্রদান।	Jla e`emvqx	30 Kg i`em
22.	পাইকারী ঔষধ বিক্রয়ের লাইসেন্স নবায়ন।	Jla e`emvqx	05 Kg i`em
23.	খুচরা ঔষধ বিক্রয়ের লাইসেন্স প্রদান।	Jla e`emvqx	90 Kg i`em
24.	Lpiv ঔষধ বিক্রয়ের লাইসেন্স নবায়ন।	Jla e`emvqx	07 Kg i`em
25.	c#gkqvj tgUuiqvj Abjg`b	Jla Avg`vbKvIK I Drcv`bKvix cizôib	30 Kg i`em
26.	KUpvjji tmm f`vjiWkb	BtÜUi/Jla Drcv`bKvix cizôib	45 Kg i`em
27.	Jla Drcv`b jvBtmYi gvijKiv n`všt i ceibjg`b	Jla Drcv`bKvix cizôib	20 Kg i`em
28.	Jla Drcv`b jvBtmYi gvijKiv c iezb	Jla Drcv`bKvix cizôib	90 Kg i`em

7|Jla ckymb Aia`Bt i i m×vš MnTYর প্রক্রিয়া

Jla ckymb Aia`Bt i i Khveix mgya বে সম্পাদনের জন্য সকল ধরনের সিদ্ধান্ত নিম্নলিখিত প্রক্রিয়ায় সম্পন্ন হয়-

msikó kvLv

mnKvix ciiPvjK

DcciiPvjK

ciiPvjK

gnvciiPvjK

msikó kvLv

Jla ZËveavqK/mnKvix jvB+mÝs
Awdmvi

DcciiPvjK

ciiPvjK

gnvciiPvjK

Jla ZËveavqKMY jvB+mÝs KZçþÿi cþÿ ঔষধ বিক্রয় jvB+mÝ BmÿI bevqb Kþi _vþK|

Jla ckymb Awa`Bþii Kvhejx mÿZvþe mœuv`þbi Rb" bgjLZ KigU, þjv mnvqZv c`vb Kþi _vþK|

- 1) Jla bqšY KigU|
- 2) Jla bqšY KigUi †UKibK"vj mveKigU|
- 3) bZb Jla kÍ "vcþbi Rb" cKÍ gþ"vqb KigU|
- 4) Jla ai gþ" bav iY elqK KigU|
- 5) Jla ai gþ" bav iþYi †UKibK"vj mve KigU|
- 6) nvej Jla GWfvBRix KigU(†UKibK"vj mveKigU-DCC)|
- 7) ÷"vÛs KigU di BgþcU Ae digvmmDik"vj |
- 8) A"WfvM Wm iþqKkb A"WfvBRix KigU|
- 9) A"WfvM Wm iþqKkb gubUis tmj |
- 10) †Rjv Wm jvB+mÝs KigU|
- 11) f"v - þbi KibK"vj Uqvj I U - þKvjRi Rb" G · cU KigU|
- 12) f"v - þbi þKig ÷ g"vþ"vKPrivi KþUvj (CMC) Gi Rb" G · cU KigU|
- 13) f"v - þbi þi , þjUix mþ ÷ þgi Rb" G · cU KigU|

ZvQvov Jla ckymb Awa`Bþii cizibia KgKZv Ašfþ Kþi miKvþii wefb GþRÝx h\_v- †Rjv Uv`þdvm, †gvevBj
†KvU, i"vþei weþkl Aifhvþb AskMnþYi gva"þg Jla tmþþii Aibqg cizþiva Kiv I kv"v gþK e"v MnY Kiv nq|

8| dskbvj þi , þjUui A_iiUt

wek "v" ms"vi " Kibþ`kbv Abjvqx GKU KvHki Jla bqšYKvix KZçþÿi 9U dskb _vKþZ nþe| dskb , þjv-

1. National Regulatory System (RS)
2. Registration and Marketing Authorization (MA)
3. Pharmacovigilance (PV)

4. Market Surveillance and Control (MC)
5. Licensing for Establishments (LI)
6. Regulatory Inspection (RI)
7. Laboratory Access and Testing (LA)
8. Clinical Trial's Oversight (CTO)
9. NRA Lot Release (LR)

GKIU KvhKi bqšYKvix ms v ntmte ek v ms vi xKUZtcZ n+j DjjLZ cLZU dskb h_vh_fvte ev evqb KiZ nte| Jla ckmb Aa`BiK dskbvj ti ,tjUu A\_wiU ntmte ek v ms v KZK. xKUZ. cLZi j+y" gvP/2016 gvm ek v ms vmn Abvb Dbqb mnthvMx cLZôvbi AskMnY GKIU tivW gvc cYqb Kiv nqQ| GB 9U dskb Gi Dci fE Kti btpv<sup>3</sup> KgKZv`i mgšq Jla ckmb Aa`Bi 9 U tmj MvB Kiv nqQt

SI.NO	Department Name	Responsible Person
1.	National Regulatory System (RS)	1. Rbve tgrt tMjvg Keliq (cLiPjK) 2. Rbve tgrt AvBqy tnvmb (mnKvix cLiPjK) 3. Rbve tgrt Bqvbq (mnKvix cLiPjK) 4. Rbve tgrt iMRej nwee (Jla ZËveaqK)
2.	Registration and Marketing Authorization (MA)	1. Rbve tgrt iûj Awgb (cLiPjK (Pt`vt))</li> <li>2. Rbve tgrt AvjZvd tnvmb (DccLiPjK)</li> <li>3. Rbve tgrt gbi Dİb Avn`g` (Jla ZËveaqK)
5.	Pharmacovigilance (PV)	1. Rbve bqv i mYzib (cLiPjK (Pt`vt)) 2. Rbve AvKZi tnvmb (mnKvix cLiPjK) 3. Rbve gney tnvmb (Jla ZËveaqK)
4.	Market Surveillance and Control (MC)	1. Rbve Avmvd tnvmb (mnKvix cLiPjK) 2. Rbve mKZ Kgi Ki (Jla ZËveaqK) 3. Rbve Gm, Gg, mveixbv BqQigb (Jla ZËveaqK)
5.	Licensing for Establishments (LI)	1. Rbve tgrnv` bvcg tMj`vi (mnKvix jvBtmYs AIdmi) 2. Rbve bvc tPšaj (Jla ZËveaqK) 3. G U Gg tMjvg Keliq Lib (Jla ZËveaqK)
6.	Regulatory Inspection (RI)	1. Rbve tgrt b+j Bmjvg (DccLiPjK) 2. Rbve tgrt gny` Bmjvg (Jla ZËveaqK)</li> <li>3. Rbve kvqv bkv` (Jla ZËveaqK)
7.	Laboratory Access and Testing (LA)	1. Rbve Avt It gmdKž ingib (tWcy Pxd-NCL) 2. Wt tgrt nvib-Ai-ink` (Gim÷÷U Pxd-DTL)</li> <li>3. Wt bmmg cLifb (e`KtUu I+jvR÷-DTL)
8.	Clinical Trial's Oversight (CTO)	1. W. tLv` Kv i QMxi Avn`g`, (DccLiPjK) 2. Rbve tgrt mvjvn Dİb (mnKvix cLiPjK) 3. Wt Avtqkv mmi İKv (dvgvKvjR÷)
9.	NRA Lot Release (LR)	1. Rbve Avt It gmdKž ingib (tWcy Pxd-NCL) 2. Rbve tgrt mvjvn Dİb (mnKvix cLiPjK) 3. Wt tgrt nvib-Ai-ink` (Gim÷÷U Pxd-DTL)</li> <li>4. Wt bmmg cLifb (e`KtUu I+jvR÷-DTL)

9| Jla ckmb Aa`Bi KZK Rbvi, 2016 n+Z Wtmxi, 2016 chš mxi`Z Kvhejx t

ক্রমিক নং	elq	msL`v (u)
9.1	Jla Drcv`bi Abjg`Z ckí	19
9.2	Jla Drcv`bKvix cLZôvbi jvBtmY bevqb	117

9.3	Jla Drcv`bKvix ciZôv#bi bZh Drcv`b jvB#mY c`vb	0
-----	---	----------

9.42016 mv#j mvgnqK ev#ZjKZ.Jl#ai Zv#jKv

bs	ciZôv#bi bvg	c#`i bvg l W.G.Avi bs	viK bs
1.	#gmvm ggvjg dvgv#mD#UK`vjm (BDbvbx), #evqv#jqv, ivRkvnx	kieZ #Rb#mb #WGAvi bs: 77-G-033	#WG/BD-07/84/17425, Zv#iL-07/11/2016
2.	H	nv#eY #bkvZ (U`ve#jU) #WGAvi bs: 77-G-015	H
3.	#gmvm #Rbdvgn (BDbvbx) #jt, dZ#v, bviqbMÄ	WzjvK`vc K`vcmY(nv#eY ggv#mK), e`vPbs-GD 002 #WGAvi bs: BD-99-G-014	#WG/BD-99/(Ask-2)/08/15563, Zv#iL-03/10/2016
4.	H	#f#q · K`vcmY(#Rb#ms), e`vPbs- VX 24005 , #WGAvi bs: BD-99-G-024	H
5.	#gmvm AvB#K dvgv#mD#UK`vjm(BDbvbx), mevcY, avgivB, XvKv	kieZ Q`i (KvW#d ·) #WGAvi bs: BD-45-G005	#WG/BD-45/08/15496, Zv#iL-02/10/2016
6.	H	kieZ `xbvi (#j#fv#g · , #WGAvi bs: BD-45-G-006	H
7.	#gmvm #Mve j`ve#iUixR(#nvgI), mv#v#vi #ivW, bvgvRMO, e, ov	#mivc #Rb#ms- Q, e`vP bs-07, #WGAvi bs: H-29-A-014	#WvR#WG/GBP-29/84/14604, Zv#iL-19/09/2016
8.	#gmvm #bD nvievj j`ve#iUixR (BDbvbx) 39#m, #e#mK #kí bMix, #MvUv#UKi, #m#jU	c` kieZ Kv#gbv Gb #WGAvi bs-BD-169-G-013	#WG/BD-216/2009/877, Zv#iLt 21/01/2016
9.	#gmvm BÉv dvgv#mD#UK`vjm (BDbvbx) ØxcPi #ivW, ejvgcY, cvebv	#Rb#mb cvm (#mivc) e`vP bs- 15 (#PvV), #WGAvi bs-BD-5-G-006	#WG/BD-05/96/1951 Zv#iLt 09/02/2016
10.	#gmvm #UK#bv WvMm #jt mv#Uicov, bi#ms`x	#g#Uv#fU #evjvm (#g#Uv#WvRj #e#c) e`vP bs-008 (bg#v) #WGAvi-304-21-77	#WG/GmGm-304/04/5192, Zvs:06/04/2016
11.	#gmvm #i · Ub dvgv (BDbvbx) #bqvGZcY, #mq`cY, #bjdv#vix	Uv#i · K`vcmY (nv#eY R`Iqv) #WGAvi-BD-11-G-009	#WG/BD-44/84/12537, Zv#iL: 09/08/2016
12.	H	mdv#i · (gvRg dvjv#mdv) #WGAvi-BD-11-G-001	H
13.	#gmvm #m>Uvj dvgv#mD#UK`vjm #jt, #gicY, ,XvKv	G#Ub U`ve#jU(#m#UvRb WvBvB#WvKv#vBW 10 #gtMvt) #WGAvi bs-060-52-28	#WvR#WG/GmGm-060/2016/5844,, Zvs:18/04/2016
14.	#gmvm #dib · #KvgK`vj j`ve#iUixR (evsjv#`k) #jt, evM`x, bi#ms`x	c`vivv#Uvgj cvm (c`vivv#Uvgj 500#gtMvt+K`v#dBb 65#gt Mvt) U`ve#jU #WGAvi bs-032-10-06	#WvR#WG/GmGm-032/2011/17416, Zvs:06/11/2016

9.52016 mv‡j ‡i‖R‡÷kb e‖ZjKZ.Jl‡ai Zv‖jKv

bs	cizô#bī big		Jl'ai enYiR'K big	#RbiK big	#iRt÷kb bs (WGAi bs)	gšē"
01	#gmm Avi Gb digmDiUK'vjm ijt, C'Mu K'ûDÜ, gqgbimsn	1.	im#fU-#fU tevjm	c'vimmUigj iec 2 Mig	172-21(V)-83	WM tU÷s j'vetiUiX, gniLijx, XiKv Ges PÆMg KZK.gibelnfZ tNmIZ nIqig JIa iBqŠb KigiUi 23/06/2016 Zwi+L AbyôZ 245Zg m fvi mɔwɪk tɔɪZ#eK mɪgɪqK enZjKZ.JIa mɔɪni #iRt÷kb enZj Kiv nq
02	#gmm idlb· #KigK'vj j'vetiUiR ijt, biims`x	2.	idlb· #iibiUWb U'vetjU	#iibiUWb BDGmic- 150igtMt	20-01-29	
03	#gmm #giWKb digmDiUK'vjm ijt, igicy, XiKv	3.	ii#evdnfb U'vetjU	ii#evdnfb iec 5 igt Mt	238-04-29	
04	#gmm ie÷j digmjt Gm-13,G-32 Ask, tKibievov, MiRicy	4.	#KtU#ivjiK U'vetjU	#KtU#ivjiK Uzg_igibB BDGmic	054-91-006	
		5.	#jv#mK 20 K'vcmy	IigciRj iec 20 igt Mt	054-25-29	
05	মেসার্স ক্রিস্টাল ফার্মাসিউটিক্যালস ijt, P_v, Kqjv	6.	ibiWb U'vetjU	tiibiUWb	182-021-055	
06	#gmm ÷'vUW j'vetiUiR ijt PÆMg	7.	#fivē-50 U'vetjU	Wb#Kt#dbiK tmmWqig BDGmic 50igtMt	021-153-65	
07	#gmm #M#e· digmDiUK'vjm ijt, Kigvjcy, bviqbMÄ	8.	igD#K#UK imivc	#eigtni· iWb mB#Wt#KviBW iec 0.080Mt/100gij	180-71-031	
08	#gmm "úvK digmDiUK'vjm 175, PicvovB#jb, Picvov gqgbimsn	9.	"úvieg K'vcmy	IigciRj iec 20igtMt	329-08-29	
		10.	"úvifu K'vcmy	WbW tdim mvj#dU iec 150.03 igt Mt + dijk GmW iec 0.5 igtMt + iRsKmvj#dU g#biniB#WU iec 61.8 igtMt	329-11-39	
		11.	"úviW· -100 K'vcmy	Wl· mBiKm iec 100igtMt	329-10-60	
		12.	"úvig· 250 K'vcmy	G#gi· immib iec 250 igtMt	329-06-60	
		13.	"úvigj G· U	c'vimmUigj iec 500 igtMt + K'#dBb iec 65 igtMt	329-07-06	
		14.	c'vix#dbiK 50	Wb#Kt#dbiK tmmWqig 50 igt Mt	130-59-65	
09	#gmm c'vivWbm #KigK'vj BÜwÖR, enikvj					
10	#gmm #ej#mb digmDiUK'vjm ijt, Kgjvcy, dhi'cy	15.	Acv U'vetjU	c'vimmUigj iec 500 igtMt	069-34-06	
11	#gmm I#q÷vi digmDiUK'vjm ijt, teviniB#iB÷iW, K#kNü, im#jU	16.	AvjmmWb U'vetjU	#iibiUWb BDGmic 150igtMt	101-24-29	
12	#gmm idlb· #KigK'vj j'vetiUiR ijt, biims`x	17.	idlb· IigciRj K'vcmy	IigciRj iec 20 igtMt	20-02-34	

bs	cZô#bi big		Jl#ai enYiR'K big	#Ribik big	#iR# ÷ kb bs (iWGAi bs)	gše"
13	#gmm #Rib_ dīgimDlUK'vjm #jt, ie-67, iemK ikí bMi, Pricy, tdbi	18.	Wb#Kibj GmAvi U've#jU	Wb#Kib#dbiK tmmWqig ieic 100 igtMt	080-162-64	
		19.	Uu#Rb K'icmy	#UumBikb niB#W#KviiBW ieic 250igtMt	080-80-60	
14	#gmm #UK#bi WMM #jt MmUicvov, bims`x	20.	cvi#i# fU teijim	c'vimmUigj ieic 2 Mt	304-52(V)-83	
15	#gmm evqim dīgimDlUK'vjm #jt, fvlqij, igRicy m`i, MmRicy	21.	ógwWb U've#jU	#ibiUWb BDGmic	57-32-29	
16	#gmm U#W dīgiv #jt iemK ikí bMi, Kvjv	22.	#cBbAiDU 400 U've#jU	AvBejc#db 400 igtMt	066-19-65	
17	#gmm ggZiR dīgimDlUK'vjm #jt, cu bs-551, ic, eo t`lov, U#z, MmRicy	23.	f#q#Rb 2% t#ymb	#Rbmqib f#q#jU ieic 2%	344-19-76	
18	#gmm igr÷K dīgimDlUK'vjm #jt, 16, em`x, bims`x	24.	cvg-20 K'icmy	Igcirj ieic 20 igtMt	121-31-29	
19	#gmm dīgK j've#iUixR #jt Lyk, PEMig	25.	#UumBikb K'icmy	#UumBikb niB#W#KviiBW250igtMt	179-43-60	
		26.	ig#KvRj-400igtMt U've#jU	#g#UmbWRj ieic 400igtMt	179-49-57	
		27.	ice`K U've#jU	im#civ · wmb niB#W#KviiBW BDGmic 500 igtMt	179-42-60	
20	#gmm B#`v-eisjv dīgimDlUK'vjm Iqikm #jt, K#jR tiW, eikvj	28.	B#`v#dbiK 100 GmAvi K'icmy	Wb#Kib#dbiK tmmWqig ieic 100 igtMt	032-49-06	
		29.	#KvUg · iWgm U've#jU	mjd#g#_v · iRj ieic 800igtMt + UBig#_icg ieic 160igtMt	032-28-59	
		30.	#Ubmvi j U've#jU	WqmRcig ieic 5 igtMt	032-63-02	
		31.	B#`v÷b Avi 150 U've#jU	#ibiUWb BDGmic 150igtMt	032-93-29	
		32.	#KvUg · mmm#cmb	mjd#g#_v · iRj ieic 4.0Mt + UBig#_icg ieic 0.80 Mt/100iglj	032-16-59	
		33.	#gUj mmm#cmb	#g#UmbWRj ieic 4.0Mg/100igtvj	032-26-56	
		34.	#gUj U've#jU	#g#UmbWRj 400 igtMt	032-25-56	
		35.	B#`v#c · -ie U've#jU	ifUmb ie-Kg#c ·	032-30-39	
		36.	c'vimmUigj U've#jU	c'vimmUigj ieic 500igtMt	032-18-06	

bs	cZô#bi big		Jl:ai enYiR'K big	#Ribik big	#iRt: + kb bs (iWGAi bs)	gše"
		56.	Rotamin DS 2tablet	Rosiglitazone 2mg + Metformin HCl 1000mg	005-586-015	
		57.	Rotamin DS 4 tablet	Rosiglitazone 4mg + Metformin HCl 1000mg	005-585-015	
		58.	Roglim 1 tablet	Rosiglitazone 4mg + Glimepride 1mg	005-529-015	
		59.	Roglim 2 tablet	Rosiglitazone 4mg + Glimepride 2mg	005-530-015	
		60.	Diatag Plus 2 tablet	Pioglitazone 30mg + Glimepride 2mg	005-667-015	
		61.	Diatag Plus 4 tablet	Pioglitazone 30mg + Glimepride 4mg	005-568-015	

9.6 jvB#mY ewZjKZ.Jla Drcv`bKviX cZô#bi ZvjKv


ক্রমিক bs	cZô#bi big I VKvbv	Drcv`b jvB#mY ewZj Gi`vik bs I Zmil
1.	#gmvm U#W dvgv #jt cU-28, eK-im, #ivW-01, #eimK #kí bMix, Kzgv	#vik bs: #WIRWG/GgGj-66/80(Ask-1)/9436, Zmil t 09-06-2016
2.	#gmvm b`vkbvj WmM #Kvt #jt AvUciov, ev#vj ciov, aigivB, XvKv	#vik bs: #WIRWG/GgGj-200/85/9435, Zmil t 09-06-2016
3.	#gmvm m#x#y dvgvD#UK`vjm GÜ #KigK`vjm #jt, 6 Avb`cy, #MÜv, XvKv	#vik bs: #WIRWG/GgGj-293/011/9425, Zmil t 09-06-2016
4.	#gmvm BD#bfvmj dvgvD#UK`vjm #jt #`jvjcy, cvebv	#vik bs: #WG/GgGj/44/95/9421, Zmil t 09-06-2016
5.	#gmvm WmJ`vÜ #jt #gRigR, gv`vmv #ivW, #m#iMÄ, b#ivqYMA	#vik bs: #WG/GgGj/260/05/9420, Zmil t 09-06-2016
6.	#gmvm Wj#db dvgvD#UK`vjm #jt 82/4, D#i hv#veox, XvKv	#vik bs: #WG/GgGj/089/012/9423, Zmil t 09-06-2016
7.	#gmvm Rvjdv j`ve#iUixR #jt #eimK #kí bMix, #m#ju	#vik bs: #WIRWG/GgGj-119/011/9424, Zmil t 09-06-2016
8.	#gmvm #iW dvgv #jt #eimK #kí bMix, b`bcy, evpYevoxqv	#vik bs: #WIRWG/GgGj-340(Ask-1)/2011/9422, Zmil t 09-06-2016
9.	#gmvm #igv #KigK`vjm #jt 235 #ZRMU #kí GjvKv, XvKv-1208	#vik bs: #WG/GgGj-318/03/9418, Zmil t 09-06-2016
10.	#gmvm K`dgv dvgvD#UK`vjm #jt #eimK #kí bMix, teMgMÄ, #bvqLvix	#vik bs: #WIRWG/GgGj-113/2011/9419, Zmil t 09-06-2016
11.	#gmvm #Me j`ve#iUixR (cit) #jt #giKv`g, UsM#evox, gyMÄ	#vik bs: #WIRWG/GgGj-118/95/10842, Zmil t 11-07-2016
12.	#gmvm #gW#Kv dvgvD#UK`vjm #jt `kbv, Av#K #ivW, isc#y	#vik bs: #WIRWG/GgGj-297/2001/11293, Zmil t 20-07-2016
13.	#gmvm b`te#j dvgvD#UK`vjm #jt PK #gv`vi, bIMU	#vik bs: #WG/GgGj-266/12/9434, Zmil t 09-06-2016
14.	#gmvm G`ve#jkb j`ve#iUixR #jt	#vik bs: #WG/GgGj-310/97/13410, Zmil t 23-08-2016

ক্রমিক bs	cıZô#bi big I ıVKıvı	Drcı`b jıB#mY emZj Gi ııiK bs I ZııiL
	331 gıbcıy, ıgıcy, XıKıvı	
15.	মেসার্স নৃতিসতা এ্যানিমেল হেলথ এন্ড ফ্রপকেয়ার লিঃ, ıe-82, ıemK ıkí bMıx, UsMı, MıRıcy, (ce bıg t tgmıv em#Kıv j`ıveııUııR ıjt)	ııiK bs: ıWG/GgGj-088/12/15970, ZııiL t 06-10-2016
16.	tgmıv Avëv dıgıv ıjt WıjıfUı, aıgıvB, XıKıvı	ııiK bs: ıWG/GgGj-168/02/13413, ZııiL t 23-08-2016ı
17.	tgmıv gıvı#Kıv j`ıveııUııR `ıMıvı tMU, ım#jUı c`ıeZ t tgmıv ımıU K#cı#ıkb dıgıvıMıDUK`ıjıvı, mıMııKıv, PıEMıgı	ııiK bs: ıWıRıWG/146/77/698, ZııiL t 15-01-2017ı
18.	tgmıv cıBııbqıı dıgıvıMıDUK`ıjıvı ıjt ıe-179,180, ım-155,156,161,162 ıemK ıkí GıvıKıv, Uıııı, MıRıcyı	ııiK bs: ıWıRıWG/GgGj-392/2017/1881, ZııiL t 12-02-2017ı

Jıa ckımb Aıa`B#ıı gıvı chı#qı KgKıı

9.7ı W`ık teıW ıfıĖK AbıvıBb ııı#cıUs ım#÷gt

13 A#ıııı, 2016 ZıııııL ııııı I cııııı Kj`ıY gšYıj#qı gıvıbxq gšx Rıııı tıgıvııı` bııııı Gg ııı Jıa ckımb Aıa`B#ıı W`ık teıW ıfıĖK AbıvıBb ııı#cıUs ım#÷g D#ıııab K#ıııı Jıa ckımb Aıa`B#ıı gıvı chı#qı KgKıııY cıııı` Zııııı gıvı chı#qı KgKıııı cıııı` AbıvıB#b tıııı K#ıııı gıvııııııK, Jıa ckımb Aıa`Bıı gıvı chıq n#Z Aıııı ııı#cıııııı W`ık teıWıııı gıa`tg gııııııı K#ıııı G#Z gıvı chı#qı KgKıııı`ı কার্যক্রমের cııııııı Pıııı cıııııı hıııı`Q, জবাবদিহিতা নিশ্চিত হচ্ছে এবং নিরাপদ ও মানসম্মত ঔষধ নিশ্চিত করার কার্যক্রম বেগবান n#ıııııı




ıPııııJıa ckımb Aıa`B#ıı W`ık teıW ıfıĖK AbıvıBb ııı#cıUs ım#÷g D#ıııab

9.8| **†gvUL** **†i** **v WM jvB†mÝ Gi msL"v** 123680U

9.9|2012 n†Z 2016 mvj chš **L** **†i** **v WM jvB†mÝ beq†bi ZžbvgtK c†imsL"v**bt


mvj	L †i v WM jvB†mÝ beq†bi msL"v
2012	21337
2013	27296
2014	27875
2015	32991
2016	34844



†PÎ 2012 n†Z 2016 mvj chš WM jvB†mÝ beq†bi ZžbvgtK †PÎ

9.10|2012 n†Z 2016 mvj chš **c†i`kbKZ.dv†gmx†c†imsL"v**bt


mvj	c†i`kbKZ.JI†ai †`vKv†bi msL"v
2012	28019
2013	34473
2014	49814
2015	57734
2016	61945



«PÎt 2012 nžZ 2015 mvj chš žRjv fĚK cĭi`kbKZ.dv†gmx iZžbvġĵK «PÎ

9.11|2012 nžZ 2015 mvj chš cĭi`kbKZ.Jla c<sup>-</sup>ZKvix KvLvbvi ZžbvġĵK cĭimsL`vb
(GKvĭaKevĭ cĭi`kbmn)t

mvj	cĭi`kbKZ.Jla c <sup>-</sup> ZKvix KvLvbvi msL`v (GKvĭaKevĭ cĭi`kbmn)
2012	787
2013	975
2014	1094
2015	1338
2016	1481



«PÎt 2012 nžZ 2016 mvj chš cĭi`kbKZ.Jla c⁻ZKvix KvLvbvi ZžbvġĵK «PÎ
(GKvĭaKevĭ cĭi`kb mn)


9.12|WM tKvU, g^v«R†÷U tKvU I ‡gvevBj †Kv†U `v†qiKZgvgjvi weeiYt

gvm	Jla Av`vj†Z gvgjv	g <sup>v</sup> «R†÷U Av`vj†Z gvgjv	‡gvevBj †Kv†U gvgjv	Riġibv (UvKv) ‡gvevBj †KvU	k ^{vĭ} ‡gvevBj †KvU KZK k ^{vĭ} I Jla ckvmb KZK.MpxZ e ^e -v	Aġea Jla Ră ‡gvevBj †KvU/ Jla ckvm†bi ĩbqigZ Aıfhu†b Ră (UvKv)
Rıbvġvıx16	5		144	5563500	4 Rb†K «ııfb †gqv†` Kvıv`Ű	3576320


gvm	Jla Av`vjZ gvgjv	g`wR÷U Av`vjZ gvgjv	gveBj tKvU gvgjv	Rigbv (UkV) gveBj tKvU	kV gveBj tKvU KZK kV / Jla ckmb KZK.MpZ e`e`v	Aea Jla Rã gveBj tKvU/ Jla ckmbi`bqgZ Aifhãb Rã (UkV)
deqvix016	2		170	4654000	2 RbK wefb tggq` Kviv`Ü, 1 U d+gmX mjmjv	1806476
gvP016	5	10	132	3495000	3 RbK wefb tggq` Kviv`Ü, 1 U d+gmX mjmjv	5934753
Gicj,16			191	3794000	6 RbK wefb tggq` Kviv`Ü, 1 U d+gmX mjmjv	1713744
g0 16	5		210	5322000	3 RbK wefb tggq` Kviv`Ü, 2 U d+gmX mjmjv	41040300
Rp0 16	11		160	8971500	7 RbK wefb tggq` Kviv`Ü	959566
RyvB016		14	113	2067500	1 RbK Kviv`Ü, 16 U KviLbv mjmjv	1038407
AvM0016	3		242	3831000	8 RbK wefb tggq` Kviv`Ü, 5 U d+gmX mjmjv	43779850
tmP0i016	1	6	191	5155800	3 RbK Kviv`Ü	4344040
A±weio16	3		255	4534900	10 RbK wefb tggq` Kviv`Ü, 5 U d+gmX mjmjv	2582116
b±f0016	5	13	245	16357000	5 RbK wefb tggq` Kviv`Ü, 3 U d+gmX mjmjv	56168092
wW±m0i016	1	25	116	2881500	6 RbK wefb tggq` Kviv`Ü, 1 U d+gmX mjmjv	4260170
tgvU	41	64	2169	66627700	58 RbK wefb tggq` Kviv`Ü, 19 U d+gmX, 16 U KviLbv mjmjv	167203834

9.13| 2012 n±Z 2016 mvj chš `v`qikZ.gvgjvi ZžbvgyK c`imsL`vbt


eQi	Jla Av`vjZ gvgjv	g`wR÷U Av`vjZ gvgjv	gveBj tKvU gvgjv	Rigbv (UkV)
2012	3	5	160	3157900
2013	19	7	646	42092000
2014	31	2	892	10571100
2015	27	6	1235	29975300
2016	41	64	2169	66627700



«PÎt2012 n†Z 2016 mvj chš Jla Av`vj†Z gvgjv`v†q†ii Zžbv†gjK «PÎ



«PÎt2012 n†Z 2016 mvj chš g`wR†÷U Av`vj†Z gvgjv`v†q†ii Zžbv†gjK «PÎ




11PÎt2012 n#Z 2016 mvj chš tgvvBj tKv#U gvgjv`v`q#i i ZžbvġġK c#i msL`vb



9.14 | 2012 n#Z 2016 mvj chšciXÿv I we#kl#Yi wbg#E WvM tU#÷s j've#iUiX#Z tciZ JI#ai bgÿi ZžbvġġK c#i msL`vb

mvj	tciZ JI#ai bgÿi msL`v
2012	2427
2013	3625
2014	5529
2015	5443
2016	5859




11PÎtJI#ai bgÿi tci#Yi ZžbvġġK c#i msL`vb

9.15 | 2012 n#Z 2016 mvj chš ivR` Av`v`q i ZžbvġġK c#i msL`vbt

mvj	ivR` Av`vq (UvKi)
-----	-------------------

2012	149021949.00
2013	175984361.00
2014	175513258.00
2015	188412095.00
2016	215385291.00



পিত2012 নং 2016 মজ চশ ইব্র আ ব্রি জব্রজক পি


9.16| ব্রব্রজ ক্রব্রজ জব্রজ, ঢাকা কর্তৃক প্রাপ্ত নমুনা পরীক্ষা ও বিশ্লেষণ সংক্রান্ত বিবরণী

gvm	cvB bgvi msL'v			ciy'v I we+kIYKZ. bgvi msL'v			gvb-DExY bgvi msL'v			gvb-ein fZ bgvi msL'v		
	Post Marketing	Pre-Marketing	Other Sources	Post Marketing	Pre-Marketing	Other Sources	Post Marketing	Pre-Marketing	Other Sources	Post Marketing	Pre-Marketing	Other Sources
Rvbgvi016	162	82	257	160	34	347	159	33	342	01	01	05
tdeqvi016	131	49	267	618	60	175	616	42	172	02	18	03
gvP016	221	196	107	354	78	316	347	60	311	07	18	05
Gicj016	244	50	235	339	159	140	339	159	136	-	-	04
tg016	141	102	330	463	80	113	461	67	113	02	13	-
Rj016	332	88	188	342	54	228	341	53	213	01	01	15

RyB016	134	78	131	267	80	124	261	76	123	06	04	01
AvM÷016	251	97	291	346	77	121	339	74	121	07	03	-
†m†B016	206	95	303	235	85	230	231	78	222	04	07	08
A±vei016	287	108	178	328	108	144	322	89	141	06	19	03
b†f016	466	54	224	197	111	189	196	104	178	01	07	11
W†m016	303	48	101	209	68	355	204	50	355	05	18	-
†gvU	2878	1047	2612	3858	994	2482	3816	885	2427	42	109	55
me†gvU	6537			7334			7128			206		

9.17| 2012 n†Z 2016 mvj chš b†vkbvj K†Uvj j†ve†iUiX, XiKv KZK.cıß bgly cıx†v I †e†kiY Gi Z†bgjK cımsL†v

mvj	cıß JI†ai bgly cıx†v I †e†kiY Gi msL†v
2012	2157
2013	4635
2014	5409
2015	6868
2016	7334




†P† 2012 n†Z 2016 mvj chš b†vkbvj K†Uvj j†ve†iUiX, XiKv KZK.cıß bgly cıx†v I †e†kiYKZ.bglyi Z†bgjK †P†

9.18| †m†Uvj W†M †U†÷s j†ve†iUiX, P†M†g KZK.cıß bgly Ges cıx†v I †e†kiY সংক্রান্ত †eeiYX

2012 n†Z 2016 mvj chš †m†Uvj W†M †U†÷s j†ve†iUiX, P†M†g KZK.cıß bgly Ges cıx†v I †e†kiY Gi Z†bgjK cımsL†v

cıß bglyi msL†v	cıx†v I †e†kiYKZ.bglyi msL†v	gvb D†Y bglyi msL†v	gvb e†nfZ bglyi msL†v
3145	1509	1492	17

mvj	cvß JI+ai bgly ciXyV I we+kIY Gi msL"v
2012	524
2013	466
2014	1036
2015	2944
2016	1509



২০১২ হতে ২০১৬ সাল পর্যন্ত সেন্ট্রাল ড্রাগ টেস্টিং ল্যাবরেটরী, চট্টগ্রাম কর্তৃক প্রাপ্ত নমুনা এবং পরীক্ষা ও বিশ্লেষণ এর তুলনামূলক চিত্র।

10|Z" AaKvi AvBb Ablyqx mieivnKZ Zt"i weeiYx

ক্রমিক bs	Zt"i Rb" Avte`bKviX bvMii+Ki big I iVKivbv	Avte`Z Zt"i eYbv	Ave`bi ZwiL	Ave`bi Ae`nv	iqZciß KgKZvi mxiSi ieix AvciJ i msL"v	AvciJ ißöüEi msL"v	KZciß KZiK`iqZciß KgKZvi ieix MqZ km`gjK e`vi msL"v
01	Rbvegiuey ig Tv ûgqj dvU bs im-10-02, Avikqiv G`vcvUtgU Kg+c·, 4 ni j tjb, k`vgjx, XvKv	Condom GK cKviContraceptive .The Drugs Act 1940-Gi 3 (11) aviv e+j KbWg Contraceptive we+ePbvq Drugs ei Jla iKbv	07/12/2016	02/01/2017 Zwi+L Z" mgr tciY Kiv n+q+Q			
02	Rbve gimy ivbv Sgy we+kl ciZe`K mvßvinnK Aciva RMZ 65 bq cëb,	1 iRG+ms I iRbmb Drcv`b I evRviRiZKi+Y tKwiq I Piqbvi iRb+mb MvQ ev nvem Ges cy+I ni+iYi gMbvf+(gmKvm) Avg`vbxKviK BDvbvx, Avqjei` I tnvigI ciZôvbmgn তালিকাসহ আমদানী সংক্রান্ত যাবতীয়	22/11/2016	01/12/2016 Zwi+L Z"v tciY Kiv			

ক্রমিক bs	Z ₁ "i Rb" Av ₁ e`bKvix bvMii ₁ Ki bvg I vKv ₁ bv	Av ₁ e ₁ `Z Z ₁ "i eYbv	Ave`bi ZwiL	Ave`bi Ae`n	`mqZcvi ₁ KgKZi ₁ mxi ₁ Si ieix Av ₁ cj ₁ i mSL`v	Av <sub>1</sub> cj <sub>1</sub> ib <sub>1</sub> ui <sub>1</sub> Ei <sub>1</sub> mSL`v	KZ ₁ c ₁ y KZ ₁ K ₁ `mqZcvi <sub>1</sub> KgKZi <sub>1</sub> ieix MpiZ k <sub>1</sub> m <sub>1</sub> g <sub>1</sub> f <sub>1</sub> K e <sub>1</sub> "e <sub>1</sub> "i mSL`v
	6ôZj _v , XvKv-1000	Z ₁ "v ₁ "`   2  tiK <sub>1</sub> Ud <sub>1</sub> vBW i <sub>1</sub> u <sub>1</sub> iU ev A <sub>1</sub> vj <sub>1</sub> Kv <sub>1</sub> nj Avg <sub>1</sub> `v ₁ b ₁ Kv ₁ iK tn ₁ vigI Jla Drcv ₁ bKv ₁ ix c ₁ u ₁ Zô ₁ bm ₁ g ₁ #ni Z ₁ v ₁ jK ₁ v Ges 2014- 2015-2016 Bs chš G ₁ v ₁ j ₁ K ₁ nj আমদানী সংক্রান্ত যাবতীয় তথ্যাদি। 3 AvBw ₁ c, #P ₁ i ₁ Li gjg I A ₁ qb ₁ g ₁ vU Drcv ₁ `b I e <sub>1</sub> vR <sub>1</sub> v <sub>1</sub> R <sub>1</sub> vZK <sub>1</sub> i <sub>1</sub> b Ab <sub>1</sub> g <sub>1</sub> v`b c ₁ v ₁ β BD ₁ b ₁ v ₁ x, Av ₁ q ₁ te ₁ " I tn ₁ vigI c ₁ u ₁ Zô ₁ bm ₁ g ₁ #ni Z ₁ v ₁ jK ₁ v ₁ m ₁ n D ₁ ³ c ₁ `m <sub>1</sub> g <sub>1</sub> #ni Z <sub>1</sub> v <sub>1</sub> jK <sub>1</sub> v <sub>1</sub> m <sub>1</sub> n D <sub>1</sub> <sup>3</sup> c <sub>1</sub> `m ₁ g ₁ #ni e ₁ v ₁ b ₁ R ₁ "K b ₁ v ₁ gi Z ₁ "v ₁ "`   4  BD <sub>1</sub> b <sub>1</sub> v <sub>1</sub> x, Av <sub>1</sub> q <sub>1</sub> te <sub>1</sub> " I tn <sub>1</sub> vigI JI <sub>1</sub> ai ib <sub>1</sub> †`kK g ₁ †" ib ₁ avi ₁ †bi Rb" i ₁ e ₁ †eP" iel ₁ †qi Z ₁ "v ₁ "`   5  i ₁ e ₁ †fb A ₁ †f ₁ †h ₁ v ₁ †M m ₁ vg ₁ i ₁ q ₁ K j ₁ v ₁ B ₁ †m ₁ Y e ₁ v ₁ z ₁ j ₁ K ₁ Z BD ₁ b ₁ v ₁ x, Av ₁ q ₁ te ₁ " I tn ₁ vigI Jla K ₁ u ₁ v ₁ b ₁ i Z ₁ v ₁ jK ₁ v I m ₁ vg ₁ i ₁ q ₁ K e ₁ v ₁ z ₁ j ₁ K ₁ Z.JI ₁ ai c ₁ `m <sub>1</sub> g <sub>1</sub> #ni Z <sub>1</sub> "v <sub>1</sub> "`		n ₁ †j W ₁ v ₁ K ₁ U †diZ Av ₁ †m			
03	Rbve g ₁ ine ₁ y i ₁ gT ₁ v ûg ₁ vq ₁ † dvU bs-i ₁ m-10- 02, Av ₁ kq ₁ v ₁ b G ₁ "vc ₁ vU†g ₁ U Kg†c ₁ ·, 4 n ₁ ij †jb, k ₁ "vg ₁ i ₁ j, XvKv- 1207	Jla ck ₁ vmb A ₁ ia`Bi KZ <sub>1</sub> K †i <sub>1</sub> R <sub>1</sub> †÷kb †`qv Avg ₁ `v <sub>1</sub> bKZ.JI <sub>1</sub> ai Z <sub>1</sub> v <sub>1</sub> jK <sub>1</sub> v  Jla ck <sub>1</sub> vmb A <sub>1</sub> ia`Bi KZ ₁ K a ₁ ihKZ. Avg ₁ `v ₁ bKZ.JI ₁ ai Z ₁ v ₁ jK ₁ v g ₁ k ₁ v ib ₁ †b e ₁ "eüZ g ₁ k ₁ v b ₁ vkK †u ₁ I K ₁ †qj The DrugAct 1940 Gi (iii) a ₁ v ₁ i ₁ v †g ₁ vZ ₁ v†eK W ₁ M i ₁ Kb ₁ v? DK ₁ z ib ₁ †b e ₁ "eüZ k ₁ "v ₁ u ₁ y ₁ b ₁ vgK Zi ₁ j c ₁ Y The DrugAct 1940 Gi (iii) a ₁ v ₁ i ₁ v †g ₁ vZ ₁ v†eK W ₁ M i ₁ Kb ₁ v?	18/10/2016	27/11/ 2016 Z ₁ v ₁ i ₁ †L Z ₁ "v ₁ "` †ciY K ₁ i ₁ v n ₁ †q ₁ †Q			

ক্রমিক bs	Z`_i Rb` Av`e`bKix bvMii`Ki bvg I vKvibv	Av`e`Z Z`_i eYbv	Ave`bi ZwiL	Ave`bi Ae`n	`wqZvib KgKZi i mxi`si ieix Avci j i mSL`v	Avci j ib`uEi mSL`v	KZic`y KZK` wqZvib KgKZi i ieix MpiZ k`w`gfk e`e`vi mSL`v
04	Rbve `gvt gvnvegy` ingvb 82/2 `yY kvnRvnbcy, XvKv	1. Wv<sup>3</sup>viMY Jla tKvauvbx t`K A`biZK সুবিধা নিয়ে রোগীর প্রেসক্রিপশনে যে ঔষধ `jLb Zvi 50 fvMB A`cv`qRbxq  Jla tKvauvbx,`j (tgnW`Kj `i`c`Rb`U`f) Gi gva`g wecy` ci`igvY A_ Wv³vi`i `cQ`b e`q K`i _v`Kb  Wv³রোগ রোগীর প্রেসক্রিপসনে ঔষধের tR`b`iK bvg bv `jL tKvauvbx i c`i`vPbvq Jla tKvauvbx i c`E` evU bvg `jL _v`Kb Jla tKvauvbx I Wv<sup>3</sup>vi`i GB ai`bi `b`Zi gvm`y `t`Q t`K i 17 tKvU RbMY D`jLZ `b`Z c`Zi`v`a Jla ckmb A`a`Bi `K ai`bi e`e`v `b`q`Q Zvi Z_` t`c`Z t`P`q`Qb </p> <p>2. 2016 mv`j tKvb tKvb tKvauv`b Jl`ai `vg evov`bvi c`ve Jla ckmb A`a`B`i cvViq, tm me tKvauv`bi bvg, Jl`ai bvg, g`j` eixi Av`e`b c`i ev c`ve c`i`i Qvq`j`ic 3. Jla ckmb A`a`B`i i tUK`bK`v`j K`igvUi m`m`f`i bvg, c`ex, g`j` eixi c`v`e`i `i`c`vU, tUK`bK`v`j K`igvUi M`e`lYv I we`kIY I g`j`v`qY Gi Z_` Ges Jla ckvm`bi cBm`dK`kmb K`igvUi m`m`f`i bvg, c`ex, K`igvUi mfvi Kvh`eeiYx I g`j` eixi Ab`g`v`b `t`q`Q Zv`vi e`vL`v mn Z_` (2016 mv`j`i) 4. Jla tKvauvbx i g`j` eixi c`ve Ab`g`v`b `t`Z Jla ckmb A`a`B`i i cvBR`dK`kmb K`igvU I tUK`bK`v`j K`igvUi m`m`iv A`ea t`j`b`t`bi gva`g Jl`ai g`j` eixi c`ve Ab`g`v`b দিয়েছে, এই সংক্রান্ত দুর্নীতির msev` MYgva`g cK`v`kZ n`q`Q, Bnvi mZ`Zv সংক্রান্ত তথ্য। ৫. চিকিৎসকগণকে রোগীদের প্রেসক্রিপসনে Jl`ai tR`b`iK bvg `jL`Z eva` Kiv n`te `K bv Ges tKvauvbx i c`E` evU bvg `b`l`x K`i Wv<sup>3</sup>vi I tKvauvbx i `b`Z eU Ki`Z e`e`v MnY Kiv n`te `K bv Zv`vi Z_` 6. tKvb tKvb Jla tKvauvbx, Jla	22/10/2016	Av`e`b Kvix Z_` A`a`Kvi AvBb- 2009 Gi `bav`iZ dig-K h_vh_ fv`e c`Y K`i Av`e`b K`i`b`b `eavq Z`K 30/10/ 2016 Z`wi`L h_vh_ fv`e `bav`iZ dig-K c`Y ceK Av`e`b Ki`Z ejv nq			


ক্রমিক bs	Z`_“i Rb” Avte`bKvix bvMii`Ki bvg I vKvibv	Avte`Z Z`_“i eybv	Ave`bi ZwiL	Ave`bi Ae`m	`mqZciB KgKZvi m`x`Si ieix Avci`ji mSL`v	Avci`j ib`u`Ei mSL`v	KZcy` KZK` KgKZvi ieix` MpxZ k`m`g`jK e`e`vi mSL`v											
		<p>ckymb Awa`Bi t`_#K Drcv`b I ecY`bi Abjgv`b`b`q` t`fRvj I gvbnxb Jla Drcv`b I ecYb Ki`Q tmB me JI`tai bvg, t`Kvau`vbx`i bvgmn Z`_` </p> <p>7. miKvii Av`k`#k 117 uU JI`tai 60 fvM Jla, t`Kvau`vbx`i`j`vi Drcv`b eva`ZvgjK n`lqv m`E`I t`Kvb t`Kvb Kau`vb miKvii Av`k`gvb`Q`bv, H me t`Kvau`vbi bvg, JI`tai bvgmn Z`_` miKvix Av`k`Agvb`Kvix t`Kvau`vbx`i ie`i`x` Jla ckymb Awa`Bi`K ai`bi AvBbMZ e`e`v`b`q`Q`Zvi Z`_` </p> <p>8. 2016 m`j`JI`tai g`j`e`ix`i`b`i` QK tgvZi`eK Z`_`t</p> <table><tr><td>b s</td><td>JI`tai i t`R`b`i iK bvg</td><td>JI`tai t`Kvau`v b`c`E` e`v`U` bvg</td><td>c`e` JI`tai ai g`j`</td><td>Abjgv`Z e`ix`ciB JI`tai g`j`</td><td>kZK iv e`ix`i mvi</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td></tr></table>	b s	JI`tai i t`R`b`i iK bvg	JI`tai t`Kvau`v b`c`E` e`v`U` bvg	c`e` JI`tai ai g`j`	Abjgv`Z e`ix`ciB JI`tai g`j`	kZK iv e`ix`i mvi										
b s	JI`tai i t`R`b`i iK bvg	JI`tai t`Kvau`v b`c`E` e`v`U` bvg	c`e` JI`tai ai g`j`	Abjgv`Z e`ix`ciB JI`tai g`j`	kZK iv e`ix`i mvi													
05	Rbve Awgb`y ingib ev`kv mmbqi ÷vd i`c`v`U`vi %`b`K`k` ³ , 3/3- m weRq bMi, 4_ Zjv, c`eb XvKv	271 tgmvm d`w`g`K j`v`e`i`U`ixR (P`E`Mvg) Gi Rb`j`M t`_#K G hveZKvj th mKj Jlamg`n`b`g`v`b`i e`j` ie`e`i`PZ n`q`Q`tm me JI`tai mve- ÷`v`U`v`W i`c`v`U`i Kic`D` <sup>3</sup> t`Kvau`vbi ie`i`x`c`i`P`v`j`Z tgvvBj t`Kv`U`i we`i`Y Ges MpxZ e`e`v`i Z`_`, me`k`l`th mKj mve-÷`v`U`v`W c`m`g`n`c`p`iv`q` Drcv`b I evRv`i`Rv`Zi AbjvZ t`lqv n`q`Q`Zvi th`S` ³ KZvnn Z`_`c`v`b`i Abjiva K`i`i`Q`b	19/04/2016	29/06/ 2016 Z`w`i`L Z`_`v` t`c`i`Y Kiv n`q`Q`														
06	Rbve Awgb`y ingib ev`kv mmbqi ÷vd i`c`v`U`vi %`b`K`k` ³ , 3/3- m weRq bMi, 4_ Zjv, c`eb XvKv	267 tgmvm Bvgx` evsjv`k` (Av`g`e`K) bvgx`c`i`Z`o`v`b`i Drcv`Z`I evRv`i`Rv`ZKZ.t`d`q`vi G`U`n`v`U`mvg bfiZ ^Zj, Sv`U`g`Ges t`e`v`i`v`c`v`m bvgK ক্রীমের অনুমোদিত রিসাইপি, এনেজার, t`j`e`j`Kv`U`b`i P`o`v`S`Abjgv`b`K`ic`mn ie`A`v`b`c`P`v`i`i`Abjgv`b`K`ic`hv`Jla ckymb Awa`Bi`KZK.c`v`b`Kiv n`q`Q`	22/03/2016	09/06/ 2016 Z`w`i`L Z`_`v` t`c`i`Y Kiv n`q`Q`														

ক্রমিক bs	Z`i Rb` Av`e`bKix bMi`Ki bvg I vKv	Av`e`Z Z`i eYv	Ave`bi ZwiL	Ave`bi Ae`n	`mqZcib KgKZi mxi` ieix Avci j i mSL`y	Avci j ib`uEi mSL`y	KZic`y KZK` KgKZi ieix MpiZ k`g`g`e`e`vi mSL`y
07	Rbve Rvjvj D`ib tR`u`mBb, cU-9, eK-GBP, tmKkb-2, `gicy, XvKv	1.Total production of paracetamol Bulk (API) of 2014 2.Approved MRP at present (of paracetamol API)	28/02/2016	07/03/ 2016 Zwi`L B- tgB`ji gva`g tciY Kiv n`q`Q			
08	Wt kigôv ivq 2/G, `e`is bs-9, tiW-3, eK-`W, ebkx, ivgc`y, XvKv	tciZ Zwi`Kv tgvZ`eK JI`ai কাঁচামালের মূল্য সংক্রান্ত তথ্য।	31/01/2016	14/02/ 2016 Zwi`L Z`v` tciY Kiv n`q`Q			
09	Rbve AveyeKi `mi`K, 72/3 e`vsK K`jvbx, mvfvi, XvKv	g`ve`Kv dvgv`mD`UK`vjm (BDvbx), tngv`qZc`y, mvfvi, XvKv bvgxq c`Zôv`bi jvB`m`Y nvjbv`Mv` Kiv n`q`Q `K? c`Zôv`U Avev`mK bv `kí GjvKvq Ae`Z? c`Zôv`Ui c`i`ek A`a`Bi I dvqvi jvB`m`Yi Kic  KviLvYv`U`Z Drcv`tb e`eüZ tgvk`bi weeiY KviLv`U`Z KZRb tKig÷ Av`Q, Zv`i `kyv mb`i d`UvKic  KviLv`Ui ti`R÷`W JI`ai Zwi`Kv	14/01/2016	20/01/ 2016 Zwi`L Z`v` tciY Kiv n`q`Q			
	Rbve gvt ia`uj Avigb, mfvic`Z, Uv`vBj tRjv tcmKve, Uv`vBj	ঢাকা জেলার ড্রাগ লাইসেন্স সংক্রান্ত Z`	30/10/16	13/11/1 6 Zwi`L Z`v` tciY Kiv n`q`Q			


11|evsjv`k`i JIa iBvbt

eZgv`b t`k`A v`jvc`v`K-266 `U, BDvbx-267 `U, Avqte`K-207 `U, tnviglc`v`K-79 `U I nvevj-32 `U, tgvU
851 `U Abtg`v`Z JIa Drcv`bKix c`Zôv`b i`q`Q | GmKj c`Zôv`b 2833 tR`bi`Ki 38473 ev`Ui JIa I
মেডিকেল ডিভাইস উৎপাদন করছে। দেশে একলক্ষ পঁচিশ হাজার লাইসেন্সধারী ঔষধ বিক্রয়কারী প্রতিষ্ঠান (ফার্মেসী)
i`q`Q|eZgv`b t`k`20 nvRvi tKvU UvKvi JI`ai gv`KU i`q`Q| t`k`Drcv`Z JIa v`iv t`k`i P`v`vi 98%
`gUv`bv m`e n`Q|54`U c`Zôv`b JIa `bqigZ iBv`b Ki`Q| evsjv`k`n`Z Av`g`iKv I BD`ivcmn 127`U t`k`JIa
iBv`b Kiv n`Q| t`k`DbZ chy`i cvq mKj ai`Yi I `Wv`Rm d`gi JIa Drcv`b Kiv n`Q| iBv`bKix t`k`i
msL`v I iBv`bxi c`igv`b mg`qi mv`_ mv`\_ e`x cv`Q| 2016 mv`j JIa iBv`b Kiv n`q`Q cvq 23 kZ tKvU UvKv|

এসজিএক মিকি KZK.নন/10 Thrust Sector-Gi গা এসজিএকি জা কী GKU| জা কীি কেKk Ges mgxi mv_ এসজিএক জা Avg`বKvix ত`ক ন`Z iBvBKvix ত`ক ciiYZ ন`q`Q| ত`Kxq Drcv`Z JI`ai gva`g ত`কি gvb`i Pwin`v gUv`b mae nIq`q JIa Avg`vbi wecy c`igvY `e`kk g`v m`kq n`Q| ত`কি জা কী R`Wc e`xi gva`g k`iqb I `vi `e`g`p`b , i`Zc`f`gKv i`L`Q| GQ`ovl G k`i`i gva`g wecy Kgms`v`bi m`p n`Q|



২০০৫ ন`Z ২০১৬ চ`হ জা iBvxi Z`b`g`K P`



২০১৬ ম`জ জা iBvxi Rb` Bm`Z.CPP (Certificate of Pharmaceutical Product), iBvxi jvB`m`Y Form-10 A, GMP (Good Manufacturing Practices) m`Ud`KU, FSC (Free Sale Certificate) Gi c`imsL`vbt

Bm`Z. CPP (Certificate of Pharmaceutical Product),	Bm`Z. FSC (Free Sale Certificate)	Bm`Z iBvxi jvB`m`Y Form-10 A	Bm`Z. GMP (Good Manufacturing Practices) m`Ud`KU
5249U	1102U	1217U	41U

১২| জা ckvmb Aia`B`i`i g`be m`u` DbqY কার্যক্রম :

cik`Y Kgk`jv (t`k)

ক্রমিক সংখ্যা	কর্ম/প্রকল্পের নাম	মুদ্রিত/প্রকাশিত তারিখ	ডকুমেন্টের নাম	মন্তব্য/সংস্থা	অন্যান্য তথ্য
1.	Office Automation for Organizational Development সংক্রান্ত কর্মসূচী	10/01/2016 ১০/০১/২০১৬	Jla ckmb Aia`Bi	NAPD	1 Dc ciiPvjK-1 Rb 2 mnKvix ciiPvjK-1 Rb 3 mnKvix jvBtmYs Amdmvi-1 Rb 4 Jla ZEvavqK -3 Rb #gvU=06 Rb
2.	Jla c-ZKvix cizôvb পরিদর্শন সংক্রান্ত প্রশিক্ষণ	16/01/2016 ১৬/০১/২০১৬	Jla ckmb Aia`Bi	MSH/ SIAPS	Dc-ciiPvjK=01 Rb mnKvix ciiPvjK=01 Rb mnKvix jvBtmYs Amdmvi-01Rb Jla ZEvavqK=03 Rb #gvU=06 Rb
3.	Jla c-ZKvix cizôvb পরিদর্শন সংক্রান্ত প্রশিক্ষণ	23/01/2016 ২৩/০১/২০১৬	Jla ckmb Aia`Bi	MSH/ SIAPS	Dc-ciiPvjK=01 Rb mnKvix ciiPvjK=01 Rb Jla ZEvavqK=04 Rb #gvU=06 Rb
4.	Jla c-ZKvix cizôvb পরিদর্শন সংক্রান্ত প্রশিক্ষণ	23/01/2016 ২৩/০১/২০১৬	Jla ckmb Aia`Bi	MSH/ SIAPS	Dc-ciiPvjK=01 Rb mnKvix ciiPvjK=01 Rb mnKvix jvBtmYs Amdmvi-01Rb Jla ZEvavqK=03 Rb #gvU=06 Rb
5.	Jla c-ZKvix cizôvb cii`kb সংক্রান্ত প্রশিক্ষণ	30/01/2016 ৩০/০১/২০১৬	Jla ckmb Aia`Bi	MSH/ SIAPS	Dc-ciiPvjK=01 Rb mnKvix ciiPvjK=01 Rb Jla ZEvavqK=04 Rb #gvU=06 Rb
6.	Jla c-ZKvix cizôvb পরিদর্শন সংক্রান্ত প্রশিক্ষণ	30/01/2016 ৩০/০১/২০১৬	Jla ckmb Aia`Bi	MSH/ SIAPS	mnKvix ciiPvjK=02 Rb mnKvix jvBtmYs Amdmvi-01Rb Jla ZEvavqK=03 Rb #gvU=06 Rb
7.	Jla c-ZKvix cizôvb পরিদর্শন সংক্রান্ত প্রশিক্ষণ	06/02/2016 ০৬/০২/২০১৬	Jla ckmb Aia`Bi	MSH/ SIAPS	mnKvix ciiPvjK=01 Rb Jla ZEvavqK=04 Rb #gvU=05 Rb
8.	Gender, Equity and Human Rights kxIK কর্মসূচী KgmP	24-28/01/2016 ২৪-২৮/০১/২০১৬	Jla ckmb Aia`Bi	HPNSDP	1 Rbre tgrt AvBqg trn#mb, mnKvix ciiPvjK 2 Rbre tgrn#mb bvcg tMvj`vi mnKvix jvBtmYs Amdmvi, #gvU=02 Rb

ক্রমিক সংখ্যা	ক্রিয়াকর্মের বিবরণ	মুদ্রিত তারিখ	ডায়েরী নং	মহামন্ত্রীর স্বাক্ষর	অনুমোদিত কর্তৃপক্ষের স্বাক্ষর
9.	Jla c ⁻ ZKvix c ⁱ Zôvb পরিদর্শন সংক্রান্ত প্রশিক্ষণ	06/02/2016 †gmvm G ⁱ i†÷vdvgt ‖jt	Jla ckymb A ⁱ a`Bi	MSH/ SIAPS	mnKvix c ⁱ iPvjK=01 Rb mnKvix jvB†m ⁱ Ýs A ⁱ dmvi- 01Rb Jla ZËveavqK=04 Rb †gvU=06 Rb
10.	Training on Pharmadex	8-9 †de:qvix, 2016	Jla ckymb A ⁱ a`Bi	MSH/ SIAPS	Dc-c ⁱ iPvjK=05 Rb mnKvix c ⁱ iPvjK=06 Rb †g ⁱ W†Kj A ⁱ dmvi-01Rb Jla ZËveavqK=07 Rb †gvU=19 Rb
11.	Intensive Training on Common Technical Documents (CTD)	18-20 †de:qvix, 2016	Jla ckymb A ⁱ a`Bi	MSH/ SIAPS	Dc-c ⁱ iPvjK=05 Rb mnKvix c ⁱ iPvjK=06 Rb †g ⁱ W†Kj A ⁱ dmvi-01Rb Jla ZËveavqK=07 Rb †gvU=19 Rb
12.	CTD / Pharmadex Practice-Gi Rb Hands on Training	23,28 I 31†k gvP Ges 6B G ⁱ cj	Jla ckymb A ⁱ a`Bi	MSH/ SIAPS	1 c <sup>i</sup> iPvjK -1 Rb 2 c <sup>i</sup> iPvjK(Pt`vt)- 1 Rb 3 Dc c ⁱ iPvjK- 4 Rb 4 mnKvix c ⁱ iPvjK- 6 Rb 5 †g ⁱ W†Kj A ⁱ dmvi - 1 Rb 6 mnKvix jvB†m ⁱ Ýs A ⁱ dmvi- 1 Rb 7 Jla ZËveavqK- 8 Rb †gvU=22 Rb
13.	Local training on Bio- pharmaceutics & Regulatory affairs management: 1.Registration Procedure of Bio- pharmaceutics	02-04Vv †g, 2016, †nv†Uj †jk†kvi, †jkvb-2, XvKv	Jla ckymb A ⁱ a`Bi	KOICA	1 c <sup>i</sup> iPvjK(Pt`vt)- 1 Rb 2 Dc c ⁱ iPvjK- 3 Rb 3 mnKvix c ⁱ iPvjK - 3 Rb 4 Jla ZËveavqK- 3 Rb †gvU=10 Rb
	Local training on Bio- pharmaceutics & Regulatory affairs management: 2. GMP Inspection of Bio-pharmaceutics	02 I 04Vv †g, 2016, †nv†Uj †jk†kvi, †jkvb-2, XvKv 3iv †g-†gmvm Bb†mPv f`vKimb ‖jt, avgivB			1 Dc c ⁱ iPvjK- 1 Rb 2 mnKvix c ⁱ iPvjK- 2 Rb 3 mnKvix jvB†m ⁱ Ýs A ⁱ dmvi- 1 Rb 5 Jla ZËveavqK- 6 Rb †gvU=10 Rb

ক্রমিক bs	চিকিৎসা ইলেক্ট্রনিক্স	মগকজি ই-ব	ডাঃ ব্রজ	মহামন্ত্র চিহ্ন	AskMnYKix KgKZ/KgPxi`i msL`v
14.	Central-Human Resource Information System Develop সংক্রান্ত Hands-on Training	04-05B তগ, 2016, GgA/BGm, এআইবি	এইচআই কজিগসইজ		1 DcciiPjK- 1 Rb 2 mnKix ciiPjK-2 Rb 3 Jla ZĖeavqK-1 Rb †gvU=04 Rb
15.	Impacts of Harmful Drugs on Vultures ক/ক চিকিৎসা কগকজি	10B তগ, 2016	International Union for Conservation of Nature (IUCN), Bangladesh		1 mnKix ciiPjK- 1 Rb 2 Jla ZĖeavqK-4 Rb †gvU=05 Rb
16.	Certificate of European গুণের Conformity Assessment ইলেক্ট্রনিক্স কগকজি	18B গুণের, 2016 বিক্রয় কপুজ জিইউই	Jla ckymb এআইবি		ciiPjK-01 Rb ciiPjK(Pt`vt)-01 Rb Dc-ciiPjK=04 Rb mnKix ciiPjK=06 Rb mnKix jvB†mĤs AmdmĤ- 01Rb Jla ZĖeavqK=09 Rb †gvU=22 Rb
17.	Total Quality Management ক/ক কগকজি	12B তগ, 2016 RvZxq ciiKíbv I Dbqb GK†Wgx	RvZxq ciiKíbv I Dbqb GK†Wgx, ciiKíbv gšYvjg		1 DcciiPjK- 1 Rb †gvU=01 Rb
18.	Public Private Partnership (PPP) in HPN Sector: Existing situation and future prospects ক/ক চিকিৎসা কগকজি	15-22†k তগ, 2016 এআইবি BDibU	এআইবি BDibU, এইচআই কজিগসইজ		1 Jla ZĖeavqK- 1 Rb †gvU=01 Rb
19.	AvĤK eĖĖcbv I AĤWU সংক্রান্ত প্রশিক্ষণ কর্মশালা	24-26†k তগ, 2016 GgA/BGm, এআইবি	AvĤK eĖĖcbv I AĤWU BDibU, এইচআই কজিগসইজ		1 Dc-ciiPjK I DPM,SDAM- 1 Rb 2 Ĥmve iĤY KgKZ(Pt`vt)- 1 Rb †gvU=02 Rb
20.	Orientation Program for the Newly Appointed Officers of DGDA	29†g-26†k R†, 2016	Jla ckymb এআইবি		1 Jla ZĖeavqK-9 Rb †gvU=09 Rb
21.	Orientation Program for the Newly Appointed Officers of DGDA	AĤ÷, 2016	Jla ckymb এআইবি		†gvU=13 Rb

ক্রমিক bs	চিকিৎসা ইলেক্ট্রনিক্স	মগ্নকর্মে ই-ব	ডাঃ ব্রজ	মহামন্ত্র চিহ্ন	AskMnYKvix KgKZv/KgPviX`i msL`v
22.	Jla ckymb Awa`Bi W`vK`evW WvUv Bbcy সংক্রান্ত প্রশিক্ষণ কর্মশালা	04 A`vei, 2016	Jla ckymb Awa`Bi	W`v Awa`Bi DHIS-2 cKí	1 mnKvix jvB`mYs Awdmvi- 01Rb 2  Jla Z`EveavqK-4 Rb `gvU=05 Rb
23.	Leadership Program for senior officials of the government	18-20 A`vei, 2016	W`v I c`ievi Kj`vY gS`vjq		1 Dc c`iPvjK-01Rb 2  mnKvix c`iPvjK-02Rb `gvU=03 Rb
		25-27`k A`vei, 2017			1 W`cyU Pxd, b`vkbvj K`Uvj j`ve`iUix-01Rb 2  ev`q`Kig÷, b`vkbvj K`Uvj j`ve`iUix-01Rb 3  mnKvix cawb, Ges miKvix we`kIK, b`vkbvj K`Uvj j`ve`iUix-02Rb `gvU=04 Rb
		22-24`k A`vei, 2017			1 c`iPvjK(Pt`vt) -02Rb 2 Dc c`iPvjK-01Rb 3  mnKvix c`iPvjK -01Rb `gvU=4 Rb
		23-27 `k A`vei, 2016	Jla ckymb Awa`Bi	WHO	1 Dc c`iPvjK-02Rb 2  c`iPvjK, tm`Uvj Wm tU÷s j`ve`iUix, PEMvg-01Rb 3  mnKvix c`iPvjK- 07Rb 4 mnKvix jvB`mYs Awdmvi- 01Rb 12  Jla Z`EveavqK-09Rb `gvU=20 Rb AeRvfit 1  c`iPvjK -01Rb 2 c`iPvjK (Pt`vt)-02Rb 3 Dcc`iPvjK- 01Rb 4  Jla Z`EveavqK-06Rb `gvU=10 Rb
24.	WHO Basic in-country Workshop on Good Manufacturing Practice Regulatory Inspection using the Quality Risk Management Approach	14 I 17 b`fai, 2016	Jla ckymb Awa`Bi	MSH/ SIAPS	1 Jla Z`EveavqK- 01Rb `gvU= 01 Rb
25.	TOT on orientation of A grade pharmacists	23-24`k b`fai, 2016	c`iKíbr Kigkb		1 Dc c`iPvjK- 01Rb 2  Jla Z`EveavqK- 02Rb `gvU=03 Rb

ক্রমিক সংখ্যা	বিবরণ	স্থান / তারিখ	সংগঠন	সংক্রান্ত নথি
4.	Workshop on “The Designing Implementation Strategy for Accredited Drug Seller Model in Bangladesh”	Tanzania 14-18B গুপ, 2016	MSH/SIAPS	ciiPvjK-01 Rb Dc-ciiPvjK-01 Rb mnKvix ciiPvjK-01 Rb Jla ZËveaqK-01 Rb #gvU=04 Rb
5.	Workshop on “Joint Working Committee (JWC) for Health Care and Medical Services”	Maldives 30-31#k গুপ, 2016	WHO	ciiPvjK-01 Rb #gvU=01 Rb
6.	Board Meeting on “South Asia Regional Anti-Doping Organization (SARADO)”	Maldives 13B গুপ, 2016	WHO	gnvciiPvjK #gvU=01 Rb
7.	Visit to Sri-lankawith Delegates.	Sri-lanka 02-05B #g, 2016	WHO	gnvciiPvjK #gvU=01 Rb
8.	Fellowship Program on “Capacity Building Program for national Lot Release of Biologics”	Korea 12-27#k #g, 2016	Ministry of Food and Drug Safety (MFDS) & KOICA	mnKvix ciiPvjK-01 Rb Jla cii`kK -01 Rb #gvU=02 Rb
9.	Workshop on “Pharmacovigilance-the Study of Adverse Drug Reactions and Related Problems”	Uppsala, Sweden 16-27#k #g, 2016	MSH/SIAPS	#gW#Kj A#dmvi -01 Rb mnKvix jvB#mYs A#dmvi -01 Rb #gvU=02 Rb
10.	WHO Workshop on Sensitization Towards Quality Management Systems (QMS) for National Regulatory Authorities (NRA)	Thailand 13-17B R#y, 2016	WHO	ciiPvjK (PjiZ`wqZ)- 01 Rb #Wcy#Px d -01 Rb #gvU=02 Rb
11.	Visit to “Hangzhou Rongda Pharmaceuticals Co. Ltd, China” for Source Validation	China 19-26#k R#y, 2016	Beacon Pharmaceuticals Ltd, Bangladesh	Dc-ciiPvjK-01 Rb mnKvix ciiPvjK-01 Rb #gvU=02 Rb
12.	WHO Workshop on implementation of recommendations to assure the quality, safety and efficacy of recombinant human papilloma virus-like particle vaccines	Thailand 12-14R#yB, 2016	WHO	ev#q#Kig÷-01 Rb #gvU=01 Rb
13.	Global Antibiotics Resistance Partnership in Bangladesh and Pakistan	Nepal 14-15 R#yB, 2016	WHO	gnvciiPvjK #gvU=01 Rb
14.	Workshop on “Pharmaceutical Safety & Regulatory Affairs Management”	South Korea 25#k A#M÷ - 7B #m#P#aj, 2016	KOICA	gnvciiPvjK--01 Rb Dc-ciiPvjK-01 Rb mnKvix ciiPvjK-03 Rb Jla ZËveaqK-10 Rb #gvU=15 Rb
15.	Joint regional workshop on the surveillance and monitoring of substandard,	Indonesia 10-12 A#±#ei, 2016	WHO	mnKvix ciiPvjK-01 Rb e`vK#Uii j#R÷-01 Rb Jla ZËveaqK-01 Rb

ক্রমিক সংখ্যা	বিষয়	স্থান ও তারিখ	সংগঠন	সংক্রান্ত নথি
	spurious, falsely-labeled, falsified, counterfeit (SSFFC) medical products			#gU=03 Rb
16.	WHO Implementation workshop on the Quality, Safety and Efficacy of Typhoid Conjugate Vaccine	<u>Indonesia</u> 8-10 b†fai, 2016	WHO	c‖iPvjK (Pj‖Z`‖qZ)- 01 Rb #gU=01 Rb
17.	Workshop on Pharmaceutical Quality by Design: A risk based approach	<u>India</u> 07-17 b†fai, 2016	WHO	mnKvix jvB†m‖Ys A‖dm‖i -01 Rb Jla ZÈvearqK-01 Rb #gU=02 Rb
18.	Workshop on Implementation of Recommendations to assure the Quality, Safety and Efficacy of Recombinant Human Papilloma Virus-Like Particle Vaccine	<u>China</u> 15-17 b†fai, 2016	WHO	G‖mm†U‖U Pxd, dvgv†KvjRx GÜ Mft Gb‖j ÷-01 Rb #gU=01 Rb
19.	First WHO Interregional Workshop on Quality of Traditional and Complementary Medicine (TCM) service	<u>Macao, SAR, China</u> 25-27 b†fai, 2016	WHO	mnKvix c‖iPvjK-01 Rb #gU=01 Rb
20.	Sixth Annual Saving Asia's Vultures from Extinction (SAVE) consortium meeting	<u>INDIA</u> 27-28b†fai, 2016		c‖iPvjK (Pj‖Z`‖qZ)- 01 Rb #gU=01 Rb
21.	17 th International Conference of Drug Regulatory Authorities (ICDAR)	<u>South Africa</u> 27b†fai †_†K 02iv ‖W†m‖i	WHO	gn‖c‖iPvjK #gU=01 Rb

13|Jl†ai ‖bivcÈv (Safety) I dvgv†K‖f‖Rj`‖Y t evsj†`k †cyvcU

figKv t ‖ek ‖v`ms ‖v (WHO) Gi g†Z- òdvgv†K‖f‖Rj`‖YÓ nj Jl†ai ‖ei‖ প্রতিক্রিয়া /ঔষধ সংশ্লিষ্ট কোন সমস্যা ‖P‖Y‖ZKiY, ‖baviY, Dcj‖äKiY/Ab‖web I ‖beviY ev c‖Z†iva সংশ্লিষ্ট বিজ্ঞান এবং কার্যক্রম।” ঔষধের নিরাপত্তা (Safety) ‖eav†b Gi ,i‖Z Ac‖imxg| 1960 mv†j ‖P‖Y‖Z e‖j e`eüZ Jla Thalidomide Gi g‖ivZK ‖ei‖c প্রতিক্রিয়ায় জন্ম নেওয়া অসংখ্য বিকলাঙ্গ শিশু বিশ্ব বিবেককে দারুণভাবে নাড়া দেয়, সচেতন হন অনেক ঔষধ উৎপাদন ও e`enviKvixivI| DcKvix G Jla‖Ui GZUv fqsKi ‖ei‖ প্রতিক্রিয়া থাকতে পারে- Av‖e`‖†ii ‖e‖fb av†ci m‖xgZ msL`K evQvB Kiv cvYx I g‖b†li Dci M†eIYvq/cixÿv-‖bixÿvq (Clinical Trial) Gi mgq Zv R‖bv hvq‖b | c‖_exi e†K ‖vq G ÿZ‖U ‖ekevmx†K R‖bv‖b ‖`†q †Mj †h, em‖R`Kf†e Drc‖`Z I evR‖iR‖ZKZ.mKj Jla ব্যবহারকালীন বিরূপ প্রতিক্রিয়া (Adverse Drug Reaction) ‖vK†Z cv†i, hv fqen i‖c †blqvi Av†MB Ab‖ÿÜvb, mbv`3KiY I e`e`‖MnY Ri‖i|

c g c`ȳc t $\overline{ek} \overline{v} \overline{ms} \overline{v}$ (WHO) KZK. $\overline{elq} \overline{U} \overline{ib} \overline{q} \overline{tR} \overline{b} \overline{f} \overline{v} \overline{m} \overline{q} \overline{j} \overline{b} \overline{Av} \overline{j} \overline{P} \overline{b} \overline{K} \overline{iv} \overline{nq} \overline{Ges} \overline{Jl} \overline{ai} \overline{ie} \overline{ic}$
 প্রতিক্রিয়া পর্যবেক্ষণ (Adverse Drug Reaction Monitoring) অর্থাৎ ফার্মাকোভিজিল্যান্স কার্যক্রম পরিচালনার সিদ্ধান্ত
 গৃহীত হয়। ১৯৬৮ সালে সুইডেন এর উপসালা শহরে বিশ্ব স্বাস্থ্য সংস্থা কর্তৃক বিশ্বব্যাপী ফার্মাকোভিজিল্যান্স কার্যক্রমের
 $\overline{mg} \overline{sq} \overline{mvab} \overline{l} \overline{mn} \overline{th} \overline{m} \overline{MZ} \overline{v} \overline{c} \overline{v} \overline{bi} \overline{Rb}$ WHO Collaborating Centre for International Drug Monitoring
 $\overline{vc} \overline{b} \overline{K} \overline{iv} \overline{nq}, \overline{hv} \overline{Uppsala} \overline{Monitoring} \overline{Centre} \overline{(UMC)} \overline{bv} \overline{tg} \overline{c} \overline{w} \overline{i} \overline{PZ} \overline{e} \overline{tki} \overline{c} \overline{w} \overline{U} \overline{t} \overline{k} \overline{WHO}$
 Collaborating Centre $\overline{i} \overline{q} \overline{Q} \overline{U} \overline{MC}$ শুধু বিশ্বব্যাপী ফার্মাকোভিজিল্যান্স কার্যক্রম Collaborate $\overline{K} \overline{i} \overline{v} \overline{K}, \overline{h} \overline{L} \overline{v} \overline{b}$
 $\overline{m} \overline{m} \overline{f} \overline{z} \overline{t} \overline{k} \overline{ms} \overline{L} \overline{v} \overline{eZg} \overline{b} \overline{147} \overline{U} \overline{evs} \overline{j} \overline{v} \overline{k} \overline{120Zg} \overline{c} \overline{y} \overline{m} \overline{m} \overline{t} \overline{k} \overline{m} \overline{m} \overline{te} \overline{Z} \overline{m} \overline{j} \overline{K} \overline{v} \overline{f} \overline{z} \overline{n} \overline{q} \overline{Jl} \overline{ai} \overline{bivc} \overline{Ev}$
 $\overline{eav} \overline{b} \overline{K} \overline{v} \overline{R} \overline{K} \overline{i} \overline{h} \overline{l} \overline{q} \overline{v} \overline{el} \overline{q} \overline{U} \overline{Uppsala} \overline{Report-68} \overline{G} \overline{t} \overline{k} \overline{g} \overline{v} \overline{b} \overline{P} \overline{Imn} \overline{m} \overline{y} \overline{i} \overline{fv} \overline{te} \overline{c} \overline{K} \overline{m} \overline{k} \overline{Z} \overline{c} \overline{P} \overline{m} \overline{i} \overline{Z} \overline{n} \overline{q} \overline{Q} \overline{U}$

c`qRb`qZv tK`vq $\overline{Av} \overline{Q} \overline{W} \overline{M} \overline{m} \overline{Gi} \overline{mv} \overline{B} \overline{W} \overline{M} \overline{m} \overline{Gi} \overline{Ae} \overline{vb} \overline{m} \overline{Z} \overline{ivs} \overline{Jla} \overline{tmeb} \overline{e} \overline{envi} \overline{ii} \overline{t} \overline{y} \overline{t} \overline{I} \overline{ti} \overline{R} \overline{v} \overline{W}$
 $\overline{Pi} \overline{K} \overline{rm} \overline{K} \overline{i} \overline{e} \overline{e} \overline{vc} \overline{I} \overline{Ab} \overline{y} \overline{i} \overline{Y} \overline{Ges} \overline{m} \overline{Z} \overline{K} \overline{Z} \overline{Ae} \overline{j} \overline{ab} \overline{K} \overline{iv} \overline{G} \overline{K} \overline{v} \overline{S} \overline{c} \overline{q} \overline{R} \overline{b} \overline{Clinical} \overline{Trial} \overline{Gi} \overline{ZZ} \overline{x} \overline{q} \overline{td} \overline{R} \overline{(ic-}$
 $\overline{gv} \overline{t} \overline{K} \overline{U} \overline{s}) \overline{ch} \overline{S} \overline{m} \overline{m} \overline{g} \overline{Z} \overline{M} \overline{te} \overline{l} \overline{Y} \overline{v} \overline{q} \overline{Ab} \overline{w} \overline{e} \overline{Z} \overline{v} \overline{K} \overline{Z} \overline{c} \overline{v} \overline{i} \overline{t} \overline{K} \overline{v} \overline{Jl} \overline{ai} \overline{g} \overline{v} \overline{iv} \overline{Z} \overline{K} \overline{S} \overline{y} \overline{K} \overline{i} \overline{el} \overline{q} \overline{U}, \overline{hv} \overline{cie} \overline{Z} \overline{x} \overline{td} \overline{R} \overline{(tc} \overline{v} \overline{v} \overline{g} \overline{v} \overline{t} \overline{K} \overline{U} \overline{s}) - \overline{G} \overline{Ab} \overline{y} \overline{U} \overline{v} \overline{bi} \overline{g} \overline{va} \overline{tg} \overline{L} \overline{y} \overline{R} \overline{c} \overline{v} \overline{l} \overline{q} \overline{v} \overline{m} \overline{ae} \overline{el} \overline{ev} \overline{R} \overline{v} \overline{i} \overline{R} \overline{v} \overline{Z} \overline{K} \overline{Z} \overline{Jla} \overline{tmeb} \overline{e} \overline{envi} \overline{K} \overline{tib} \overline{t} \overline{K} \overline{v} \overline{U} \overline{t} \overline{K} \overline{v} \overline{U} \overline{t} \overline{fv} \overline{z} \overline{v} \overline{hv} \overline{t} \overline{i} \overline{g} \overline{ta} \overline{i} \overline{q} \overline{Q} \overline{b} \overline{ik} \overline{i}, \overline{we} \overline{fb} \overline{eqm} \overline{cy} \overline{el} \overline{l} \overline{g} \overline{m} \overline{j} \overline{v}, \overline{Pregnant} \overline{\&} \overline{Lactating} \overline{mother} \overline{Ges} \overline{G} \overline{K} \overline{w} \overline{ak} \overline{R} \overline{U} \overline{j} \overline{t} \overline{iv} \overline{t} \overline{M}$
 আক্রান্ত রোগী- $\overline{hv} \overline{t} \overline{i} \overline{K} \overline{G} \overline{K} \overline{B} \overline{mv} \overline{t} \overline{K} \overline{q} \overline{K} \overline{c} \overline{K} \overline{v} \overline{i} \overline{Jla} \overline{Mn} \overline{Y} \overline{K} \overline{i} \overline{Z} \overline{nq} \overline{Z} \overline{v} \overline{Q} \overline{v} \overline{ov} \overline{we} \overline{fb} \overline{Lv} \overline{v}, \overline{kv} \overline{i} \overline{m} \overline{i} \overline{K} \overline{l} \overline{ci} \overline{t} \overline{ek} \overline{M} \overline{Z}$
 অবস্থার কারণেও বিরূপ প্রতিক্রিয়া পরিলক্ষিত হতে পারে। সুতরাং কোন্ ঔষধ কখন কার সাথে কিরূপ আচরণ করবে তা
 $\overline{m} \overline{v} \overline{K} \overline{fv} \overline{te} \overline{bi} \overline{z} \overline{c} \overline{Y} \overline{K} \overline{iv} \overline{m} \overline{ae} \overline{ev} \overline{Gi} \overline{Benefit} \overline{/Risk} \overline{Ab} \overline{y} \overline{v} \overline{t} \overline{Z} \overline{h} \overline{v} \overline{g} \overline{f} \overline{v} \overline{q} \overline{Y} \overline{nq} \overline{Post} \overline{Marketing} \overline{Surveillance}$
 ev Pharmacovigilance (PV) $\overline{Gi} \overline{g} \overline{va} \overline{tg} \overline{G} \overline{K} \overline{v} \overline{i} \overline{Y} \overline{dv} \overline{g} \overline{t} \overline{K} \overline{w} \overline{f} \overline{R} \overline{j} \overline{v} \overline{Y} \overline{c} \overline{w} \overline{Z} \overline{U} \overline{t} \overline{k} \overline{i} \overline{Drug} \overline{Regulatory}$
 Authority (NRA) $\overline{Gi} \overline{Ab} \overline{Z} \overline{g} \overline{,} \overline{iz} \overline{c} \overline{y} \overline{G} \overline{K} \overline{U} \overline{K} \overline{v} \overline{R} \overline{hv} \overline{Jla} \overline{l} \overline{t} \overline{iv} \overline{M} \overline{x} \overline{i} \overline{bivc} \overline{Ev} \overline{(Safety)} \overline{Ges} \overline{Jl} \overline{ai} \overline{th} \overline{S} \overline{K}$
 $\overline{e} \overline{envi} \overline{b} \overline{i} \overline{d} \overline{Z} \overline{K} \overline{i} \overline{Z} \overline{Am} \overline{ig} \overline{v} \overline{b} \overline{f} \overline{tg} \overline{K} \overline{v} \overline{iv} \overline{L} \overline{G} \overline{U} \overline{ev} \overline{t} \overline{q} \overline{m} \overline{UK}, \overline{t} \overline{v} \overline{i} \overline{q} \overline{W} \overline{l} \overline{ni} \overline{tg} \overline{v} \overline{R} \overline{v} \overline{Z} \overline{x} \overline{q} \overline{m} \overline{K} \overline{j} \overline{Jla} \overline{Ges} \overline{dv} \overline{g} \overline{t} \overline{K} \overline{w} \overline{c} \overline{q} \overline{q}$
 $\overline{A} \overline{S} \overline{f} \overline{z} \overline{nq} \overline{ib} \overline{K} \overline{S} \overline{ev} \overline{R} \overline{v} \overline{i} \overline{c} \overline{P} \overline{i} \overline{j} \overline{Z} \overline{G} \overline{gb} \overline{Jla} \overline{(h} \overline{v} \overline{-INN} \overline{Product}) \overline{e} \overline{envi} \overline{ii} \overline{t} \overline{y} \overline{t} \overline{I} \overline{m} \overline{Z} \overline{K} \overline{Z} \overline{Ae} \overline{j} \overline{ab} \overline{fiel} \overline{r} \overline{t} \overline{h} \overline{v} \overline{M}$
 $\overline{t} \overline{K} \overline{i} \overline{y} \overline{v} \overline{K} \overline{i} \overline{Z} \overline{c} \overline{v} \overline{i} \overline{dv} \overline{g} \overline{t} \overline{K} \overline{w} \overline{f} \overline{R} \overline{j} \overline{v} \overline{t} \overline{Y} \overline{i} \overline{m} \overline{g} \overline{t} \overline{c} \overline{L} \overline{exi} \overline{A} \overline{t} \overline{b} \overline{K} \overline{t} \overline{k} \overline{A} \overline{t} \overline{b} \overline{K} \overline{Jla} \overline{e} \overline{envi} \overline{bq} \overline{S} \overline{Y} \overline{b} \overline{i} \overline{l} \overline{x} \overline{en} \overline{Z} \overline{j} \overline{ev}$
 $\overline{c} \overline{Z} \overline{v} \overline{nv} \overline{t} \overline{ii} \overline{b} \overline{Ri} \overline{i} \overline{q} \overline{Q} \overline{U} \overline{G} \overline{gb} \overline{K} \overline{Safety} \overline{-Gi} \overline{el} \overline{q} \overline{U} \overline{t} \overline{K} \overline{c} \overline{v} \overline{av} \overline{b} \overline{t} \overline{q} \overline{A} \overline{t} \overline{b} \overline{K} \overline{A} \overline{we} \overline{v} \overline{i} \overline{K} \overline{c} \overline{w} \overline{Z} \overline{ov} \overline{b} \overline{t} \overline{R} \overline{t} \overline{i} \overline{e} \overline{vc} \overline{K}$
 $\overline{Av} \overline{K} \overline{y} \overline{v} \overline{Z} \overline{tg} \overline{t} \overline{b} \overline{b} \overline{t} \overline{q} \overline{g} \overline{v} \overline{be} \overline{Z} \overline{vi} \overline{c} \overline{w} \overline{i} \overline{P} \overline{q} \overline{t} \overline{q} \overline{Q} \overline{U}$


evsjv`k t পৃথিবীর অনেক দেশের মত বাংলাদেশে ফার্মাকোভিজিল্যান্স কার্যক্রম চালু রয়েছে। ১৯৯৯ সালে বাংলা $\overline{t} \overline{k} \overline{G}$
 কার্যক্রম প্রথম শুরু হলেও $\overline{we} \overline{fb} \overline{ev} \overline{e} \overline{Z} \overline{vi} \overline{K} \overline{v} \overline{i} \overline{Y} \overline{K} \overline{v} \overline{h} \overline{K} \overline{i} \overline{fv} \overline{te} \overline{c} \overline{w} \overline{i} \overline{P} \overline{v} \overline{j} \overline{b} \overline{v} \overline{K} \overline{iv} \overline{m} \overline{ae} \overline{nq} \overline{ib} \overline{2013} \overline{m} \overline{v} \overline{j} \overline{i} \overline{1j} \overline{v} \overline{R} \overline{v} \overline{b} \overline{g} \overline{v} \overline{i} \overline{x} \overline{Z}$
 $\overline{Jla} \overline{ck} \overline{vmb} \overline{A} \overline{a} \overline{B} \overline{i} \overline{(DGDA)} \overline{G} \overline{W} \overline{A} \overline{v} \overline{i} \overline{g} \overline{ib} \overline{U} \overline{is} \overline{tm} \overline{j} \overline{M} \overline{v} \overline{t} \overline{bi} \overline{g} \overline{va} \overline{tg} \overline{Ges} \overline{USAID} \overline{c} \overline{w} \overline{i} \overline{P} \overline{w} \overline{j} \overline{Z} \overline{ms} \overline{v}$
 MSH/SIAPS Program এর কারিগরী সহায়তায় ফার্মাকোভিজিল্যান্স কার্যক্রম নতুন উদ্যোগে শুরু করেছে। বিভিন্ন
 $\overline{dv} \overline{g} \overline{v} \overline{m} \overline{D} \overline{i} \overline{UK} \overline{v} \overline{j} \overline{B} \overline{U} \overline{v} \overline{v} \overline{,} \overline{nm} \overline{cv} \overline{Z} \overline{v} \overline{j} \overline{Ges} \overline{tn} \overline{j} \overline{t} \overline{K} \overline{q} \overline{i} \overline{c} \overline{t} \overline{dk} \overline{bv} \overline{j} \overline{t} \overline{i} \overline{Ask} \overline{Mn} \overline{Y} \overline{l} \overline{সহযোগিতায়} \overline{পর্যায়ক্রমে} \overline{তা} \overline{গতিলাভ}$
 $\overline{K} \overline{i} \overline{Q}, \overline{c} \overline{v} \overline{B} \overline{i} \overline{t} \overline{c} \overline{v} \overline{U} \overline{i} \overline{ms} \overline{L} \overline{v} \overline{b} \overline{b} \overline{e} \overline{x} \overline{c} \overline{v} \overline{t} \overline{Q} \overline{Jla} \overline{ck} \overline{vmb} \overline{A} \overline{a} \overline{B} \overline{i} \overline{we} \overline{fb} \overline{ch} \overline{v} \overline{t} \overline{qi} \overline{c} \overline{ik} \overline{y} \overline{Y} \overline{i} \overline{Av} \overline{q} \overline{v} \overline{R} \overline{b} \overline{K} \overline{i} \overline{Q},$
 $\overline{t} \overline{cv} \overline{v} \overline{i}, \overline{c} \overline{v} \overline{g} \overline{t} \overline{c} \overline{U} \overline{l} \overline{we} \overline{A} \overline{B} \overline{/n} \overline{v} \overline{U} \overline{ie} \overline{j} \overline{c} \overline{P} \overline{v} \overline{i} \overline{i} \overline{g} \overline{va} \overline{tg} \overline{mv} \overline{iv} \overline{t} \overline{k} \overline{i} \overline{we} \overline{fb} \overline{nm} \overline{cv} \overline{Z} \overline{v} \overline{j} \overline{-K} \overline{ib} \overline{K}, \overline{tg} \overline{W} \overline{t} \overline{K} \overline{j} \overline{K} \overline{t} \overline{j} \overline{R}, \overline{t} \overline{K} \overline{v} \overline{U}$
 প্রাপ্তন, স্টেশন/ টার্মিনালের মত জনবহুল এলাকা, ঔষধ ক্রেতা ও বিক্রেতাসহ সর্বস্তরে সচেতনতা বৃদ্ধির প্রচেষ্টা অব্যাহত
 রেখেছে। ঔষধ সেবন/ব্যবহারকালীন কোন রোগীর বিরূপ প্রতিক্রিয়া (Suspected Adverse Event) $\overline{c} \overline{w} \overline{i} \overline{j} \overline{y} \overline{Z} \overline{n} \overline{j}$
 $\overline{el} \overline{q} \overline{U} \overline{Pi} \overline{K} \overline{rm} \overline{K} \overline{K} \overline{R} \overline{v} \overline{b} \overline{t} \overline{b} \overline{v} \overline{Ges} \overline{Jla} \overline{ck} \overline{vmb} \overline{i} \overline{b} \overline{R} \overline{ওয়েবসাইটে} \overline{থাকা} \overline{নির্দিষ্ট} \overline{ফর্মে} \overline{এতৎসংক্রান্ত} \overline{রিপোর্ট} \overline{প্রেরণের} \overline{জন্য}$
 $\overline{mv} \overline{iv} \overline{t} \overline{k} \overline{i} \overline{we} \overline{fb} \overline{fv} \overline{te} \overline{Av} \overline{nev} \overline{R} \overline{v} \overline{b} \overline{t} \overline{b} \overline{v} \overline{n} \overline{t} \overline{Q} \overline{D} \overline{t} \overline{j} \overline{L} \overline{th}, \overline{ফার্মাকোভিজিল্যান্স} \overline{কার্যক্রমের} \overline{প্রতি} \overline{g} \overline{v} \overline{b} \overline{b} \overline{x} \overline{c} \overline{av} \overline{bg} \overline{S} \overline{x} \overline{i} \overline{K} \overline{v} \overline{h} \overline{v} \overline{t} \overline{qi}$
 $\overline{we} \overline{t} \overline{k} \overline{l} \overline{ষ্টি} \overline{রয়েছে} \overline{।} \overline{এ} \overline{কার্যক্রম} \overline{কিভাবে} \overline{আরও} \overline{M} \overline{i} \overline{Z} \overline{k} \overline{x} \overline{nq}, \overline{m} \overline{K} \overline{j} \overline{t} \overline{K} \overline{i} \overline{Y} \overline{i} \overline{g} \overline{v} \overline{b} \overline{y} \overline{mn} \overline{t} \overline{R} \overline{G} \overline{U} \overline{e} \overline{S} \overline{t} \overline{Z}, \overline{m} \overline{a} \overline{u} \overline{z} \overline{n} \overline{Z} \overline{l} \overline{i} \overline{t} \overline{c} \overline{v} \overline{U}$
 $\overline{K} \overline{i} \overline{Z} \overline{c} \overline{v} \overline{ib} \overline{Ges} \overline{K} \overline{fv} \overline{te} \overline{G} \overline{t} \overline{k} \overline{i} \overline{g} \overline{v} \overline{b} \overline{t} \overline{i} \overline{tek} \overline{K} \overline{j} \overline{v} \overline{Y} \overline{Av} \overline{m} \overline{t} \overline{Z} \overline{c} \overline{v} \overline{i} \overline{Z} \overline{vi} \overline{Rb} \overline{c} \overline{t} \overline{q} \overline{v} \overline{R} \overline{b} \overline{x} \overline{q} \overline{e} \overline{e} \overline{v} \overline{t} \overline{bl} \overline{q} \overline{v} \overline{n} \overline{t} \overline{Q} \overline{U}$
 National PV Centre $\overline{Gi} \overline{m} \overline{y} \overline{g} \overline{Z} \overline{v} \overline{ev} \overline{ov} \overline{t} \overline{b} \overline{v}, \overline{Centre} \overline{Gi} \overline{ms} \overline{L} \overline{v} \overline{e} \overline{x} \overline{K} \overline{i} \overline{Y}, \overline{t} \overline{K} \overline{S} \overline{k} \overline{j} \overline{l} \overline{ch} \overline{y} \overline{M} \overline{Z} \overline{D} \overline{b} \overline{q} \overline{b} \overline{mn} \overline{tek} \overline{K} \overline{Q} \overline{Z}$
 $\overline{c} \overline{w} \overline{i} \overline{K} \overline{i} \overline{b} \overline{v} \overline{Jla} \overline{ck} \overline{vmb} \overline{A} \overline{a} \overline{B} \overline{t} \overline{i} \overline{i} \overline{eZg} \overline{v} \overline{b} \overline{gn} \overline{vc} \overline{i} \overline{P} \overline{v} \overline{K} \overline{g} \overline{t} \overline{nv} \overline{t} \overline{qi} \overline{i} \overline{q} \overline{Q} \overline{U}$

cZ`ekx t`k,tjvi Ae`vb t

নব্বই এর দশকে আমাদের পার্শ্ববর্তী দেশ ভারতে ফার্মাকোভিজিল্যান্স কার্যক্রম প্রথম দফায় শুরু হয়, বিভিন্ন অসুবিধার কারণে
 $\overline{Zv} \overline{P} \overline{j} \overline{g} \overline{v} \overline{b} \overline{iv} \overline{Lv} \overline{m} \overline{ae} \overline{nq} \overline{ib} \overline{Zv} \overline{ici} \overline{v} \overline{Z} \overline{x} \overline{q} \overline{ch} \overline{v} \overline{t} \overline{q} \overline{Ges} \overline{me} \overline{t} \overline{k} \overline{l} \overline{2010} \overline{m} \overline{v} \overline{j} \overline{ZZ} \overline{x} \overline{q} \overline{ch} \overline{v} \overline{t} \overline{q} \overline{ii} \overline{n} \overline{l} \overline{q} \overline{dv} \overline{g} \overline{t} \overline{K} \overline{w} \overline{f} \overline{R} \overline{j} \overline{v} \overline{Y}$
 কার্যক্রম বর্তমানে সেখানে সফলতার মুখ দেখছে। অনেক $\overline{p} \overline{w} \overline{Z} \overline{K} \overline{Z} \overline{v} \overline{t} \overline{c} \overline{w} \overline{i} \overline{t} \overline{q} \overline{f} \overline{vi} \overline{t} \overline{Z} \overline{v} \overline{q} \overline{Z} \overline{v} \overline{m} \overline{Z} \overline{c} \overline{w} \overline{i} \overline{Z} \overline{ov} \overline{b} \overline{Indian}$
 Pharmacopoeia Commission (IPC) KZK. $\overline{bq} \overline{w} \overline{j} \overline{x} \overline{i} \overline{M} \overline{m} \overline{R} \overline{q} \overline{v} \overline{ev} \overline{t} \overline{Ae} \overline{v} \overline{Z} \overline{National} \overline{PV} \overline{Centre} \overline{Gi}$
 $\overline{c} \overline{t} \overline{q} \overline{v} \overline{R} \overline{b} \overline{x} \overline{m} \overline{K} \overline{j} \overline{m} \overline{y} \overline{e} \overline{av} \overline{i} \overline{b} \overline{i} \overline{d} \overline{Z} \overline{K} \overline{iv} \overline{n} \overline{t} \overline{q} \overline{Q}, \overline{c} \overline{w} \overline{i} \overline{U} \overline{c} \overline{t} \overline{k} \overline{G} \overline{K} \overline{w} \overline{ak} \overline{eo} \overline{mi} \overline{K} \overline{w} \overline{i} \overline{nm} \overline{cv} \overline{Z} \overline{v} \overline{j} \overline{ADR} \overline{Monitoring}$
 Centre (AMC) $\overline{w} \overline{c} \overline{Z} \overline{n} \overline{t} \overline{q} \overline{Q} \overline{U} \overline{Active}, \overline{Passive} \overline{/Spontaneous} \overline{(ICSR)} \overline{Ges} \overline{Mandatory} \overline{(PSUR)}$
 reporting system $\overline{i} \overline{t} \overline{q} \overline{Q} \overline{tm} \overline{Lv} \overline{t} \overline{b} \overline{m} \overline{Z} \overline{ivs} \overline{dv} \overline{g} \overline{t} \overline{K} \overline{w} \overline{f} \overline{R} \overline{j} \overline{v} \overline{Y} \overline{Ges} \overline{Jl} \overline{ai} \overline{bivc} \overline{Ev} \overline{eav} \overline{b} \overline{f} \overline{vi} \overline{t} \overline{Z} \overline{i} \overline{eZg} \overline{v} \overline{b} \overline{m} \overline{v} \overline{d} \overline{t} \overline{j} \overline{i}$
 জন্য প্রায় ২৫ বছরের বেশী সময় ধরে কাজ করতে হয়েছে। ফার্মাকোভিজিল্যান্স কার্যক্রমে প্রতিক $\overline{t} \overline{Z} \overline{v} \overline{Q} \overline{j} \overline{Av} \overline{t} \overline{Q} \overline{v} \overline{B} \overline{j} \overline{v} \overline{t} \overline{U} \overline{l}$
 ১৯৮৫ সালে সেখানে প্রথম কার্যক্রম শুরু হয়। বর্তমানে সেদেশে সফলভাবে এ জনগুরুত্বপূর্ণ কার্যক্রম চালিয়ে যাওয়ার পেছনে

mnáúZK Ric t eisjvʔ`#k "A Study on Pharmacovigilance to improve the Drug Safety in Bangladesh" kxIK mnáúZK GK MteIYq Wm tmdU i Rb" dvgtKw fRj`vY KZUkz, iZcY Ges Gʔ`#k Sustainable PV System Gi Rb" tKvb KVRUi Immediate action ctqvRb Gi Dci XvKv mU Kctvikb, XvKv wefvM, ivRkvn wefvM I Lybv wefvMi tgvU 134 Rb PIRmK, 140 Rb dvgnm ÷, 103 Rb ikYK (tgWtKj, dvtgmx I bwns), 78 Rb Jla cZKvix cUzõrtbi gnjK Ges 41 Rb Jla ckymb AwaBtii KgKZmn metgvU 496 Rb e"3 i gta" Rlic Pvjvbn nqQ|Gi djvdj wbaic t

Type of Respondents	Respondents				Total
	Extremely Important	Important	No Comments	Not Important	
Doctor	93	40	1	0	134
Pharmacist	112	26	1	1	140
Academician	73	27	2	1	103
Medicine Manufacturer	47	29	2	0	78
DGDA inspector	30	11	0	0	41
Total =n (%)	355 (71.6%)	133 (26.8%)	6 (1.2%)	2 (0.4%)	496 (100%)



Oesjv`#k nvmcvZvj I JI#ai t`vKv#b MvR\$qu digwm÷ ||bhÿ bv _vKv digv#KwfiRj`vÝ KgKvÜ c||Pvj bvi ক্ষেত্রে একটি অতীব গুরুত্বপূর্ণ সমস্যা” প্রশ্ন করা হলে ৫৩% এবং ৩৯% উত্তরদাতা যথাক্রমে Strongly Agree Ges Agree K#i#Ob|

c₂₂K 11ZbU c†k- hvi c1Z1U†Z 91U K†i Ackb 11†q Zv †_†K 11ZbU K†i (Multiple) DĒi 11†Z Abjiva Kivq
496 Rb †imcb†W1U Gi mK†jb †hf†e qZ1qZ 11†q†Qb Zvi ms1Yß 11eeiY 11ba1ic t

K) $\varepsilon_{\text{sv}} \neq \text{ki}$ Jla $\text{ckvm} \neq \text{bi}$ eo $\text{mgm} \neq \text{v}$ $\text{wntm} \neq \text{e}$ $\text{wP} \neq \text{yZ}$ $\text{K} \neq \text{i} \neq \text{Qb}$ - Kg Rbej - 74% $\text{jwR} \neq \text{K}$ $\text{mv} \neq \text{cv} \neq \text{Ui}$ Afve - 50.6% Ges Ávb $\text{l} \neq \text{ýZvi}$ Afve - 40.3% |

Patientaddress

Age _____ Weight (kg) _____ Height (cm) _____ Gender ☐ Male ☐ Female

B. SUSPECTED ADVERSE EVENT INFORMATION

C. OTHER CONCOMITANT PRODUCT INFORMATION

	Product 1	Product 2	Product 3	Product 4
Brand name				
Generic name				
Indication				
Dosage form				
Route				

- D™veb I A||f#hV M c||ZKv#i i gva#g tmevi gv#bvbqb
- Av||K e'e'vcbr i Dbqb

Kvhej (Functions) t

- ১। ঔষধ উৎপাদনকারী ও বিক্রয়কারী প্রতিষ্ঠানের অনুকূলে ঔষধ উৎপাদন লাইসেন্স প্রদান।
- ২। ঔষধ উৎপাদনকারী ও বিক্রয়কারী প্রতিষ্ঠানের লাইসেন্স নবায়ন।
- 3। JI#ai t iR#÷kb c`vb|
- 4। JI#ai ,bMZgvb vb|ðZKi#Yi j#ÿ" bgb| msMn, cixÿv I #e#kIY|
- 5। JIa iBvbx i jvB#mY c`vb|
- 6। Avg`vbxKZ.Kv|vgj, c`ZKZ.JI#ai eK-||j ÷/Bb#WU/tc|digv Bbf#qm Ab#gv`b Ges QvocÎ c`vb|
- 7। ||RGg||c tgvZv#eK JIa Drcv`bKvix c||Zôvb c||i`kb|
- 8। d|vg#Kv||f|R#jY (PV) সংক্রান্ত কার্যক্রম পরিচয়|bv|
- 9। bKj, t fRvj, Avb-রেজিস্টার্ড, কাউন্টারফিট, মিসব্রাভেড ঔষধ প্রদর্শন, সংরক্ষণ, বিক্রয়, বিতরণ, মান-e|nfZ JIa উৎপাদন/বাজারজাতকরণ এবং লাইসেন্স বিহীন ঔষধ উৎপাদন ও বিক্রয়কারী প্রতিষ্ঠান/ব্যক্তি i #e|t#x cP||jZ JIa AvBb Ab#vqx e'e'v MnY|
- 10। c#qvRbxq c||kÿ#Yi gva#g JIa ckvmbi KgKZv/KgPvix#`i tckvMZ `ÿZv e||x Ges ||RGg||c c||kÿY c`v#bi gva#g JIa Drcv`bKvix c||Zôvb vb#q||RZ tKvq||j dvBW e`||³e#Mi `ÿZv e||x Kiv|

বার্ষিক কর্মসম্পাদন সংক্রান্ত সমঝোতা স্মারক (APA)- JIa ckvmb A||a`B#i i Performance tK Improve Ki#Z mnvqZv Ki#Q| তকননা, এর কর্মসম্পাদন সূচক সমূহকে নির্বাচন করা হয়েছে ঔষধ প্রশাসন অধিদপ্তরের সকল কার্যক্রমকে #e#ePbv K#iB| Gi mdjZv JIa ckvmb A||a`B#i i mKj `#i i KgKZv KgPvix#`i Performance Gi Dci নির্ভরশীল। বার্ষিক কর্মসম্পাদন সংক্রান্ত সমঝোতা স্মারক এর কার্যক্রমকে যেহেতু মনিটরিং করা হয়, t#m#nZzJIa ckvmb A||a`B#i i mKj `#i i KgKZv - KgPvix#`i Zv#`i c||Z||U KivR h_vmg#q m#ÿv#e m#úv`b Kivi GK||U eva`evaKZv `Zix n#q#Q|

15। evsjv#`#k tgvW#Kj ||WfvBm ||bqšY

evsjv#`#k JI#ai RvZxq ||bqšYKvix KZçÿ (National Regulatory Authority) ||n#m#e JIa ckvmb অধিদপ্তরের অন্যতম দায়িত্ব হল মেডিকেল ডিভাইসের উৎপাদন, সংরক্ষণ, বিক্রয়, #eZiY I Avg`vbx ||bqšY Kiv| এতদুদ্দেশ্যে মেডিকেল ডিভাইসের রেজিস্ট্রেশন প্রক্রিয়া চালুকরণ এবং সহজীকরণের নিমিত্তে আন্তর্জাতিক গাইড লাইন ও ÷`vUWmg# Ab#vYceK `v` I c||ievi Kj`vY gšYvj q KZK.MvZ #e#kIÁ K||g||U ô#gvW#Kj ||WfvBm MvBWjvBb-20150 cYqb K#i hv D³ gšYvj#qi `v|iK bs Rbm`n`-1/#e#ea-6/2008-314,Zv||L 20-10-2015 Øviv cieZx#Z Ab#gv`Z nq| tgvW#Kj ||WfvBmmg# The Drug Act-1940-Gi 3(#e) (i), (ii), (iii) I (v) aviv tgvZv#eK JIa ||n#m#e #e#ePZ, t#m tgvZv#eK JIa ckvmb A||a`B i KZK tgvW#Kj ||WfvBmmg#n i t iR#÷kb c`vb করা হচ্ছে। মেডিকেল ডিভাইসের গাইডলাইনটি রেজিস্ট্রেশন প্রক্রিয়ার নির্দেশিকা। cYxZ tgvW#Kj ||WfvBm MvBWjvB#b `v` m#ú||KZ/e`enviR|bZ SyKi ||`K #e#ePbv K#i tgvW#Kj ||WfvBmmg#K ||b#av³ Pvi||U tKvY#Z veb` Kiv n#q#Q|

Class	Risk level	Device Examples
A	Low Risk	Surgical retractors/tongue depressors
B	Low-moderate Risk	Hypodermic Needles /suction equipment
C	Moderate-high Risk	Lung ventilator /bone fixation plate
D	High Risk	Heart valves/Implantable defibrillator

Class A e`ZxZ mKj tgvW#Kj ||WfvBm Gi Rb` t iR#mUkb MnY eva`Zvgj#K| Drcv`bKvix/Avg`vbxKvix c||Zôvb t iR#÷kb c||B i ci evRv|RvZ Ki#Yi mgq Zu c||Z||U t iR#÷W c#Y`i tgv#K Aek`B evsjv fvlvq (Avg`vbx i tÿ#Î) Av#gvPbxq Kv||j m#j/gÿb-Gi gva#g c#Y`i bvg, ||WGAvi bs, Drcv`b I tgvq` DËx#Yi Zv||L, m#ev`P L#v|v g#` I Drcv`bKvix/Avg`vbxKvix#Ki bvg D#jL Ki#Z n#e| tgvW#Kj ||WfvBm JIa #eavq tgvW#Kj ||WfvB#m i

1| %bZKZv KigU

tdvKvj c†qU ‖baviYmn c†B (05) m`m" ‖eikó `bZKZv KigU MVb Kiv n†q†Q|

- | | | | |
|---|--------------------------|--|-----------|
| 1 | gnvc†iPvjK | Jla ckymb Aia`Bi | AvnYvqK |
| 2 | Rbve t†gt †Mvjvg ‖Keviqv | c†iPvjK, Jla ckymb Aia`Bi              | m`m" |
| 3 | t†gt i†ûj Avigb | c†iPvjK (Pj†Z `v†qZ), Jla ckymb Aia`Bi | m`m" |
| 4 | t†gt AvKZvi †nv†mb | mnKvix c†iPvjK, Jla ckymb, M†Rxcy | m`m" |
| 5 | t†gt mvjvD†İb | mnKvix c†iPvjK, Jla ckymb Aia`Bi       | m`m"-m†Pe |

Jla ckymb Aia`Bi i i†xvPvi K†iK†iUi K†h†i†at

- (K) Aia`Bi i i†xvPvi c†Zôvi t†y†İ A†RZ m†dj" Ges AŠivq ‖P†yZKiY|
- (L) c†i†j†yZ AŠivq `†Ki†Y mgqve× Kgc†iK†i†b† c†Yqb|
- (M) Kgc†iK†i†b† ev†evq†bi `v†qZ Kv†`i Dci b†`_vK†e Zv ‖baviY|
- (N) m†ikó †m††i i†xvPvi c†Zôvq M†xZ Kgc†iK†i†b† ev†evqb I c†i†ex†yY|
- (O) ev†IK m†óv`Z GK†U Av†bK Kg g†`vqb c†x†Z Ges c†Yv`bv I c†i†Z†IK e†e†n†i ceZb|
- (P) c†Z e†i ‖bq†gZ†f†e kb" c†`i KgKZv/KgPvix ‖b†q†M ‖b†đZ Kiv|
- (Q) KgKZv/KgPvix†`i m†y†gZv Dbq†bi Rb" KgKvj†b c†ik†yY c†iPvj†b|
- (R) miKv†i †mevq K†hKv†iZv Av†qb I M†y†gb†i Kv†Q Zv `Z I m†nRj†f" Kivi j†y" B-M†f†yY ceZb I Zvi c†m†i|
- (S) miKv†i `Bim††i A†f†h†M e†e†n†ic†b†i Rb" †dvKvj c†qU ‖baviY Ges Rbm†v†iY†K Ae†nZKiY|

2016 m†j Jla ckymb Aia`Bi KZK i†xvPvi ev†evq†bi j†y" †h me KgK†U c†iP†jZ n†q

1| ‖m†U†Rb P†UW†

nvj†b†M†`KZ.‖m†U†Rb P†U†i I†qem†B†U c†K†v Kiv n†q†Q| ‖m†U†Rb P†U†iU Jla ckymb Aia`Bi i †b†Uk †ev†W c†`kZ Av†Q| RbMY ‖m†U†Rb P†U†i n†Z Aia`Bi i †mev c`vb c†x†Z, †mev c`v†bi mgqmxgv, c†q†Rb†q KvMR-c†f†v` I Rbm††Yi c†q†Rb†q c†v†b†m†ó†K R†b†Z c†i†Q Ges Jla ckymb Aia`Bi i KgKZv I KgPvix†, `bav†iZ †mev c`v†bi mgqmxgv† g†a" †mev c`vb Ki†Qb|

2| Kg†y†İ Dc†Z†

mKj KgKZv I KgPvix†i h_vmg†q Kg†y†İ Dc†Z† ‖b†đZ Kiv n†q†Q| Jla ckymb Aia`Bi i gnvc†iPvjK g†nv`q c†Z†`b mKvj 9:00†gt KgKZv I KgPvix†`i n†Riv LvZv ch†ey†b K†ib|

3| m†f†t

c†Z†`b 9:00†gt n†Z 10:00Uv chŠ Aia`Bi i m†fv K†y mKj KgKZv†`i gZ†ev†bgq m†fv Ab†đZ n†q| D³ m†fvq KgKZv KgPvix†`i m†y†eav-A†y†eav I `bZKZv ‖el†q Av†jvP†v†n Rbm††Yi ‖bKU Jla ckymb Aia`Bi i †mevm††m†nRj†f" I AvŠ†iKZ†c†K†i†v† ‖el†q Av†jvP†v† n†q_v†K|

4| ‖M†f†Y n†v†U†js A†dm†v†t

- Rbm†v†iY †_†K ‖e†fb A†f†h†M M†nY I ‖b†ó†E†i j†y" GK (01) Rb Dc-c†iPvjK c`ghv`vi KgKZv†K `v†qZ দেওয়া হয়েছে । তিনি প্রতি মাসে এ সংক্রান্ত রিপোর্ট প্রদান করে থাকেন ।
- ‖M†f†Y n†v†U†js A†dm†v†t Gi b†vg, c`ex, t†g†ev†Bj b†i, B†g†Bj Av†B†W Jla ckymb Aia`Bi i I†qe m†BU, W†vk †ev†W I Jla ckymb Aia`Bi i †ev†bi m†y†L m†vB†ev†W †`I†qv Av†Q|

5| Bbdi†gkb †i†R†v†i I complain box†

- Rbm†v†iY †_†K ‖e†fb A†f†h†M M†nY Gi Rb" †n†i †W†` GK†U Bbdi†gkb †i†R†v†i †`I†qv Av†Q

- Jla ckymb Aia`B`iii fe#bi m#yL RbmvaY Gi #bKU n#Z wefb A#f#hM MnY Gi Rb" GK#U complain box vcb Kiv Av#Q|
- c#Z#`b RbmvaY Gi #bKU n#Z wefb A#f#hM MnY I Z\_" mieiv#ni Rb" GK Rb KgKZv Jla ckymb Aia`B`iii tn# tw# mKvj 10:00 n#Z `gy 1:00 N#UKv ch# e#mb|

6| Z_" tKvIt

RbM#Yi Z_" AiaKvi #b#Z Kivi j#y" GK#U Z_" tKvI i#q#Q| D³ Z_" tKvI Jla ckymb Aia`B`iii hveZxq Z_" v#` msiyY Kiv nq Ges Z\_" AiaKvi AvBb-2009 tgvZ#eK RbmvaY#bi Pvin`v Abjvq# Z_" mieivn Kiv nq|

7| G UzAvB Gi AvIZvab cK#mgnt

gvbbxq carbq#xi Kvhvj#qi G UzAvB cK#i i আওতায় একটি সফটওয়্যার তৈরীর কার্যক্রম চলমান, যা অচিরেই সম্পন্ন n#e| D³ mdU Iq#vi ^Zix n#j t#ki RbMY tgv#Bj t#vb e#envi K#i

- bKj, t#Rvj, Avb#iR÷w, KvD#Uv#dU, #gmev#UW JI#ai #el#q Z_" Av`vb-c`vb Ki#Z cvi#e,
- Adverse Drug Reaction #el#q Z_" Av`vb-c`vb Ki#Z cvi#e,
- JI#ai A#Z#i³ g#` m#y#K Zvr#YK tgv#Bj A#cm Gi gva#g #i#cvU Ki#Z cvi#e|

8| e#IK c#Z#e`bt

c#Z eQi Jla ckymb Aia`B`iii e#IK c#Ze`b cYqb Kiv nq| D<sup>3</sup> c#Z#e`b Aia`B`iii e#IK KgKv#mn RbM#Yi Rb" Jla নিয়ন্ত্রণ সংক্রান্ত বিভিন্ন Z_" cKvk Kiv n#q #v#K| c#Z#e`b#U Aia`B`iii I#qe mvB#UI cKvk Kiv nq|

9| Jla ckymb Aia`B`iii I#qe mvB#U

Jla ckymb Aia`B`iii GK#U #bR# I#qe mvBU i#q#Q hv (www.dgda.gov.bd) b#tg c#i#PZ| D³ I#qe mvB#Ui gva#g gby#etki wefb cv# t#K mKj ai#Yi tmev, thgbtJla #bq#YKvix KZc#y, Jla #bq#Y e#e`v, ঔষধ উৎপাদনকারী ও বিক্রয়কারী প্রতিষ্ঠানের তথ্যাদি, রেজিস্টার্ড ঔষধ সম্পর্কিত তথ্যাদি Ges Ab`vb" tmev D³ I#qe mvB#Ui gva#g MnY Ki#Z cvi#Q|

10| Jla ckymb Aia`B`iii t#dBme#t

Jla ckymb Aia`B`iii GK#U #bR# t#dBme# t#R i#q#Q hv <https://www.facebook.com/dgda.gov.bd> | t#dBme# t#R G Jla ckymb Aia`B`iii wefb KgKv# cKvk Kiv nq I b#M#iK#` i #bKU n#Z cvB A#f#hM #b#U#E Kiv nq Ges wefb Z\_" c`vb Kiv nq| Jla ckymb Aia`B`iii t#dBme# t#R Gi Bbe#` cvB wefb Z\_" tgvZ#eK g#v ch#q A#f#hM c#i#Pvj#v Kiv nq| Jla ckymb Aia`B`iii t#dBme# t#R#U AZ#` Rb#cqZv ARb K#i#Q|

11| Jla ckymb Aia`B`iii B-#gBjt

Jla ckymb Aia`B`iii GK#U #bR# B-#gBj i#q#Q hv dgda.gov@gmail.com | B-#gB#ji gva#g b#M#iK#` i KvQ n#Z cvB A#f#hM #b#U#E Kiv nq Ges wefb Z\_" c`vb Kiv nq|

12| gvV ch#qi কার্যক্রমের অনলাইন রিপোর্টিং ও ড্যাশ বোর্ডের মাধ্যমে মনিটরিং

Jla ckymb Aia`B`i i#v#Pvi Kgc#iK#i#v#i gva#g RbM#Yi Rb" #bivc` I g#bm#Z Jla #b#Z Kivi #b#gt#E c#Z#bqZ KivR K#i hv#Q| Jla ckymb Aia`B`iii gvV ch#qi KgKZvMY c#Z#`b bKj, t#Rvj c#Z#iv#a Zv#i i gvV ch#q KgKv#Ui c#Z#e`b AbjvB#b t#iY K#ib| g#v#c#i#PvjK g#nv`q W`vk tev#Wi gva#g ^`bK gvV ch#qi KgKv#U g#b#Uis K#ib| এতে করে তাদের কার্যক্রমের জবাবদিহিতা নিশ্চিত হচ্ছে এবং জনগণের জন্য নিরাপদ ও মানসম্মত ঔষধ নিশ্চিত করার কার্যক্রম বেগবান হচ্ছে।

13| c#y#t

Jla ckymb Aia`B`iii KgKZv-Kg#Pvix#` i Kg`yZv e#x#i j#y" t#k I we#`k #bq#Z Ab-`v-Re t#U#s Ges Ae-`v-Re t#U#s c`vb Kiv n#Q| 2016 mv#j 46 Rb KgKZv#K #e#`kK t#U#s Ges 299 Rb (GK#iK evi) KgKZv I Kg#Pvix#K Af`#ixY t#U#s c`vb Kiv n#q#Q| g#Yvj#qi #b#`kbv tgvZ#eK c#Z`K KgKZv I Kg#Pvix#i 60 ঘন্টা প্রশিক্ষণ প্রদানের কার্যক্রম চলমান রয়েছে।

19| RvZxq JlabxZ-2016t

RvZxq JlabxZ 2005 chv+jvPbv K+i JlabxZ 2016 cYqb Kiv nq+Q hv weMZ 19/12/2016 Bs Zvwi+L miKvi KZK.Abtg\`Z nq+Q| b\`ZU 23 gvP, 2017 Zvwi+L tM+RU AvK+i cKvk t+c+Q| G JlabxZ+Z JI+ai bivc`E (Safety), KvHKvviZv (Efficacy), thS`K e`envi, KvHKi JIa bqSY e`e`v, JIa Drcv`b, wecyb, weZiY, msiyY Ges JIa Avg`vb-iBvbi t+y+I m\`o`K b`kbv i+q+Q|

RvZxq JlabxZ 2016 G m\`b+eKZ bZb weIq\`t

১। সংক্রামক ব্যাধি প্রতিরোধ ও নির্মূলকরণের লক্ষ্যে এবং শিশু ও মাতৃস্বাস্থ্যের উন্নয়নে সংশ্লিষ্ট ঔষধের সহজলভ্যতা নিশ্চিত করা n+e|

2। ÔcigZ P\`Krmv b`+`kKvô (Standard Treatment Guideline-STG) Abtgvx JI+ai thS`K I bivc` e`envi b\`ôZ Kiv n+e|

3। mKj nvmcvZv+jj Rb`B ÔG\`Uevq\`UK e`envi b`+`kKvô cYqb I Abtgi+Yi e`e`v MnY Kiv n+e|

৪। ঔষধ সংক্রান্ত তথ্যাদি অবহিতকরণ এবং যৌগিক e`envi b\`ôZK+i JIa bqSY KZc+yi Abtgv`b mv+c+y Ôevsjv`k b`kbvj dg\`v iô ev weWGbGd (Bangladesh National Formulary-BDNF) bqigZfv+e nvjbvMv` I I+qe mvB+U cKvk Kiv n+e| GKBfv+e JIa bqSY KZc+yi Abtgv`b mv+c+y Ôevsjv`k RvZxq Avgte`K dg\`v iô, Ôevsjv`k RvZxq BDbvbx dg\`v iô, Ôevsjv`k RvZxq nvej dg\`v iô Ges Ôevsjv`k tnvigIc`v\`K dvgv+Kvcqô bqigZ cYqb, nvjbvMv` I I+qe mvB+U cKvk Kiv n+e|

৫। রোগীকে ঔষধের যথার্থ ব্যবহারবিধি ও সংরক্ষণের বিষয়ে পরামর্শ প্রদানের জন্য ঔষধ বিক্রি অথবা পরিবেশন (Dispensing) কার্যক্রম পেশাজীবী ফার্মাসিস্ট+i cZ`I ZÊvear+b c\`iP\`jZ n+e| G j+y` KigDibvU dv+gm\` (Community Pharmacy) c\`Zôv I Dbqtb c+qRbxq e`e`v MnY Kiv n+e|

৫। দেশে পর্যায়ক্রমে সব সরকারি ও বেসরকারি হাসপাতালে স্নাতক ফার্মাসিস্ট এর প্রত্যক্ষ তত্ত্বাবধানে 'হসপিটাল ফার্মেসী' (Hospital Pharmacy) কার্যক্রম পিPvjvri c+qRbxq e`e`v MnY Kiv n+e|

6। mKj xKZ.c\`iZi JI+ai c\`iPq mevi Kv+Q mnR Kivi j+y` evY\`R`K bvtgi cvkvcmk úofv+e tR+bvIK ev bR bR dg+j+iZ D+jLZ bvtg JIa Drcv`b/ecyb Ki+Z n+e|

7। G\`Uevq\`UKmn me ai+Yi JI+ai thS`K e`envi b\`ôZ Kivi j+y` t`+ki mKj miKvi I temiKvi nvmcvZv+jj ÔWvMm GÜ t\`ivcD\`UK Kig\`Uô c\`Zôv Kiv n+e|

8। P\`Krmvq AZ`vek`Kxq cZxqgvb bv n+j gkyRvZxq (Combination) A`+jvc`v\`K JI+ai weÜb mvariYfv+e bi+rmvvnZ Kiv n+e| msikó Combination Product Gi t+y+I Ace`env+i mavebv i+Zi mv+ we+Pbvq ivL+Z n+e| A`+jvc`v\`K JI+ai ti+R+kb c`v+bi t+y+I United States Food & Drug Administration (US-FDA) ev The Medicines & Healthcare Products Regulatory Agency (MHRA) KZK.Abtg`+bi ev British National Formulary (BNF) G Ašfy+i Z`v\` AbtgiY Ki+Z n+e| cP+jZ Combination Product-mg+ni weÜb c+qRb Abtgvx c\`g+j`vqb Kiv n+e|

9। c\`vYm\` I grm` P\`Krmv JI+ai Avg`vb ti+R+kb i+t\`i m\`o`K t`+ki d tmj mviUd+KU`vLj Gi kZ+ivc Kiv nq+Q|

10। Avg`vbKZ.JIa I KuPvg+jmgn h\_vh\_fv+e RGGv c Abtgi+Y Drcv`Z nq Kbv tm weI+q b\`ôZ nIqv i+j`+` cZ`qbcI` v\`L+jj e`e`v mn c+qRb+ev+e RvZxq JIa bqSYKvix KZc+I i c\`I t`+K Drcv`bKvix c\`Zôv c\`i`kb Kiv n+e| GMP MvBWjvBb Ges cYxZ Check List Gi Av+jv+K iBvbkvIK t`+ki JIa KviLvbv Validation I Certification Kiv n+e |

11। JIa Drcv`+bi t+y+I wek`v` ms`vi current Good Manufacturing Practices (cGMP) b`+`kbvmgn K+i vfv+e AbtgiY Kiv n+e|

12। c`ZKvIKMY JIa ckvmb A\`a`B+i cYxZ tPK+j÷ (Check list) AbtgiY K+i b\`o` mgq Aš i Af`šixb biv+yv (Internal Audit) c\`iPvjvri Ki+eb| JIa ckvmb A\`a`Bi, cYxZ tPK+j÷ bqigZ nvjbvMv` Ki+e|

13। JIa Drcv`+bi wefb kZ thgb tKv+cmvbi thvM` Rbej, vcbv/tcigmm, BD\`Uj\`U/mv\`f+mm, v\`cZ t\`gkbv\`i/BK\`g+gU, Drcv`Z JI+ai t\`ivcD\`UK tKvY Ges tW+Rm dg BZ`v\` we+Pbv K+i Zv+iK JIa Drcv`+bi mv\` Abtgvx tKvYeb`vm Kiv n+e|

14। JI+ai KuPvgj Drcv`+bi Rb` Avg`vbKZ.tKigK+v+jj I ci gmK/Ki gIK\`di weI+q Af`šixY m\`u` wefvM তথা জাতীয় রাজস্ব বোর্ডের সঙ্গে আলোচনাক্রমে যৌগিক ch+q nvmmn wefb c+yv`bvi D`vM tbiqv n+e| G j+y` JI+ai KvPvg+jj Dci M+eIYvq b\`qv\`RZ c\`Zôvbmgn+K DrmvinZ Kiv n+e Ges c+qRbxq c+yv`bv t`Iqv n+e| KuPvgj Drcv`+bi Rb` Bm\`KZ.jvB+m+Yi AvIZvq d\`ibmW Wm Drcv`b Kiv hv+e bv|

15| JIa¹ K¹ f¹ qsm¹ úY¹ AR¹ bi Rb¹ mKj¹ KZ¹ cv¹ x¹ Zi JI¹ ai K¹ úgv¹ ji I ci¹ e¹ k¹ bfiZ¹ nvm Kiv n¹ e| JI¹ ai K¹ úgv¹ j Drc¹ b¹ i Rb¹ k¹ vcb, Pz¹ f¹ i¹ EK Drc¹ b, e¹ k¹ tKv¹ úvbi mv¹ Under License¹ f¹ i¹ EK Drc¹ b Ges¹ t¹ k¹ x¹ e¹ k¹ th¹ s¹ e¹ b¹ tq¹ M¹ K¹ e¹ f¹ b chv¹ q c¹ Y¹ v¹ b¹ t¹ I qv¹ D¹ t¹ v¹ M MnY Kiv n¹ e| GKbf¹ v¹ t¹ k¹ x¹ c¹ v¹ t¹ K¹ iRs¹ k¹ i¹ eKv¹ k¹ Drmn¹ t¹ I qv¹ n¹ e|

16| t¹ k¹ Drc¹ v¹ Z JI¹ a e¹ eüZ K¹ úgv¹ j ms¹ kó dvg¹ t¹ K¹ v¹ c¹ q¹ D¹ j¹ LZ¹ t¹ ú¹ m¹ d¹ t¹ K¹ kb Ab¹ j¹ v¹ q¹ g¹ v¹ b¹ m¹ úb¹ n¹ t¹ Z n¹ e|

17| JI¹ a I JI¹ ai K¹ úgv¹ ji Drc¹ b¹ t¹ tem¹ iK¹ v¹ i cix¹ y¹ v¹ m¹ t¹ i cix¹ y¹ v¹ I e¹ k¹ iY Gi m¹ t¹ h¹ v¹ M c¹ v¹ b |

18| JI¹ a Drc¹ v¹ b¹ i c¹ i¹ g¹ v¹ Y e¹ eüZ K¹ úgv¹ j I tid¹ t¹ iY ÷¹ v¹ úW Drc¹ v¹ b¹ K¹ v¹ i c¹ i¹ Zô¹ bmg¹ t¹ h¹ s¹ f¹ v¹ t¹ e JI¹ a প্রশাসন অধিদপ্তরের অনুমোদনক্রমে আমদানি করতে পারবে।

19| t¹ k¹ i Ri¹ i¹ x¹ c¹ t¹ q¹ iR¹ b¹ ev Rb¹ v¹ i¹ q¹ v¹ q¹ t¹ h¹ t¹ K¹ v¹ b JI¹ a c¹ Z¹ K¹ v¹ i¹ K¹ miK¹ v¹ i t¹ h¹ t¹ K¹ v¹ b JI¹ a Drc¹ v¹ b¹ i¹ b¹ t¹ k¹ v¹ t¹ Z c¹ v¹ i¹ t¹ e Ges¹ c¹ i¹ Zô¹ b¹ t¹ j¹ v¹ Z¹ v¹ Drc¹ v¹ b¹ ev¹ a¹ v¹ K¹ t¹ e|

20| t¹ q¹ Z¹ v¹ e¹ x¹ i Rb¹ JI¹ a ck¹ v¹ mb¹ A¹ i¹ a¹ B¹ t¹ i¹ c¹ i¹ k¹ K¹ t¹ i¹ b¹ q¹ i¹ g¹ Z¹ i¹ RG¹ g¹ i¹ c¹ I Ab¹ v¹ b¹ c¹ v¹ m¹ t¹ K¹ e¹ l¹ t¹ q¹ c¹ i¹ k¹ i¹ Y c¹ v¹ b করা হবে। দেশে ও বিদেশে উল্লিখিত প্রশিক্ষণের জন্য প্রয়োজনীয় উদ্যোগ গ্রহণ করা হবে এবং প্রশিক্ষণ সংক্রান্ত তহবিলের e¹ e¹ v¹ Kiv n¹ e|

21| Ri¹ Z¹ q¹ JI¹ a i¹ b¹ q¹ s¹ Y KZ¹ c¹ i¹ (National Regulatory Authority-NRA) i¹ n¹ t¹ m¹ t¹ e K¹ i¹ v¹ h¹ K¹ i Kiv i Rb¹ JI¹ a ck¹ v¹ mb¹ A¹ i¹ a¹ B¹ i¹ t¹ K¹ Av¹ i¹ l¹ k¹ i¹ v¹ k¹ v¹ j¹ Kiv |

22| Ri¹ Z¹ q¹ JI¹ a i¹ b¹ q¹ s¹ Y K¹ v¹ i¹ x¹ KZ¹ c¹ t¹ i¹ y¹ I t¹ q¹ em¹ v¹ BU i¹ b¹ q¹ i¹ g¹ Z¹ f¹ v¹ t¹ e n¹ v¹ j¹ b¹ v¹ M¹ Kiv n¹ e Ges¹ A¹ i¹ a¹ B¹ t¹ i¹ c¹ v¹ m¹ t¹ K¹ Z¹ v¹ t¹ e, c¹ x¹ i¹ Z¹ I M¹ p¹ i¹ x¹ e¹ e¹ v¹ m¹ i¹ b¹ t¹ e¹ k¹ Z হবে। গতিশীলতা বৃদ্ধির লক্ষ্যে পর্যায়ক্রমে অধিদপ্তরের বিভিন্ন কার্যক্রম অন-জ¹ v¹ B¹ t¹ b¹ (Online) c¹ i¹ v¹ j¹ b¹ v¹ i¹ e¹ e¹ v¹ t¹ b¹ l¹ q¹ n¹ e|

23। নকল, ভেজাল, মোয়াদোত্তীর্ণ, নিবন্ধনবিহীন, কাউন্টারফেইট ও মিসব্রান্ডেড ঔষধ বিক্রি শাস্তিযোগ্য অপরাধ এবং ঔষধ e¹ e¹ v¹ cb¹ q¹ m¹ k¹ v¹ m¹ t¹ b¹ i A¹ s¹ i¹ v¹ q¹ e¹ a¹ i¹ q¹ Drc¹ v¹ K¹ I Avg¹ v¹ b¹ K¹ v¹ i¹ k¹ প্রতিষ্ঠান, পাইকারী ও খুচরা বিক্রেতা এ বিষয়ে দায়বদ্ধ। এরূপ ঔষধের উৎপাদন, বিপণন, বিক্রয়, বিতরণ ও মজুদের সাথে সংশ্লিষ্ট ব্যক্তি I c¹ i¹ Zô¹ v¹ b¹ i¹ e¹ i¹ t¹ x¹ Av¹ B¹ v¹ b¹ y¹ K¹ t¹ v¹ i¹ e¹ e¹ v¹ MnYmn JI¹ a ck¹ v¹ mb¹ A¹ i¹ a¹ B¹ i¹ KZ¹ k¹ ms¹ kó j¹ v¹ B¹ t¹ m¹ Y¹ e¹ v¹ Z¹ j¹ Kiv n¹ e|

24| i¹ b¹ g¹ g¹ v¹ b¹, b¹ K¹ j¹, t¹ f¹ R¹ v¹ j¹ I i¹ b¹ e¹ Ü¹ i¹ e¹ n¹ x¹ b JI¹ a (A¹ i¹ t¹ j¹ v¹ c¹ v¹ K¹, Avg¹ t¹ e¹ K¹, BD¹ b¹ v¹ b¹, n¹ v¹ e¹ j¹, t¹ n¹ v¹ i¹ g¹ l¹ c¹ v¹ K¹ I ev¹ t¹ q¹ t¹ K¹ i¹ g¹ K¹) Ges¹ d¹ v¹ t¹ m¹ v¹ c¹ t¹ g¹ t¹ U¹ i¹ b¹ v¹ t¹ g¹ JI¹ a Ri¹ Z¹ q¹ পণ্যের অননুমোদিত উৎপাদক ও বিক্রেতা, ব্যবস্বহাপত্র c¹ v¹ b¹ K¹ v¹ i¹ x¹ P¹ i¹ K¹ r¹ m¹ K¹ I P¹ i¹ K¹ r¹ m¹ v¹ c¹ i¹ Zô¹ v¹ b¹ i¹ Rb¹ t¹ p¹ i¹ s¹ g¹ j¹ K¹ k¹ v¹ c¹ v¹ b¹ i¹ b¹ i¹ ð¹ Z¹ Ki¹ t¹ Z¹ e¹ e¹ v¹ g¹ v¹ b¹ Av¹ B¹ t¹ b¹ i¹ ms¹ v¹ i¹ Kiv n¹ e|

25| t¹ g¹ q¹ v¹ D¹ E¹ x¹ Y JI¹ a d¹ v¹ t¹ g¹ m¹ x¹ Z¹ g¹ l¹ R¹ y¹, c¹ k¹ b¹, JI¹ ai t¹ g¹ v¹ o¹ K¹ ev¹ av¹ i¹ t¹ K¹ i D¹ ci¹ i¹ b¹ t¹ k¹ Z¹ t¹ g¹ q¹ v¹ c¹ i¹ e¹ Z¹ b¹ ev¹ A¹ ú¹ o¹ করে বিক্রয় শাস্তিযোগ্য অপরাধ হিসেবে গণ্য হবে।

26| i¹ b¹ g¹ g¹ v¹ b¹ b¹ K¹ j¹ t¹ f¹ R¹ v¹ j¹ t¹ P¹ i¹ v¹ P¹ v¹ j¹ v¹ b¹ KZ¹. L¹ v¹ ev¹ JI¹ a m¹ v¹ g¹ M¹ x¹ e¹ e¹ n¹ v¹ t¹ i¹ q¹ i¹ Z¹ M¹ n¹ t¹ j¹ t¹ f¹ v¹ t¹ v¹ i¹ D¹ ch¹ y¹ q¹ i¹ Z¹ c¹ t¹ y¹ i¹ b¹ i¹ ð¹ Z¹ Ki¹ t¹ Z¹ e¹ e¹ v¹ g¹ v¹ b¹ Av¹ B¹ b¹ ms¹ t¹ k¹ v¹ ab¹ Kiv n¹ e|

27। ঔষধ বিতরণ গাইড লাইন সংক্রান্ত।

28| ঔষধের যথাযথ সংগ্রহ, সংরক্ষণ ও বিক্রয়/বিতরণ নিশ্চিত করার লক্ষ্যে বাংলাদেশ ফার্মেসী কাউন্সিলের নিবন্ধিত d¹ v¹ g¹ v¹ m¹ t¹ ÷¹ i¹ Z¹ E¹ v¹ e¹ a¹ t¹ b¹ m¹ K¹ j¹ d¹ v¹ t¹ g¹ m¹ x¹, miK¹ v¹ i¹ I tem¹ iK¹ v¹ i JI¹ a m¹ si¹ y¹ v¹ v¹ i¹ Ges¹ n¹ v¹ m¹ c¹ v¹ Z¹ j¹ d¹ v¹ t¹ g¹ m¹ x¹ c¹ i¹ v¹ P¹ v¹ j¹ Z¹ n¹ e|

29| Avg¹ t¹ e¹ K¹, BD¹ b¹ v¹ b¹, n¹ v¹ e¹ j¹ I t¹ n¹ v¹ i¹ g¹ l¹ c¹ v¹ K¹-বারোকেমিক ঔষধের যথাযথ সংগ্রহ, সংরক্ষণ, বিক্রয় ও বিতরণ নিশ্চিত Kiv i j¹ t¹ q¹ ms¹ kó c¹ x¹ i¹ Z¹ i¹ b¹ e¹ i¹ Ü¹ Z¹ P¹ i¹ K¹ r¹ m¹ K¹ A¹ ev¹ i¹ b¹ e¹ i¹ Ü¹ Z¹ d¹ v¹ g¹ v¹ m¹ t¹ ÷¹ i¹ Z¹ E¹ v¹ e¹ a¹ t¹ b¹ d¹ v¹ t¹ g¹ m¹ x¹ c¹ i¹ v¹ P¹ v¹ j¹ Z¹ n¹ e|

30| JI¹ ai e¹ Á¹ v¹ cb¹ I c¹ P¹ v¹ i¹ i¹ b¹ q¹ s¹ Y|

31| Rb¹ m¹ t¹ Y¹ i Ae¹ m¹ i¹ Z¹ i¹ Rb¹ m¹ K¹ j¹ JI¹ ai L¹ y¹ i¹ v¹ g¹ j¹ JI¹ a ck¹ v¹ mb¹ A¹ i¹ a¹ B¹ t¹ i¹ i¹ t¹ q¹ em¹ v¹ BU-G c¹ K¹ v¹ k¹ Kiv n¹ e|

32| t¹ k¹ Drc¹ v¹ Z¹ I Avg¹ v¹ b¹ KZ¹. Avg¹ t¹ e¹ K¹, BD¹ b¹ v¹ b¹, n¹ v¹ e¹ j¹ I t¹ n¹ v¹ i¹ g¹ l¹ c¹ v¹ K¹-ev¹ t¹ q¹ t¹ K¹ i¹ g¹ K¹ JI¹ ai g¹ j¹ miK¹ v¹ i KZ¹. i¹ b¹ a¹ v¹ i¹ Z¹ n¹ e|

33| i¹ b¹ a¹ v¹ i¹ Z¹ g¹ j¹ i¹ t¹ P¹ t¹ q¹ A¹ i¹ Z¹ i¹ 3 মূল্যে ঔষধ বিক্রয় করলে সংশ্লিষ্ট ব্যক্তি ev¹ c¹ i¹ Zô¹ v¹ b¹ i¹ e¹ i¹ t¹ x¹ Av¹ B¹ v¹ b¹ y¹ e¹ e¹ v¹ t¹ b¹ l¹ q¹ n¹ e|

34| t¹ k¹ b¹ Z¹ b¹ ch¹ y¹ I K¹ v¹ i¹ M¹ i¹ Á¹ v¹ b¹ n¹ v¹ š¹ i¹ |

35| JI¹ a M¹ t¹ e¹ l¹ Y¹ I Db¹ q¹ t¹ b¹ m¹ g¹ i¹ b¹ Z¹ t¹ h¹ s¹ D¹ t¹ v¹ M¹ c¹ m¹ t¹ t¹ 2 t¹ v¹ b¹ x¹ q¹ I e¹ ú¹ R¹ v¹ i¹ Z¹ K¹ JI¹ a I JI¹ ai K¹ úgv¹ j¹ c¹ Z¹ K¹ v¹ i¹ K¹ D¹ f¹ q¹ t¹ KB¹ t¹ k¹ M¹ t¹ e¹ l¹ Y¹ I Db¹ q¹ b¹ (Research and Development-R&D) m¹ y¹ e¹ a¹ v¹ v¹ cb¹ Kiv i Rb¹ Drmn¹ c¹ v¹ b¹ Kiv n¹ e| me¹ KZ¹. d¹ v¹ t¹ g¹ m¹ x¹ e¹ l¹ q¹ K¹ t¹ K¹ v¹ t¹ m¹ b¹ Z¹ b¹ e¹ l¹ q¹ A¹ š¹ f¹ 2 Kiv |

36। ফার্মাকোভিজিলেন্স অথবা ঔষধের বিরূপ প্রতিক্রিয়াসমূহের (Adverse Drug Reactions-ADR) Dch¹ y¹ c¹ i¹ e¹ x¹ i¹ q¹ Y¹ |

37| JI¹ ai i¹ B¹ v¹ b¹ e¹ l¹ q¹ K¹ me¹ i¹ é¹ I A¹ i¹ é¹ c¹ i¹ Z¹ e¹ Ü¹ KZ¹ v¹ t¹ K¹ i¹ v¹ n¹ e|

52| $Rb^- \nVdash i$ $Rb^- \nVdash ZKi$ Jla $e \nVdash Zj$ Kiv |

Pewš wepewbvwq evsjv`tki mwsnz c`vebvui 10u j` I Alakvsk j`g`v`lvB RvZmsN MnxZ GmWvRiZ mivmii
 cizdijz nqQ| GUB evsjv`k c`-vebvi e`vcK mvdj; mikvii c`Póvi `Zvi cizdjb|
 GUB RvZmsN MnxZ nIqvi ci ciB evsjv`tk GmWvRi ev`evqb I c`iex`Yi elqU cavbgšxi Kvhwjq `tk
 ev`-evqb I chv`jvPbv Rb` g` mPe Avej Kvjvg AvRv`K AvvYqK Kti GKU D`P chv`qi KigU MvB Kiv nq|
 MZ 28 Rv c`MvZ G KigU m`m` msL`v 16| PjZ eQ`ii 6 Rvbgvii RBW `K WI `jUv`ii (Dc-AvbgvmbK
 cI) GmWvR mskó wefb gšYvjq I wefvMi mmbqi mPe I mPe`i KvQ GmWvR g`vics cvVv`bv nq|
 BZvgta`B GmWvR j`mgn`Kvb gšYvjq ev wefvM `Kvb, j ev`evqb KiGe Ges `Kvb gšYvjq jW G`RvY
 n`mte KvR KiGe Gi GKU Lmov g`vics `Zvi KtiQ| wefb mgq g`vics-Gi Ici Av`jvPbv, gZvgZ MnY mfv
 AbjôZ nq| me`kl g`vics`q jC, `Kv-jW Ges A`v`mvm`qU gšYvjq I wefvM baviY Kti Lmov `Zvi I evsjv`k
 c`imsL`vb e`yiv I Ab`vb` Z`-DcvE cYqb/c`vbKvix wefb ms`vi mnvqZvg GmWvRi c`iex`YI I Kg-maúv`b
 g`v`q`b evsjv`tk we`g`v Z`-DcvEi NvU`Z I bZ`v`vte K K Z` DcvE msMn KtiZ nte Zv m`b`v`vte
 P`yZ Kti GKU c`Z`e`b (GmWvRGm `WUv M`vc A`v`v`vBmm) RBW c`Z KtiQ| c`yiv`g PjQ GmWvR
 ev`evq`b`iG`vKkb c`vb PewšKtiYi j`I` chv`jvPbv|
 BZvgta`B mBg c`AewIK c`iKíbi ev`evqb i`yn`q`Q| Gi ga` `q GmWvRI ev`evqb ej`Z M`j i`yn`q`Q|
 RBW mBg c`AewIK c`iKíbi GmWvRi D`ik` (AfXó) I j`g`v`lvmg` mg`SZ KtiQ| gšYvjq/ wefvMfiEK
 KvH-সংশ্লিষ্টতা (ম্যাপিং) নির্ধারণ ও সমন্বিত করে একটি সার্বিক এসডিজি ev`evqb KgmP cYqb KiQ c`iKíbi
 Kigk`bi maviY A`b`vZ wefvM|
 MZ `m`P`oi, 2016 g`m Abjôq RvZmsNi 71Zg maviY Ala`ek`b GmWvRi j`g`v`lv, j`vi ev`evqb c`iex`YI
 I g`v`q`bi Rb` `ekK chv`e ২৩০টি সূচক সর্বসম্মতিক্রমে চূড়ান্ত Kiv nq | mBg c`AewIK c`iKíbi (2016-20)
 Av`jv`K mevB`K `b`q mg`SZ`v`te GmWvR Kgc`iKíbi ev`evqb Kiv m`eci n`j evsjv`tki A`b`vZK ceix.
 ewIK Av`iv kb` `k`qK 5 kZvsk chš ew. cvte | G `ek Dbqb G`RÚv ev`evq`b evsjv`tk mikvi m`v`EK D``VM
 MnY KtiQ| evsjv`tk GmWvR AR`bi g`Zv GmWvR ev`evq`b`i`I` mdj I AMVgx GKU cavb `k nte; G
 j`I`B mikvi Gm`q hv`Q| Gi ga` `q`b evsjv`tk D`P ga`g Av`qi, `vi` I `g`y` `tk c`iYZ nte, GUB
 `btm` `n cZ`v`v`v Kiv hvq|

21 |Antibiotic Resistance:

এন্টিবায়োটিক হচ্ছে ব্যাকটেরিয়া ঘটিত সংক্রমণে ব্যবহৃত জীবন রক্ষাকারী একটি ঔষধ। তবে এ জন্য যথাযথ মাত্রায়
 G`Uev`q`m`U`Ki e`envi ,iZcY| c`q`v`bi tP`q `i g`v`lv, A`h`š`³Kfvte I Am`úY` tgq`v` G`Uev`q`m`UK
 e`env`ii KviY RvexYgn` ক্রমবয়ে প্রতিরোধী হয়ে ওঠে, যা এন্টিবায়োটিক রেজিস্ট্যান্স নামে পরিচিত।

G`Uev`q`m`UK t`iR`÷`Y` Gi KviY eZgvb I f`iel`r cR`b`i gZ`S`yK evo`Q| Rg I `bj-Gi 2015 mv`ji GKU
 `i`cvU Abj`v`x eZgvb প্রতিবছর ৭০,০০০ মানুষ এন্টিবায়োটিক রেজিস্ট্যান্স জীবাণুর দ্বারা সংক্রমণের কারণে মারা যাচ্ছে।
 G Ae`v Pj`Z `vK`j AvMvgx 2050 mv`j c`ZeQi 1 tKvU t`jvK G`Uev`q`m`UK t`iR`÷`Y` Gi KviY g`v`v`v`te|
 G Ae`v c`Z`iv`ta Jla ckvmb Ala`Bi tek KQ`Z`v`hKi c``yc MnY KtiQ I KiQ| Zvigt`a D`jL`h`vM` nj
 প্রেসকিপশন বা ব্যবস্থাপত্র মনিটরিং, এন্টিবায়োটিকের বিক্রয় রেজিস্ট্রার সংরক্ষণ, মডেল ফার্মেসীতে এন্টিবায়োটিক সেবনের
 KvDvY`js BZ`v` | GQovv I g`vbm`úb G`Uev`q`m`UK Drcv`b K`v`i`fvte RGGic Abj`v`i `b`ôZ Kiv n`Q|

Antibiotic t`iR`÷`Y` c`Z`iv`ta I Gi th`š`<sup>3</sup>K e`env`ii Rb` `v`v` Ala`Bi, grm` Ala`Bi, c`i m`ú` Ala`Bi,
 `v`v` tckvR`ex Ges Av`SRvZK ms`vi ms`M Jla ckvmb Ala`Bi GK thv`M Kiv KiQ| G j`y` Jla ckvmb`bi
 AMYx fvgKvq Av`SRvZK ms`v CDDEP(The Center for Disease Dynamics, Economics & Policy)Gi
 mn`h`vMZvq evsjv`tk Global Antibiotic Resistance Partnership (GARP) R`v`B 2016 mv`j MvB Kiv
 n`q`Q Ges Jla ckvmb Ala`Bi Gi Kvhwjq `vcb Kiv n`q`Q| evsjv`tk mn 10(`k)U t`tk GARP Antibiotic
 Resistance c`Z`iv`ta Kiv Kti hv`Q| AlaKŠ Jla ckvmb Ala`Bi`i `b`k`bvq RvZiq JlabvZ 2016 tZ
 G`Uev`q`m`U`Ki m`b`q`šZ I th`š`³K e`envi `b`ôZKti`i`K `b`k`bv i`q`Q|

Antibiotic t`iR`÷`Y` c`Z`iv`ta Avgv`i mK`ji `tekKQ`Z`iYq weIq i`q`Q|

- 1| শুধুমাত্র রেজিস্টার্ড চিকিৎসকের ব্যবস্থাপত্র মোতাবেক এন্টিবায়োটিক বিক্রয় সেবন বা গ্রহণ kiv (we`kl t`y`I
 t`Kej mikvii b`vZgvjv Abj`v`x c`k`y`Z `v`v`Kgx KZK m`ieivn KZ.G`Uev`q`m`UK t`meb Kiv hvte|)
- 2| e`e`vc`I D`ijvLZ mgq I `b`k`bv tg`b Pjv|
- 3| kv`i`iKfvte m`y` Abj`v`e Ki`j I G`Uev`q`m`UK cY`tKv m`ú`v Kiv|
- 4| কোনও কারণে বিরূপ প্রতিক্রিয়া c`Lv `j Ziv`y`YKfvte P`iKrm`Ki civgk tbqv|
- 5| সময় মত সবগুলো টিকা গ্রহণের মাধ্যমে জীবাণু সংক্রমণ প্রতিরোধ করা।
- 6| nvZ t`v`v`v`v mKj maviY `v`v`v`v`v tg`b Pjv|

22| গৃহ দ্বিগুণ I গৃহ তৃণমূল ক

আবু কবি আলী ডব্লিউ এনসিবি জিএসআইসি গৃহ ফার্মেসী স্থাপনের কার্যক্রম হাতে নেওয়া হয়েছে।
এসজিএক মিকিইবি I সিএবি কেজি গৃহ জিএসআইসি KZK জিএফ-1 I জিএফ-2 মডেল ফার্মেসীর ক্রাইটেরিয়া
অবগতি নতুন জিএফ-1-ক গৃহ দ্বিগুণ Ges জিএফ-2 ক তৃণমূল ক ইনসিবি বিগকিই কি নতুন জিএসআইসি
মিকিই KZK গৃহ দ্বিগুণ I তৃণমূল ক Gi Rb` c`K জিএফ-1 কি নতুন জিএসআইসি GB জিএফ-1 L RbMY গৃহ
দ্বিগুণ I জিএফ-2 ক পিএস সিএবি G-এম এমআইসি ডিএম-এ Gi Zএএবি জিএফ-1 গৃহ দ্বিগুণ সিএপিএস
নতুন জিএসআইসি জিএফ-2 ডিএম-এ i Zএএবি জিএফ-2 তৃণমূল ক সিএপিএস নতুন গৃহ দ্বিগুণ I গৃহ তৃণমূল
শপ এর ক্রাইটেরিয়া নির্ধারণ করা হয়েছে। সারা দেশব্যাপী পাইলটিং এর কাজ চলছে। GmKj গৃহ দ্বিগুণ I গৃহ
তৃণমূল ক G h_vh_ Zvcgııvq Jla msiyY Kiv nte| Zvc mste`bkxj Jla tiıdRvıiUıi msiyY Kiv nte|
bKj, tıRvıj , AvbıiR÷vW I tgqvı`vEıY Jযব বিক্রি Kiv nte bı| Jla mııK KıDıYıjs Kiv nte| Drug
Information c`vb Kiv nte| GmKj গৃহ দ্বিগুণ I গৃহ তৃণমূল ক G h_vh_fvte GPP(Good
Pharmacy Practice) AbııY Kiv nte|GLvb t_K RbMY mıVK gıj` gıv mııb Jla cvte| OTC(over the
counter) Qıov Ab` tıvb JIয প্রেসক্রিপশন ছাড়া ক্রয় বা বিক্রয় করা হতে bı| গৃহ দ্বিগুণ I গৃহ তৃণমূল
kıcOTC ঔষধগুলো আলাদা র্যাকে রাখার ব্যবস্থা করা হয়েছে। এখানে পূর্ণ কোর্স ছাড়া এন্টিবায়োটিক বিক্রি করা হবে না।
tKbbı cY tKıv Qıov GıUevıqıUK tmeıb GıUıqıUK iıR÷`vY`Zıx nq, GıZ Kıi GıUevıqıUK KıR Kıi bı|



23| Digital Expo-2016:

The country's largest digital expo "Digital World-2016" began on Wednesday 19th October, 2016 morning to showcase the technology-based innovations and achievements and facilitate in a single platform for sharing ICT knowledge and ideas. Honorable Prime Minister Sheikh Hasina inaugurated the three-day flagship annual event of the country's ICT sector with the theme "Non-stop Bangladesh" at the International Convention City Bashundhara (ICCB) in the capital.

The ICT Division organised the event with assistance of the Bangladesh Computer Council (BCC), Bangladesh Association of Software and Information Services (BASIS) and A2I programme of the Prime Minister's office. Different ministry showcased e-services in order to feature the development of e-governance in achieving the vision 2021 "Digital Bangladesh".

Like all other government agencies the visitors flocked to DGDA stall that was well attended by officials throughout the expo on behalf of DGDA. Different exhibitors showcasing the technology driven innovations & achievements. DGDA stall exhibited **ONLINE ADR REPORTING SYSTEM, FAKE DRUG IDENTIFICATION, Nationwide Daily Activity based DASHBOARD monitoring & The Web portal of DGDA.** The information about registered drugs, manufacturing company, drug sellers, importers were attracted the visitors and they expressed their feeling.

The prompt & accelerated transformation of DGDA from being traditional to a digital one in an efficient and transparent manner got visitors attraction & appreciation.

Its purpose was to exhibit government online service, as well as exchange information between the government and a variety of recipients, citizens, business and also other government.

The expo mainly focused on the prompt and accelerated transformation of Bangladesh, from being a traditional government to a digital one in a convenient, efficient and transparent manner.

This year over 40 stalls exhibited various e-services provided by the government.



24] Jla ckymb Aa`B`iii cavb Kvhwj`qi bZk feb D`vab

“v” I c`ievi Kj`vY gS`Yvj`qi gvbbxq gS` Rbve tgvnv`b` b`vimg Gg`ic g`nv`q 15 G`icj, 2014 Z`viiL gnvLv`jx, XvKvq Jla ckymb Aa`B`iii cavb Kvhwj`qi fe`bi w`f`E`c` “vc`b K`ib| gv`l`B` eQ`iii g`a” 13 A`±vei, 2016 Z`viiL Jla ckymb Aa`B`iii cavb Kvhwj`qi be w`b`gZ feb D`vab K`ib|



25| B#b#fkb #Ug t

Jla ckymb Aia`B#ii tmev c`vb প্রক্রিয়া এবং কাজের আভ্যন্তরীণ প্রক্রিয়ায় গুণগত পরিবর্তন আনয়নের লক্ষ্যে স্বাস্থ্য ও c#ievi Kj`vY gšYvj#qi `vik bs-45.137.116.00.004.2012-646, ZwiL 13-05-2013-Gi cwi#c#y#Z g#šc#il` #efv#Mi `vik bs-04.00.0000.232.35.006.13.21, ZwiL 25-04-2013-Gi Av#jv#K Jla ckymb Aia`B#ii GK#U B#b#fkb #Ug Mvb Kiv n#q#Q|

0Jl#ai #e#ic c#তিক্রিয়া রিপোর্টিং, নকল ঊষধ এবং ঊষধের নির্ধারিত মূল্যের অধিক মূল্যে বিক্রয়ের বিষয়ে অনলাইন ভিত্তিক A#f#h#M `#L#ji Rb` I#qe #cvUvj I #gve#Bj G`#c#Kkb0

I#qe#cvU#j hv hv #K#Q t

- JI#ar বিরূপ প্রতিক্রিয়া রিপোর্টিং (বিস্তারিত)
- BD#bK #Kv#Wi gva`g bKj Jla #P#y#ZKiY
- Jla ckymb Aia`Bi KZK #ba#iZ JI#ai g#` hv#P#B
- #h #Kiv #el#q A#f#h#M `#L#j

#gve#Bj A`#B#Kkb (#U #d#b) hv hv #K#Q t

- JI#ai #e#ic c#তিক্রিয়া রিপোর্টিং (ms#i#B)
- BD#bK #Kv#W Ges QR code `#bs-Gi gva`g bKj Jla #P#y#ZKiY
- Jla ckymb Aia`Bi KZK #ba#iZ JI#ai g#` hv#P#B
- #h #Kiv #el#q A#f#h#M `#L#j
- G#q#W I Av#B#Gm (Av#B#d#b) D#f#q Acv#i#U #m#÷g Gi Rb` c#h#R`

mva#iY #gve#B#j hv #K#Q t

BD#bK #Kv#Wi gva`g (GmGgGm Gi gva`g) bKj Jla #P#y#ZKiY

26| Z` #chy#i e`envi t

(K) I#qe m#BU-G cK#wkZ Z`#t #W#RUvj evsjv#`k Mov eZg#b miKv#ii GK#U Ab`Zg c`#yc| Jla ckymb ও ঊষধ সংক্রান্ত বিভিন্ন তথ্যাদির জন্য www.dgda.gov.bd #k#ivb#g GK#U I#qe m#BU I#q#Q| MSH/SIAPS-evsjv#`ki K#iMi mnvqZ#q D<sup>3</sup> I#qe m#BU GK#U Wqbw#gK I#qe #cvU#j Db#Z Kiv n#q#Q| g#V chv#qi KgKZ#MY D<sup>3</sup> I#qe #cvU#ji gva`g Ab-jvB#b c#Z#e`b #ciY Ki#Z cv#i। ঊষধ সংক্রান্ত বিস্তারিত তথ্যাদি ওয়েব m#B#U Ašf#y Kiv n#q#Q| Jla ckymb Aia`B#ii cavb K#hvj#q #W#RUvj c#x#Z#Z Z` Av`vb-c`v#bi Rb` Local Area Network রয়েছে। ঊষধ সংক্রান্ত হালনাগাদ তথ্য উপাত্ত এবং নিয়ন্ত্রণ ব্যবস্থা সম্পর্কে তথ্যাদি প্রাপ্তির লক্ষ্যে ঊষধ প্রশাসন অধিদপ্তরে ব্রডব্যান্ড ইন্টারনেট কানেকশন ও বিভিন্ন ঊষধ সংক্রান্ত তথ্যাদির একটি ডাটাবেজ রয়েছে। উ³ W#U#eR I#qe m#B#Ui m#_ #jsK Kiv Av#Q| W#U#eR#U#K Av#iv Z` #mg#x Kivi Rb` c`#yc MnY Kiv n#q#Q|

(L) Av#B#iU m#ú#KZ Z`#t Jla ckymb Aia`B#ii I#qemv#U#U (www.dgda.gov.bd) m#ú#bZ# i#c Avc#WU I Avc#MWK#i#bi gva`g I#qe-#cvUvj-G i#cv#iZ Kiv n#q#Q| D<sup>3</sup> #cvU#j Jla ckymb I ঊষধ নিয়ন্ত্রণ সংক্রান্ত #e#f#b Z`#t m#b#e#kZ Av#Q| Jla ckymb Aia`B#ii KgiZ mKj chv#qi KgKZ#MY hv#Z Zv#`i `Kg`j n#Z m#ú#Z hveZ#q Kv#Ri AbjvBb #f#E#K #i#cvU c`vb Ki#Z cv#i Zvi e`e`v MpxZ n#q#Q| Rbmva#i#Yi m#eav#\_ A#Aia`Bi n#Z c#`q #`#ki mKj jvB#m#Yavix #`vKivmg#ni ZvjKv B#Zvg#a` cK#k Kiv n#q#Q hv #bq#gZ fv#e Avc#WU Kiv n#`Q| GQ#ov#I Rbm#Yi #ea Jla m#ú#KZ Z`#t mn#R c#i#Bi #bi#g#E Jla ckvm#bi W#M W#U#eR-#K #cvU#j msh#y K#i 0B-W#M W#U#eR0 G i#v#si Kiv n#q#Q| I#qe #cvUvj-G #e`g#b mKj K#U#U #bq#gZ হালনাগাদকরণ ও তথ্য সমৃদ্ধ করা এবং পোর্টাল সংক্রান্ত যে কোন সমস্যা দ্রুততম সময়ে নিষ্পত্তির লক্ষ্যে ঊষধ প্রশাসনের KgKZ#`i mgš#q cv#m`m` #e#kó GK#U 0K#U#U g#v#bR#g#U U#g0 Mvb Kiv Av#Q| evsjv#`k K#ú#DUvi K#D#Y#j KZK.ev`evq#vaxb 0#W#f#j#c#g#U Ae b`vkbvj Av#B#iU Bbdv-#bU#q#K di evsjv#`k MfY#g#U (evsjv#M#bU)0 k#IK cK#i#i Av#I#v#q Jla ckymb Aia`Bi-G B#Zvg#a` c#q#vR#q mKj hšc#W B#Y#j#k#bi K#R m#ú#b n#q#Q| A#v#jvc#_K JI#ai #i#R#÷k#bi #bi#g#E CTD tgv#Z#eK Dossier প্রণয়ন ও মূল্যায়নের প্রশিক্ষণ কার্যক্রম চলেছে। রেজিস্ট্রেশন প্রক্রিয়া ট্র্যাকিং-Gi Rb` AbjvBb #f#E#K m#U#q#i Pharmadex ev`evq#bi c#iK#i#b MpxZ n#q#Q|

Content of web-site

Home Page Welcome note from the DGDA.	About DGDA ➤ Background ➤ Committees ➤ List of officers in DGDA ➤ Designated Officers for Providing Information ➤ Annual Report	Information Center ➤ Right to Information ➤ Drug Control Committee(DCC) Minutes ➤ Guidance Documents ➤ Directive Documents ➤ Forms ➤ Drug Manufacturers ➤ List of Raw Materials Indentors ➤ Valid Sources of Raw Materials ➤ Registered Imported Drugs
Registered Products ➤ Allopathic ➤ Ayurvedic ➤ Unani ➤ Herbal ➤ Homeopathic And Biochemic	Pharmacies ➤ Allopathic Retail Pharmacy ➤ Ayurvedic Retail Pharmacy ➤ Unani Retail Pharmacy ➤ Herbal Retail Pharmacy ➤ Homeopathic and Biochemic Retail Pharmacy ➤ Whole Sale Pharmacy	ADRM ➤ ADRM News ➤ ADR Monitoring ➤ ADRM Reports ➤ Instructions for Completing ADE Reporting Form ➤ ADRM Reporting Form
Export ➤ Export Countries in World Map ➤ Export Reports	NCL ➤ Sample Requirements ➤ Quality Manual ➤ Organogram	Footer Menu ➤ Site Map ➤ Discussion Board ➤ Feedback ➤ Related Links ➤ Gallery ➤ Search ➤ FAQ

27| Jla ckymb Aia`Bti 2010 nZ 2016 mVj chš A|RZ mvdj" t

(K) Jla ckymb cii`BtiK Aia`Bti DbZKiYt

mgx I AvZbfikxj RvZ MVb eZgVb miKvii AbZg cZkZ| mgx RvZ MVb Rbm"n" GKU , iZc+
elq| tivM cZKvi I cZiv#a Jla I tgnWKvj WfvBm AZvek"K Dcvvb| t`tki cZU gvyli Rb" KvKi I
gvbmúB Jla I tgnWKvj WfvBm bōZ Kiv miKvii AbZg jy" GKU k³kvjx I KvKi Jla bqšY
KZçyB gvbmbúB Jla I I tgnWKvj WfvBmi bōqZv eavb KiZ cvi| t`tki Jla í`ž eKvkgvb| t`tk
DrcwZ Jla t`tki Pvn`vi 98% fVM gUvZ mýg| t`k nZ cPy ciigY Jla DbZ ek thgb-hy ivR",
hy ivó, A÷jvq I BDivcxq BDibqbfy t`kmn eeki 127u t`k iBvbx n"Q| Jla bqšY e"v AiaKZi
KvKi I k³kvjxiYi elqU gvbvxq carbgs Mxfivfve Abxweb Ktib Ges eMZ 17-01-2010 ZwiL Jla
ckymb cii`BtiK AiaZi<sup>3</sup> 150 Rb Rbejmn Aia`Bti DbZ Ktib| Jla ckymb cii`BtiK Aia`Bti DbZKiY
eZgVb miKvii GKU hMŠKvix c`ýc| GZ RbmYi eúj cZyZ cZvkv cY nqQ| GKRb gnvciPvjK I
PviRb ciPvjKmn Rbej 370 Rb DbZ Kiv nqQ| BZvgta" 1g I 2q tkYxi teikifvM kb" c` cGmm-Gi
gva"tg cY Kiv nqQ| miKvi Aelkó kb" c` ,jv cYi c`ýc Mny KtiQ| ZZxq, PZz tkYxi 173 u c`
cY Kiv nqQ|

gvbbxq cavbgšxi Kvhvj#qi A`vK#mm UzBbdi#gkb (GUAVB) tcvM#gi AvIZvaxb mvmfm B#b#fkb dvU KZK. `vLjKZ.0Jl#ai #eijc cতক্রিয়া রিপোর্টিং, নকল ঔষধ ও নির্ধারিত মূল্যের অধিক মূল্যে বিক্রয়ের বিষয়ে অনলাইনভিত্তিক A#f#hM `vL#ji Rb" I#q# tcvUvj I tgv#Bj A`vK#Kkb0 kxIK cK#i KVR cvq m#ub n#q#Q| GB cK#j|ci gva#g RbMY GmGgGm Gi gva#g 1. bKj Jla mbv³ Ki#Z cvi#e, 2. #baw#iZ g#j`i অধিক মূল্যে ঔষধ বিক্রয়ের #el#q Jla ckymb A#a`B#ii #bKU th tKvb #el#q AbjvBb#f#EK A#f#hM `vLj Ki#Z cvi#e Ges 3. Jl#ai বিরূপ প্রতিক্রিয়া রিপোর্টিং করতে পারবে।

(P) iB#b #j#t

evsjv#`k eZgv#b #`#ki P#m`vi cvq 98 kZ#sk Jla `vbxq Drcv`#bi gva#g #gUv#Z m#l#g| i#g#i #KQ#mB#UK cW#± (eW cW#±, e#q#m#gjvi cW#±, G#UK`vYvi Wm, f`vKmb BZ`v) Avg`v#b Kiv nq | evsjv#`k B#Zvg#a" Jla Avg`v#bKvix #`k n#Z iB#bKvix #`k c#iYZ n#q#Q Ges m#iv #e#k evsjv#`#ki Jla B#Zvg#a" m#vg Arb K#i#Q| miKv#ii m#eK m#h#M#Zvq Jla iB#bi c#igvY D#i#Ei e#x cv#Q| 2014 m#j 92#U #`#k #g#U 733.27 #K#U UvKv, 2015 m#j 120#U #`#k #g#U 812 #K#U 51 j#U UvKv Ges 2016 m#j #g#U 127#U #`#k 2247.05 #K#U UvKv Jla, Jl#ai K#vgj I t#gW#Kj #Wf#Bm iB#b K#i#Q| miKv#ii #e#f#B D#`vM I m#h#M#Zvi d#j Jla iB#bi c#igvY I #`#ki m#L`v D#i#Ei e#x cv#Q|

(Q) #e#`kx #e#b#q#Mm D"P chy<sup>8</sup> i Jla Drcv`bt

d#v# t#m#±i #e#`kx #e#b#q#M AvKI#Y eZgv#b miKvi Zrci| G miKv#ii Avg#j #Zb#U #e#`kx c#Z#b evsjv#`#k Zv#`i KviLv#v `vcb K#i#Q Ges Ab" 1#U #e#`kx c#Z#b #`kx c#Z#b m#v#i #e#b#q#M K#i#Q| d#j B#Zvg#a" d#v# t#m#±i cvq 400 #K#U UvKv #e#`kx #e#b#q#M G#m#Q| miKvi D"P chy⁸র ঔষধ উৎপাদনের জন্য সক্রিয় পদক্ষেপ M#Yi d#j #`#k G#U K`vYvi, #c#d#i #m#i#A, #gUvi #W#R Bb#njvi, Bbm#j#b, j#B#dvjvBRW RvZxq Bb#RKkb, ni#g#b, e`W #cW#± Ges f`vKmb RvZxq Jla Drcv`b Kiv m#e n#`Q|

evsjv#`kK K#vgj Drcv`#bi `qsm#u#Zv AR#bi j#`l" miKvi B#Zvg#a" c`#l#c M#Y K#i#Q Ges g#Y#M#A #Rjv MR#iqq K#vgj Drcv`#bi #b#g#E G#CAvB (Active Pharmaceutical Ingredients) cvK `vcbi Rb" R#g eiv#i c`vb K#i#Q| D³ G#CAvB cv#Ki R#g Dbqbm Ab`vb" KVR B#Zvg#a" cvq m#ub n#q#Q| A#P#iB D<sup>3</sup> cv#K G#CAvB Drcv`bKvix c#Z#b Zv#`i KviLv#v `vcbনের নিমিত্তে কার্যক্রম শুরু Ki#Z cvi#e| d#j evsjv#`k K#vgj Drcv`b `qsm#u#Zv Arb Ki#Z cvi#e hv eZgv#b miKv#ii GK#U h#v#Kvix c`#l#c|

(জ) মাঠ পর্যায়ের কার্যক্রম :

Jla ckymb A#a`B#ii KgKZ#MY #bq#gZ Jla Drcv#bকারী ও বিক্রয়কারী প্র#Z#b c#i`kb K#i `v#K| Drcv`Z I evRvRvZKZ.Jl#ai b#v# m#Mn K#i g#v ch#qi KgKZ#MY c#x#l#v I #e#kl#Yi Rb" W#M #U#÷s j`ve#iUix#Z #ciY K#i `v#K| #g#vBj #KvU Aa`v#`k-2009 G W#M G`v± 1940 R#vB/2012-#Z A#f#<sup>3</sup> Kivi ci m#iv#`#k #vg#g#b Av`vjZ c#iP#j#v #Rvi`vi Kiv n#q#Q Ges #m#P#i/2012 nB#Z R#vB/2016 ch#- #vg#g#b Av`vj#Z 5136#U g#gjv `v#qi K#i met#vU 17,82,41,700/- (m#Zi #K#U #eiv#k j#U GKPljk n#Rvi m#Zk) UvKv R#ig#v Av`vq Kiv n#q#Q I #g#U 348Rb Avm#g#K #e#f#b #gq#` (m#e#P 2 eQi, m#bg 7 #`b) Kviv`U c`vb Kiv n#q#Q Ges 201#U c#Z#b #m#j#v Kiv n#q#Q| GQ#v eZgv#b miKv#ii Avg#j bZ# Rbej (KgKZv) #b#q#M Kivq Jla ckymb A#a`B#ii g#v ch#q Z`viKx e#k পেয়েছে। ফলে নকল ভেজাল ঔষধ বিক্রয়, বিতরণ #bq#Z n#q#Q Ges ivR` Av`vq e#x #c#q#Q|

Pharmacovigilance সংক্রান্ত কার্যক্রম পরিচালনার জন্য ২০১৪ সালে ঔষধ প্রশাসন অধিদপ্তর এর ADRM Cell #K National Drug Monitoring Center #N#l#v KiZt #ek `v`ms`vi Uppsala Monitoring Center (UMC) Gi 120Zg c#m`m`c` c`vb K#i#Q|

Pharmacovigilance সংক্রান্ত কার্যক্রম প#iP#j#v Rb" 2014 m#j Jla ckymb A#a`B#i Gi ADRM Cell #K National Drug Monitoring Center #N#l#vKiZt #ek `v`ms`vi Uppsala Monitoring Center (UMC) Gi 120Zg c#m`m`c` c`vb K#i#Q|

(S) g#Wj dv#gmx I g#Wj t#W#mb kc `vcbt

ফার্মেসী ব্যবস্থাপনা উন্নয়নের লক্ষ্যে উন্নত বিশ্বের আদলে গ্রাজুয়েট ফার্মাসিস্টের তত্ত্বাবধানে মডেল ফার্মেসী স্থাপনের কার্যক্রম
i i n q Q

(T) KgKZv I KgPvix`i`i`b`qM`e`ag`jv` Abjg`b` t

1976 m`j Jla ckvmb c`i`i`Bi`n`m`e`h`v`i`i`y`K`i`j`I` KgPvix`i`i`b`qM`-c`i`v`b`Zi`i`b`g`E`t`K`v`b`qM`e`a`Q`j`b`v`| Jla ckvmb A`a`B`i`i` KgKZv I KgPvix`i`i`b`qM`e`ag`jv`-2012 Abjg`Z` n`q`Q, d`j` KgPvix`i`i`b`qM`-c`i`v`b`Zi`i`b`g`E`t`K`v`b`qM`e`a`Q`j`b`v`|

(U) Rbej`i`b`qM`I`c`i`v`b`Zt`e`Z`g`v`m`i`K`v`i`K`Z`K` KgKZv I KgPvix`i`i`b`qM`e`ag`jv` c`Y`q`b`i`d`j``x`N`i`b`i`R`U`j`Z`v`i`b`i`m`b`n`q`Q`| B`Z`v`g`a`1g`t`K`Y`i`72`R`b`I`2q`t`K`Y`i`04`R`b`KgKZv`i`b`qM`f`q`n`q`Q`Ges`c`i`P`i`j`K`c`i`3`R`b`Dc`-c`i`P`i`j`K`c`i`9`R`b`m`n`K`v`i`x`c`i`P`i`j`K`c`i`17`R`b`Ges`Jla`Z`E`v`e`a`q`K`c`i`7`R`b`KgKZv`i`K`c`i`v`b`Z`c`v`b`K`i`v`n`q`Q`| G`Q`v`v`3q`t`K`Y`i`31`R`b`KgPvix`i`K`c`i`v`b`Z`c`v`b`K`i`v`n`q`Q`| 1g`I`2q`t`K`Y`i`e`v`K`x`k`b`c`i`b`qM`i`R`b`e`v`j`v`t`k`c`v`e`j`K`m`v`f`m`K`i`k`g`b`K`Z`K`e`A`i`B`c`K`v`K`i`v`n`q`Q`Ges`KgPvix`i`i`k`b`c`i`55`R`b`K`i`b`qM`f`q`n`q`Q`|

(V) i`e`f`b`M`v`B`W`j`v`B`b`c`Y`q`b` t

Jl`i`a`i`Y`M`Z`g`v`e`i`x`i`j`i`B`Z`v`g`a`" Good Clinical Practice (GCP) Guideline c`Y`q`b`I`Abjg`Z`n`q`Q`| GB`GCP`M`v`B`W`j`v`B`b`e`v`j`v`t`k`Bioequivalence`Study`I`Clinical`Trial`c`i`P`i`j`b`v`K`i`v`i`f`i`b`Z`j`i`M`S`i`D`b`v`P`b`K`i`i`Q`| M`v`B`W`j`v`B`b`U`Pharmaceutical`Researcher`i`R`b`i`K`b`i`b`k`b`I`Human`Subjects`Gi`i`b`i`v`c`E`v`e`a`b`K`i`e`| i`b`i`v`c`g`v`b`m`u`b`Ges`Proper`Performance`Gi`t`g`W`K`j`i`W`f`v`B`m`b`i`d`Z`K`i`v`i`j`i`f`i`t`g`W`K`j`i`W`f`v`B`m`g`n`i`t`i`R`i`b`k`b`I`b`q`S`Y`i`R`b`G`K`U`t`g`W`K`v`j`i`W`f`v`B`m`M`v`B`W`j`v`B`b`c`Y`Z`I`Abjg`Z`n`q`Q`|

(W) b`Z`j`i`b`R`f`e`b`A`i`d`m`v`b`i`t`

বর্তমান সরকারের সক্রিয় সহযোগিতায় ঔষধ প্রশাসন অধিদপ্তর-Gi`c`a`v`b`K`i`h`v`j`q`g`v`Z`S`j`e`v`i`Y`R`K`G`j`v`K`v`X`i`K`v`n`Z`g`v`L`v`j`x`Z`b`i`e`b`g`Z`Jla`f`e`b`(i`b`R`f`e`b)`MZ`03-01-2016`Z`v`i`i`L`v`b`i`t`K`i`v`n`q`Q`|

28| Jla`ck`v`m`b`A`i`a`B`i`i`m`x`g`v`e`x`Z`v`m`g`n`I`i`b`i`m`b`i`D`c`i`q` t

ক্রমিক bs	mgm`v/mxgve×Zv	▮bim`bibi Dcvq																								
01	<p>Ach▮B Rbej t Jla ck▮mb A▮a`B▮i i AMv▮bvMv`tg tgvU 370▮U c` i`q▮Q. t▮mM▮y▮vi g`a` 118▮U c_g t`kYxi c` , 25▮U ▮QZxq t`kYxi c` , 115▮U ZZxq t`kYxi c` Ges 112▮U PZZ t`kYxi c` eZgv▮b Kgiz KgKZv, KgPvix I kb` c`i` Z_`v▮` ▮bgic t</b></p> <table><tr><th>t`kYx</th><th>Abjg▮`Z c`</th><th>Kgiz</th><th>kb` c`</th></tr><tr><td>1g</td><td>118</td><td>95</td><td>23</td></tr><tr><td>2q</td><td>25</td><td>15</td><td>10</td></tr><tr><td>3q</td><td>115</td><td>76</td><td>39</td></tr><tr><td>4_</td><td>112 (57+AvDU t▮mvims 55)</td><td>97</td><td>15</td></tr><tr><td>tgvU</td><td>370</td><td>283</td><td>87</td></tr></table> <p>A▮a`B▮i i ▮e Z. KgKvU c▮iPvjbv i Rb` Rbej AZ`S AcZ▮ </p>	t`kYx	Abjg▮`Z c`	Kgiz	kb` c`	1g	118	95	23	2q	25	15	10	3q	115	76	39	4_	112 (57+AvDU t▮mvims 55)	97	15	tgvU	370	283	87	Abjg▮`Z ▮b`qvM▮e▮a Abjv▮x ▮e▮fb chv`qi kb` c`mgn c`Y Kiv Jla I tgnWK`v j ডিভাইস উৎপাদন, আমদানি, বিক্রয় ও বিতরণ chv`q Avil Kv hKi I m▮y▮ ▮bqšY e`e`v c▮Zōi j`y` GK▮U mg`qv c`h▮Mx AMv▮bvMv g Abjg▮`b I t▮m Abjv▮x t`jvKej ▮b`qvM Kiv  GKBm▮t_ eZgvb AMv▮bvMv`gi Av IZvq ▮di পর্যায় কার্যক্রম জোরদারের লক্ষ্যে এবং U`v▮Wk▮vj, n▮ev j I d▮▮ m▮v c`g`U RvZxq Jla I c`Y`i h_vh_ ▮bqš`Yi D`i`k` Jla ck▮mb A▮a`B▮i K c`qvRb▮x Av`iv Rbej mg▮ K▮i Lv`▮ I Jla ck▮mb A▮a`B▮i DbxZ Kiv
t`kYx	Abjg▮`Z c`	Kgiz	kb` c`																							
1g	118	95	23																							
2q	25	15	10																							
3q	115	76	39																							
4_	112 (57+AvDU t▮mvims 55)	97	15																							
tgvU	370	283	87																							
02	Insufficient Logistic Supportt Jla প্রশাসন অধিদপ্তরের তিনটি মাইক্রোবাস, ছয়টি জিপ, দু'টি Kvi, AvUk▮U tgvUi m▮B▮Kj Av`Q  gv▮ chv`q hveZxq কার্যক্রম পরিচালনার জন্য প্রয়োজনীয় সংখ্যক যানবাহনের GKvš c`qvRb	Strengthening of Drug Administration and management cK`i i AvIZvq পর্যায়ক্রমে সারাদেশে c▮i`kb Ges Monitoring কার্যক্রম পরিচালনার নিমিত্তে c`qvRb▮x msL`K Vehicle ক্রয় করা																								

ক্রমিক bs	mgm`v/mxgveXZv	ibim#bi Dciq
		Jla ckvm#bi Kvhc`iai teiki fVM KivR gvV chv#q weavq G Awa`B#ii KgKZv#i gvV chv#qi KgKvU mPvi#i#c m#u`#bi Rb` c#qvRbxq hibeinb c`v#bi Ges Ri#ix f#E#Z chvB msL`K WvBfvi #b#qv#Mi e`e`v MnY
03	Awdm feb t Jla ckymb Awa`B#ii 08 (AvU) Zjv f#Ei Dci cavb fe#bi KivR mvto #Zb Zjv chS m#ub n#q#Q   mKj KgKvU m#Zv#e c#iPvjvbi Rb` Avil f`um c#qvRb  Jla ckymb Awa`B#ii #Rjv chv#qi Kvhvj#q, #jv fiov Kiv fe#b Ae#Z #Rjv chv#q #bR` #Kib feb b#B	cavb Kvhvj#qi evKx Zjv, #jv #bgvY Kiv পর্যায়ক্রমে অন্যান্য বিভাগ ও জেলা পর্যায়ে Awdm feb #bgvY Kiv
04	AvBbA #b#qvM t Jla #m#i A#bqg c#Z#iv#A AvBb#b# e`e`v MnY Jla ckymb Awa`B#ii GK#U Ab`Zg`wqZ, Avi G`wqZ cvj#b cvqB we#fb Av`vj#Z gvgjv i#RyI c#iPjv Ki#Z nq  Jla ckymb KZK MpxZ #m#vS/ c`y#ci we#i#x gv#S gv#SB ixU Kiv nq G mKj , i#Zc#gvgjv I ixU m#Z KvhKif#e c#iPvjvbi #b#E AvBib c#vgk c`v#bi Rb` Jla ckymb Awa`B#ii #Kib AvBbA b#B Ges Gi Rb` #Kib dvU b#B	Jla ckymb Awa`B#ii we#fb gvgjv c#iPvjvbi Rb` AvBb# c#vgk c`v#bi #b#E K#NB AvBbA #b#qvM Ges c#qvRbxq LiP #gUv#bvi dvU Gi e`e`v Kiv
05	Training facilities: Jla ckymb GK#U #UK#bK`vj #WcvU#gU  #UK#bK`vj, ckvm#bK I dvBb#b#kqvj we#l#q Rbe#ji`yZv e#xi Rb` c#k#Y AcZ#	#`k Jla Drcv`#b DbZ I AvaybK chy# c#qvM n#Q AvaybK I D`P chy# m#u#K #u# avibv, nvjbvM` Z`w`, Jla Drcv`bKix c#Z#v#bi myeav# h_vh_fv#e g#v#q#bi Rb` DbZZi c#k#Y c#qvRb Jla Drcv`#bi AvaybK chy#, Drcv`b myeav#, cGMP,QA, Biological drugs, Clinical trial, #g#W#vj #WfvB#mm g#v#qY, GCP MvBW jvBb ev`evqb, d#v#Kv#f#Rj`vY, KivDv#i#dBU/ #gmev#UW Wm m#u#K #`ki #fZ#i I evB#i c#k#Y#Yi e`e`v Kiv  GQvov KvhKif#e ckvm#bK KgKvU c#iPvjvbi Rb` we#fb chv#qi Rbe#ji Rb` #`ki #fZ#i Ges evB#i Financial Management, Administrative Management, Computer and IT we#l#q Training-Gi e`e`v Kiv
06	Rational use of Drug (RUD), Adverse Drug Reactions Monitoring (ADRM) & Drug Information KgKv#U#i Rb` Jla ckymb Awa`B#ii AeKv#v#g#MZ e`e`v, Rbej Ges #bq#gZ LiP #gUv#bvi c#qvRbxq dvU b#B	Jla ckymb Awa`B#ii Aax#b GK#U c#K National Drug Information Centre c#Z#v Ki#Z n#e Ges D`3 centre-Gi #bq#gZ LiP #gUv#bvi dvU-Gi e`e`v Kivmn Rbej #b#qvM I c#k#Y#Yi e`e`v Ki#Z n#e, Zrm#1/2 JI#ai Ace`envi Ges Ac#P#Krmv #iv#A I JI#ai th#3K e`envi I Jla m#k# we#l#q Rbm#PZbZv e#xi Rb` #bq#gZ #c#U I B#jKU#bK #g#Wqvq weAvcb cP#i#i e`e`v Ki#Z n#e  we#fb #`K- tnv#vi#i mv#_gZ#e#bqg m#fvi Av#q#Rb

ক্রমিক bs	mgm`v/mxgveXZv	ibim#bi Dcvq
		Kiv
07	NCL-Gi AMv#bVmg cYqbceK BtZvgta" gSYvj#q #ciY Kiv n#q#Q A`veia Abtgv`b cvlqv hvq bvB	NCL-Gi AMv#bVmg Abtgv`#bi e`e`v MnY Kiv

29| fel`r ciIKÍbv t

- (K) Jla ckymb Aia`B#ii mKj কার্যক্রম Avil mgyI KvHKi fve cwiPvjbvI Rb" AMv#bVmg m#mviYceK c#qvRbxq #jvKej #btq#M Kivi c`#yc MnY Kiv|
- (L) National Regulatory Authority(NRA)-tK WHO KZK. Functional NRA #n#m#e`xK#Z ARb Kiv|
- (M) NCL-Gi AvIZvq Animal House vcb Ges cixyv I #e#kl#Yi h_vh_ e`e`v MnY Kiv Ges NCL-tK WHO Prequalified Laboratory #n#m#e`xK#Z ARb Kiv|
- (N) NCL Ges Drug Testing Laboratory-Gi Rb" chv# dvU Gi e`e`v Kiv|
- (O) c#qvRbxq #jvKej I AvB#U BK#C#gUmn Jla ckym#bi Af`#i GK#U AvB#U #mj Mvb Kiv|
- (P) Jla ckymb Aia`B#ii KgKvU A#Uv#gkb প্রক্রিয়ায় m#ub Kivi c`#yc MnY Kiv n#e|
- (Q) RvZxq Jla bx#Z-2016 #gvZ#teK JI#ai cvkvicwK RbM#Yi Rb" gvbma#ub I #bivc` Jla msikó Lv` I Jla msikó cmvabmvgMx #b#dZK#i G RvZxq `e`# Jla ckym#bi #bqSYf³ K#i DbZ #e#ki Av`#j Jla ckymb#K Food & Drug Administration-G ijcv#i Kiv|
- (R) BDbvbx, Avqte`K, #nvglc`v_K I nvej Jlamg#ni cixyv I #e#kl#Yi #big#E GK#U AvaybK j`ve#iUix`vcb Kiv|
- (S) Jla AvBb-1940 I Jla (#bqSY) Aa`v#`k-1982 GKxfZ K#i Ges c#qvRbxq Ab`vb" #elq#` A#f# K#i evsjv fvlvq GK#U Lmov AvBb cYqbceK gSYvj#q #ciY Kiv n#q#Q| AvB#U Abtgv`#bi c`#yc MnY Kiv Ges cYxZ AvB#bi AvIZvq c#qvRbxq #eia cYqb Kiv|
- (T) পর্যায়ক্রমে দেশের সকল বিভাগীয়, জেলা ও উপজেলা পর্যায়ের হাসপাতালগুলোতে ADR Focal point #baviY Kiv Ges mviv #`ke`vcx D³ কার্যক্রম জোরদার করা।
- (U) mKj Jla Drcv`b I Avg`vbxKvIK c#Z#b KZK Z#`i evRvRvZKZ.JI#ai Adverse Drug Reaction (ADR) #bq#gZ g#bU#isceK Jla ckymb Aia`Bi eivei #i#cvU #ci#Yi e`e`v #b#dZ Kiv|
- (V) পর্যায়ক্রমে সকল বিভাগীয় ও জেলা পর্যায়ে Jla ckymb Aia`B#ii A#dm feb #bgvY Kiv|
- (W) RvZxq Jlab#Z-2016 Gi #b`# kbvmg#ev evq#bi D#`vM MnY Kiv|
- (X) #`#k JI#ai Bioavailability, Bioequivalence Ges Clinical Trial-Gi Rb" c#qvRbxq m#eam` m#oi D#`vM MnY Kiv|
- (ন) পর্যায়ক্রমে সকল মেডিক্যাল ডিভাইস নিবন্ধন করা এবং মূল্য নির্ধারণ করা।
- (Z) CTD-Format G JI#ai #i#R#÷kb Av#e`b MnY Kiv|
- (_) #eKí avivi JI#ai Rb" GMP MvBW jvBb cYqb Kiv|
- (.) Bio-similar product m#Zl KvHKi fve #bqS#Yi Rb" #i#R#÷kb MvBW jvBb cYqb Kiv|
- (a) Jla ckymb Aia`B#ii feb#U cuPZjv chS #bgvY KvR m#ub Kiv|

30| Dcmsnvi t

Jla ckymb KZK 2016 mv#j m#m#`Z #e#fb KgKv#U#i Ges Jla ckymb সংক্রান্ত #e#fb Z`v#` m#b#ek K#i e#iK c#Z#e`b-2016 cYqb Kiv n#q#Q| cYxZ c#Z#e`b#U Jla ckymb I ckym#bi কার্যক্রমের m#ieK #Pí Dc`vicZ n#q#Q| RbMY G c#Z#e`b n#Z Jla ckym#bi mvg#MK e`e`vcbv I KgKvU m#u#K aviyv c#te| AvMvg#`b, #jv#Z Avil KvHKi I m#Z#te KvH m#u#`b G c#Z#e`b KgKZv I KgPvix`i I #K#b#`kbv #`#e| G c#Z#e`b ckym#bi mKj ch#qi KgKv#U#i "QZv I Reve`nZv #b#dZ Ki#e| RbM#Yi Kv#LZ #mev c#B#Z G c#Z#e`b mnvqK n#e| c#Z#e`b cK#kZ Z` Jla Drcv`bKvix, Avg`vbxKvix I বিক্রয়কারী c#Z#bmg#ni KgKvU cwiPvjbv mn#hvMx n#e| gvbma#ub Jla Drcv`b I #ecbb #b#dZ Ki#Z GK#U k#<sup>3</sup>kvjx I KvHKi Jla ckym#bi #eKí bvB| c#ZeQi cK#kZ c#Z#e`b ckym#bi `#j#`K I mgm`v, #jv Z#j aiv nq, #bim#bi Dcvq I AvMvg#`#bi Kg-ciIKÍbv Dc`vicZ nq| #m #gvZ#teK ckymb#K k#<sup>3</sup>kvjx I KvHKi Kivi c`#yc MnY Kiv nq| Jla ckym#bi mn#hvMxZvq

I ॥`K॥b†`kbvq evsjv†`†ki ঔষধশিল্পে প্রমাণিত G॥M†q hv†"Q, RbM†Yi Rb" gvb mൠb I lḡ ॥b॥ðZ Kiv mൠe n†"Q,
 †`k JI†a ̄qsmൠú†n†"Q Ges JIa iβvb†i c॥igvY mg†qi mv†_ mv†_ eḡ× cv†"Q|
 Rb̄v†_ Gijc c॥Z†e`b c॥Z eQi cKvk Kiv n†e|

c*i*ikó t

**c*i*ikó-K t Jla ckymb Aia`β*i*i** বিভিন্ন কার্যক্রমের আবেদনের সাথে `v*Lj*#h*M*" c#q*v*R*b*xq K*v*M*Rc*Î*v*`i

Z*v*j*Kv* t

K.1 Jla Drc*v*`b K*v*iL*lv*i`vc#*bi* bZ*ly*ck*I* Ab*ty*g*v*`#*bi* R*b*" c#q*v*R*b*xq K*v*M*Rc*Î*v*`/Z_`v*v*`

- 1| c*K*#*i* b*v*g|
- 2| c*K*#*i* v*K*i*b*v|
- 3| D#`v<sup>3</sup>*vi* k*y*v*MZ* #h*v*M`Z*v* Ges c*K*#*i* A*M*v#*b*v*M*g|
- 4| †K*v*ac*v**b*i aiY (c*v*B#f*U*, c*v*e*j*K †j*t*/e`³ g*v*j*K*v*b*)|
(†j*ig*#U*W* †K*v*ac*v**b*i †y#Î R#qÊ ÷ K †K*v*ac*v**b*i m*v*iU*id*#K*U* Ae B*b*K#c*v*#i*k*b `v*Lj* K*i*#Z n#e)
- 5| c*K*#*i* m#e*g*U †e*b*#q*v*M|
- 6| A#_i D*r*m|
- 7| B*K*ÎU|
- 8| c`Z*v*eZ †g*ik**b**v*i#R*i* g*v*a#g e*v*iK Drc*v*`b y*g*Z*v*|
- 9| c*K*#*i* eZ*g**v*b Ae`n*v*|
- 10| AeK*v*W#g*v*MZ m*y*e*a*v`|
- 11| A*b*`v*b* m*y*e*a*v`|
- 12| Drc*v*`b †g*ik**b**v*i#R*i* Z*v*j*K*v|
- 13| g*v*b-†bqš#Y*i* hšc*v*Z*i* Z*v*j*K*v|
- 14| †c*v*W*K*k*b* †c*v*M*g*|
- 15| c#q*v*R*b*xq K*U*g*v*j I †g*vo*K*m*g*M*x*i* †e*e*iY|
- 16| K*v*iM*i*x `yZ*v*m*ac*b R*b*e#j*i* Z*v*j*K*v|
- 17| প্রাক্কলিত বিক্রয়।
- 18| m*ave* A*v*q|
- 19| †eK B#f*b* G*b**v*j*v*B*im*m|
- 20| †h m*K*j c` Drc*v*`b K*v*i n#e Z*v*i h*y*šKZ*v*|
- 21| c*K*#*i* c*Y*#j-A*v*D*U* c`v*b*|
- 22| D#`v<sup>3</sup>*vi* R*v*Z*x*qZ*v* m*b*`|
- 23| D#`v<sup>3</sup>*vi* e`v*s*K m"Q*j*Z*v* m*b*`|
- 24| †U*W* j*v*B#m*Y*|
- 25| c*i*#e*k* Aia`β*i* n#Z A*b**v*c#E m*b*`|
- 26| †e*m*A*v*B*m*/†e*W* Ae B*b*#f ÷ †gÊ n#Z c#R± †b*e*Ü*b* m*b*`|
- 27| c*Y*R †e*b*#q*v*MK*v*i*x*/D#`v<sup>3</sup>*vi* †U*A*vB*G*b m*b*`|

†et`*t* A*m*ac*Y*A*v*#e`b †e#eP*b**v*#h*v*M" b*q*|

*†e#k*l* †y#Î D*v*j#LZ Z*v*j*K*vq K*v*M*Rc*Î*v*` m#h*v*R*b*/c#i*e*Z#*bi* y*g*Z*v* KZ*ç*y m*s*i*y*Y K#i|

K.2 Drc*v*`#*bi* R*b*" cP*j*Z A`†j*v*c`v*v*\_K JI#ai †i*m*i*c* Ab*ty*g*v*`#*bi* R*b*" c#q*v*R*b*xq K*v*M*Rc*Î*v*`/Z\_`v*v*`

- 1| g*v*i*c*#iP*v*j*K*, Jla ckymb Aia`β*i* e*e**v*i A*v*#e`b*c*Î|
- 2| Jla ckymb KZ*K* c*Y**X*Z d*ig* †W*G*-1/88 A_e*v* d*ig* †W*G*-2/88 G D*v*j#LZ Z_`v*v*`/K*v*M*Rc*Î*v*`|
- 3| †i*m*i*c* g#v*q*b †d e*v*e` 5000/- U*v*K*v*i †U*R**v*i*x* P*v*j*v*#*bi* g#K*i*c|
U*v*K*v* R*g*v †I*q**v*i †K*v*W t

1	2	7	1	5	0	0	0	0	1	8	6	3
---	---	---	---	---	---	---	---	---	---	---	---	---

- 4| উৎপাদন লাইসেন্স হালনাগাদ নবায়নের সনদ। লাইসেন্স নবায়ন প্রক্রিয়াধীন থাকলে সে সংক্রান্ত তথ্যাদি।
- 5| j*v*B#m#Y Aš*f*y †W#R*m* d*ig* I JI#ai †k*Y**x*|
- 6| K*v*iL*lv*bq †b#q*v*RZ †K*v*q*v*j*d**v*BW e`v³#i Z*v*j*K*v|
- 7| A*v*#e`Z c`U †W*m*i*m* (W*M* K#Ê*v*j K*ig*U) KZ*K* Ab*ty*g*v*`#*bi* c#y Z\_`v*v*`|

*†e#k*l* †y#Î D*v*j#LZ Z*v*j*K*vq K*v*M*Rc*Î*v*` m#h*v*R*b*/c#i*e*Z#*bi* y*g*Z*v* KZ*ç*y m*s*i*y*Y K#i|

K.3 A*v*B*G*b*G*b (INN) Z*v*j*K*i*f*³ c#`i b*g**h* c*i**x**y* I †e#k*l*#Y*i* R*b*" c#q*v*R*b*xq K*v*M*Rc*Î*v*`

- 1| g*v*i*c*#iP*v*j*K*, Jla ckymb Aia`β*i* e*e**v*i A*v*#e`b*c*Î|
- 2| †i*m*i*c* Ab*ty*g*v*`b c#Î*i* K*i*c|
- 3| c*i**x**y* I †e#k*l*#Y*i* †d e*v*e` 15,000/- U*v*K*v*i †U*R**v*i*x* P*v*j*v*#*bi* g#K*i*c|

UvKv Rgv t` Iqvi tKvW t

1 2 7 1 5 0 0 0 0 1 8 6 3

- 4| ~~Uvfb~~ tWtRm dig-Gi Jla ckymb KZK ~~ibaw~~iZ cwigv bgtv |
5| সক্রিয় কাঁচামালের Drcv`bKvix cizôvb KZK c`q tU÷ tcvUKj/cixÿv I ~~we~~kl†Yi tg_W|
6| সক্রিয় কাঁচামালের সার্টিফিকেট অব এনালাইসিস-Gi Klc|
7| সক্রিয় কাঁচামালের রেফারেন্স/ওয়ার্কিং স্ট্যান্ডার্ড।
* ~~we~~kl†y†Î DvjLZ ZvjKvq KvMRcÎv` ms†hvRb/cwieZ†bi ÿgZv KZçÿ msiÿY K†i|

K.4 bZp A`†jvc`m K Jla Drcv`b jvB†mY BmYi Rb` c†qvRbxq KvMRcÎv`

- 1| h_vh_fv†e c†YKZ.dig bs-12 Ges dig bs-15|
2| bZp jvB†mY id t ev†qvjRK`vj-1,00,000/- (GK jÿ UvKv)
bb-ev†qvjRK`vj-50,000/- (cÂvk nvrvi UvKv)
id e`vs†K Rgv w`†q †URvix Pvjvb Gi g† Klc|

UvKv Rgv t` Iqvi tKvW t

1 2 7 1 5 0 0 0 0 1 8 6 3

- 3| cK†í c`ZweZ c`mg†ni†iimic|
4| nvjbvMv`†UW jvB†mY-Gi Klc|
5| ~~n~~vicZ hšÎcviZi ZvjKv (Drcv`b I gvb`bqšÎY ~~we~~fv†Mi c„K ZvjKv)|
6| †KvqvjdıBW e`w`3†`i ZvjKv (ZvjKvq c`ex, †kyvMZ †hvM`Zv, †czvi bvg, ~~n~~vq I eZgıv †VKıvı D†jL_vK†Z n†e)|
7| †KvqvjdıBW e`w`3†`i †b†qvMcÎ, †hvM`vbcÎ, mb` c†îi Klc I A½Kvıbvıgı|
8| gıvıK/cııPvj†Ki ZvjKv (ZvjKvq †czvi bvg, ~~n~~vq I eZgıv †VKıvı D†jL_vK†Z n†e)|
9| KvıLvııı†j-AvDU c`vb|
10| Drcv`b I gvb`bqšÎ†Yi Rb` c†qvRbxq †ıdı†ıY eB†qi ZvjKv|
11| cK†ı Ab†gı`†bi m†ıı†Ki Klc|
12| cizôv†bi AMv†bvıvgı|
13| mvBU gv÷vi dıBj|
14| cıı†ek Aıa`Bi n†Z cıı†ekMZ mb`|
* ~~we~~kl†y†Î DvjLZ ZvjKvq KvMRcÎv` ms†hvRb/cwieZ†bi ÿgZv KZçÿ msiÿY K†i|

K.5 A`†jvc`m K Jla Drcv`b jvB†mY c` Ašf†ı Rb` c†qvRbxq KvMRcÎv`

- 1| gıvıııPvjK, Jla ckymb Aıa`Bi eıvei Av†e`bcÎ|
2| Jla ckymb n†Z cvB †iimic Ab†gı`b c†îi Klc|
3| †cWı± Ašfı† id eve` 10,000/- UvKvi †URvix Pıjıv†bi g† Klc|

UvKv Rgv t` Iqvi tKvW t

1 2 7 1 5 0 0 0 0 1 8 6 3

- 4| c`U AvBGbGb ZııjKıf`3 c` n†j cıxÿv I ~~we~~kl†Yi Rb` Jla ckymb KZK ~~ibaw~~iZ cwigvY bgtv I †U÷ c†UvKj/cıxÿv-~~we~~kl†Yi c×ıZ|
5| bgtv cıxÿv-~~we~~kl†Yi id t AvBGbGb ZııjKıf`3 n†j 15000/- UvKvi †URvix Pıjıv†bi g† Klc| ~~we~~c/BDGmıc Ašf`3 †cWı± 5000/- UvKvi †URvix Pıjıv†bi g† Klc|

- 6| Lıııı†gııKııgMııı Text|
7| c†`ı ZiııııZ ~~n~~ııııııZ cıxÿvı WıUı (Accelerated Stability Study Data)|
8| c†`ı A`†ıb`vı|
* ~~we~~kl†y†Î DvjLZ ZvjKvq KvMRcÎv` ms†hvRb/cwieZ†bi ÿgZv KZçÿ msiÿY K†i|

K.6 †gııKııgMıı Ab†gı`†bi Rb` c†qvRbxq KvMRcÎv`/Z`v`

- 1| cııZôv†bi ~~ibaw~~iZ c`v†W gıvıııPvjK Jla ckymb eıvei Av†e`bcÎ|
2| Jla ckymb KZK †iimic Ab†gı`†bi m†ıı†Ki Klc|
3| c` Ašfı† Ges cıxÿv-~~we~~klıY id-Gi †URvix Pıjıv†bi g† Klc|
4| cııZıU c†`ı Rb` 2(†) †ııU †gııK mııgMııı Lıııı Text|

`mLjKZ.KıU†bıbg eıYZ Z`v`_vK†Z n†e t

Jl'ai tɣoʔK Z_ c`vʔbi tɣʔÎ cYxZ ɛlqK æGuideline for product information on packaging material” Abɣvq Z\_ c`vb KiʔZ nʔe|
 *ɛʔkl tɣʔÎ DɿjLZ ZvjKvq KvMRcÎv` msthvRb/cwieZʔbi ɣgZv KZçy msiyY Kʔi|

K.7 t`k Drcv`Z I gʔ` ɪbqʔSZ ZvjKv fʔ A`vʔjvc`v\_K Jl'ai mʔev`P Lɣiv gʔ` ɪbav iY/gʔ` ɪbqʔSY ZvjKv ɛɪnfZ Jl'ai f`vU c`vʔbi ɪbqʔE ɪbʔ`kK gʔ` mbʔ`i Rb` cʔqvRbq KvMRcÎv`

- 1| gnvciPvjK, Jla ckvmb Aia`Bi eivei Avʔe`bcÎ|
 - 2| gʔ` ɪbqʔÎZ ZvjKv fʔ Jla I gʔ` ɪbqʔSY ZvjKv ɛɪnfZ Jl'ai Rb` c\_K c`Zvebv mseijZ Avʔe`b|
 gʔ` ɪbqʔÎZ Jl'ai mʔev`P Lɣiv gʔ` ɪbav iYi Rb` c`vebvq Jl'ai ɛvYiR`K bvg, tRʔbi iK bvg, c`vK mʔBR, miKvi KZK ɪbav iZ gʔ`, tUW cʔBm, gʔK tʔvM` gʔ`, f`vU ɛ`ZZ mʔev`P Lɣiv gʔ`, f`vU mn mʔev`P Lɣiv gʔ` DʔjL KiʔZ nʔe|
 - 3| Avʔe`Z cʔ`i ɛea tɣqʔ`i A`vʔb`vi Kic|
 - 4| সক্রিয় উপব`vb mʔMʔni Abɣvq`Z eKij ÷ (ea tɣqʔ`i) A_ev Bb fʔqm Kic|
 - 5| mʔev`P Lɣiv gʔ` cʔt ɪbav iY/f`vU c`vʔbi ɪbqʔE cʔtaviKZ.ɪbʔ`kK gʔ` mbʔ`i Rb` BZtcʔe BmYKZ.gʔ` mbʔ`i Kic|
- *ɛʔkl tɣʔÎ DɿjLZ ZvjKvq KvMRcÎv` msthvRb/cwieZʔbi ɣgZv KZçy msiyY Kʔi|

K.8 Jla Drcv`ʔbi ɪbqʔE Avg`vbKZ.KvPvgj/c`vKs g`vʔU iqvj-Gi eKij ÷ Abɣv`ʔbi Rb` cʔqvRbq KvMRcÎv`

- 1| gnvciPvjK, Jla ckvmb Aia`Bi eivei Avʔe`bcÎ|
 - 2| ɪbav iZ tcvdigv Abɣvq cYxZ eKij ÷ 08(AvU) Kic|
eKij ÷ tcvdigv ɪbgeYZ Z_`v` DʔjL KiʔZ nʔe t
 - cʔZôvʔbi bvg I ɪVKivbv|
 - ɪmɪmAvB I BGM K`vUvMix Ges ʔiɪRʔ ÷ kb bɔi|
 - ɪeMZ ermʔii Avg`vbx i cʔigvY|
 - jvBʔmʔYi aiY|
 - Port of Arrival
 - ɪeMZ ermʔi f`vU c`vʔbi cʔigvY|
 - KvPvgj/c`vKs g`vʔU iqvj Gi bvg I ʔ`úim dʔKkb|
 - c`ZKviK I mieivnKvix cʔZôvʔbi bvg I ɪVKivbv|
 - Pɪn`vKZ.KvPvgj i cʔigvY (K_vq I AsʔK)|
 - KvPvgj I c`vKs g`vʔU iqvj Gi cʔZ BDibʔUi gʔ` (AvʔRvZK gʔvq)|
 - ʔgvU Pɪn`vKZ.KvPvgj i gʔ` UvKvq|
 - KvPvgj/c`vKs g`vʔU iqvj Gi ɪecixʔZ Abɣv`Z ɪdɪbmW ʔcvWvʔ Gi bvg I ɪeMZ ermʔi Bnvi Drcv`b Ges KvPvgj/c`vKs g`vʔU iqvj Avg`vbx i cʔigvY|
 - PjvZ eQʔii D³ KvPvgj/c`vKs g`vʔU iqvj Abɣv`ʔbi Ges ʔgvU Pɪn`vi cʔigvY|
 - 3| আবেদিত সক্রিয় কাঁচামালের প্রস্তুতকারক ঔষধ প্রশাসন কর্তৃক ভ্যালিডেটেড হতে হবে।
 - 4| eKij ÷ ʔiɪR ÷ vW digv m ÷ KZK mʔYiZ nʔZ nʔe|
- *ɛʔkl tɣʔÎ DɿjLZ ZvjKvq KvMRcÎv` msthvRb/cwieZʔbi ɣgZv KZçy msiyY Kʔi|

K.9 A`vʔjvc`v_K Jla Drcv`b jvBʔmY bevqʔbi ɪbqʔE cʔqvRbq KvMRcÎv`

- 1| gnvciPvjK, Jla ckvmb Aia`Bi eivei Avʔe`bcÎ|
- 2| h_vh_ fʔvʔe cʔYKZ.WvM iym 1946 G ɛvYZ Avʔe`b dig bs-12 Ges dig bs-15|
- 3| jvBʔmY bevqʔ ɪd Gi ʔURvix Pvjvʔbi gʔ` Kic|
 UvKv Rgv t` I qvi ʔKvW t

1	2	7	1	5	0	0	0	0	1	8	6	3
---	---	---	---	---	---	---	---	---	---	---	---	---

jvBʔmY bevqʔ ɪd Gi cʔigvY t
 (K) bb-evʔqv jRK`vj Jla Drcv`b jvBʔmY bevqʔ ɪd 15,000/- UvKv |
 (L) evʔqv jRK`vj jvBʔmY bevqʔ ɪd 30,000/- UvKv |
- 4| ɪeMZ jvBʔmY bevqʔ mbʔ`i gʔ` Kic|

- 5| c`i ZvjKv (ZvjKvq eYR`K bvg, R`bIK bvg, gV, WGAvi bs Ges tggv` DExYi ZvIL D`jL _vKZ nte)|
- 6| jvBmYf`3 tggv` DExY c`i Annexure Gi gj`Kic|
- 7| tggv` DExY c`i bevqb id eve` 10,000/- UvKvi tURvix Pvjv`bi gj`Kic|
- 8| bevqb`bi Rb` c`ZveZ c`/c`mg`ni PevS tgvokmvgMx|
- 9| KvILvbi tj-AvDU c`vb| c`g`mm Gi c`imi, KfW Gviq, IqvKs Gviq Ges Gviq c`iPiz mn mvBU gv`vi dvBj|
- 10| e`e`nvcbv c`iPvjK KZK mv`iZ c`Zov`bi AMv`bMvg|
- 11| tKqvjdBW c`mb`i ZvjKv (bvg, c`Zvi bvg, c`ex, tKqvjd`Kkb, t`R`÷kb bs, AfÁZv, c`Zov`b thvM`v`bi ZvIL, `nvq I eZgvb vKvbi D`jL KiZ nte)|
- 12| tKqvjdBW e`v`3`i thvM`vbc`I I AsMxKvibvg|
- 13| c`iPvjK/gvjK`i ZvjKv (c`ex, c`Zvi bvg, `nvq I eZgvb vKvbm)|
- 14| e`e`nvcbv c`iPvjK`i mv`iKZ.hšIcviZi ZvjKv (Drcv`b I gvb`bqšY efv`Mi c`K ZvjKv)|
- 15| eMZ 2(8) erm`ii Drcv`b eeiYx|
- *e`kl t`y`I D`jLZ ZvjKvq KvMRC`v` ms`hRb/c`ieZ`bi ygZv KZçy msi`yY K`i|

K.10 A`t`jvc`w\_K Jla Drcv`b jvBmY Gi gvjKvbi c`ieZb`nvbš`ii bvg`E c`qvRbq KvMRC`v`

- 1| gnv`iPvjK, Jla ckvmb Aia`Bi eivei Av`e`bc`I|
- 2| Jla ckvmb Aia`Bi n`Z gvjKvbi n`vš`ii c`vbtg`v`b c`I I Kic|
- 3| c`Zov`bU j`t tKv`c`v` n`j Memorandum & Article of Association Ges Certificate of Incorporation Gi Kic, e`v`3 gvjKvbi n`j gvjKvbi n`vš`ii Gid`WieU Gi Kic|
- 4| e`v`3 gvjKvbi jvBmY n`j gvjKvbi c`ieZb id Gi tURvix Pvjv`bi gj`Kic|

UvKv Rgv t` Iqv tKvW t

1	2	7	1	5	0	0	0	0	1	8	6	3
---	---	---	---	---	---	---	---	---	---	---	---	---

jvBmY-Gi gvjKvbi c`ieZb id Gi c`igY t

(K) bb-evtqv`RK`vj Jla Drcv`b jvBmY`i gvjKvbi c`ieZb id 1,00,000/- UvKv|

(L) evtqv`RK`vj Jla Drcv`b jvBmY`i gvjKvbi c`ieZb id 2,00,000/- UvKv|

- 5| nvjbmV` tUW jvBmY Gi Kic|
- 6| c`i ZvjKv (ZvjKvq eYR`K bvg, R`bIK bvg, gV, WGAvi bs Ges tggv` DExYi ZvIL D`jL _vKZ nte)|
- 7| c`ZveZ KvILvbi tj-AvDU c`vb| c`g`mm Gi c`imi, KfW Gviq, IqvKs Gviq Ges Gviq c`iPiz mn mvBU gv`vi dvBj|
- 8| e`e`nvcbv c`iPvjK/gvjK KZK mv`iZ c`Zov`bi AMv`bMvg|
- 9| vbtq`RZ tKqvjdBW c`mb`i ZvjKv (bvg, c`Zvi bvg, c`ex, tKqvjd`Kkb, t`R`÷kb bs, AfÁZv, c`Zov`b thvM`v`bi ZvIL, `nvq I eZgvb vKvbi D`jL KiZ nte)|
- 10| tKqvjdBW e`v`3`i thvM`vbc`I I AsMxKvibvg|
- 11| c`iPvjK/gvjK`i ZvjKv (c`ex, c`Zvi bvg, `nvq I eZgvb vKvbm) c`iPvjK/gvjK`i bvmiKZ mb`|
- 12| e`e`nvcbv c`iPvjK/gvjK KZK mv`iKZ.hšIcviZi ZvjKv (Drcv`b I gvb`bqšY efv`Mi c`K ZvjKv)|
- 13| e`v`K m`QjZv mb`i Kic|
- 14| c`i`ek Aia`Bi n`Z c`i`ekMZ mb`i Kic|
- 15| `nvbš`ii t`y`I c`ZveZ vKvbiq KvILvbi Ae`nvb m`c`K msi`kó KZçy`i mb`|
- 16| KvILvbiU bRm c`g`mm-G c`ZvôZ n`j gvjKvbi c`y` j`jc`I, fvo`KZ.c`v`b n`j fvo`Py`bvgi Kic|
- 17| `nvbš`ii t`y`I c`ZveZ vKvbi t`gRvi bvg|
- 18| c`Zov`bi bvg tKvbi e`v`K ev Ab` tKvbi c`Zov`b n`Z BZtc`e FY MnY K`i _vK`j Zvi eeiY Ges tm FY c`i`k`ai A`xKvibvg|

*e`kl t`y`I D`jLZ ZvjKvq KvMRC`v` ms`hRb/c`ieZ`bi ygZv KZçy msi`yY K`i|

K.11 e`kx Jla t`iR`÷k`bi Rb` c`qvRbq KvMRC`v`

- 1| e`kx Jla c`ZvKvix c`Zov`b KZK g`bvbiZ `nvbq (evjv`kx) c`Zv`ia KZK Av`e`bc`I|
- 2| h_vh_fv`e c`YKZ.Form DA-1/88|

- 3| $\dagger i\text{m}\text{m}\text{c} \text{ g}\ddot{\text{f}}\text{v}\text{q}\text{b} \text{ d} \text{ eve} \text{ ` } 35,000/- \text{ U}\text{v}\text{K}\text{v} \text{ } \dagger \text{U}\text{R}\text{v}\text{i}\text{x} \text{ P}\text{v}\text{j}\text{v}\ddot{\text{b}}\text{i} \text{ g}\ddot{\text{f}}\text{K}\text{i}\text{c} |$
 4| $\dagger \text{K}\text{v}\text{a}\text{c}\text{v}\text{b}\text{x} \text{ } \dagger \text{c}\text{v}\text{d}\text{v}\text{B}\text{j} |$
 5| $\dagger \text{c}\text{v}\text{W}\text{v}\pm \text{ } \dagger \text{c}\text{v}\text{d}\text{v}\text{B}\text{j} |$
 6| $\text{Drcv}\text{`bKvix} \text{ } \ddot{\text{f}}\text{`k}\text{i} \text{ Health Authority KZK m}\ddot{\text{v}}\text{y}\text{i}\text{Z CPP/FSC h}\text{v}\text{n}\text{v} \text{ evs}\text{j}\text{v}\ddot{\text{f}}\text{`k} \text{ `Zvevm KZK mZ}\text{v}\text{i}\text{q}\text{Z} |$
 7| Human Medicine Registration-Gi $\ddot{\text{f}}\text{y}\ddot{\text{f}}\text{t}$
 K) $\text{h}\text{m}\text{` Drcv}\text{`bKvix} \text{ } \ddot{\text{f}}\text{`k} \text{ A}\ddot{\text{f}}\div\text{v}\text{j}\text{q}\text{v}, \text{ d}\text{v}\text{Y}, \text{ R}\text{v}\text{g}\text{v}\text{b}\text{x}, \text{ R}\text{v}\text{c}\text{v}\text{b}, \text{ m}\text{B}\text{R}\text{v}\text{i}\text{j}\text{v}\text{U}, \text{ h}\text{y}\text{v}\text{R}\text{` ev h}\text{y}\text{v}\text{v}\div \text{ nq } \text{tm } \ddot{\text{f}}\text{y}\ddot{\text{f}}\text{t}$
 Country of Origin-Gi CPP/FSC.
 L) $\text{Drcv}\text{`bKvix} \text{ } \ddot{\text{f}}\text{`k} \text{ h}\text{m}\text{` D}\text{i}\text{j}\text{v}\text{LZ} \text{ 7}\text{v}\text{U} \text{ } \ddot{\text{f}}\text{`k}\text{i} \text{ evB}\text{i} \text{ nq } \text{tm } \ddot{\text{f}}\text{y}\ddot{\text{f}}\text{t}$ Country of Origin / $\text{D}\text{i}\text{j}\text{v}\text{LZ} \text{ 7}\text{v}\text{U} \text{ } \ddot{\text{f}}\text{`k}\text{i}$
 $\text{ } \ddot{\text{f}}\text{h} \text{ } \dagger \text{K}\text{v}\text{b} \text{ G}\text{K}\text{v}\text{U} \text{ } \ddot{\text{f}}\text{`k}\text{i} \text{ FSC/ CPP.}$
 8| Veterinary Medicine Registration-Gi $\ddot{\text{f}}\text{y}\ddot{\text{f}}\text{t}$
 K) $\text{h}\text{m}\text{` Drcv}\text{`bKvix} \text{ } \ddot{\text{f}}\text{`k} \text{ Australia, Austria, Belgium, Canada, Denmark, Finland, France, Germany, Hungary, Ireland, Italy, Japan, The Netherlands, Norway, Singapore, Sweden, Switzerland, UK, USA, Russia, Poland, Spain, South Korea or Czechoslovakia nq } \text{tm } \ddot{\text{f}}\text{y}\ddot{\text{f}}\text{t}$
 Country of Origin-Gi FSC/ CPP.
 L) $\text{Drcv}\text{`bKvix} \text{ } \ddot{\text{f}}\text{`k} \text{ h}\text{m}\text{` D}\text{i}\text{j}\text{v}\text{LZ} \text{ 24}\text{v}\text{U} \text{ } \ddot{\text{f}}\text{`k}\text{i} \text{ evB}\text{i} \text{ nq } \text{tm } \ddot{\text{f}}\text{y}\ddot{\text{f}}\text{t}$ Country of Origin / $\text{D}\text{i}\text{j}\text{v}\text{LZ} \text{ 24}\text{v}\text{U}$
 $\text{ } \ddot{\text{f}}\text{`k}\text{i} \text{ } \ddot{\text{f}}\text{h} \text{ } \dagger \text{K}\text{v}\text{b} \text{ G}\text{K}\text{v}\text{U} \text{ } \ddot{\text{f}}\text{`k}\text{i} \text{ FSC/ CPP.}$

9| $\text{c}\text{`U}\text{i} \text{ B}\ddot{\text{s}}\text{i}\text{R}\text{v}\text{evs}\text{j}\text{v} \text{ f}\text{v}\text{I}\text{v}\text{q} \text{ g}\text{y}\text{Z} \text{ t}\text{g}\text{v}\text{oK}\text{m}\text{v}\text{g}\text{M}\text{x}\text{i} \text{ b}\text{g}\text{b}\text{v} \text{ Ges } \ddot{\text{f}}\text{W}\text{m}\text{m}\text{q}\text{v}\text{i} |$
 $\text{*}\text{e}\ddot{\text{f}}\text{e}\text{k}\text{l} \text{ } \ddot{\text{f}}\text{y}\ddot{\text{f}}\text{t} \text{ D}\text{i}\text{j}\text{v}\text{LZ} \text{ Z}\text{v}\text{i}\text{j}\text{K}\text{v}\text{q} \text{ K}\text{v}\text{M}\text{R}\text{c}\text{v}\text{v}\text{` ms}\ddot{\text{f}}\text{h}\text{v}\text{R}\text{b}/\text{c}\text{v}\text{i}\text{eZ}\ddot{\text{f}}\text{b}\text{i} \text{ } \ddot{\text{y}}\text{g}\text{Z}\text{v} \text{ KZ}\text{c}\text{y} \text{ m}\text{s}\text{i}\text{y}\text{Y} \text{ K}\ddot{\text{f}}\text{i} |$
K.12 eW e'vM, vBWjm mn mviRK'vj BKbc'gU I tgvW'Kj vWf'vBmm Avg`vbi Av'e`bi Rb` c'qvRbxq KvMRc'v`

- 1| $\text{Av}\ddot{\text{f}}\text{e}\text{`bKvix}\text{i} \text{ G}\ddot{\text{f}}\text{R}\text{Y}\text{x} \text{ G}\text{v}\text{M}\ddot{\text{g}}\text{U} |$
 2| $\text{Av}\ddot{\text{f}}\text{e}\text{`bKZ.c}\ddot{\text{f}}\text{`i} \text{ c}\text{`ZKv}\text{i}\text{K}\ddot{\text{f}}\text{`i} \text{ } \dagger \text{K}\text{v}\text{a}\text{v}\text{b}\text{x} \text{ } \dagger \text{c}\text{v}\text{d}\text{v}\text{B}\text{j} |$
 3| $\text{Av}\ddot{\text{f}}\text{e}\text{`bKZ.c}\ddot{\text{f}}\text{`i} \text{ } \dagger \text{c}\text{v}\text{W}\text{v}\pm \text{ } \dagger \text{W}\text{m}\text{m}\text{q}\text{v}\text{i} |$
 4| $\text{Drcv}\text{`bKvix} \text{ c}\text{v}\text{Z}\ddot{\text{o}}\text{v}\ddot{\text{f}}\text{b}\text{i} \text{ D}\text{r}\text{m} \text{ (Country of Origin) } \ddot{\text{f}}\text{`k}\text{i} \text{ Registration Competent Authority n}\ddot{\text{f}}\text{Z} \text{ Free Sale Certificate (evs}\text{j}\text{v}\ddot{\text{f}}\text{`k} \text{ `Zvevm KZK mZ}\text{v}\text{i}\text{q}\text{Z}) |$
 5| Form DA-1/88 (for introduced product), Form DA-2/88 (for non-introduced product), $\text{c}\ddot{\text{f}}\text{b} \text{ K}\text{i}\ddot{\text{f}}\text{Z} \text{ n}\ddot{\text{f}}\text{e} |$
 6| $\dagger i\text{m}\text{m}\text{c} \text{ d} \text{ c}\text{v}\text{Z} \text{ c}\text{v}\text{W}\text{v}\pm \text{ i} \text{ Rb}\text{` } 5000/- \text{ U}\text{v}\text{K}\text{v} |$
 7| $\dagger i\text{v}\text{R}\ddot{\text{f}}\div \text{kb} \text{ d} \text{ 35000/- c}\text{v}\text{Z} \text{ } \dagger \text{c}\text{v}\text{W}\text{v}\pm \text{ Ges } \text{t}\text{U}\ddot{\text{o}} \text{ d} \text{ 5000/- U}\text{v}\text{K}\text{v} \text{ compendial product Gi Rb}\text{` Ges } 15000/- \text{ INN product Gi Rb}\text{` } |$

UvKv Rgv $\text{t}\text{`Iqvi} \text{ } \dagger \text{KvW} \text{ t}$

1	2	7	1	5	0	0	0	0	1	8	6	3
---	---	---	---	---	---	---	---	---	---	---	---	---

- 5| $\text{Av}\ddot{\text{f}}\text{e}\text{`bKZ.c}\ddot{\text{f}}\text{`i} \text{ } \ddot{\text{f}}\text{j}\text{e}\text{e}\text{j} \text{ I } \text{t}\text{g}\text{v}\text{oK} \text{ m}\text{v}\text{g}\text{M}\text{x}\ddot{\text{f}}\text{Z} \text{ v}\text{b}\ddot{\text{f}}\text{v}\text{v}\text{ } ^3 \text{ v}\text{e}\text{I}\text{q} \text{ D}\ddot{\text{f}}\text{j}\text{L} \text{ _K}\ddot{\text{f}}\text{Z} \text{ n}\ddot{\text{f}}\text{e} |$
 K) $\text{c}\text{`ZKvix} \text{ c}\text{v}\text{Z}\ddot{\text{o}}\text{v}\ddot{\text{f}}\text{b}\text{i} \text{ b}\text{v}\text{g} \text{ I } \text{c}\text{`v}\text{K}\text{v}\text{b}\text{v} |$
 L) $\text{e}\text{v}\text{P} \text{ b}\text{s}/\text{j}\text{U} \text{ b}\text{v}\text{i} |$
 M) $\text{c}\ddot{\text{f}}\text{`i} \text{ } \dagger \text{v}\text{v}\text{m}\text{d}\ddot{\text{f}}\text{K}\text{kb} \text{ I } \text{c}\text{`v}\text{K} \text{ m}\text{v}\text{B}\text{R} |$
 N) $\text{Drcv}\text{`b}\text{i} \text{ Z}\text{v}\text{i}\text{L} |$
 O) $\text{t}\text{g}\text{q}\text{v}\text{` D}\ddot{\text{E}}\text{x}\ddot{\text{f}}\text{b}\text{i} \text{ Z}\text{v}\text{i}\text{L} |$
 P) $\text{R}\text{v}\text{e}\text{b}\text{g}\text{y} \text{ (}\text{t}\div \text{v}\text{B}\text{j}\text{)} |$

K.13 Avg`vbiKZ.JI'ai Bb'WÈ'f'c'idigv Bbf'qm Ab'g'v`bi Rb` c'qvRbxq KvMRc'v`

- 1| $\text{g}\text{v}\text{v}\text{c}\text{v}\text{i}\text{P}\text{v}\text{j}\text{K}, \text{J}\text{I}\text{a} \text{ c}\text{v}\text{m}\text{b} \text{ A}\text{i}\text{a}\text{`B}\text{i} \text{ e}\text{i}\text{v}\text{e}\text{i} \text{ Av}\ddot{\text{f}}\text{e}\text{`b}\text{c}\text{f} |$
 2| $\text{Bb}\ddot{\text{f}}\text{WÈ}/\text{f}\text{c}\text{v}\text{d}\text{i}\text{g}\text{v} \text{ Bb}\ddot{\text{f}}\text{q}\text{m}\text{-02} \text{ (} \text{B} \text{) K}\text{i}\text{c} |$
 3| $\dagger i\text{v}\text{R}\ddot{\text{f}}\div \text{kb} \text{ m}\text{b}\text{`c}\ddot{\text{f}}\text{t} \text{ i} \text{ d}\ddot{\text{f}}\text{U}\text{v}\text{K}\text{i}\text{c} |$
 4| $\text{g}\ddot{\text{f}}\text{`v}\text{b}\text{av}\text{i}\text{Y} \text{ m}\text{b}\text{`c}\ddot{\text{f}}\text{t} \text{ i} \text{ d}\ddot{\text{f}}\text{U}\text{v}\text{K}\text{i}\text{c} \text{ (}\text{v}\text{Z}\text{x}\text{q}\text{e}\text{v}\text{i} \text{ Avg}\text{`v}\text{b}\text{i} \text{ } \ddot{\text{f}}\text{y}\ddot{\text{f}}\text{t}) |$
 5| $\text{W}\text{m} \text{ j}\text{v}\text{B}\ddot{\text{f}}\text{m}\ddot{\text{f}}\text{Y}\text{i} \text{ d}\ddot{\text{f}}\text{U}\text{v}\text{K}\text{i}\text{c} |$
 6| $\text{t}\text{J}\text{U}\text{v}\text{i} \text{ Ae } \text{A}_\text{v}\text{B}\ddot{\text{f}}\text{R}\text{kb} \text{ (c}\ddot{\text{f}}\text{h}\text{v}\text{R}\text{` } \ddot{\text{f}}\text{y}\ddot{\text{f}}\text{t}) |$
 7| FSC (Free Sale Certificate) – 07 vU DbZ $\ddot{\text{f}}\text{`k}\text{i} \text{ } \ddot{\text{f}}\text{h} \text{ } \dagger \text{K}\text{v}\text{b} \text{ 01 vUi} |$
 $\text{(m}\text{v}\text{Z}\text{v}\text{U} \text{ DbZ } \ddot{\text{f}}\text{`k} \text{ t } \text{B}\text{D}\text{G}\text{m}\text{G}, \text{ B}\text{D}\ddot{\text{f}}\text{K}, \text{ R}\text{v}\text{g}\text{v}\text{b}\text{x}, \text{ m}\text{B}\text{R}\text{v}\text{i}\text{j}\text{v}\text{U}, \text{ d}\text{v}\text{Y}, \text{ R}\text{v}\text{c}\text{v}\text{b} \text{ I } \text{A}\ddot{\text{f}}\div \text{v}\text{j}\text{q}\text{v})$
 $\text{*}\text{e}\ddot{\text{f}}\text{e}\text{k}\text{l} \text{ } \ddot{\text{f}}\text{y}\ddot{\text{f}}\text{t} \text{ D}\text{i}\text{j}\text{v}\text{LZ} \text{ Z}\text{v}\text{i}\text{j}\text{K}\text{v}\text{q} \text{ K}\text{v}\text{M}\text{R}\text{c}\text{v}\text{v}\text{` ms}\ddot{\text{f}}\text{h}\text{v}\text{R}\text{b}/\text{c}\text{v}\text{i}\text{eZ}\ddot{\text{f}}\text{b}\text{i} \text{ } \ddot{\text{y}}\text{g}\text{Z}\text{v} \text{ KZ}\text{c}\text{y} \text{ m}\text{s}\text{i}\text{y}\text{Y} \text{ K}\ddot{\text{f}}\text{i} |$

K.14 Avg`vbiKZ.Kv'gij/c`ZKZ.JI'ai Qoc'fi Rb` c'qvRbxq KvMRc'v`

1| **ibawiZ dig-G Avte`b|**
 2| 02 (**B**) K_{ic} Bb_fq_m|
 3| Avg`vb<sub>KZ</sub>.K<sub>U</sub>vg<sub>vj</sub>/Jl<sub>ai</sub> m<sub>U</sub>U<sub>d</sub>ku Ae Gb<sub>v</sub>jb<sub>imm</sub> (Drcv`bK_{vix} c_iZô_v KZ_K Bm_jKZ)|
 4| **ea** **gqv**†`i Ab_gg_v Z Bb_fW_E†c_vdig_v Bb_fq_m/eK_vj ÷ |
 5| **WM iym** 1945 G D_{ij}LZ dig-9|

***tekl** †y†Î D_{ij}LZ Z_vjK_{vq} K_vM_{Rc}Î_v ms_{thv}Rb/c_vieZ†bi ygZ_v KZ_çy msiÿY K†i|

**K.15 Avg`vb<sub>KZ</sub>.Jl<sub>ai</sub> mte<sub>v</sub>P L<sub>pi</sub> g<sub>j</sub> ibaviY/c<sub>h</sub>t<sub>h</sub>avi†Yi Rb** c†q<sub>v</sub>Rb<sub>xq</sub> K<sub>v</sub>M<sub>Rc</sub>Î<sub>v</sub>`

1| g_{nv}c_{ii}P_vjK, Jla ck_vmb A_{ia}`Bi eivei Avte`bcÎ|
 2| Ab_gg_v Z Bb_fW_E†c_vdig_v Bb_fq_m Gi K_{ic}|
 3| **ej** Ae G_iE_iej Ae †j_WS/G_q_vi l†q_R **ej** |
 4| †i_R†÷kb mb†`i K_{ic}|

5| **g_j c_ht_havi†Yi †y†Î B_zv_c†e Bm_jKZ.g_j mb†`i K_{ic}|**

***tekl** †y†Î D_{ij}LZ Z_vjK_{vq} K_vM_{Rc}Î_v ms_{thv}Rb/c_vieZ†bi ygZ_v KZ_çy msiÿY K†i|

**K.16 BDbv_x/Avq_{je}`K/nvej Jl<sub>ai</sub> †im<sub>ic</sub> Ab<sub>g</sub>g<sub>v</sub>†bi Rb** c†q<sub>v</sub>Rb<sub>xq</sub> **id I** K<sub>v</sub>M<sub>Rc</sub>Î<sub>v</sub>`/Z_`v`

1| g_{nv}c_{ii}P_vjK, Jla ck_vmb A_{ia}`Bi eivei Avte`bcÎ|
 2| **evs**v†`k R<sub>v</sub>Z<sub>iq</sub> BDbv<sub>x</sub> I Avq<sub>je</sub>`K dg_jvix Ab_gg_v†Y c`ZKZ.†im_{ic} (cô_v bs D†jLmn)
 3| **nvej Jl_{ai} †y†Î m_{KZ}.nvej dv_g†K_vcq_v Ab_gg_v†Y c`ZKZ.†im_{ic}|**
 4| †im_{ic} g_jvq_b **id** eve` 500/- U_vK_v n†i †UR_vix P_vjv†bi g_j K_{ic}|

U_vK_v Rgv †`Iq_vi †K_Wt

1	2	7	1	5	0	0	0	0	1	8	6	3
---	---	---	---	---	---	---	---	---	---	---	---	---

5| উৎপাদন লাইসেন্সের (হালনাগাদ নবায়নকৃত) ফটোকপি/লাইসেন্স নবায়ন প্রক্রিয়াধীন থাকলে সে সংক্রান্ত তথ্য।

6| **ib_qv_{RZ} `y Rbe†ji Z_vjK_v|**

7| B_zv_c†e j_vB†m†Y Ašf_y Jl_{ai} aiY†kY_x|

***tekl** †y†Î D_{ij}LZ Z_vjK_{vq} K_vM_{Rc}Î_v ms_{thv}Rb/c_vieZ†bi ygZ_v KZ_çy msiÿY K†i|

K.17 bZ_y BDbv_x/Avq_{je}`K/nvej Jla Drcv`b j_vB†m†Y Bm_j Rb c†q_vRb_{xq} **id I** K_vM_{Rc}Î_v`

1| g_{nv}c_{ii}P_vjK, Jla ck_vmb A_{ia}`Bi eivei Avte`bcÎ|
 2| **bZ_y j_vB†m†Y id** eve` 10,000 ( `k n_vR_vi) U_vK_vi †UR_vix P_vjv†bi g_j K_{ic}|
 U_vK_v Rgv †`Iq_vi †K_Wt

1	2	7	1	5	0	0	0	0	1	8	6	3
---	---	---	---	---	---	---	---	---	---	---	---	---

3| cK†i c`veZ c`mg†ni †im_{ic}|

4| n_vj_bv_M† UW j_vB†m†Yi mZ`wqZ K_{ic}|

5| K_viL_vb_vi †j-A_vDU c`vb|

6| K_viL_vb_vq`n<sub>ic</sub>Z Jla Drcv`b I g_vb_{ib}qšÎY hšc_WZi Z_vjK_v|

7| K_viL_vb_vq **ib_qv_{RZ} `y Rbe†ji Z<sub>v</sub>jK<sub>v</sub> (Z<sub>v</sub>jK<sub>v</sub>q c`ex, †kÿvMZ †hvM`Z<sub>v</sub>, †cZ<sub>v</sub>i b<sub>v</sub>g, `n_vq_x I eZg_vb †VK_vb_v D†jL`vK†Z n†e)|**

8| Drcv`b I g<sub>v</sub>b<sub>ib</sub>qšÎ†Yi `v_{iq}†Z **ib_qv_{RZ} e`<sup>3</sup>i †hvM`vbcÎ, mb†`i mZ`wqZ K_{ic} I A_½K_vi_bv_g|**

9| Drcv`b I g<sub>v</sub>b<sub>ib</sub>qšÎ†Yi Rb`†id†iY eB†qi Z_vjK_v|

10| K_viL_vb_vi †VK_vb_vq c_{ii}†ek A_{ia}`Bi n†Z c<sub>ii</sub>†ekMZ Q<sub>io</sub>c†Îi mb`|

***tekl** †y†Î D_{ij}LZ Z_vjK_{vq} K_vM_{Rc}Î_v ms_{thv}Rb/c_vieZ†bi ygZ_v KZ_çy msiÿY K†i|

**K.18 BDbv_x/Avq_{je}`K/nvej Jl<sub>ai</sub> †g<sub>v</sub>oK m<sub>vg</sub>M<sub>x</sub> Ab<sub>g</sub>g<sub>v</sub>†bi Rb** c†q<sub>v</sub>Rb<sub>xq</sub> K<sub>v</sub>M<sub>Rc</sub>Î<sub>v</sub>`/Z_`v`

1| g_{nv}c_{ii}P_vjK, Jla ck_vmb A_{ia}`Bi eivei Avte`bcÎ|
 2| **evs**v†`k R<sub>v</sub>Z<sub>iq</sub> BDbv<sub>x</sub>/Avq<sub>je</sub>`K dg_jvix/m_{KZ}.nvej dv_g†K_vcq_v Ab_gg_vq_x L_mov/P_ov†g_voK m_{vg}M_x|
 3| c†`i Ab<sub>g</sub>g<sub>v</sub> Z A`†b·†i i d†U_vK_{ic}|

tekl †y†Î D_{ij}LZ Z_vjK_{vq} K_vM_{Rc}Î_v ms_{thv}Rb/c_vieZ†bi ygZ_v KZ_çy msiÿY K†i|

**K.19 BDbv_x/Avq_{je}`K/nvej Jl<sub>ai</sub> Ab<sub>g</sub>g<sub>v</sub> Z †im<sub>ic</sub>-Gi bg<sub>h</sub> cix<sub>y</sub> I tekl†Yi Rb** c†q<sub>v</sub>Rb<sub>xq</sub> K<sub>v</sub>M<sub>Rc</sub>Î<sub>v</sub>`/Z_`v`

1| g_{nv}c_{ii}P_vjK, Jla ck_vmb A_{ia}`Bi eivei Avte`bcÎ|
 2| Jla ck_vmb A_{ia}`Bi KZ_K †W†fb †W†Rm dig Gi **ibawiZ c_{ii}g_vY bg_h|**
 3| পদের টেস্ট ত্রাইটেরিয়া (উৎপাদন ও মান-†bqšY KgKZ_v KZ_K m_v†iZ)|
 4| **bg_h cix_y I tekl†Y id** 500/- U_vK_v n†i †UR_vix P_vjv†bi g_j K_{ic}|

UrKv Rgv t`qvi tKw t

1 2 7 1 5 0 0 0 0 1 8 6 3

*e#kl t#y#l D#j#LZ Z#jKvq KvMRc#l# ms#hvRb/c#ieZ#bi ygZv KZ#y msi#Y K#i|

K.20 BDb#b/A#q#e#K/#ve#j Jla Drc#b jvB#m#Y c` A#fy#i Rb` c#qvRb#q #d I KvMRc#l#`

1| gnv#iPvjK, Jla ck#mb A#a`Bi eivei Av#e`bc#l|

2| c#`i i#i#mic Ab#gv`b c#l#i d#UvK#c|

3| c#Z c` A#fy#i #d eve` 2000/- UrKv nv#i t#URvix Pvj#bi g# K#c|

UrKv Rgv t`Iqvi tKw t

1 2 7 1 5 0 0 0 0 1 8 6 3

4| c#`i A#v#b`v#i|

5| c#`i Lmov tgvOKmvgMx (t#ej, KvUb, d#qj I Bbm#U)|

*e#kl t#y#l D#j#LZ Z#jKvq KvMRc#l# ms#hvRb/c#ieZ#bi ygZv KZ#y msi#Y K#i|

K.21 BDb#b/A#q#e#K/#ve#j Jla Drc#b jvB#m#Y bevq#bi Rb` c#qvRb#q #d I KvMRc#l#`

1| gnv#iPvjK, Jla ck#mb A#a`Bi eivei Av#e`bc#l|

2| jvB#m#Y bevq#b #d Gi t#URvix Pvj#bi g# K#c|

jvB#m#Y bevq#b #d Gi c#igvY t 5,000/- UrKv|

UrKv Rgv t`Iqvi tKw t

1 2 7 1 5 0 0 0 0 1 8 6 3

3| jvB#m#Yi g#K#c|

4| #eMZ`B erm#i#i Drc#b#i #nmve #eeiYx|

5| nvj b#Mv` tUW jvB#m#Yi mZ`v#qZ K#c|

6| 05(c#) ermi t#qv#`i Kv#Lv# feb f#ovi P#b#gv#bRm RvqMvq n#j`#jj ev cgvbc#l#i mZ`v#qZ K#c|

7| Kv#Lv#vq #b#q#RZ`y Rbe#ji Z#jKv#mn Drc#b I gvb#bq#l#Y #b#q#RZ #hvM`e`#i#i #hvM`vbc#l#, mb#`i mZ`v#qZ K#c I A#x#Kv#b#v|

8| Kv#Lv#v#i t#j-AvDU cvb|

9| Jla Drc#b I gvb#bq#Y h#sc#v#Zi Z#jKv|

*e#kl t#y#l D#j#LZ Z#jKvq KvMRc#l# ms#hvRb/c#ieZ#bi ygZv KZ#y msi#Y K#i|

K.22 BDb#b/A#q#e#K/#ve#j Jla Drc#b jvB#m#Yi g#jKv#v n`Z#l#i c#v#b#v#b#i Rb` c#qvRb#q KvMRc#l#`/Z`#`

1| eZgvb g#jK#i Av#e`b (c`#veZ g#jK/g#jK#`i b#g I n`v#l#i#i Kv#Y D#jL Ki#Z n#e)|

2| Jla Drc#b jvB#m#Yi mZ`v#qZ d#UvK#c|

3| jvB#m#Y A#f`# c#`i m#L`v|

4| c`#veZ g#jK/g#jK#`i m#gv#ZmPK Av#e`b (RvZ#q c#iPqc#l#i d#UvK#c Ges c#m#cvU mvB#Ri mZ`v#qZ Q#e)|

৫। প্রতিষ্ঠানটির বিরুদ্ধে লাইসেন্স অথবা পদ বিষয়ক মামলা থাকলে সে সংক্রান্ত Z`#`|

৬। প্রতিষ্ঠানটির বিরুদ্ধে মালিকানা বিষয়ক মামলা থাকলে সে সংক্রান্ত তথ্য।

7| eZgvb g#jK/g#jK#`i RvZ#q c#iPqc#l#i d#UvK#c Ges c#m#cvU mvB#Ri mZ`v#qZ Q#e|

8| c#Z#b#iUi tUW jvB#m#Y|

9| jvB#m#Yi eZgvb Ae`v (ev#Zj/mvg#qK ev#Zj/Drc#b`b`#MZ)|

10| jvB#m#Y B#Zvc#e G#d#W#e#Ui g#a`#g Ab` Kv#iv #bKU n`v#l#i#i Kiv n#q#Q #Kb#|

*e#kl t#y#l D#j#LZ Z#jKvq KvMRc#l# ms#hvRb/c#ieZ#bi ygZv KZ#y msi#Y K#i|

K.23 BDb#b/A#q#e#K/#ve#j Jla Drc#b Kv#Lv#v`n#b#l#i Ab#gv`#bi Rb` c#qvRb#q KvMRc#l#`

1| gnv#iPvjK, Jla ck#mb A#a`Bi eivei Av#e`bc#l|

2| Kv#Lv#v#i bZ# c`Z#veZ #VK#b#vq tUW jvB#m#Yi mZ`v#qZ K#c|

3| Kv#Lv#v#i feb f#ov#KZ.n#j f#ov#i 05(c#) erm#i#i P#b#gv#i mZ`v#qZ K#c A`ev #bRm RvqMvq n#j cgvbc#l#i mZ`v#qZ K#c|

4| Kv#Lv#v#i c`Z#veZ #VK#b#vq c#i#ek A#a`B#i#i Q#voc#l#i mZ`v#qZ K#c|

5| KviLvbiq ‖b†q‖RZ `ÿ Rbe†ji Z‖jKv, Drcv`b I gvb-‖bqšÎY KgKZvi †h‖M`vbcÎ, mb†`i mZ`‖qZ
K‖cmn A½xKvibvgv|
6| Jla Drcv`b I gvb-‖bqšY hšc‖Zi Z‖jKv|
7| KviLvbi †j-AvDU c`vb|
*‖e†kl †ÿ†Î D‖j‖LZ Z‖jKvq KvMRcÎ‖` ms†h‖Rb/c‖ieZ†bi ÿgZv KZçÿ msiÿY K†i|

K.24 BDvbv/Avqje‖K/nvej Jla Drcv`bKvix c‖Zôv†bi bvg c‖ieZ†bi Rb` c†qvRbxq KvMRcÎ‖`

1| gnv‖iPvjK, Jla ck‖mb A‖a`Bi eivei Av†e`bcÎ|
2| c`Z‖eZ c‖Zôv†bi b†g †UW jvB†m†Yi mZ`‖qZ K‖c|
3| RvZq ‖`‖bK c‖ÎKvq cK‖kZ ‖eÁc†bi Kic (g† c‖ÎK‖mn)|
4| Jla Drcv`b jvB†m†Yi mZ`‖qZ K‖c|
5| AvBb‖e‖a j•N†bi Kvi†Y BZtc†e c‖Zôv†bi Jla Drcv`b jvB†m†Y m‖g‖qK e‖Zj/c‖Zôv†bi ‖ei†× gvgjv
থাকলে সে সংক্রান্ত তথ্য।
*‖e†kl †ÿ†Î D‖j‖LZ Z‖jKvq KvMRcÎ‖` ms†h‖Rb/c‖ieZ†bi ÿgZv KZçÿ msiÿY K†i|

K.25 BDvbv/Avqje‖K/nvej Jla Drcv`b jvB†m†Yi g‖jKvix c‖ieZ†bi Rb` c†qvRbxq KvMRcÎ‖`

1| gnv‖iPvjK, Jla ck‖mb A‖a`Bi eivei Av†e`bcÎ|
2| g‖jKvix n`Zvš†ii c‖b†g‖`b c†Îi mZ`‖qZ K‖c|
3| h_vh_ ‖bqg‖b†q‖x g‖jKvix n`Zvš†ii njdbvgv/`‖jj Gi mZ`‖qZ K‖cmn g† K‖c|
4| g‖jKvix c‖ieZ†bi Rb` miKvi ‖ba‖iZ ‖d 50,000/- UvKvi †URvix Pvjv†bi g† K‖c|
UvKv Rgv †`Iqvi †K‖W t

1

2	7	1	5
---	---	---	---

0	0	0	0
---	---	---	---

1	8	6	3
---	---	---	---

5| jvB†m†Yi g† K‖c|
6| nvjb‖Mv` †UW jvB†m†Yi mZ`‖qZ K‖c|
7| g‖j†Ki b‖M‖iK†Zi mb` I e`vsK m`QjZvi mb`|
8| KviLvbi †j-AvDU c‖b|
9| KviLvbiq ‖b†q‖RZ `ÿ Rbe†ji Z‖jK‖mn Drcv`b I gvb‖bqš†Y ‖b†q‖RZ †h‖M` e`³i †h‖M`vbcÎ, mb†`i
mZ`‖qZ K‖c I A½xKvibvgv|
10| KviLvbi f‖oiKZ. fe†b n†j 05(c‖t) erm†ii f‖oi Pj†bvgvi mZ`‖qZ K‖c A_e‖ ‖bRm RvqMvq n†j
cg‖bc†Îi mZ`‖qZ K‖c|
*‖e†kl †ÿ†Î D‖j‖LZ Z‖jKvq KvMRcÎ‖` ms†h‖Rb/c‖ieZ†bi ÿgZv KZçÿ msiÿY K†i|

K.26 †n‖glc`‖\_K JI†ai †i‖m‖c Ab†g‖`†bi Rb` c†qvRbxq ‖d I KvMRcÎ‖`/Z_`‖`

1| gnv‖iPvjK, Jla ck‖mb A‖a`Bi eivei Av†e`bcÎ|
2| m‖KZ.†n‖gl d‖g†K‖icq‖ Ab†i†Y c`ZKZ.c†`i †i‖m‖c (c‖v bs D†jLmn)|
3| †i‖m‖c g†vqb ‖d eve` 500/- UvKv n‖†i †URvix Pvjv†bi g† K‖c|
UvKv Rgv †`Iqvi †K‖W t

1

2	7	1	5
---	---	---	---

0	0	0	0
---	---	---	---

1	8	6	3
---	---	---	---

4| উপাদান লাইসেন্সের (হালনাগাদ নবায়নকৃত) ফটোকপি/লাইসেন্স নবায়ন প্রক্রিয়াধীন থাকলে সে সংক্রান্ত তথ্য।
5| ‖b†q‖RZ `ÿ Rbe†ji Z‖jKv|
6| c†e Ašf³ JI†ai aiY/†kYx|
*‖e†kl †ÿ†Î D‖j‖LZ Z‖jKvq KvMRcÎ‖` ms†h‖Rb/c‖ieZ†bi ÿgZv KZçÿ msiÿY K†i|

K.27 *bnwglc`v\_K Jla Drcv`b jvBtmY BmYi Rb` c`qvRbxq id I KvMRcIv`*

- 1| *gnvciiPvjK, Jla ckvmb Aia`Bi eivei Avte`bcI`|*
- 2| *bnw jvBtmY id eve` 10,000/- UvKvi tURvix Pvjv#bi gj` Kic|*
UvKv Rgv t` Iqvi tKwW t

1	2	7	1	5	0	0	0	0	1	8	6	3
---	---	---	---	---	---	---	---	---	---	---	---	---
- 3| *ckI` c` weZ c` mg#ni iimic|*
- 4| *njbmV` tUW jvBtmYi mZ`wqZ Kic|*
- 5| *KviLvbi tj-AvDU cvb|*
- 6| *KviLvbiq`nwicZ Jla Drcv`b I gvb`bqSY hScwZi ZvjKv|*
- 7| *KviLvbiq`b#qVRZ`y Rbe#ji ZvjKv (ZvjKvq`cZvi bvg,`nvq` I eZgvb`VKvbi D#jL`vK#Z n#e)|*
- 8| *Drcv`b I gvb`bqS#IYi`wq#Z`b#qVRZ`e`i`i`hM`vbcI`, mb#`i mZ`wqZ Kic I A#Kvibvgv|*
- 9| *Drcv`b I gvb`bqS#IYi Rb` #idv#iY eB#qi ZvjKv|*
- 10| *KviLvbi`VKvbiq`c#iek Aia`Bi n#Z ci#ekMZ Qvoc#Ii mb`|*
**#ekI`y#I` D#jLZ ZvjKvq KvMRcIv` ms#hvRb/c#ieZ#bi ygZv KZcy` msiyY K#i|*

K.28 *bnwglc`v\_K JI#ai Abjgv`Z iimic Gi bgv`cixYv I #ekI#Yi Rb` c`qvRbxq KvMRcIv`/Z`v`*

- 1| *gnvciiPvjK, Jla ckvmb Aia`Bi eivei Avte`bcI`|*
- 2| *Jla ckvmb KZK`#fb`W#Rm dig Gi`baw#Z cigvY|*
- 3| *পদের টেস্ট ক্রাইটেরিয়া (উৎপাদন ও মান-#bqS#IY KgKZv KZK`mvY#iZ)|*
- 4| *bgv`cixYv I #ekIY id 500/- UvKv n#i tURvix Pvjv#bi gj` Kic|*
UvKv Rgv t` Iqvi tKwW t

1	2	7	1	5	0	0	0	0	1	8	6	3
---	---	---	---	---	---	---	---	---	---	---	---	---
- *#ekI`y#I` D#jLZ ZvjKvq KvMRcIv` ms#hvRb/c#ieZ#bi ygZv KZcy` msiyY K#i|*

K.29 *bnwglc`v\_K JI#ai #gvoK mvgMx Abjgv`#bi Rb` c`qvRbxq KvMRcIv`/Z`v`*

- 1| *gnvciiPvjK, Jla ckvmb Aia`Bi eivei Avte`bcI`|*
- 2| *bnwgl`dvgtKvncqv Abjgv`Lmov/PovS`#gvoKmvGMx|*
- 3| *c#`i Abjgv`Z A`v#b`v#i i d#UvKic|*
#ekI`y#I` D#jLZ ZvjKvq KvMRcIv` ms#hvRb/c#ieZ#bi ygZv KZcy` msiyY K#i|

K.30 *bnwglc`v\_K Jla Drcv`b jvBtmY c`Ašfy`i Rb` c`qvRbxq id I KvMRcIv`*

- 1| *gnvciiPvjK, Jla ckvmb Aia`Bi eivei Avte`bcI`|*
- 2| *c#`i iimic Abjgv`b c#I`i d#UvKic|*
- 3| *c#Z c` Ašfy`i id eve` 2,000/- UvKv n#i tURvix Pvjv#bi gj` Kic|*
UvKv Rgv t` Iqvi tKwW t

1	2	7	1	5	0	0	0	0	1	8	6	3
---	---	---	---	---	---	---	---	---	---	---	---	---
- 4| *c#`i A`v#b`vi|*
- 5| *c#`i Lmov`gvoKmvGMx (#j#ej, KvUj, d#qj I BbmVU)|*
**#ekI`y#I` D#jLZ ZvjKvq KvMRcIv` ms#hvRb/c#ieZ#bi ygZv KZcy` msiyY K#i|*

K.31 *bnwglc`v\_K Jla Drcv`b jvBtmY bevq#bi Rb` c`qvRbxq id I KvMRcIv`*

- 1| *gnvciiPvjK, Jla ckvmb Aia`Bi eivei Avte`bcI`|*
- 2| *jvBtmY bevqb id Gi tURvix Pvjv#bi gj` Kic|*
jvBtmY bevqb id Gi c#igvY t 5.000/- UvKv| jvBtmYi`gqv` DEx#Yi ci Rgv`#j`#ej` idmn 10,000/- UvKv|
UvKv Rgv t` Iqvi tKwW t

1	2	7	1	5	0	0	0	0	1	8	6	3
---	---	---	---	---	---	---	---	---	---	---	---	---
- 3| *jvBtmYi`gj` Kic|*
- 4| *#MZ`B`erm#i i Drcv`#bi`nmve`eeiYx|*
- 5| *nj bV` tUW jvBtmYi mZ`wqZ Kic|*

6| 05(cuP) ermi tgvv`i KviLvbi feb fivov Py<sup>8</sup> bvgv/bRm RvqMvq n+j `jj ev cgvbc†îi mZ`vqZ Kic|
 7| KviLvbiq †b†q†RZ `ÿ Rbe†ji ZvjKvnmn Drcv`b I gvb-†bqš†Y †b†q†RZ †hvm e`i<sup>3</sup> i †hvm`vbcî, mb†`i mZ`vqZ Kic I A½xKvibvgv|
 8| KviLvbi †j-AvDU cvb|
 9| Jla Drcv`b I gvb-†bqš†Y hšîc†Zi ZvjKv|
 *†e†kl †ÿ†î D†j†LZ ZvjKvq KvMRc†v` ms†hvb/c†ieZ†bi ÿgZv KZçÿ msi`Y K†i|

K.32 t†v†g†l†c`v\_K Jla Drcv`b jvB†m†Yi g†vjKvbi n`Zvš†ii c†v†g†v`†bi Rb` c†q†Rb†q KvMRc†v`/Z_`v`

1| g†v†c†i†P†jK, Jla ck†mb A†a`†Bi e†vei n`Zvš†ii KviY D†j†Lmn Av†e`bc†î|
 2| Jla Drcv`b jvB†m†Yi mZ`vqZ d†U†Kic|
 3| jvB†m†Y Ašfÿ c†`i mSL`v Ges evR†i†R†ZKZ.Jl†ai ZvjKv|
 4| g†vjKvbi Mn†Y B`Q† e`i³ i m†g†Z c†î|
 5| AvBb/†e†a j•N†bi Kvi†Y B†Zvc†e c†Zô†bi Jla Drcv`b jvB†m†Y m†g†qK ev†Zj/c†Zô†bi

বিরুদ্ধে মামলা থাকলে সে সংক্রান্ত তথ্য।

*†e†kl †ÿ†î D†j†LZ ZvjKvq KvMRc†v` ms†hvb/c†ieZ†bi ÿgZv KZçÿ msiÿY K†i|

K.33 t†v†g†l†c`v\_K Jla Drcv`b KviLvbi n`v†bš†i Ab†g†v`†bi Rb` c†q†Rb†q KvMRc†v`

1| g†v†c†i†P†jK, Jla ck†mb A†a`†Bi e†vei Av†e`bc†î|
 2| bZ† c`Z†eZ KviLvbi †VKvbiq †UW jvB†m†Yi mZ`vqZ Kic|
 3| KviLvbi feb fivovKZ.n†j fivov 05(cuP) erm†ii Py⁸ bvgv mZ`vqZ Kic A\_ev †bRm RvqMvq n+j cgvbc†îi mZ`vqZ Kic|
 4| KviLvbi c`Z†eZ †VKvbiq c†i†ek A†a`†Bi†i Q†v†c†îi mZ`vqZ Kic|
 5| KviLvbiq †b†q†RZ `ÿ Rbe†ji ZvjKv, Drcv`b I gvb†bqš†Y KgKZvi †hvm`vbcî, mb†`i mZ`vqZ Kicmn A½xKvibvgv|
 6| Jla Drcv`b I gvb†bqš†Y hšîc†Zi ZvjKv|
 7| KviLvbi †j-AvDU cvb|

*†e†kl †ÿ†î D†j†LZ ZvjKvq KvMRc†v` ms†hvb/c†ieZ†bi ÿgZv KZçÿ msiÿY K†i|

K.34 t†v†g†l†c`v\_K Jla Drcv`bKvi†c†Zô†bi b†g c†ieZ†bi Rb` c†q†Rb†q KvMRc†v`/Z_`v`

1| g†v†c†i†P†jK, Jla ck†mb A†a`†Bi e†vei Av†e`bc†î|
 2| c`Z†eZ c†Zô†bi b†g †UW jvB†m†Yi mZ`vqZ Kic|
 3| R†Z†q †`†bK c†îK†q cK†kZ †eÁvc†bi Kic (g† c†îK†mn)|
 4| Jla Drcv`b jvB†m†Yi mZ`vqZ Kic|
 5| AvBb/†e†a j•N†bi Kvi†Y B†Zvc†e c†Zô†bi Jla Drcv`b jvB†m†Y m†g†qK ev†Zj/c†Zô†bi †e†i†x g†g†v

থাকলে সে সংক্রান্ত তথ্য।

*†e†kl †ÿ†î D†j†LZ ZvjKvq KvMRc†v` ms†hvb/c†ieZ†bi ÿgZv KZçÿ msiÿY K†i|

K.35 t†v†g†l†c`v\_K Jla Drcv`b jvB†m†Yi g†vjKvbi c†ieZ†bi Rb` c†q†Rb†q KvMRc†v`

1| g†v†c†i†P†jK, Jla ck†mb A†a`†Bi e†vei Av†e`bc†î|
 2| g†vjKvbi n`Zvš†ii c†v†g†v`b c†îi mZ`vqZ Kic|
 3| h_vh_†bq†v†b†q†x g†vjKvbi n`Zvš†ii n†jdb†g†v`†jj Gi mZ`vqZ Kicmn g† Kic|
 4| g†vjKvbi c†ieZ†bi Rb` miKvi †bav†iZ †d 50,000/- U†Kvi †UR†i†x P†j†bi g† Kic|
 U†Kv Rgv †`I†q†i †K†W t

 5| jvB†m†Yi g† Kic|
 6| n†jb†M†v` †UW jvB†m†Yi mZ`vqZ Kic|
 7| g†vj†Ki b†M†i†K†Zi mb` I e`vsK m`Q†Z†i mb`|
 8| KviLvbi †j-AvDU c`v†b|
 9| KviLvbiq †b†q†RZ `ÿ Rbe†ji ZvjKvnmn Drcv`b I gvb-†bqš†Y †b†q†RZ †hvm e`i<sup>3</sup> i †hvm`vbcî, mb†`i mZ`vqZ Kic I A½xKvibvgv|

10| KviLvby fvoV KZ. fe#b n#j 05(cu) erm#ii fvoVi Py#bvgvi mZ"vqZ Klc A_ev WbRm RvqMvq n#j
 cgvbc#i mZ"vqZ Klc|
 *e#kl #y#i D#jLZ Z#jKvq KvMRc#i` ms#hvRb/c#ieZ#bi ygZv KZcy msiyy K#i|

K.36 tnvglc"K K#ngv Avg`vbx i eK#j ÷ Abjg`#bi #big#E c#qvRbx KvMRc#i`/Z`"v`

- 1| gnvciPvjK, Jla ckymb A#a`Bi eive#i Av#e`bc#i|
 - 2| Jla ckymb A#a`Bi cYxZ #cvdigv Abjg#x eK#j ÷ - 3 Klc|
 - 3| উৎপাদন লাইসেন্সের (হালনাগাদ নবায়নকৃত) ফটোকপি/লাইসেন্স নবায়ন প্রক্রিয়াধীন থাকলে সে সংক্রান্ত তথ্য।
 - 4| Avg`vbx jvB#m#Yi Klc|
 - 5| nvjbvMv` tUW jvB#m#Yi mZ"vqZ d#UvKlc|
 - 6| jvB#m#Yi Ašfy# c#`i Z#jKv|
 - 7| B#U#E Klc|
 - 8| WbJkb jvB#m#Yi Klc|
- *e#kl #y#i D#jLZ Z#jKvq KvMRc#i` ms#hvRb/c#ieZ#bi ygZv KZcy msiyy K#i|

K.37 tnvglc"K Jla Avg`vbx i Abjg`#bi #big#E c#qvRbx KvMRc#i`/Z`"v`

- 1| gnvciPvjK, Jla ckymb A#a`Bi eive#i Av#e`bc#i|
 - 2| Jla ckymb c#i`B#ii cYxZ #cvdigv Abjg#x eK#j ÷ - 3 Klc I #cvdigv Bbf#qm-1 Klc|
 - 3| nvjbvMv` Wm jvB#m#Yi mZ"vqZ d#UvKlc|
 - 4| Avg`vbx jvB#m#Yi Klc|
 - 5| nvjbvMv` tUW jvB#m#Yi mZ"vqZ d#UvKlc|
- *e#kl #y#i D#jLZ Z#jKvq KvMRc#i` ms#hvRb/c#ieZ#bi ygZv KZcy msiyy K#i|

K.38 Jla iB#bi Rb" c#qvRbx KvMRc#i`

- 1| **CPP/FSC c#Bi Rb" c#qvRbx KvMRc#i` t**
 K) gnvciPvjK, Jla ckymb A#a`Bi eive#i Av#e`bc#i|
 L) iB#bi Rb" Av#e`Z c#`i #ea #gqv#`i A`v#b·v#ii Klc|
 M) h#` iB#bi Rb" evU big c#ieZb Kiv nq Z#e #m #y#i evU bvg Abjg`#bi m#i#Ki Klc|
 N) WHO Format Abjg#x c#YKZ.CPP A_ev Jla ckymb cYxZ di#gu #gvZ#eK FSC-Gi Klc|
 O) সংশ্লিষ্ট পদগুলির রপ্তানী সংক্রান্ত কাগজপত্রাদি।
 - 2| **GMP mb` c#Bi Rb" c#qvRbx KvMRc#i` t**
 K) gnvciPvjK, Jla ckymb A#a`Bi eive#i Av#e`bc#i|
 L) Jla Drcv`b jvB#m#Yi-Gi Klc|
 M) jvB#m#Yi-G Ašfy# c#`i A`v#b·v#ii Klc|
 N) #Kivacvbx #c#dvBj|
 - 3| **Export licence (Form 10-A) c#Bi Rb" c#qvRbx KvMRc#i` t**
 K) Wm iy 1945-G e#YZ Form No.-8 Gi gva`#g Av#e`b|
 L) h_vh_fv#e c#YKZ.Form 9-A Gi Klc Av#e`#bi mv#`_v#Lj Ki#Z n#e (Wm iy 1945-G e#YZ)|
 M) c#YKZ.Form 10-A|
- *e#kl #y#i D#jLZ Z#jKvq KvMRc#i` ms#hvRb/c#ieZ#bi ygZv KZcy msiyy K#i|

K.39 bZyLyi A`v#jvc"K/Avq#e`K/BDvbx/#nvglc"K I e#qv#KigK/n#ievj Wm jvB#m#Yi Gi Rb" c#qvRbx KvMRc#i`

- 1| h_vh_fv#e c#YKZ.`iLv`Z dig bs-7 (#e#j Wm iy, 1946 G D#jLZ)|
- 2| #b#qvRZ dvgv#m ÷ /K#ievR/nv#Kg/#nvgl Wv`vi Gi #i#R#÷kb mb#`i g# Klc I mZ"vqZ d#UvKlc|
- 3| #b#qvRZ dvgv#m ÷ /K#ievR/nv#Kg/#nvgl Wv`vi Gi A`v#Kvibvgv|
- 4| jvB#m#Yi d Gi tURvix Pvjv#bi g# Klc|
 (A`v#jvc"K t t#šimfv I #g#Uvc#jUb GjvKvi Rb" #d-2,500/- UvKv, BD#bqb KvD#Y#ji Ašfy# GjvKvi Rb" 1,500/- UvKv, Avq#e`K/BDvbx/#nvglc"K I e#qv#KigK/n#ievj t t#šimfv I #g#Uvc#jUb GjvKvi Rb" #d-2,000/- UvKv, BD#bqb KvD#Y#ji Ašf` GjvKvi Rb" 1,000/- UvKv)|

5| t`vKv#bi tUW jvB#mY-Gi mZ`vqZ d#UvKic|
 6| gvi j#Ki bvmiKZ mb#`i mZ`vqZ d#UvKic|
 7| t`vKvb fvoivi Py#bvgv/fvoivi iik#`i mZ`vqZ d#UvKic|
 8| gvi j#Ki Avl_K m"QjZvi mb` (e"vsK mj#f#Y mviUd#KU)|
 *te#kl t#y#l DiiLZ Zvi jKvq KvMRcÎv` ms#hvRb/c#ieZ#bi ygZv KZçy msiyY K#i|

K.40 Lpiv A`jvc`v_K/Avqjei`K/BDvbv/tngl c`v_K I ev#q#KigK/nviej Wm jvB#mY bevqb Gi Rb` c#qRbq KvMRcÎv`

1| h_vh_fvte c#YKZ.`iLv`Z dig bs-7 (te½j Wm iy, 1946 G DiiLZ)|
 2| #b#qviRZ dvgv#m÷/K#ievR/nviKg/tngl Wv 3vi Gi t#iR#÷kb mb#`i gj Kic I mZ`vqZ d#UvKic|
 3| #b#qviRZ dvgv#m÷/K#ievR/nviKg/tngl Wv 3vi Gi A½Kvibvgv|
 4| jvB#mY bevqb #d Gi tURvix Pvjv#bi gj Kic|
 (A`jvc`v_K t t#c\$ Gi jvKvi #fZ#ii Rb` #d-1,800/- UvKv,
 t#c\$ Gi jvKvi evin#ii Rb` #d-700/- UvKv
 Avqjei`K/BDvbv/tngl c`v_K I ev#q#KigK/nviej t
 t#c\$ Gi jvKvi #fZ#ii Rb` #d-1,500/- UvKv,
 t#c\$ Gi jvKvi evin#ii Rb` #d-700/- UvKv)|

5| t`vKv#bi tUW jvB#mY-Gi mZ`vqZ d#UvKic|
 6| gvi j#Ki bvmiKZ mb#`i mZ`vqZ d#UvKic|
 7| t`vKvb fvoivi Py#bvgv/fvoivi iik#`i mZ`vqZ d#UvKic|
 8| gvi j#Ki Avl_K m"QjZvi mb` (e"vsK mj#f#Y mviUd#KU)|
 *te#kl t#y#l DiiLZ Zvi jKvq KvMRcÎv` ms#hvRb/c#ieZ#bi ygZv KZçy msiyY K#i|

K.41 bzYcBKvix A`jvc`v_K/Avqjei`K/BDvbv/tngl c`v_K/nviej Wm jvB#mY Gi Rb` c#qRbq KvMRcÎv`

1| h_vh_fvte c#YKZ.`iLv`Z dig bs-7 (te½j Wm iy, 1946-G DiiLZ)|
 2| jvB#mY #d eve` 10,000/- UvKvi tURvix Pvjv#bi gj Kic|
 3| t`vKvb/W#cv tUW jvB#mY Gi mZ`vqZ d#UvKic|
 4| gvi jK/e`e`nvcv c#iPvjK Gi bvmiKZ mb#`i mZ`vqZ d#UvKic|
 5| t`vKvb/W#cv fvoivi Py#bvgv mZ`vqZ d#UvKic|
 6| gvi j#Ki Avl_K m"QjZvi mb` (e"vsK mj#f#Y mviUd#KU)|
 7| Jla Drcv`bKvix c#Zô#bi #W#cv jvB#mYi t#y#l Jla Drcv`b jvB#mY-Gi d#UvKic/jvB#mY me#kl bevq#bi mb#`i Kic|
 8| Jla Avg`vbxKviK#`i t#y#l IRC Gi d#UvKic|
 *te#kl t#y#l DiiLZ Zvi jKvq KvMRcÎv` ms#hvRb/c#ieZ#bi ygZv KZçy msiyY K#i|

42. Application checklist for permission for Manufacture & import of Medical devices

1. Name, address and communication details of the Manufacturer /Agent in Bangladesh
2. Authorisation letter of the Authorised Agent
3. Name address and communication details of the manufacturer
4. Are the products already imported in Bangladesh, if so since when
5. Name of the product, including its generic name, if any
6. Device class and classification system followed. Attached conformity assessment certificate.
7. Details of the Conformatory Assessment body
8. Since how long the device is being used commercially? Has clinical evaluation and safety issues been addressed for the device?
9. Principle use of the device
10. Is it a drug-device combination?
11. If the above is “yes”, is the drug a new drug

12. Is it a kit comprising of more than one device?
13. Sizes of the device
14. Is Device Master File submitted
15. Short description of the Manufacturing process
16. Procedure for sterilization
17. Procedure for release of the Device in the market
18. Name and qualifications of technical personnel for manufacture and quality assurance
19. Layout plan of the premises accompanied by the floor plan.
20. Details of QMS and manual
21. Is the product tested before release, if yes, submit details; if no, specify criteria for release
22. Has the product been withdrawn due to any reasons? If yes please specify.
23. Recall procedure to be followed in case the product has to be withdrawn
24. Names of the countries where the device is exported.

43. Criteria for CRO/Clinical Trial Centre:

1. CRO Profile to be submitted
2. Organogram
3. CV of Researchers and members
4. Job Description
5. Whether every person involved in the clinical trial has each got GCP training.
6. Clinical trial site master file.
7. Whether the Clinical Trial Center/CRO has Bio-analytical Lab
 - a. If not, have they got any contract with any Bio-analytical/analytical Lab having Biological Sample Analytical Facility.
 - b. Biological Sample storage & Carrying facility.
 - c. Whether the Analytical Laboratory got any accreditation.
8. Whether any chief investigator designated or contracted to the CRO or Clinical Trial Center.
9. Whether the CRO got IRB/IEC
 - a. Structure of IRB/IEC
 - b. Whether IRB/IEC registered from BMRC or approved by Law/Authority
10. Storage Facility of IP
 - a. Whether Temperature Sensitive Product Storage Facility
11. SOP for Handling of IP
12. Archive Facility
 - a. Is the Archive Facility has Controlled Access
 - b. Is the Archive Storage Area Fire Proof & Pest Control
13. Does the CRO/Clinical Trial Center has hospital facility
14. Whether they have emergency handling facility such as, Intensive Care Facility in the Hospital or has contract with any nearby intensive care unit.
15. Emergency Trolley & Ambulance Facility
16. Quality Management Systems

**ciikó-L t Jla ckymb Aia`B#ii 2016-2017 A_eQ#ii ev#RU t
(K) Dbqb ev#RU t**

**G#Wic eiv# Abj#qx
cK#íi ev#RU eiv# efvRb (ms#yB)**

A_eQi	t	2016-2017
gšYvjq	t	“ ” I cievi Kj`Y gšYvjq
ev`ZevqbKvix ms`v	t	Jla ckymb Aia`Bi
cK#íi tKW	t	5-2715-5010
cK#íi bvg	t	Strengthening of Drug Administration and Management
cK#íi tgv`	t	2011-2016
Abj#`bi chvq	t	Abj#`Z
cKí ciPvj#Ki bvg	t	tgRi tRbv#ij tgv`v`dRy ingvb
tUj#dib bs	t	9880864/9880897/9880924

(AsK mgr`j`y UvKvq)

A_#b#ZK tKW t#iÄ I #eeiY		#R I#e	cK í mrvnh"			me#gvU
			Avi#cG (#R I#ei gva"tg)	Avi#cG (Ab"vb")	#Wi#cG (Avi#cG e"ZZ cK í mrvnh")	
ivR e"q				-		
4800	miev# I tmev	10.00	36.00	-		46.00
4900	tgingZ I msiyY	00	64.00	-	-	64.00
tgvU ivR e"q t		10.00	100.00	-	-	110.00
gfab e"q						
6800	সম্পদ সংগ্রহ/ক্রয়	-	160.00	-	-	160.00
7000	#bgvY I cZ	190.00	00.00	-	-	190.00
tgvU gfab e"q		190.00	600.00	-	-	350.00
me#gvU		200.00	260.00	-	-	460.00

(L) Abj#qb ev#RU

(AsK mgr`n#Rvi UvKvq)

A_#b#ZK tKW	#eeiY	ms#kwaZ 2016-17	ev#RU 2016-17
	Abj#qb ivR`e`q		
4500	Aidmvi#`i teZb		
4501	Aidmvi#`i teZb	3,40,00	2,94,35
	Dc#gvU- Aidmvi#`i teZb	3,40,00	2,94,35
4600	c#Zôib KgPvix#`i teZb		
4601	c#Zôib KgPvix#`i teZb	2,37,38	2,37,38
	Dc#gvU-c#Zôib KgPvix#`i teZb	2,37,38	2,37,38
4700	f#Z#`		
4705	evio f#ov f#Zv	1,68,00	1,68,00
4709	kviš #e#b#`b f#Zv	18,77	14,77
4713	Drme f#Zv	88,62	88,62
4714	evsjv beel f#Zv	8,86	8,86
4717	#P#Krmv f#Zv	38,78	38,78
4721	c#vnox f#Zv	30	30
4725	#avjvB f#Zv	25	25
4733	Avc`vqb f#Zv	5	5
4737	`vqZfvi f#Zv	50	50
4755	#U#db f#Zv	2,13	2,13

A_#bZK †KvW	¶eeiY	ms†kv#aZ 2016-17	e†RU 2016-17
4765	hVZvqV fVZv	2,50	2,50
4773	¶k¶V fVZv	11,67	11,67
4795	Ab`vb` fVZv	6,00	6,00
	Dc†gU- fVZv`	3,46,43	3,42,43
4800	mieivn I †mev		
4801	ãgY e`q	12,00	12,00
4805	I fviUvBg	3,60	3,60
4806	fvoI-Avdm	46,00	40,00
4810	†cšIKi	3,00	3,00
4815	WvK	1,00	1,00
4816	†Uvj†dvb	2,00	2,00
4817	BvUvi†bU	6,00	4,50
4819	cmb	6,00	5,00
4821	¶e`y	15,00	15,00
4822	M`vm I Rvjvbx	60	60
4828	†ókbvix	2,00	2,00
4833	cPvi I ¶eAvcb	8,00	3,00
4836	BDvbdg	1,00	1,00
4851	kvgK gRyK	1,26,50	1,00,00
4883	mavvbx fVZv	90	90
4888	Kv¶cDUvi mvgMx	2,50	2,50
4899	Ab`vb` e`vq	35,00	30,00
	Dc†gU- mieivn I †mev	2,71,10	2,26,10
4900	†givgZ I msi¶¶Y		
4911	Kv¶cDUvi I Avdm miAvg	20	20
	Dc†gU- †givgZ I msi¶¶Y	20	20
	Dc†gU- Abvqb ivR` e`q	11,95,11	11,00,46
	Abvqb gvab e`q		
6800	সম্পদ সংগ্রহ/ক্রয়		
6815	Kv¶cDUvi I hšvsk	2,50	2,50
	Dc†gU- সম্পদ সংগ্রহ/ক্রয়	2,50	2,50
	Dc†gU- Abvqb gvab e`q	2,50	2,50
	†gU- JIa ckvmb A¶a`Bi	11,97,61	11,02,96
	†gU- JIa ckvmb A¶a`Bi	11,97,61	11,02,96

ciikó-M t Jla ckymb Aia`B#ii KgKZv`i`vqZ (Re তদসক্রিপশন) t gnvciPvjK

- 1| WwM A`v±-1940, WwM i:jm 1945 I 1946, WwM (K±Uvj) A`Wb`vY 1982 Ges D<sup>3</sup> ms`kvabxmn D³ AvBbmgn`ni c`qvM`b`ðZ Kiv|
- 2| jvB#mYs KZçY (WwM) `nmv`e Kg m`úv`b Kiv|
- 3| Jla ckymb Aia`B#ii Av`K I ckymbK`el`q cavb`bevn`nmv`e`vqZ cvjb Kiv|
- 4| ঔষধের উৎপাদন, আমদানী, রপ্তানী, বিতরণ এবং বিক্রয় সংক্রান্ত নীতি নির্ধারণী বিষয়ে সরকারের প্রতিনিধি হিসাবে KVR Kiv Ges miKvi`K mn`h`MZv Kiv|
- 5| WTO, TRIPS, GATT BZ`v`elqK bxZ`bavi`Y miKvi`K mn`h`MZv Kiv|
- 6| WHO, UNICEF, WB, UNDP Ges Ab`vb`AvSR`vZK ms`nvi minZ Jla ms`kó`el`q civgk/আলোচনাক্রমে কার্য সম্পাদন করা।
- 7| Jla ckymb Aia`B#i KgKZv/KgPvi`i`b`qvM, c`v`bZ, e`jx, Qy, Aemi fvZv, e`IK tMvcbxq c`Z`e`b BZ`v`g`vqb I Ab`g`v`b Kiv|
- 8| Jla ckymb Aia`B#ii Av`jK A`dmmg`হের কার্যক্রম সমন্বয় ও তদারকী করা।
- 9| ms`kó সকলের সহিত পরামর্শক্রমে যাবতীয় ঔষধ`mgMx`bqSYKvi`KZçY`n`m`e Kvh m`úv`b Kiv|
- 10| Jla I Jlaসামগ্রীর উৎপাদন, আমদানী, রপ্তানী, বিক্রয় ও বিজ্ঞাপন তদারকী করা।
- 11| evRviRvZKZ.JI`ai gvb`b`ðZ Kiv|
- 12| dv`g`mD`UK`vj B`U`ðZ GMP, GLP Ges GPP Ab`viY`b`ðZ Kiv|
- 13| evRviRvZKZ.JI`ai AD (Adverse Drug Reaction) Z`viKx Kiv Ges dv`g`iK`f`R`j`Y`b`ðZ Kiv|
- 14| Jla ckymb Aia`Bivab WwM tUv`÷s j`ve`iUixmg`ni Rb`c`qvRbxq h`scvZ Ges tKigK`vj`i`q`R`U I c`qvRbxq tidv`i`Y`ek I Rv`b`l`ক্রয় ও সরবরাহ করা।
- 15| JI`ai th`³K e`envi`b`ðZKi`Y ms`kó mKj`K Drm`v`nZ Kiv|
- 16| দেশে ক্লিনিক্যাল ট্রায়াল, ঔষধ সংক্রান্ত রিসার্চ এবং ডেভেলপমেন্ট কাজে সহযোগিতা প্রদান করা।
- 17| JI`ai g`j`bqSY Kiv|
- 18| RvZq I AvSR`vZK chv`q Ab`ðZ dv`g`mD`UK`vj Kb`fbkb, t`mgv`i I m`úv`Rqv`g Ask MnY Kiv|
- 19| ভটেরিনারি ঔষধের লাইসেন্সিং অথরিটি (ড্রাগস) হিসাবে কার্য সম্পাদন এবং এতৎ সংক্রান্ত নীতি নির্ধারণে সরকারকে mn`h`MZv Kiv|
- 20| miKvi KZK mgq mgq c`E`Ab`vb`vqZ cvjb Kiv|

ciPvjK, tKvqm`juU K±Uvj

- 1| ঔষধ সংক্রান্ত নীতি নির্ধা`iY I e`e`nvc`b`q gnvciPvjK, Jla ckymb Aia`B#iK mnvqZv/mn`h`MZv Kiv|
- 2| Post Marketing Surveillance কার্যক্রমের মাধ্যমে দেশে ভাল মানের ঔষধ উৎপাদন ও বিপণন নিশ্চিত করা।
- 3| evRviRvZKZ.JI`ai gvb`bqSY gnvciPvjK, Jla ckymb Aia`B#iK mnvqZv Kiv|
- 4| JI`ai th`³K e`envi`b`ðZKi`Y gnvciPvjK, Jla ckymb Aia`B#iK mnvqZv Kiv|
- 5| JI`ai`eic-প্রতিক্রিয়া তদারকীতে মহাপরিচালক, ঔষধ প্রশাসন অধিদপ্তরকে সহায়তা করা।
- 6| WHO, GMP M`BWjvBb ev`evq`b gnvciPvjK, Jla ckymb Aia`B#iK mnvqZv Kiv|
- 7| Aaxb`KgKZv/KgPvi`i`Z`viKx Kiv|
- 8| ঔষধ সংক্রান্ত আইন প্রয়োগে মহাপরিচালক, ঔষধ প্রশাসন অধিদপ্তরকে সহায়তা করা।
- 9| gnvciPvjK KZK c`E`Ab`vb`vqZ cvjb Kiv|
- 10| Jla cmvkb Aia`B#ii Aaxb`NCL Ges CDTL এর সার্বিক কার্যক্রম ev`evq`b I Z`viK Kiv Ges Bnv`i`AvaybKiqb I m`cmv`i`b gnvciPvjK`K mnvqZv Kiv|

ciPvjK, tiR`÷kb Ges jvB#mYs

- 1| ঔষধ সংক্রান্ত নীতি নির্ধারণ ও ব্যবস্থাপনায় মহাপরিচালক, ঔষধ প্রশাসন অধিদপ্তরকে সহায়তা করা।
- 2| JI`ai Registration I Licensing কার্যক্রমে মহাপরিচালক, ঔষধ প্রশাসন অধিদপ্তরকে সহায়তা করা।
- 3| ঔষধের স্থানীয় উৎপাদন, সংরক্ষণ, বিতরণ, বিক্রয়, পর্যাণ্ডতা, `e`Ávcb, `K`bK`j`U`qv`j, g`j`baviY, Avg`vbx`i`vbx, e`envi BZ`v`bqSY`b`ðZKi`Y gnvciPvjK, Jla ckymb Aia`B#iK mnvqZv Kiv|
- 4| Jla AvBb c`qv`M gnvciPvjK, Jla ckymb Aia`B#iK mnvqZv Kiv|
- 5| Aaxb`KgKZv-KgPvi`i`Z`viKx Kiv|
- 6| gnvciPvjK KZK c`E`Ab`vb`vqZ cvjb Kiv|

ciPvjK, ckymb, Ljiv I ciBKvi`jvB#mY

- 1| এমআইএস সংক্রান্ত নীতি নির্ধারণ ও ব্যবস্থাপনায় মহাপরিচালক, ঊষধ প্রশাসন অধিদপ্তরকে সহায়তা করা।
- 2| *DbZ I KvHKix GgAvBGm WcUtgU PvjKixY gnciIPvjK, Jla ckymb Aia`BiK mnvqZv Kiv|*
- 3| *Jla mংক্রান্ত যাবতীয় ডাটা (স্থানীয় উৎপাদনকারী প্রতিষ্ঠানের সংখ্যা, পাইকারী ও খুচরা বিক্রয়কারীর সংখ্যা beÜbKZ.Wv³vi, digwm÷, nKxg, KieivR BZ`i ZWjKv) msMnceK WUv e`vsk %Zix I Gi iyYieyY gnciIPvjK, Jla ckymb Aia`BiK mnvqZv Kiv|*
- 4| *Jla ckymb Aia`Bivaxb weifb LvZz bawiz miKwi ivRm Av`vq I Rgv bÜZKiY Ges miKwi nncbvi bivcEv bÜZz gnciIPvjK, Jla ckymb Aia`BiK mnvqZv Kiv|*
- 5| *gnciIPvjK, Jla ckymb Aia`Bi Gi c`y` ygZvcvB eivIKvix KgKZv nmte`vqZ cvjb Kiv|*
- 6| *cvBKvix I Lpiv WM jvBtmY c`vn, নবায়ন, সাময়িক বাতিল ও বাতিল সংক্রান্ত বিষয়ে তদারকী করা।*
- 7| *gnciIPvjK KZK c`E Ab`vb` `vqZ cvjb Kiv|*

cIPvjK, tfUibwi Jla

- 1| ভট্টেরিনারি ঊষধ সংক্রান্ত নীতি নির্ধারণ ও ব্যবস্থাপনায় মহাপরিচালক, ঊষধ প্রশাসন অধিদপ্তরকে সহায়তা করা।
- 2| *tfUibwi Jla i`R÷kb I jvBtmYs G gnciIPvjK, Jla ckymb Aia`BiK mnvqZv Kiv|*
- 3| *tfUibwi Jla i`nvbxq Drcv`b, Avg`vbx-রপ্তানী, বিক্রয়, বিতরণ, পর্যাণ্ততা, বিজ্ঞাপন ও ব্যবহার নিয়ন্ত্রণে bÜZKiY gnciIPvjK, Jla ckymb Aia`BiK mnvqZv Kiv|*
- 4| *gnciIPvjK, Jla ckymb Aia`B`ii c`y` ygZvcvB eivIKvix KgKZv nmte`vqZ cvjb Kiv|*
- 5| *cPijZ AvBb c`qvM gnciIPvjK, Jla ckymb Aia`BiK mnvqZv Kiv|*
- 6| *Aaxb` KgKZv-KgPvix`i Z`viKx Kiv|*
- 7| *gnciIPvjK KZK c`E Ab`vb` `vqZ cvjb Kiv|*

cIPvjK, WM tU÷s j`ve`iUix

- 1| *Zu Dci AicZ `vqZ cvj`bi gva`g msikó cIPvjK`K mnvqZv Kiv|*
- 2| *WM G`v± I Bnvi Aaxb cYxZ i`jm Abvix miKvix etKIK nmte`vqZ cvjb Kiv|*
- 3| *cixYz bgv i AbKzj mviUid`KU Ae GbvjvBimm c`vb Kiv|*
- 4| *msikó cIPvjK KZK AicZ Ab`vb` `vqZ cvjb Kiv|*
- 5| *Aaxb` KgKZv-KgPvix`i Z`viKx Kiv|*

DccIPvjK

- 1| *Zunvi Dci jvLZfvte AicZ `vqZ cvj`bi gva`g msikó cIPvjK`K mn`hwmZv Kiv|*
- 2| *gnciIPvjK/cIPvjK KZK c`E Ab`vb` `vqZ cvjb|*

DccIPvjK, tfUibwi tgmWmb

- 1| *Zu Dci AicZ `vqZ cvj`bi gva`g cIPvjK (tfUibwi tgmWmb) `K mnvqZv Kiv|*
- 2| *cIPvjK (tfUibwi tgmWmb) KZK AicZ Ab`vb` `vqZ cvjb Kiv|*

mnKvix cIPvjK

- 1| *Zu Dci AicZ `vqZ cvjb Kiv|*
- 2| *cIPvjK/DccIPvjK KZK AicZ Ab`vb` `vqZ cvjb Kiv|*

mnKvix cIPvjK, tfUibwi tgmWmb

- 1| *Zunvi Dci jvLZfvte AicZ `vqZ cvjb Kiv|*
- 2| *cIPvjK/DccIPvjK KZK AicZ Ab`vb` `vqZ cvjb Kiv|*

tgmW`Kj Aidm i

- 1| *weÁvcb bqs`Y msikó mnKvix cIPvjK`K mn`hwmZv Kiv|*
- 2| *Aaab` KgPvix`i Z`viKx Kiv|*
- 3| *cIPvjK/DccIPvjK/mnKvix cIPvjK KZK AicZ Ab`vb` `vqZ cvjb Kiv|*

Jla ZĖeavqK

- 1| Jla AvBb I GZ`msikó i:jm ev`evqtb msikó mnKvix ciiPvjK#K mnvqZv Kiv|
- 2| JI#ai tiR#÷ kb GŪ jvB#mŷs, bglv mSMn Ges gvbibqšY, gĵ" baviY, Avg`vbx, iBvbx, QvocĪ c`vb, বাজার তদারকী কার্যক্রম, পরিদর্শন, স্থানীয় উৎপাদন, সংরক্ষণ, বিতরণ, বিক্রয়, আইনগত ব্যবস্থা গ্রহণ এবং এতৎসংশ্লিষ্ট অন্যান্য কার্যক্রম পরিচালনার মাধ্যমে সংশ্লিষ্ট সহকারী পরিচালককে সহযোগিতা করা।
- 3| তাহার নিয়ন্ত্রণাধীন এলাকায় ঔষধ আইন অনুযায়ী সক্রিয় থাকা।
- 4| cixŷv I #e#kl#Yi #big#Ė JI#ai bglv mSMn Kiv|
- 5| A#ab` KgPvix#`i Z`viKx Kiv|
- 6| Zvnyi Dci A#CZ Ab`vb" th #Kib `wqZ cvjb Kiv|

Jla ZĖeavqK, #f#Uibni tgiWmb

- 1| Jla AvBb I GZrmsikó i:jm ev`evqtb msikó mnKvix ciiPvjK#K mnvqZv Kiv|
- 2| JI#ai tiR#ók kb GŪ jvB#mŷs, bglv mSMn Ges gvbibqšY, gĵ" baviY, Avg`vbx, iBvbx, QvocĪ c`vb, বাজার তদারকী কার্যক্রম, পরিদর্শন, স্থানীয় উৎপাদন, সংরক্ষণ, বিতরণ, বিক্রয়, আইনগত ব্যবস্থা গ্রহণ এবং এতৎসংশ্লিষ্ট অন্যান্য কার্যক্রম পরিচালনার মাধ্যমে সংশ্লিষ্ট সহকারী পরিচালককে সহযোগিতা করা।
- 3| তাহার নিয়ন্ত্রণাধীন এলাকায় ঔষধ আইন অনুযায়ী সক্রিয় থাকা।
- 4| A#ab` KgPvix#`i Z`viKx Kiv|
- 5| cixŷv I #e#kl#Yi #big#Ė JI#ai bglv mSMn Kiv|
- 6| Zvnyi Dci A#CZ Ab`vb" th #Kib `wqZ cvjb Kiv|

mnKvix jvB#mŷs Andmvi

- 1| Jla AvBb I GZrmsikó i:jm ev`evqtb msikó mnKvix ciiPvjK#K mnvqZv Kiv|
- 2| JI#ai tiR#ók kb GŪ jvB#mŷs, bglv mSMn Ges gvbibqšY, gĵ" baviY, Avg`vbx, iBvbx, QvocĪ c`vb, বাজার তদারকী কার্যক্রম, পরিদর্শন, স্থানীয় উৎপাদন, সংরক্ষণ, বিতরণ, বিক্রয়, আইনগত ব্যবস্থা গ্রহণ এবং এতৎসংশ্লিষ্ট অন্যান্য কার্যক্রম পরিচালনার মাধ্যমে সংশ্লিষ্ট সহকারী পরিচালককে সহযোগিতা করা।
- 3| Zvnyi #bqšbvaxb GjvKvq Jla AvBb অনুযায়ী সক্রিয় থাকা।
- 4| A#ab` KgPvix#`i Z`viKx Kiv|
- 5| cixŷv I #e#kl#Yi #big#Ė JI#ai bglv mSMn Kiv|
- 6| Zvnyi Dci A#CZ Ab`vb" th #Kib `wqZ cvjb Kiv|

#mbqi mv#q#UidK Andmvi

- 1| Jla AvBb I GZrmsikó i:jm ev`evqtb msikó mnKvix ciiPvjK#K mnvqZv Kiv|
- 2| JI#ai tiR#ók kb GŪ jvB#mŷs, bglv mSMn Ges gvbibqšY, gĵ" baviY, Avg`vbx, iBvbx, QvocĪ c`vb, বাজার তদারকী কার্যক্রম, পরিদর্শন, স্থানীয় উৎপাদন, সংরক্ষণ, বিতরণ, বিক্রয়, আইনগত ব্যবস্থা গ্রহণ এবং এতৎসংশ্লিষ্ট অন্যান্য কার্যক্রম পরিচালনার মাধ্যমে সংশ্লিষ্ট সহকারী পরিচালককে সহ#mMZv Kiv|
- 3| তাহার নিয়ন্ত্রণাধীন এলাকায় ঔষধ আইন অনুযায়ী সক্রিয় থাকা।
- 4| A#ab` KgPvix#`i Z`viKx Kiv|
- 5| cixŷv I #e#kl#Yi #big#Ė JI#ai bglv mSMn Kiv|
- 6| Zvnyi Dci A#CZ Ab`vb" th #Kib `wqZ cvjb Kiv|

AvBb KgKZv

- 1| AvBib #el#q msikó mnKvix ciiPvjK#`i#K mnvqZv Kiv Ges #e`gvb Jla AvBb jsN#bi `v#q gvgjv `v#q#i i e`vc#i Jla cii`kK#`i#K AvBib mnvqZv c`vb Kiv|
- 2| Zvnyi A#ab` KgPvix#`i Z`viKx Kiv|
- 3| Ab`vb" A#CZ `wqZ cvjb Kiv|

mnKvix R#e#b#`

- 1| JI#ai cixŷv I #e#kl#Y msikó mnKvix ciiPvjK#K mnvqZv Kiv|
- 2| A#ab` KgPvix#`i Z`viKx Kiv|
- 3| A#CZ Ab`vb" `wqZ cvjb Kiv|

mnKvix R#e#b#`

- 1| JI#ai cixÿv I #e#kl#Y msikó mnKvix c#iPvjK#K mnvqZv Kiv|
- 2| Aaxb⁻ KgPvix#`i Z`viKx Kiv|
- 3| A#cZ Ab`vb` `wqZ cvjb Kiv|

nmve iÿY KgKZv

- 1| JIa ckymb A#a`Bরের হিসাব রক্ষণ ও বাজেট প্রণয়ন কার্যক্রমে সংশ্লিষ্ট সহকারী পরিচালককে সহায়তা প্রদান করা।
- 2| Aaxb⁻ KgPvix#`i Z`viKx Kiv|

Gimm#Uu tcmgvi

- 1| ঔষধ প্রশাসন অধিদপ্তরের যাবতীয় কার্যক্রম (স্থানীয় উৎপাদন, আমদানীকৃত ঔষধ নিবন্ধনকৃত ঔষধ, ঔষধ Drcv`bKvix c#Zôv#bi ZvjKv, c#BKvix I Lpiv WvM jvB#mY Gi ZvjKv, #beÜbKZ.Wv<sup>3</sup>vi, dvgnimó, nvKg, K#eivR BZ`v#`i ZvjKv) m#UvKZ WvUve`vsK cYqb I msiÿ#Y msikó mnKvix c#iPvjK#K mnvqZv c`vb Kiv|
- 2| JIa ckymb A#a`B#i i c#qvR#b c#qvRbxq mdUlqvi %Zix Kiv|
- 3| Aaxb⁻ KgPvix#`i Z`viKx Kiv|

c#imsL`vb KgKZv

- 1| ঔষধ উৎপাদনকারী প্রতিষ্ঠান, বিক্রয়কারী প্রতিষ্ঠান, আমদানীকারী প্রতিষ্ঠান, রপ্তানীকারী প্রতিষ্ঠান ও নিবন্ধনকৃত ঔষধের ZvjKv msiÿY Kiv|
- 2| Avg`vbxKZ.JI#ai K#vgj, tgvok `e`v#` I c`ZKZ.JI#ai ZvjKv msiÿb Kiv|
- 3| `nvbxqfv#e Drcv`Z JI#ai K#vgj, tgvok mvgMx I Drcv`Z JI#ai ZvjKv msiÿY Kiv|
- 4| evvYiR`K I tR#biK JI#ai ZvjKv msiÿY Kiv|
- 5| msMpxZ bgbvi msL`v, MpxZ #e#kIY c#Z#e`#bi msL`v (gvbm#Z I gvb-বহির্ভূত) সংক্রান্ত তথ্য সংরক্ষণ করা।
- 6| গৃহীত আইনগত ব্যবস্থা সংক্রান্ত তথ্যাদি সংরক্ষণ করা।
- 7| G#WAvi g#bU#i# সংক্রান্ত তথ্য সংরক্ষণ করা।
- 8| মহাপরিচালক, ঔষধ প্রশাসন অধিদপ্তর এর অন্যান্য কার্যক্রম সংক্রান্ত ডাটা সংরক্ষণ করা।

c#ikó-N t JIa ckymb A#a`B#i i KgKZv#`i bvg, Kv#vj#qi bvg I c`ex t

ক্রমিক bs	KgKZi bvg	c`ex	Kv#vj#qi bvg
1.	tgRi tRb#i#j tgv #gv`v#dRy ingvb	gnvc#iPvjK	JIa ckymb A#a`Bi, XvKv
2.	tgv tMvjg #Keiqv	c#iPvjK	JIa ckymb A#a`Bi, XvKv
3.	tgv i#új Awgb	c#iPvjK (Pj#Z`wqZ)	JIa ckymb A#a`Bi, XvKv
4.	bqv i myZvbv	c#iPvjK (Pj#Z`wqZ)	JIa ckymb A#a`Bi, XvKv
5.	Avt It g#ndK# ingvb	Dc c#iPvjK	WvM tU#÷s j`ve#iUix, XvKv
6.	W. tLv`Kvi QMxi Avn#g`	Dc c#iPvjK	JIa ckymb A#a`Bi, XvKv
7.	#gv AvjZvd #nv#mb	Dc c#iPvjK	JIa ckymb A#a`Bi, XvKv
8.	tgv b#y Bmjvg	Dc c#iPvjK	JIa ckymb A#a`Bi, XvKv
9.	tgv tgv`v#dRy ingvb	Dc c#iPvjK	#m>Uvj WvM tU#÷s j`ve#iUix, P#Mvg A#Z#i ³ `wqZt P#Mvg #efvMxq Kv#vj#q, P#Mvg
10.	#gv AvBq# #nv#mb	mnKvix c#iPvjK	JIa ckymb A#a`Bi, XvKv
11.	tgv Avkivd #nv#mb	mnKvix c#iPvjK	JIa ckymb A#a`Bi, XvKv
12.	#gRv tgv Av#bqv#i#j ev#m`	mnKvix c#iPvjK	JIa ckymb, ivRkvn#
13.	#gvnv#` #gRv#i#j #nv#mb	mnKvix c#iPvjK	JIa Z#veav#Ki Kv#vj#q, JIa ckymb,P#Mvg
14.	tgv BqvnBqv	mnKvix c#iPvjK	JIa ckymb A#a`Bi, XvKv
15.	tgv mvjvn DiTb	mnKvix c#iPvjK	JIa ckymb A#a`Bi, XvKv
16.	#gv kidK# Bmjvg	mnKvix c#iPvjK	JIa ckymb A#a`Bi, XvKv
17.	W. tgv Av#Ke #nv#mb	mnKvix c#iPvjK	JIa ckymb A#a`Bi, XvKv A#Z#i <sup>3</sup> `wqZt XvKv #efvMxq Kv#vj#q, g#Z#Sj,

ক্রমিক bs	KgKZvi big	c`ex	Kvhj+qi big
			XvKv
18.	†gvt AvKZvi tnv+mb	mnKvix ciiPvjK	Jla ckymb, MvRxcy
19.	†gvnvq` bvCg †Mvj`vi	mnKvix jvB+miYs Aiidmvi	Jla ckymb Aia`Bi, XvKv
20.	†gvt nviab Ai ink`	Jla ZĖvearqK	Jla ZĖvearq+Ki Kvhvjg, Jla ckymb, Kzjv
21.	†gvt b+ij Avjg	Jla ZĖvearqK	Jla ZĖvearq+Ki Kvhvjg, Jla ckymb, kixqZcy
22.	†gvt Ave`y gv+jK	Jla ZĖvearqK	Jla ZĖvearq+Ki Kvhvjg, Jla ckymb, WkZMu
23.	†gvt mvdKz Bmjvg	Jla ZĖvearqK	Jla ZĖvearq+Ki Kvhvjg, Jla ckymb, im+jU
24.	†gvt Iqvin`y ingvb	Jla ZĖvearqK	Jla ZĖvearq+Ki Kvhvjg, Jla ckymb, Kzqv
25.	†gvt gvm+yvgvb Lvb	Jla ZĖvearqK	Jla ZĖvearq+Ki Kvhvjg, Jla ckymb, †b†+Kvbv
26.	†gvt mvgQyDvİb	Jla ZĖvearqK	Jla ZĖvearq+Ki Kvhvjg, Jla ckymb, gyMÄ
27.	Wvt Avqkv imvİKv	dvgv†KvjR÷	WvM †Uv÷s j`ve†iUix, XvKv AvZvi 3`vqZt Jla ckymb Aia`Bi, XvKv
28.	†gvt †kL Avnmvb Djvn	Jla ZĖvearqK	Jla ZĖvearq+Ki Kvhvjg, Jla ckymb, i+vgvU
29.	†nmvBb †gvnvq` Bgivb	Jla ZĖvearqK	Jla ZĖvearq+Ki Kvhvjg, Jla ckymb, †bvqvLvix
30.	mKY Avn+g`	Jla ZĖvearqK	Jla ZĖvearq+Ki Kvhvjg, Jla ckymb, PqWv+Zv
31.	Zvbfxi Avn+g`	Jla ZĖvearqK	Jla ZĖvearq+Ki Kvhvjg, Jla ckymb, eikvj
32.	, jkvb Rvmb	Jla ZĖvearqK	Jla ckymb Aia`Bi, XvKv mshyt Jla ckymb, PÆMvg
33.	†gvt BKej tnv+mb	Jla ZĖvearqK	Jla ZĖvearq+Ki Kvhvjg, Jla ckymb, imivRMÄ
34.	†gvt ivdKz Bmjvg	Jla ZĖvearqK	Jla ZĖvearq+Ki Kvhvjg, Jla ckymb, v`bvRcy
35.	†gvt Ave`y evix	Jla ZĖvearqK	Jla ZĖvearq+Ki Kvhvjg, Jla ckymb, Uv+ZvBj
36.	gvingy tnv+mb	Jla ZĖvearqK	Jla ZĖvearq+Ki Kvhvjg, Jla ckymb, Lybv
37.	†gt ksKi Kzvi miKvi	Jla ZĖvearqK	Jla ZĖvearq+Ki Kvhvjg, Jla ckymb, evpYevioqv
38.	†Mšix ivbx emvK	Jla ZĖvearqK	Jla ZĖvearq+Ki Kvhvjg, Jla ckymb, gvbKMA
39.	†gt %mKZ Kzvi Ki	Jla ZĖvearqK	Jla ckymb Aia`Bi, XvKv
40.	†gvQvt bvMxm Av 3vi	Jla ZĖvearqK	Jla ZĖvearq+Ki Kvhvjg, Jla ckymb, iscy
41.	†gvt mivLv IqvZ tnv+mb ivRy AvKv`	Jla ZĖvearqK	Jla ZĖvearq+Ki Kvhvjg, Jla ckymb, gqgbimsn
42.	†K, Gg, gpmxibb gvney	Jla ZĖvearqK	Jla ZĖvearq+Ki Kvhvjg, Jla ckymb, ciebv

ক্রমিক bs	KgKZvi big	c`ex	Kvhj#qi big
70.	#gv: Kvgi: j nvmvb	Jla ZĖvearqK	Jla ZĖvearq#Ki Kvhvj q, Jla ckymb, cUqLv jx
71.	†gvQvt nwig`v teMg	Jla ZĖvearqK	Jla ckymb Aia`Bi, XvKv mshy†t Wm †U÷s j`ve†iUix, XvKv
72.	ûgvqiv Avid†ivR	Jla ZĖvearqK	Jla ZĖvearq#Ki Kvhvj q, Jla ckymb, biims`x
73.	†PÎV miKvi	mnKvix imvqbie`	†m>Uvj Wm †U÷s j`ve†iUix, PÆMvg mshy†t Wm †U÷s j`ve†iUix, XvKv
74.	dviRvbi kebg`ekvLx	Jla ZĖvearqK	Jla ZĖvearq#Ki Kvhvj q, Jla ckymb, ev†MinvU
75.	Aia`Z`Yv	Jla ZĖvearqK	Jla ZĖvearq#Ki Kvhvj q, Jla ckymb, †c†ivRcÿ
76.	gi:gg miKvi	Jla ZĖvearqK	Jla ZĖvearq#Ki Kvhvj q, Jla ckymb, bIMvu
77.	#gvt tg†n`x AvidRvj	Jla ZĖvearqK	Jla ZĖvearq#Ki Kvhvj q, Jla ckymb, jvjgmbinvU
78.	jvebx ev‰o	Jla ZĖvearqK	Jla ckymb Aia`Bi, XvKv mshy†t Wm †U÷s j`ve†iUix, XvKv
79.	#gšmgx Av³vi	Jla ZĖvearqK	Jla ZĖvearq#Ki Kvhvj q, Jla ckymb, Pivcÿ
80.	mv†eiv Zvevmmg Iqvinn`	Jla ZĖvearqK	Jla ZĖvearq#Ki Kvhvj q, Jla ckymb, †SbvB`n
81.	kvqjv bIkv`	Jla ZĖvearqK	Jla ckymb Aia`Bi, XvKv
82.	#gvt gkvdkZ ingvb	†mbqi mvB†UvdK A†dmvi	†m>Uvj Wm †U÷s j`ve†iUix, PÆMvg
83.	#gvt dvi:K †nv†mb	mnKvix imvqbie`	†m>Uvj Wm †U÷s j`ve†iUix, PÆMvg mshy†t Wm †U÷s j`ve†iUix, XvKv
84.	#gvt dRjÿ nK	Jla ZĖvearqK (fvicvß)	Jla ZĖvearq#Ki Kvhvj q, Jla ckymb, jÿxcÿ
85.	exv_ ivbx gûj	Jla ZĖvearqK (fvicvß)	Jla ZĖvearq#Ki Kvhvj q, Jla ckymb, gv`vixcÿ
86.	†iv†gj gvjK	Jla ZĖvearqK (fvicvß)	Jla ckymb Aia`Bi, XvKv mshy†t Wm †U÷s j`ve†iUix, XvKv
87.	kx †MŠZg P>` miKvi	Jla ZĖvearqK (fvicvß)	Jla ZĖvearq#Ki Kvhvj q, Jla ckymb, MvBeivUv
88.	#gvt tgvK†Q`ÿ Avigb	Jla ZĖvearqK (fvicvß)	Jla ckymb Aia`Bi, XvKv mshy†t Wm †U÷s j`ve†iUix, XvKv
89.	mKxj Kgi Xvjx	Jla ZĖvearqK (fvicvß)	Jla ZĖvearq#Ki Kvhvj q, Jla ckymb, ei, bv
90.	KvRx †bZz	Jla ZĖvearqK (fvicvß)	Jla ZĖvearq#Ki Kvhvj q, Jla ckymb, RqcÿnvU
91.	†cqvsKv `vk, Bv	Jla ZĖvearqK (fvicvß)	Jla ZĖvearq#Ki Kvhvj q, Jla ckymb, K·eiRvi
92.	#gvt Rvinn`ÿ Bmjvg	Jla ZĖvearqK (fvicvß)	Jla ZĖvearq#Ki Kvhvj q, Jla ckymb, MvRxcÿ
93.	ivRxe `vm	Jla ZĖvearqK (fvicvß)	Jla ZĖvearq#Ki Kvhvj q, Jla ckymb, RqcÿnvU
94.	Zvniig` Rviggj	Jla ZĖvearqK (fvicvß)	Jla ZĖvearq#Ki Kvhvj q, Jla ckymb, †kicÿ

ক্রমিক bs	KgKZvi bvg	c`ex	Kvhj#qi bvg
95.	bvmb Avj Avjg	Jla ci`kK	XvKv wefvMxq Kvhvj q, gZiSj, XvKv
96.	møZ cvj	mnKvix Gbvj ÷	nmve i`yY KgKZv (P.`v.)
97.	#ivgvbv iiqvR	mnKvix Gbvj ÷	nmve i`yY KgKZv (P.`v.)
98.	#gvt Avey gbmj	nmve i`yY KgKZv (P.`v.)	Jla ckmb Aia`Bi, XvKv

ciikó-0 t Z_`c`vbKvix KgKZv#`i ZvjKv t

ক্রমিক bs	Kvhj#qi bvg	Z_`c`vbKvix KgKZvi bvg I c`ex	†Uj#dib b#i	B-#gBj
01	Jla ckmb Aia`Bi, XvKv	Rbie #gvt AvBqg #nv#mb, mnKvix ciPvjK	01711670282	ayub_hossain@yahoo.com
02	Jla ckmb Aia`Bi, XvKv	ig#mm. Gm, Gg, mveixbv BqvQigb, Jla ZÊveavqK (ieKí KgKZv)	01722903474	sabrinayesmin222@yahoo.com
03	#m>Uvj WM †Uj ÷ s j`ve†iUix, AvMev`, PÆMig	Rbie tgv† tgv`wdRy ingvb, DcciiPvjK	01711109585	orliscor07@gmail.com
04	WM †Uj ÷ s j`ve†iUix, XvKv	Rbie Avt It gmdKz ingvb, DcciiPvjK	01912920757	rahamanmushfiq06@gmail.com
05	Jla ZÊveavq#Ki Kvhjq, Jla ckmb, ivRKvix	Rbie igRv† tgv† Av#bvqvizj ev#m`, mnKvix ciPvjK	01711811194	mirzaanwarul@yahoo.com
06	Jla ZÊveavq#Ki Kvhjq, Jla ckmb, MvRcy	Rbie tgv† AvKZvi †nv#mb, mnKvix ciPvjK	01711071010	akterh4@yahoo.com
07	Jla ZÊveavq#Ki Kvhjq, Jla ckmb, Kzjv	Rbie tgv† nvizb Ai iik`, Jla ZÊveavqK	01711129706	bharun2010@yahoo.com
08	Jla ZÊveavq#Ki Kvhjq, Jla ckmb, kixqZcy	Rbie tgv† b#j Avjg, Jla ZÊveavqK	01714218525	mnalam00 @gmail.com
09	Jla ZÊveavq#Ki Kvhjq, Jla ckmb, VvKzVv	Rbie tgv† Ave`y gvtjK, Jla ZÊveavqK	01728052447	md.malekbiodu@gmail.com
10	Jla ZÊveavq#Ki Kvhjq, Jla ckmb, vmtjU	Rbie tgv† mvdKz Bmjvg, Jla ZÊveavqK	01712270390	safiqislam52@gmail.com
11	Jla ZÊveavq#Ki Kvhjq, Jla ckmb, Kzqv	Rbie tgv† lqvnn`y ingvb, Jla ZÊveavqK	01715304429	wahidrahman8@gmail.com
12	Jla ZÊveavq#Ki Kvhjq, Jla ckmb, gyMÄ	Rbie tgv† mvgQvDilb, Jla ZÊveavqK	01712117440	shamsu.ilti@gmail.com
13	Jla ZÊveavq#Ki Kvhjq, Jla ckmb, #bI#Kv	Rbie tgv† gvmYgvgvb Lvb, Jla ZÊveavqK	01917742530	masud_khan2008@yahoo.com
14	Jla ZÊveavq#Ki Kvhjq, Jla ckmb, PÆMig	Rbie tgv† kvdKz ingvb, Jla ZÊveavqK	01818244711	shafikurpr@gmail.com
15	Jla ZÊveavq#Ki Kvhjq, Jla ckmb, h#kvi	Rbie tgv† †invb nvmb Jla ZÊveavqK	01911025305	rehan.pharm@gmail.com
16	Jla ZÊveavq#Ki Kvhjq, Jla ckmb, #bvqvLv jx	Rbie †nvmbBb tgv† gvg` Bgivb, Jla ZÊveavqK	01716609033	imranacct@yahoo.com
17	Jla ZÊveavq#Ki Kvhjq, Jla ckmb, biims`x	Rbie ôgvqv Avd#ivR, Jla ZÊveavqK	01199421554	hafroz_du@yahoo.com
18	Jla ZÊveavq#Ki Kvhjq, Jla ckmb, vmiivRMÄ	Rbie tgv† Bkev j †nv#mb, Jla ZÊveavqK	01721324206	iqbal_bcmb42@yahoo.com
19	Jla ZÊveavq#Ki Kvhjq, Jla ckmb, v`bvRcy	Rbie tgv† ivdKz Bmjvg, Jla ZÊveavqK	01914724210	mithu_bmb@yahoo.com
20	Jla ZÊveavq#Ki Kvhjq, Jla ckmb, UvsvMBj	Rbie tgv† Ave`y evix, Jla ZÊveavqK	01718683831	barisddgda@gmail.com

ক্রমিক bs	Kvhj#qi bvg	Z_ c`vbKvix KgKZvi bvg I c`ex	tUj#dib bxi	B-#gBj
47	Jla ZĖearq#Ki Kvhjq, Jla ckymb, #c#ivRcy	Rbie Aiv`Z`Yv, , Jla ZĖearqK	01714756772	auditi_swarna@yahoo.com
48	Jla ZĖearq#Ki Kvhjq, Jla ckymb, bIMvu	Rbie gi#gq miKvi, Jla ZĖearqK	01713504521	marumoy_1402@yahoo.com
49	Jla ZĖearq#Ki Kvhjq, Jla ckymb, jvjgibivU	Rbie #gvt tg#n`x AvdRvj, Jla ZĖearqK	01718241208	pallab_509r@yahoo.com
50	Jla ZĖearq#Ki Kvhjq, Jla ckymb, Piucy	Rbie #gsmgx Av`vi, Jla ZĖearqK	01771955868	mowbph01@gmail.com
51	Jla ZĖearq#Ki Kvhjq, Jla ckymb, j`ycy	Rbie #gvt dRjy`nK, Jla ZĖearqK (fvicvB)	01717228672	fazlvet@gmail.com
52	Jla ZĖearq#Ki Kvhjq, Jla ckymb, gv`vixcy	Rbie ex_ ivbx gUj, Jla ZĖearqK (fvicvB)	01766784220	nipa9mandal@yahoo.com
53	Jla ZĖearq#Ki Kvhjq, Jla ckymb, MBeivUv	kx tMSZg P` miKvi, Jla ZĖearqK (fvicvB)	01737033782	-
54	Jla ZĖearq#Ki Kvhjq, Jla ckymb, RqcynvU	Rbie ivRie`vm, Jla ZĖearqK (fvicvB)	01721128571	rajibdas4646@yahoo.com
55	Jla ZĖearq#Ki Kvhjq, Jla ckymb, #kicy	Rbie Zivng`Rvgj, Jla ZĖearqK (fvicvB)	01825402271	tahmid.jamil27@gmail.com

ciikó-P t mc#Yv`Z Z\_ cKv#ki #b#`kKv t figKv

**K) Jla ckymb Aia`Bit** vaxbZvi c#e Jla ckymb #Qj c#K`Zvb tK`xq miKvi ciip#jZ GK#U`Bi| 1971 mv#ji ci G#U mv`n` I RbmsL`v #bqšY gšYvj#qi GK#U mshy বিভাগ হিসেবে কার্যক্রম চালাচ্ছিল। ১৯৭৬ সালে mv`n` I ci#evi Kj`vY gšYvj#qi Aaxb Jla ckymb GK#U Avjv`v ci#B#i ci#YZ nq| me#kI 2010 mv#j Jla ckymb ci#Bi#K Aia`B#i DbxZ Kiv nq| Jla ckymb Aia`Bi MYcRvZšx evsj#`k miKv#ii mv`n` I ci#evi কল্যাণ মন্ত্রণালয়ের অধীন দেশের একমাত্র ঔষধের লাইসেন্সিং ও নিয়ন্ত্রণকারী কর্তৃপক্ষ। ঔষধ প্রশাসন ঔষধ নিয়ন্ত্রণ সংক্রান্ত mKj KgKvU ciip#jv I cP#jZ Jla AvBb c#qM K#i`v#K| D<sup>3</sup> Aia`B#ii AM#bM#g tgvU 370 #U c` i#q#Q. tmM#jvi g#a` 118 #U c_g #kYxi c`, 25 #U #QZxq #kYxi c`, 115 #U ZZxq #kYxi c` Ges 112 #U PZz #kYxi c` i#q#Q| gnvciip#jK Jla ckymb Aia`B#ii cavb| gnvciip#jK jvB#m#s KZcy (W#Mm) #n#m#e ygZvcvB| Jla ckymb Aia`B#ii cavb Kvhjq, XivKvq Ae#Z, tRjv chv#q 48 #U Kvhjq i#q#Q|

(L) Jla ckymb Aia`B#ii cavb cavb Kihvjx t

- (1) Jla Drcv`b KviLvbi bZy cKí g#`vqb|
- (2) Jla c`ZyZi Rb` jvB#mY c`vb I bevqb|
- (3) খুচরা ও পাইকারী ঔষধ বিক্রয় লাইসেন্স প্রদান ও নবায়ন।
- (4) Jla#ai ti#R#÷kb c`vb I bevqb|
- (5) Jla#ai g#`#baviY I g#`mb` c`vb|
- (6) ঔষধ উৎপাদন কারখানা ও বিক্রয়কারী ডিপো এবং ফার্মেসী পরিদর্শন
- (7) Jla#ai K#vgvj I tgvok mvgMx Avg`vbx i Rb` eK#j ÷ Ab#gv`b|
- (8) Jla Avg`vbx i t#y#Î B#ÛÈ Ab#gv`b|
- (9) Avg`vbxKZ %Zix Jla I Jla#ai K#vgvj i QvocÎ c`vb|
- (10) Jla#ai evRvi Z`v#KKiY|
- (11) #e#fb Av#e`#bi ci#ci#y#Z AZ`š c#q#Rbxq ti#R#÷kb#enxb Jla#ai Abvc#E mb` c`vb|
- (12) cP#jZ Jla AvBb j#NbKvix#`i #ei#x W#M tKvU, g`wR#÷U tKvU I tgv#Bj tKv#U gvgjv`v#qi Kiv|
- (13) Jla iB#m#i Rb` jvB#mY, CPP/FSC I GMP m#U#d#KU c`vb|
- (14) Jla#ai #eÁvcb Ab#gv`b/ #bqšY|
- (15) Jla Drcv`bKvix ci#Z#b #b#q#RZ tKvq#jd#BW e`#³#`i ci#kyY c`vb|

(M) **c`vebv t t`#ki Jla** *¶kí, Jla Drcv`b, iBvbx, mieivn, ¶ecbb, mnRjf`Zv, thš¶³K e`envi, Jla ¶bqšY e`e`nv m¶c#K Rbm¶\_ mD#`v¶M I mc#Y¶`Z n#g c#qvRbxq Z\_`v¶` cKvk Kiv D¶PZ| JI¶ai gZ Rxb iŷvKvix Dcv`vb e`envi i tŷ#Î RbMY hv#Z m¶VK ¶m×vš MnY Ki#Z cv#i, Jla Ges JI¶ai ¶bqšY e`e`nv m¶c#K mg`K aviYv t#Z cv#i tm Rbv* ঔষধ সংক্রান্ত তথ্যাদি সহজলভ্য হওয়া প্রয়োজন। তথ্য পাওয়া জনগণের আইনগত অধিকার। *¶bqgZ¶šKfv#e Z_` cKv#ki tŷ#Î mc#Y¶`Z Z_` cKv#ki ¶b#`kKv mnvqK n#e|*

¶b#`kKvi jŷ`

- 1| *m¶aviY gbyhv#Z c#qvRbxq, KvHKi, ¶bivc` I gvbmpúb Jla Ges JI¶ai jf`Zv m¶c#K Z_` t#Z cv#i Zv ¶bðZ Kiv |*
 - 2| *t`#ki Jla ¶bqšY e`e`nv m¶c#K RbMY#K chvB aviYv t`Iqv|*
 - 3| *t`#ki Jla m¶c#K RbM#Yi Av`nv e¶× Kiv|*
 - 4| *Jla Drcv`b, ¶ecbb, Avg`vbx I iBvbx i m¶_ ms¶Kó e`¶<sup>3</sup>#` i#K cP¶jZ Jla AvBb, ¶eagvjv, Jla bxZ I ¶bqgveij m¶c#K Ae¶nz Kiv|*
- ৫। ঔষধ সংক্রান্ত বিভ্রান্তি নিরসন করা।

mc#Y¶`Z Z\_` cKv#ki AvBbMZ ¶f¶Ė

Z_` A¶Kvi AvBb 2009 I Z\_` A¶Kvi ¶eagvjv 2009| Z_` cKv#ki tŷ#Î D³ AvBb I ¶eagvjv h_vh fv#e Ab¶iY Kiv n#e|

Z_` cKv#ki gva`g

- mc#Y¶`Z Z\_` ¶bge¶YZ gva`g cKvk Ki#Z n#e|*
- (K) *¶cĖ ¶g¶Wqv t tcv÷¶is, msev`cĖ, ¶e#kI eŷj¶Ub, ev¶IK c¶Z#e`b|*
- (L) *B#j±bK ¶g¶Wqv t Website, ti¶WI, tUj¶fkb|*
- (M) *ckvm#bi tb¶Uk teW|*

ঔষধ প্রশাসন অধিদপ্তরের স্বপ্রণোদিত তথ্য প্রকাশের প্রক্রিয়া

- 1| *¶i#Zi Dci ¶e#ePbv K#i Z_`mgn¶e¶fb gva`g cKvk Kiv n#e|*
- 2| *cKvkZ Z_` c¶Z 3 (¶Zb) gvm Aši nvjbvMv` Kiv n#e| D³ mg¶qi c#e #Kvb Z_` c¶ie¶ZZ n#j Zvrŷ¶YK fv#e ms#kvab Kiv n#e|*
- 3| *Jla ckymb A¶a`B#ii cavb Kvhvj#q GK¶U Z\_` tKv¶I Mvb Kiv n#e|ev¶IK c¶Z#e`bmn Website, ti¶WI, tUj¶fkb, #b¶Uk teW Ges msev`cĖ cKvkZ mKj Z#_`i nvW I mdU¶Kc D<sup>3</sup> Z\_` tKv¶I msiŷY Kiv n#e|*
- 4| *cKvk#hvM` bZŷ tKvb Z\_` cv¶Iqv i m¶_ m¶_ hZ `æZ mæ Zv cKvk Kiv n#e |*

mc#Y¶`Zfv#e Jla ckymb A¶a`Bi KZ¶, ¶bge¶YZ Z_`v¶` cKvk Kiv n#e

- 1| **c¶Zô¶bK Z_`v¶` t**
 - K) *c¶Zôv#bi AvBbMZ ¶f¶Ė|*
 - L) *Av f`šixb c¶eavbgvjv|*
 - M) *Kvhv¶` I ŷgZv |*

2| Jla ckymb A¶a`B#ii mvsMvibK Z\_`v¶` t

- K) *AMv#bvMvg |*
- খ) নিয়োজিত জনবল সংক্রান্ত তথ্যাদি।
- M) *KgKZv/KgPvix#`i bvg, thvMv#hv#Mi tUj#dvb bs, B-#gBj I A¶dm ¶VKvbv |*

৩। কার্যক্রম সংক্রান্ত তথ্যাদি :

- K) *c¶iKíbv|*
- L) *bxZgvjv|*
- M) *Kvhv¶` |*

ঘ) কাজের প্রক্রিয়া।

O) $\dot{y}gZ_{\nu} \text{ } Acb|$

P) $c\|Z\ddot{e}^{\prime}b|$

Q) $Z^{\prime}vi\|K \text{ } I \text{ } g\dot{j}^{\prime}vqb|$

R) $Ab^{\prime}vb^{\prime\prime} \text{ } \dagger K\dot{s}kj, \text{ } WK\dot{y}g\dot{E}m, \text{ } WwU_{\nu} \text{ } BZ^{\prime}w^{\prime} \text{ } |$

4| $Rb\dot{m}e\|g\dot{j}K \text{ } Z_{\nu}^{\prime}w^{\prime} \text{ } t$

ক) জনসেবা সংক্রান্ত বিবরণ।

L) $\|b\dot{z}^{\prime}kb_{\nu}|$

M) $e\dot{k}\dot{j}U \text{ } Ges \text{ } \|j\dot{d}\dot{j}U|$

N) $\dagger c_{\nu} \div \|is|$

ঙ) ফি এবং ফি দাখিলের সময়সীমা সংক্রান্ত তথ্যাদি।

P) $\|e\|fb \text{ } dig|$

৫। অর্থ সংক্রান্ত তথ্যাদি :

K) $c\dot{z}\ddot{y}\|cZ \text{ } e\dot{v}\dot{R}U|$

L) $cKZ.A\dot{v}q$ -ব্যয় সংক্রান্ত তথ্যাদি(বেতন ভাতাদি সংক্রান্ত তথ্য)।

M) $Ab^{\prime}vb^{\prime\prime}$ অর্থ সংক্রান্ত তথ্যাদি।

N) $A\|WU \text{ } \|i\dot{z}c_{\nu}U|$

৬। সরকারি ক্রয় সংক্রান্ত তথ্যাদি :

সরকারি ক্রয় সংক্রান্ত বিস্তারিত তথ্য, মানদণ্ড, টেন্ডার প্রক্রিয়ায় অংশগ্রহণকারীদের আবেদন $mg\#ni \text{ } Dci \text{ } M\dot{p}_{\nu}Z \text{ } \|m\times\dot{v}\dot{S}|$

7| $Z\|jK_{\nu}, \dagger i\|R \div \|W \text{ } Ges \text{ } WwU\dot{z}eR \text{ } t$

K) $\|e\|fb \text{ } Z\|jK_{\nu}q, \dagger i\|R \div \dot{v}\dot{z}i \text{ } Ges \text{ } WwU\dot{z}eR \text{ } e\|YZ \text{ } Z_{\nu}^{\prime}w^{\prime} \text{ } |$

খ) তালিকা রেজিস্টার এবং ডাটাবেজের অবস্থান সংক্রান্ত তথ্যাদি।

৮। তথ্যের অবস্থান সংক্রান্ত তথ্যাদি :

K) তথ্য সংক্রান্ত ইনডেক্স বা রেজিস্টারের অবস্থান।

L) $WwU\dot{v}te\dot{z}R \text{ } A\dot{s}f\dot{y} \text{ } \|e^{\prime}w\|iZ \text{ } Z_{\nu}^{\prime}w^{\prime} \text{ } |$

৯। প্রকাশনা প্রকাশ সংক্রান্ত তথ্যাদি :

ক) প্রকাশনা প্রকাশ সংক্রান্ত $Z_{\nu}^{\prime}w^{\prime} \text{ } |$

L) $cK\dot{v}kb_{\nu}$ সমূহ বিনামূল্যে কিনা অথবা বিক্রয়যোগ্য হলে নির্ধারিত মূল্য সংক্রান্ত তথ্যাদি।

10| $Z_{\nu}^{\prime}w^{\prime} \text{ } A\|aK_{\nu}i \text{ } m\dot{p}c\|KZ \text{ } Z_{\nu}^{\prime}w^{\prime} \text{ } t$

ক) তথ্য প্রাপ্তির অধিকার সংক্রান্ত তথ্যাদি এবং তথ্য প্রাপ্তির জন্য আবেদনের প্রক্রিয়া (আবেদনের ফর্ম, আপিল এবং $A\|f\dot{z}h_{\nu}M)|$

L) $Z_{\nu}^{\prime}w^{\prime} \text{ } c^{\prime}vbK_{\nu}ix \text{ } KgKZ_{\nu} \text{ } Ges \text{ } Zu \text{ } A\|c\dot{j}K_{\nu}ix \text{ } KZ\dot{c}\dot{z}\dot{y}i \text{ } \dagger h\dot{v}M\dot{v}\dot{h}\dot{v}\dot{z}Mi \text{ } Z_{\nu}^{\prime}w^{\prime} \text{ } |$

M) $Z\dot{z}^{\prime}w^{\prime} \text{ } i \text{ } Rb^{\prime\prime} \text{ } A\dot{v}\dot{z}e^{\prime}bK_{\nu}ix \text{ } b\|M\|i\dot{z}Ki \text{ } b\dot{v}g, \text{ } \|VK\dot{v}b_{\nu} \text{ } |$

N) $A\dot{v}\dot{z}e^{\prime}\dot{z}bi \text{ } Z\|iLmn \text{ } A\dot{v}\dot{z}e\| \text{ } Z \text{ } Z\dot{z}^{\prime}w^{\prime} \text{ } i \text{ } eYb_{\nu} \text{ } |$

O) $A\dot{v}\dot{z}e^{\prime}\dot{z}bi \text{ } Ae^{\prime}n_{\nu} \text{ } |$

P) $cZ^{\prime}vL\dot{v}\dot{z}bi \text{ } \|e\dot{z}\dot{z}\times \text{ } A\|c\dot{j} \text{ } |$

Q) $Z_{\nu}^{\prime}w^{\prime} \text{ } K\|gk\dot{z}b^{\prime}w\|LjKZ.A\|f\dot{z}h_{\nu}\dot{z}Mi \text{ } eYb_{\nu} \text{ } |$

R) $Z_{\nu}^{\prime}w^{\prime} \text{ } K\|gk\dot{z}bi \text{ } P\dot{v}\dot{S} \text{ } A\dot{v}\dot{z}^{\prime}k|$

$KZ\dot{c}\dot{z}\dot{y} \text{ } \|bge\|YZ \text{ } Z_{\nu}^{\prime}w^{\prime} \text{ } cK\dot{v}k \text{ } Ki\dot{z}Z \text{ } e\dot{v}a^{\prime\prime} \text{ } bq$

- 1| $\dagger K_{\text{v}}b\ Z_''\ cK_{\text{v}}\dagger ki\ d\dagger j\ \dagger K_{\text{v}}b\ Z\ Z_{\text{q}}\ c\dagger y_i\ e_{\text{y}}e_{\text{e}}\ddot{E}K\ m\acute{o}c\dagger`i\ A_{\text{v}}aK_{\text{v}}i\ \ddot{y}_{\text{v}}ZM\bar{Z}\ n\dagger Z\ c\dagger i\ G_{\text{ij}}c\ e_{\text{v}}Y_{\text{v}}R^{\text{v}}K\ e_{\text{v}}\ e^{\text{v}}em_{\text{v}}iqK\ A\check{s}_{\text{v}}b_{\text{v}}nZ\ \dagger M_{\text{v}}cb_{\text{v}}qZ_{\text{v}}\ \text{v}elqK, K_{\text{v}}i\text{v}BU\ e_{\text{v}}\ e_{\text{y}}e_{\text{e}}\ddot{E}K\ m\acute{o}c\` (Intellectual Property Right)\ m\acute{o}c_{\text{v}}KZ\ Z_''\ |$
- 2| $\dagger K_{\text{v}}b\ Z_''\ cK_{\text{v}}\dagger ki\ d\dagger j\ cP_{\text{v}}jZ\ A_{\text{v}}B_{\text{v}}b_{\text{v}}i\ c\dagger q_{\text{v}}M\ e_{\text{v}}a_{\text{v}}M\bar{\text{v}}\ n\dagger Z\ c\dagger i\ e_{\text{v}}\ A_{\text{v}}c_{\text{v}}i_{\text{v}}a\ e_{\text{v}}\times\ \dagger c\dagger Z\ c\dagger i\ G_{\text{ij}}c\ Z_''\ |$
- 3| $A_{\text{v}}B_{\text{v}}b\ c\dagger q_{\text{v}}MK_{\text{v}}i_{\text{v}}x\ m\check{s}\bar{\text{v}}\ n_{\text{v}}i\ m_{\text{v}}n_{\text{v}}qZ_{\text{v}}i\ Rb^{\text{v}}\ \dagger K_{\text{v}}b\ e^{\text{v}}_{\text{v}}{}^3\ KZ_{\text{v}}K\ \dagger M_{\text{v}}c_{\text{v}}b\ c\`E\ \dagger K_{\text{v}}b\ Z_''\ |$
- 4| $A_{\text{v}}\`v\ j\dagger Z\ \text{v}eP_{\text{v}}i_{\text{v}}a_{\text{v}}b\ \dagger K_{\text{v}}b\ \text{v}elq\ Ges\ h_{\text{v}}n_{\text{v}}\ cK_{\text{v}}\dagger k\ A_{\text{v}}\`v\ jZ\ e_{\text{v}}\ U_{\text{v}}Be_{\text{v}}\ddot{y}_{\text{v}}b_{\text{v}}\dagger j_{\text{v}}i\ \text{v}b_{\text{v}}\dagger la_{\text{v}}\acute{A}_{\text{v}}\ i\dagger q_{\text{v}}\ddot{Q}\ A_{\text{v}}e_{\text{v}}\ h_{\text{v}}i\ cK_{\text{v}}k\ A_{\text{v}}\`v\ jZ\ A_{\text{v}}e_{\text{v}}\ddot{y}_{\text{v}}b_{\text{v}}b_{\text{v}}i\ k_{\text{v}}\text{v}g_{\text{v}}j, G\ i_{\text{v}}c\ Z_''\ |$
- 5| $Z\`s_{\text{v}}a_{\text{v}}x_{\text{v}}b\ \dagger K_{\text{v}}b\ \text{v}elq\ h_{\text{v}}i\ cK_{\text{v}}k\ Z\`s\ K_{\text{v}}\dagger R\ \text{v}eN\ NU_{\text{v}}\dagger Z\ c\dagger i\ G\ i_{\text{v}}c\ Z_''\ |$
- 6| কোন অপরাধের তদন্ত প্রক্রিয়া এবং অপরাধীর গ্রেফতার $i\ I\ k_{\text{v}}\bar{\text{v}}\ Z_{\text{v}}\dagger K\ c_{\text{v}}f_{\text{v}}\text{v}eZ\ Ki_{\text{v}}\dagger Z\ c_{\text{v}}\dagger i\ G_{\text{ij}}c\ Z_''\ |$
- 7| $A_{\text{v}}B_{\text{v}}b\ Ab_{\text{v}}\text{v}n_{\text{v}}\dagger i\ \dagger Ke_{\text{v}}j\ GK_{\text{v}}U\ \text{v}b_{\text{v}}\`o\ m_{\text{v}}g_{\text{v}}\dagger qi\ Rb^{\text{v}}\ cK_{\text{v}}\dagger ki\ e_{\text{v}}a^{\text{v}}e_{\text{v}}aKZ_{\text{v}}\ i\dagger q_{\text{v}}\ddot{Q}\ G_{\text{ij}}c\ Z_''\ |$
- 8| $\dagger K_{\text{v}}\check{s}_{\text{v}}k_{\text{v}}jMZ\ I\ e_{\text{v}}Y_{\text{v}}R^{\text{v}}K\ K_{\text{v}}i_{\text{v}}\dagger Y\ \dagger M_{\text{v}}c_{\text{v}}b\ i_{\text{v}}vL_{\text{v}}\ e_{\text{v}}\acute{A}_{\text{v}}b_{\text{v}}q\ G\ i_{\text{v}}c\ K_{\text{v}}\text{v}i_{\text{v}}M_{\text{v}}i_{\text{v}}x\ e_{\text{v}}\ ^e\acute{A}_{\text{v}}\text{v}b_{\text{v}}K\ M_{\text{v}}e_{\text{v}}I_{\text{v}}Y_{\text{v}}j\times\ \dagger K_{\text{v}}b\ Z_''\ |$
- 9| কোন ক্রয় কার্যক্রম সম্পূর্ণ হওয়ার পূর্বে বা উ³ $\text{v}el_{\text{v}}\dagger q\ \text{v}m\times v\check{s}\ Mn_{\text{v}}\dagger Yi\ c_{\text{v}}\#e\ m_{\text{v}}s_{\text{v}}ik_{\text{v}}\check{s}$ ক্রয় বা উহার কার্যক্রম সংক্রান্ত কোন তথ্য।
- 10| $R_{\text{v}}i_{\text{v}}Z_{\text{v}}q\ m_{\text{v}}sm_{\text{v}}\dagger`i\ \text{v}e_{\text{v}}\dagger k_{\text{v}}I\ A_{\text{v}}aK_{\text{v}}i_{\text{v}}n_{\text{v}}\text{v}b_{\text{v}}i\ K_{\text{v}}i_{\text{v}}Y\ n\dagger Z\ c_{\text{v}}\dagger i\ G_{\text{ij}}c\ Z_''\ |$
- 11| $\dagger K_{\text{v}}b\ e^{\text{v}}_{\text{v}}{}^3\ i\ A_{\text{v}}B_{\text{v}}b\ \emptyset_{\text{v}}i_{\text{v}}v\ m_{\text{v}}s_{\text{v}}i_{\text{v}}\text{v}y_{\text{v}}Z\ \dagger M_{\text{v}}c_{\text{v}}b_{\text{v}}q\ Z_''\ |$

ငါးကိစ္စ-၇ တံအဓိကကျသော ဖုန်းနံပါတ် (အသုံးပြုသော) K

List of Essential Drugs (Allopathic)

Sl. #	1. ANAESTHETICS	
	1.1 General anaesthetics and oxygen	
	1.1.1 Inhalational medicines	
1	Halothane	
2	Nitrous Oxide-Oxygen for Anaesthesia	
3	Oxygen	Inhalation
	1.1.2 Injectable medicines	
4	Thiopental Sodium	Injection
5	Ketamine	Injection
	1.2 Local anaesthetics	
6	Lignocaine with or without Adrenaline	Injection 1% and 2%
7	Procaine Hydrochloride	Injection (Various Strengths)
8	Bupivacaine Hydrochloride	Injection
	1.3 Preoperative medication and sedation for short-term procedures	
9	Atropine Sulphate	Injection
10	Morphine Sulphate	Injection
	2. ANALGESICS, ANTIPYRETICS, NON-STEROIDAL ANTI-INFLAMMATORY MEDICINES (NSAIDs), MEDICINES USED TO TREAT GOUT AND DISEASE MODIFYING AGENTS IN RHEUMATOID DISORDERS (DMARDs)	
	2.1 Non-opioids and non-steroidal anti-inflammatory medicines (NSAIDs)	
11	Aspirin	Tablet 75-100 mg
12	Paracetamol	Tablet/Syrup/Suspension/ Suppository
13	Pethidine Hydrochloride	Injection
14	Indomethacin	Capsule/Suppository/Sustained Release Tablet
15	Ibuprofen	Tablet
16	Naproxen	Tablet
	2.2 Opioid analgesics	
	SL No - 10	
	2.3 Medicines used to treat gout	
17	Allopurinol	Tablet
18	Colchicine	Tablet
	2.4 Disease modifying agents used in rheumatoid disorders (DMARDs)	
19	Penicillamine	Tablet
20	Sulphasalazine	Tablet
21	Sodium Aurothiomalate	Injection
22	Methotrexate	Tablet/Injection
23	Chloroquine	Oral liquid/Tablet

	3. ANTIALLERGICS AND MEDICINES USED IN ANAPHYLAXIS	
24	Chlorpheniramine Maleate	Tablet/Syrup/Injection
25	Prednisolone	Tablet
26	Dexamethasone	Tablet/Cream/Injection
27	Hydrocortisone	Injection/Cream/Ointment
28	Promethazine Hydrochloride	Tablet/Injection
	4. ANTIDOTES AND OTHER SUBSTANCES USED IN POISONINGS	
	4.1 Non-specific	
29	Activated Charcoal	Tablet
	4.2 Specific	
30	Naloxone Hydrochloride	Injection
31	Pralidoxime Mesylate	Injection
	SL No - 09	Injection/Eye drop/ointment
	5. ANTICONVULSANTS/ANTIEPILEPTICS	
32	Phenobarbitone	Tablet/Injection
33	Phenytoin	Tablet/Capsule/Elixir
34	Ethosuximide	Capsule
35	Magnesium Sulphate 50%	Injection
	6. ANTI-INFECTIVE MEDICINES	
	6.1 Anthelmintics	
	6.1.1 Intestinal anthelmintics	
36	Mebendazole	Tablet
37	Albendazole	Chewable Tablet
38	Levamisole	Tablet/Syrup
39	Niclosamide	Tablet
	6.1.2 Antifilarials	
40	Diethylcarbamazine	Tablet/Suspension
	SL No - 37	
	6.2 Antibacterials	
	6.2.1 Beta Lactam medicines	
41	Amoxycillin	Capsule/Dry Syrup /Injection
42	Ampicillin	Capsule/Dry Syrup /Injection
43	Phenoxymethyl Penicillin	Tablet/Syrup
44	Benzathine Penicillin	Injection
45	Flucloxacillin	Capsule/Syrup/Injection
46	Procaine Penicillin	Injection
47	Cephadrine	Capsule/Syrup/Injection
48	Cephalexin	Capsule/Tablet/Syrup
49	Benzyl Penicillin	Injection
50	Cloxacillin	Capsule/Syrup/Injection
51	Amoxiclav	Tablet/Capsules/ Dry Syrup/Injection

	6.2.2 Other antibacterials	
52	Erythromycin	Tablet/Oral Suspension /Injection
53	Chloramphenicol	Eye/Ear Drops/Ointment
54	Doxycycline	Capsule
55	Co-Trimoxazole	Tablet/Suspension
56	Metronidazole	Tablet/Oral Liquid/Injection
57	Tetracycline/Oxytetracycline Hydrochloride	Capsule/Injection
58	Nalidixic Acid	Tablet/Syrup
59	Trimethoprim	Tablet/Suspension/Injection
	6.2.3 Antileprosy medicines	
60	Clofazimine	Capsule
61	Dapsone	Tablet
	6.2.4 Antituberculosis medicines	
62	Ethambutol	Tablet
63	Isoniazid with or without Ethambutol	Tablet
64	Pyrazinamide	Tablet
65	Rifampicin with or without Isoniazid	Tablet
66	Streptomycin Sulphate	Injection
67	Rifampicin + Isoniazid + Pyrazinamide with or without Ethambutol	combination tablet
68	Rifampicin + Isoniazid + Ethambutol	Tablet
	6.3 Antifungal medicines	
69	Griseofulvin	Tablet
70	Clotrimazole	Cream/Pessaries/Solution/Dusting Powder
71	Nystatin	Tablet/Suspension/Cream/Gel
72	Preparations of Imidazole or Nystatin for Vaginal and Vulval Candidiasis	
	6.4 Antiviral medicines	
73	Acyclovir	Tablet/Cream /Eye ointment/ Intravenous Infusion
74	Nelfinavir (NVP)	Oral powder/tablet
	6.4.1 Antiherpes medicines	
75	Idoxuridine	Eye Drops
	6.4.2 Antiretrovirals	
	6.4.2.1 Nucleoside/Nucleotide reverse transcriptase inhibitors	
76	Abacavir (ABC)	Oral Liquid/ Tablet
77	Lamivudine (3TC)	Oral liquid,/Tablet
78	Tenofovir disoproxil fumarate (TDF)	Tablet
79	Zidovudine (ZDV or AZT)	Capsul/ Oral liquid/ IV infusion/ injection/Tablet
	6.4.2.2 Non-nucleoside reverse transcriptase inhibitors	
80	Efavirenz	Capsule/ Oral Liquid/ Tablet
81	Nevirapine (NVP)	Oral Liquid/ Tablet
	6.4.3 Other antivirals	
82	Oseltamivir	Tablet

	6.5 Antiprotozoal medicines	
	6.5.1 Antiamoebic and anti giardiasis medicines	
83	Diloxanide	Tablet
	6.5.2 Antileishmaniasis medicines	
84	Sodium Stibogluconate	Injection
	6.5.3 Antimalarial medicines	
	6.5.3.1 For curative treatment	
85	Artemether with Lumefantrine	Tablet
86	Primaquine	Tablet
87	Sulfadoxin with Pyrimethamine	Tablet
88	Artesunate	Injection,/ Tablet
89	Mefloquine	Tablet
90	Quinine	Injection,/Tablet
	6.5.4 Antipneumocystosis and antitoxoplasmosis medicines	
91	Pyrimethamine	Tablet
	7. ANTIMIGRAINE MEDICINES	
	7.1 For treatment of acute attack	
92	Sumatriptan Succinate	Tablet/Injection/Nasal Spray
93	Acetylsalicylic acid	Suppository/Tablet
	SL No - 11	
	SL No - 12	
	7.2 For prophylaxis	
94	Propranolol	Tablet
	8. ANTINEOPLASTIC, IMMUNOSUPPRESSIVES AND MEDICINES USED IN PALLIATIVE CARE	
	8.1 Immunosuppressive medicines	
95	Azathioprine	Tablet/Injection
96	Cyclosporin	Capsule/Oral Solution/IV Infusion
	8.2 Cytotoxic and adjuvant medicines	
97	Actinomycin D/Dactinomycin	Injection
98	Bleomycin	Injection
99	Calcium Folate/Calcium Leucovorin	Tablet/Injection
100	Cyclophosphamide	Tablet
101	Busulphan	Tablet
102	Cisplatin	Injection
103	Chlorambucil	Tablet
104	Crisantaspase/L-asparaginase	Injection
105	Thioguanine	Tablet
106	Vinblastine Sulphate	Injection
107	Vincristine Sulphate	Injection
108	Doxorubicin	Injection
109	Mercaptopurine	Tablet
110	Lomustine	Capsule
111	Melphalan	Tablet/Injection
112	Mitomycin	Injection
113	Mustine Hydrochloride	Injection

	8.3 Hormones and antihormones	
114	Tamoxifen	Tablet/Capsule
115	Vasopressin	Injection
116	Liothyronine Sodium	Tablet/Injection
117	Stilboestrol/Diethylstilboestrol	Tablet
	SL No - 26	Injection
	SL No - 27	Injection
	8.4 Medicines used in palliative care	
118	Hyoscine Butylbromide	Tablet/Injection
119	Amitriptyline	Tablet
120	Propantheline Bromide	Tablet
121	Lactulose	Powder/Solution
	SL No - 26	Tablet/ Injection
	9. ANTIPARKINSONISM MEDICINES	
122	Levodopa with Carbidopa	Tablet
	10. MEDICINES AFFECTING THE BLOOD	
	10.1 Antianaemia medicines	
123	Ferrous Sulphate/Fumarate, with or without Folic Acid	Tablet/Syrup
124	Folic Acid	Tablet
	10.2 Medicines affecting coagulation	
125	Heparin	Injection
126	Dipyridamole	Tablet/Oral Suspension/Injection
127	Protamine sulfate	Injection
	11. BLOOD PRODUCTS AND PLASMA SUBSTITUTES	
	11.1 Plasma substitutes	
128	ACD Blood Pack/Double Bag/Triple Bag	
129	Plasma Substitutes/Dextran-40/ Succinylated Gelatin Intravenous Infusions	
130	Dextran 70	Injection
	11.2 Plasma fractions for specific use	
131	Plasma Fractions/Human Albumin	Solution for IV infusion
	12. CARDIOVASCULAR MEDICINES	
	12.1 Antianginal medicines	
132	Metoprolol Tartrate	Tablet
133	Glyceryl Trinitrate	Tablet /Spray
134	Isosorbide dinitrate	Tablet /Injection
135	Isosorbide Mononitrate	Tablet
	12.2 Antiarrhythmic medicines	
136	Procainamide	Injection/Capsule
137	Digoxin	Tablet/Injection
138	Disopyramide	Tablet/Capsule
	12.3 Antihypertensive medicines	
139	Atenolol	Tablet
	SL No 94	Tablet /Injection
140	Methyldopa	
141	Captopril	Tablet
142	Diazoxide	Injection
143	Sodium Nitroprusside	Injection
144	Prazocin Hydrochloride	Tablet

145	Enalapril	Tablet
146	Spironolactone	Tablet
147	Hydrochlorothiazide	Tablet
	12.4 Medicines used in heart failure	
148	Dopamine	Injection
	SL No - 137	
	SL No - 144	
	12.5 Antithrombotic medicines	
149	Clopidogrel	Tablet
	12.6 Lipid-lowering agents	
150	Simvastatin	Tablet
	12.7 Anti- Hypotensive medicine	
151	Metaraminol	Injection
	13. DERMATOLOGICAL MEDICINES (topical)	
	13.1 Antifungal medicines	
152	Miconazole	Cream/ Dusting Powder/Spray/Oral Gel
153	Sodium thiosulfate	Solution
	13.2 Anti-infective medicines	
154	Potassium Permanganate	Crystal/Solution (0.1%)
	SI No 57	Ointment
155	Silver sulfadiazine	Cream
	13.3 Anti-inflammatory and antipruritic medicines	
156	Calamine	Lotion
157	Betamethasone	Ointment, Cream
158	Betamethasone with Neomycin	Ointment
159	Neomycin sulfate with Bacitracin	Ointment/Powder
	SL No - 26	Cream
	SL No - 27	Cream/ Ointment
	13.4 Medicines affecting skin differentiation and proliferation	
160	Salicylic Acid + Benzoic Acid	Ointment, Cream
161	Fluorouracil	Capsule/Injection/Cream
162	Salicylic acid	Solution
	13.5 Scabicides and pediculicides	
163	Benzyl Benzoate	Lotion
164	Permethrin	Cream/ Lotion
	14. DIAGNOSTIC AGENTS	
	14.1 Ophthalmic medicines	
165	Fluorescein	Eye drops
166	Tropicamide	Eye drops
	14.2 Radiocontrast media	
167	Barium Sulphate (X-Ray Grade)	
168	Iodipamide	Injection
169	Iothalamic Acid with Meglumine	Oral Solution
	15. DISINFECTANTS AND ANTISEPTICS	
	15.1 Antiseptics	
170	Chlorhexidine with or without Cetrimide	Solution/Cream
171	Povidone-Iodine 10%	Alcoholic Solution
172	Bismuth, Iodoform and Paraffin Paste (BIPP)	For Nasal Pack

	15.2 Disinfectants	
173	Chloroxylenol	Solution/Cream
	16. DIURETICS	
174	Frusemide	Tablet/Injection
175	Bendrofluazide	Tablet
	SL No - 146	Tablet/Capsule
176	Mannitol Infusion Solution	10% and 20%
	SL No - 147	
	17. GASTROINTESTINAL MEDICINES	
	17.1 Antiulcer medicines	
177	Aluminium Hydroxide Gel with or without Magnesium Trisilicate	Tablet/ Suspension
178	Ranitidine	Tablet /Injection
179	Omeprazole	Capsule/Tablet /Injection
	17.2 Antiemetic medicines	
180	Cinnarizine	Tablet
181	Metoclopramide Hydrochloride	Tablet/Oral Solution/Injection
182	Prochlorperazine	Tablet/Injection
	SL No - 28	
	17.3 Anti-inflammatory medicines	
	SL No-20	Suppository
	17.4 Laxatives	
183	Glycerin/Glycerol	Suppositoryfor adult/child/infant
184	Senna/Sennosides	Tablet
	17.5 Medicines used in diarrhoea	
	17.5.1 Oral rehydration	
185	Potassium Chloride	Tablet/Syrup
186	Sodium Chloride 0.9%, without or with Dextrose	Intravenous Infusion
187	Sodium Bicarbonate	Infusion (Various Strengths)
	17.5.2 Medicines for diarrhoea in children	
188	Zinc sulfate	Oral liquid/Tablet
	18. HORMONES, OTHER ENDOCRINE MEDICINES AND CONTRACEPTIVES	
	18.1 Adrenal hormones and synthetic substitutes	
189	ACTH	Injection
	SL No - 26	Injection
	18.2 Androgens	
190	Danazol	Capsule
	18.3 Contraceptives	
	18.3.1 Oral hormonal contraceptives	
191	Ethinylestradiol + Levonorgestrel	Tablet : 30 micrograms + 150 micrograms
192	Ethinylestradiol + Lynestrenol	Tablet 0.0375mg+0.75mg
193	Desogesterol + Ethinylestradiol	Tablet:0.15mg+0.03mg
194	Levonorgestrel	Tablet 750microgram
	18.3.2 Injectable hormonal contraceptives	
195	Depot Medroxyprogesterone	Injection
	18.3.3 Intrauterine devices	
196	Copper-T containing device	
	18.3.4 Barrier methods	
197	Condoms	

	18.3.5 Implantable contraceptives	
198	Levonorgestrel-releasing implant	
	18.4 Estrogens	
199	Oestrogens with or without Progestogens for HRT	
	18.5 Insulins and other medicines used for diabetes	
200	Glibenclamide	Tablet
201	Insulin	Various preparations
202	Chlorpropamide	Tablet
203	Metformin Hydrochloride	Tablet
	18.6 Ovulation inducers	
204	Clomiphene Citrate	Tablet
	18.7 Progestogens	
205	Medroxyprogesterone acetate	Tablet: 5 mg.
	18.8 Thyroid hormones and antithyroid medicines	
206	Carbimazole	Tablet
207	Aqueous Iodine	Oral Solution (Lugol's Solution)
208	Thyroxine Sodium	Tablet
209	Levothyroxine	Tablet
	19. IMMUNOLOGICALS	
	19.1 Diagnostic agents	
210	Sodium Diatrizoate with Meglumine Sodium	Injection
211	Tuberculin, purified protein derivative	Injection
	19.2 Sera and immunoglobulins	
212	Diphtheria Antitoxin	
213	Polyvalent Antivenoms	
214	Tetanus Antitoxin	Injection (Minimum 10,000 IU Dose)
215	Human Normal Immunoglobulin	Injection
	19.3 Vaccines	
216	BCG Vaccine	
217	DPT Vaccine	
218	Pentavalent vaccine(DPT,HepatitisB ,Hib)	
219	Pneumococcal Vaccine(PCV)	
220	Poliomyelitis Vaccine(OPV &IPV))	
221	MR Vaccine (Measles &Rubella)	
222	Measles vaccine	Injection
223	Hepatitis- B Vaccine	Injection
	20. MUSCLE RELAXANTS (PERIPHERALLY-ACTING) AND CHOLINESTERASE INHIBITORS	
224	Neostigmine	Tablet/Injection
225	Suxamethonium Chloride	Injection
226	Pancurium Bromide	Injection
227	Gallamine Triethiodide	Injection
	21. OPHTHALMOLOGICAL PREPARATIONS	
	21.1 Anti-infective agents	
228	Framycetin Sulphate	Eye Drops/Ointment
229	Gentamycin	Injection/Eye Drops/Ointment
230	Tetracaine/Amethocaine	Eye Drops
	SL No - 53	Eye Drops/ Ointment

	21.2 Anti-inflammatory agents	
231	Corticosteroid	Eye drops/Ointment
	SL No - 158	Eye Drops
	21.3 Local anaesthetics	
	SL No - 230	
	21.4 Miotics and antiglaucoma medicines	
232	Pilocarpine	Eye Drops (Various Strengths)
233	Acetazolamide	Tablet
234	Carbachol	Tablet/Eye Drops
	SL No - 151	
	21.5 Mydriatics	
235	Phenylephrine Hydrochloride	Eye drops
236	Homatropine	Eye drops
	SL No - 09	Injection/eye drop/ointment
	22. OXYTOCICS AND ANTIOXYTOCICS	
	22.1 Oxytocics	
237	Trifluoperazine	Tablet/Oral Solution
238	Oxytocin	Injection
239	Ergometrine	Injection
	22.2 Antioxytocics (tocolytics)	
240	Nifedipine	Capsule
	23. PERITONEAL DIALYSIS SOLUTION	
241	Intraperitoneal dialysis solution (of appropriate composition)	Parenteral solution.
	24. MEDICINES FOR MENTAL AND BEHAVIOURAL DISORDERS	
	24.1 Medicines used in psychotic disorders	
242	Chlorpromazine Hydrochloride	Tablet/Syrup/Injection
243	Haloperidol	Tablet/Capsule/Oral Liquid
	24.2 Medicines used in mood disorders	
	24.2.1 Medicines used in depressive disorders	
244	Imipramine Hydrochloride	Tablet/Syrup
245	Nortriptyline	Tablet
246	Flupenthixol Dihydrochloride/Decanoate	Tablet/Injection
	SL No - 119	
	24.2.2 Medicines used in bipolar disorders	
247	Carbamazepine	Tablet/Oral Liquid/Suppository
248	Lithium Carbonate/Citrate	Tablet/Oral liquid
	24.3 Medicines for anxiety disorders	
249	Diazepam	Tablet/Injection
250	Clobazam	Tablet
	24.4 Medicines used for obsessive compulsive disorders	
251	Clomipramine Hydrochloride	Tablet/Syrup/Capsule/Injection
	24.5 Medicines for disorders due to psychoactive substance use	
252	Methadone Hydrochloride	Tablet/Injection
	25. MEDICINES ACTING ON THE RESPIRATORY TRACT	
	25.1 Antiasthmatic and medicines for chronic obstructive pulmonary disease	
253	Salbutamol	Tablet/Elixir
254	Adrenaline/Epinephrine	Injection

1. ʔɪdʲv Pɔ
2. Zɪjkɪv` Pɔ
3. AɪecɪĖKi Pɔ
4. ʔbšɪv` Pɔ
5. cɪʲvɪj Pɔ
6. ʔmɪʔZvcjɪv` Pɔ
7. ʔnsMvóK Pɔ
8. Bme,j
9. ʔmɪjgɪib
10. hgvɔx AK
11. iʔmɪvɪv` Kv_
12. ʔMɪʲjɪv` Kv_
13. `kgɪ Kv_
14. gɪvksL eɪU
15. Akni eɪU
16. iRt ceZbɔx eɪU
17. Pɔ`cfv eUx
18. ʔbevib eUx
19. kɪj eɪRbɔx eUx
20. bɪMɔ` eUx
21. cfvKi eUx
22. KÉ mæv
23. AvɪɪvM` eabɔx
24. AɪMKgɪi im (MnYɔx)
25. gɪvɪvR bɔɪZej f
26. kvɪmKɪi im
27. KdɪKZzim
28. ʔchɪejɔx im
29. imɪvR im
30. ʔkɪɪbZvMj im
31. ʔkv_ Kvɪvɔj im
32. Kcɪim
33. kɔx iɪgeɪb im
34. ʔhɪɪɪb` im
35. gɪvɪbK` im
36. kvɪm Kvɪm ʔPšɪgɪb
37. epr eɪZ ʔPšɪ gɪb
38. kɔx Kò.PZgɪ
39. gKɪaɪvR imɪvɔb
40. eR ʲvɪ
41. jɔxjv ʔejvɪm
42. bɪvɪ`xq gɪvɪjɪx ʔejvɪk
43. gZɪʔq im
44. feɪbki
45. epr eɪZ MRvɪɪk
46. epr eɪɪkɪ im
47. emš KɔgɪKɪi im
48. epr cɪPɔ` im
49. AɪcɪĖšK im
50. bevqm ɪjɪš
51. ɔP`vɪv` ɪjɪš
52. eɪɪbɪv` ɪjɪš
53. avɪx ɪjɪš
54. c`iɪšK ɪjɪš
55. ʔccjv` ɪjɪš
56. kɪjɪvR ɪjɪš
57. hKɔ.ɪx ɪjɪš

58. KvKvɔb ɔoKv
59. epr thvMɪvR ɔM,jɪ
60. beKvɪIK ɔM,jɪ
61. eɪZvɪ ɔM,jɪ
62. cĖZ³ NZ ɔM,j~
63. ʔmsnbv` ɔM,jɪ
64. fvMx ɔo
65. AvgɪKɔx imɪvɔb
66. eɪʲx imɪvɔb
67. mĖxɛbɔx imɪvɔb
68. KɪRvɪó
69. gɪKvɪó
70. Afqɪvɪó
71. AgZvɪó
72. ɪvɪvɪvZKvɪó
73. AkMÜvɪó
74. ejvɪó
75. `kgɪvɪó
76. eɪmKvɪvɪó
77. gɪvɪvɪvɪvɪó
78. ARɪvɪó
79. AɪkvKvɪvɪó
80. mɪvɪvɪv`vɪó
81. Lɪv`vɪvɪó
82. RɪvKv`vɪó
83. ɪjɪšvme
84. iɪv`vme
85. cɪʲvɪvme
86. gɪĖvme
87. mɪvɪvɪv`vme
88. Dkvɪvme
89. cĖvɪvme
90. Pɔ`bɪvme
91. Aɪvɪv`vme
92. KbKvme
93. cmɪvɔx mÜvɔb
94. P`ebcɪk
95. nɪvZKɔx LÜ
96. fv`i jeb
97. epr gɪvP`vɪv`^Zj
98. epr KvɪvKvɪv`^Zj
99. MÜK gjg
100. eɪZ iɪvɪvɔx ^Zj

চরিত্রক-স ত AZ'ek'Kiq BDb/bx JI'ai Zm jKv t

(List of Essential Unani Medicine)

ক্রমিক bs	JI'ai tR'biK bvg	Dosage Form
01	GiIdj DmZL' (Etrifal Ustukhudus)	Avai-KiVb
02	GiIdj Kvkb/hx (Etrifal Kashnizi)	Avai-KiVb
03	GiIdj evi`qib (Etrifal Badian)	Avai-KiVb
04	GiIdj gyKj (Etrifal Muqil)	Avai-KiVb
05	GiIdj mKgybq (Etrifal Saqmunia)	Avai-KiVb
06	GiIdj hgibx (Etrifal Zamani)	Avai-KiVb
07	GiIdj kvnZviv (Etrifal Shahatara)	Avai-KiVb
08	GiIdj gyU (Etrifal Mundi)	Avai-KiVb
09	GiIdj Kexi (Etrifal Kabir)	Avai-KiVb
10	GiIdj ,`x (Etrifal Gudadi)	Avai-KiVb
11	Lvgxiv Ave'ikg/Ave'ikg Avikv`x (Khamira Abresham/Abresham Arshadi)	Avai-KiVb
12	Lvgxiv LvLvk (Khamira Khashkhash)	Avai-KiVb
13	Lvgxiv MvIRevb (Khamira Gawjaban)	Avai-KiVb
14	Lvgxiv MvIRevb Avix (Khamira Gawjaban Ambari)	Avai-KiVb
15	Lvgxiv gviIqiv`/Av'bk`viv jyjx (Khamira Marwareed/Anoshdaro Liluvi)	Avai-KiVb
16	Lvgxiv hni'gniv (Khamira Zaharmohara)	Avai-KiVb
17	Lvgxiv ebdkv (Khamira Banafsha)	Avai-KiVb
18	Lvgxiv bvhjx (Khamira Nazli)	Avai-KiVb
19	RIqwik D` Zk (Jowarish Ood Tursh)	Avai-KiVb
20	RIqwik D` ikixb (Jowarish Ood Shireen)	Avai-KiVb
21	RIqwik Kgbx Kexi (Jowarish Kamuni Kabir)	Avai-KiVb
22	RIqwik Kz'y (Jowarish Kundur)	Avai-KiVb
23	RIqwik Kz'Zg (Jowarish Qurtum)	Avai-KiVb
24	RIqwik hiDbx (Jowarish Zarooni)	Avai-KiVb
25	RIqwik hwiK (Jowarish Zarishk)	Avai-KiVb
26	RIqwik kvn'iqui (Jowarish Shahreyaran)	Avai-KiVb
27	RIqwik Rvjxbm (Jowarish Jalinoos)	Avai-KiVb
28	RIqwik dvjvdx (Jowarish Falafili)	Avai-KiVb
29	RIqwik gQZMx (Jowarish Mustagi)	Avai-KiVb
30	RIqwik Avgjv (Jowarish Amla)	Avai-KiVb
31	RIqwik Kgbx (Jowarish Kamuni)	Avai-KiVb
32	RIqwik Zgi in`x (Jowarish Tamar Hindi)	Avai-KiVb
33	RIqwik memmv (Jowarish Bishbasa)	Avai-KiVb
34	RIqwik hvAvexj (Jowarish Zanjabeel)	Avai-KiVb
35	RIqwik kvnx (Jowarish Shahi)	Avai-KiVb
36	`vIqDj-igmK gjZv`j (Dawaul Misk Mutadil)	Avai-KiVb
37	gvRb AvKei (Majoon Aqbar)	Avai-KiVb
38	gvRb AvIRvAvhviKx (Majoon Awja/Azaraqi)	Avai-KiVb
39	gvRb Avi' tLrigv (Majoon Arad-e Khorma)	Avai-KiVb
40	gvRb Ikev/PePxbx (Majoon Ushba/Choobchini)	Avai-KiVb
41	gvRb Qv'je/ggmK (Majoon Sa'lab/Mumsik)	Avai-KiVb
42	gvRb dvjvmdv (Majoon Falasefa)	Avai-KiVb
43	gvRb myAvb (Majoon Suranjan)	Avai-KiVb

ক্রমিক bs	Jl'ai tR:biK big	Dosage Form
44	gVbRb tMvMvMv (Majoon Sohagsoonth)	Avav-KiVb
45	gVbRb tgVvMv jR (Majoon Mughalliz)	Avav-KiVb
46	gVbRb nVRi: j qin~ (Majoon Hazrul Yahood)	Avav-KiVb
47	gVbRb nvg j Avax (Majoon Humal Ambari)	Avav-KiVb
48	gVbRb `ex`y` lqV` (Majoon Dabeedul Ward)	Avav-KiVb
49	gVbRb bvbLvN (Majoon Nankhah)	Avav-KiVb
50	gVbRb mVv iCVK (Majoon Suparipak)	Avav-KiVb
51	gVbRb thvMivR tMv, j (Majoon Jograj Gogul)	Avav-KiVb
52	gVbRb ivvNZ (Majoon Rahat)	Avav-KiVb
53	gVbRb jvbv (Majoon Lana)	Avav-KiVb
54	gVbRb Kv jKv jvbvR (Majoon Kalkalanaj)	Avav-KiVb
55	gVbRb L` i (Majoon Khadar)	Avav-KiVb
56	gVbRb L` i/hete (Majoon Khadar/Jabeeb)	Avav-KiVb
57	gVbRb kxi Avdhv (Majoon Seer Afza)	Avav-KiVb
58	gVbRb m½` vbv (Majoon Sangdana)	Avav-KiVb
59	jDK Avg jZvm (Laoq Amaltas)	Avav-KiVb
60	jDK G`vRvgb (Laoq Asthmin)	Avav-KiVb
61	jDK ev`vg (Laoq Badam)	Avav-KiVb
62	jDK KiZvb/mvC` vb (Laoq Katahw/Sapistan)	Avav-KiVb
63	jDK `vgv fxb/RvKz bvdvm (Laoq Damavin/Zeequnnafas)	Avav-KiVb
64	jgg Kexi (Lubub Kabir)	Avav-KiVb
65	jgg QMxi (Lubub Saghir)	Avav-KiVb
66	nV j lqv Qv jve/eqRv (Halwa Sa'lab/Baiza)	Avav-KiVb
67	KkZv AveiK mqvN (Kushta Abrak Siyah)	f@j
68	KkZv Kjqx (Kushta Qalyee)	f@j
69	KkZv Q`d (Kushta Sadaf)	f@j
70	KkZv vR` (Kushta Jist)	f@j
71	KkZv d l jv` (Kushta Faulad)	f@j
72	KkZv eqRv (Kushta Baiza)	f@j
73	KkZv evvmsNv (Kushta Barasingha)	f@j
74	KkZv gvi lqvix` (Kushta Marwareed)	f@j
75	KkZv gviRvb (Kushta Marjan)	f@j
76	KkZv hni:gvni (Kushta Zahrmohra)	f@j
77	KkZv nVRi: j-qin~ (Kushta Hajrul Yahood)	f@j
78	KkZv tMv` Šx (Kushta Gowdanti)	f@j
79	KkZv eymy (Kushta Bussud)	f@j
80	KkZv gviRvb R lqvni`vi (Kushta Marjan Jawahirdar)	f@j
81	KkZv hgyi`/qvke (Kushta Zamurrad/Yashab)	f@j
82	KkZv Dmi: e (Kushta Ustrub)	f@j
83	KkZv vgiMv½ (Kushta Mirgang)	f@j
84	KkZv gV jvQ (Kushta Musallas)	f@j
85	KkZv vZjv (Kushta Tila)	%Zj
86	KkZv bKiv (Kushta Nuqra)	f@j
87	Av: e bgK vki: b (Aab-e Namak Shireen)	Zij
88	AviK AvdmvZib (Arq Afsanteen)	Zij
89	AviK AvRIqvBb (Arq Ajwain)	Zij
90	AviK evv`qv (Arq Badian)	Zij

ক্রমিক সংখ্যা	ঔষধের নাম	Dosage Form
91	Arq Choobchini	Zij
92	Arq Nankhah	Zij
93	Arq Faulin	Zij
94	Arq Bokhar	Zij
95	Arq Maul-Lahm/Lahmina	Zij
96	Arq Muhallil	Zij
97	Arq Baranjasuf	Zij
98	Sharbat Anjebar	Zij
99	Sharbat Arzani/Unnab	Zij
100	Sharbat Kaknaj	Zij
101	Sharbat Jiryani	Zij
102	Sharbat Jinsin/Mavez	Zij
103	Sharbat Dimaghi	Zij
104	Sharbat Mudir	Zij
105	Sharbat Mundin	Zij
106	Sharbat Tamarixin	Zij
107	Sharbat Ejaz	Zij
108	Sharbat Khansina	Zij
109	Sharbat Ushba	Zij
110	Sharbat Chylosin	Zij
111	Sharbat Deenar	Zij
112	Sharbat Kirmin	Zij
113	Sharbat Musaffi	Zij
114	Sharbat Nazla	Zij
115	Sharbat Neelofar	Zij
116	Sharbat Faulad	Zij
117	Sharbat Buzuri	Zij
118	Sharbat Santara	Zij
119	Sharbat Belgiri	Zij
120	Sharbat Niswan	Zij
121	Sharbat Nisa	Zij
122	Sharbat Shahqa	Zij
123	Sharbat Shefa	Zij
124	Sharbat Misali	Zij
125	Sharbat Mavez	Zij
126	Sharbat Seb	Zij
127	Sharbat Shehat Afza	Zij
128	Sharbat Atfal	Zij
129	Sharbat Tiflin	Zij
130	Sharbat Talkh	Zij
131	Sharbat Toot	Zij
132	Marwareed Saiyal	Zij
133	Qurs Asfar	U'vetju
134	Qurs Ziabit	U'vetju
135	Qurs Muqavvi Khas/Mubahhi	U'vetju
136	Qurs Munashshif	U'vetju
137	Qurs Muhazzil	U'vetju

ক্রমিক bs	Jl:ai tR:biK b'g	Dosage Form
138	KzQ m'qjvb (Qurs Sailan)	U'vet:jU
139	KzQ m'jvRzZ (Qurs Salajeet)	U'vet:jU
140	KzQ GhZj'ig (Qurs Ehtelam)	U'vet:jU
141	KzQ ,j'bi (Qurs Gulnar)	U'vet:jU
142	KzQ eiQ'ibv (Qurs Barsina)	U'vet:jU
143	KzQ n'Rigbv (Qurs Hazmina)	Zij
144	KzQ BbdBv (Qurs Infuza)	U'vet:jU
145	KzQ t'cIPk (Qurs Pechish)	U'vet:jU
146	KzQ hnx'i (Qurs Zaheer)	U'vet:jU
147	KzQ e'k (Qurs Bandish)	U'vet:jU
148	KzQ g'fBt'qb (Qurs Mulayin)	U'vet:jU
149	KzQ AvIRv (Qurs Awja)	U'vet:jU
150	KzQ `x'vb (Qurs Deedan)	U'vet:jU
151	KzQ j'vihxb (Qurs Larzin)	U'vet:jU
152	M'jK cvjm (Garlic Pearls)	U'vet:jU
153	n'teY AvhviKx (Habb-e Azaraqi)	U'vet:jU
154	n'teY Avg'i (Habb-e Ahmar)	U'vet:jU
155	n'teY Av' i t'g'g'q'q' (Habb-e Ambar Momiyae)	U'vet:jU
156	n'teY Bq'vIR (Habb-e Iyariz)	U'vet:jU
157	n'teY IQ'iv/kieZ m'bv (Habb-e Usara/Sharbat Sana)	U'vet:jU
158	n'teY Ke'vZ (Habb-e Kibreet)	U'vet:jU
159	n'teY Kv_ (Habb-e Kath)	U'vet:jU
160	n'teY R`Iq'i (Habb-e Jadwar)	U'vet:jU
161	n'teY Ry (Habb-e Jund)	U'vet:jU
162	n'teY Z've'kxi (Habb-e Tabasheer)	U'vet:jU
163	n'teY ZiBq'vKv/ZiBq'vK Q'v'g'v'q'v (Habb-e Tiryagi/Tiryag Samania)	U'vet:jU
164	n'teY t'Znvj (Habb-e Tehal)	U'vet:jU
165	n'teY w'bkvZ (Habb-e Nishat)	U'vet:jU
166	n'teY g'v'vi (Habb-e Madar)	U'vet:jU
167	n'teY i'tm'SZ (Habb-e Rasaut)	U'vet:jU
168	n'teY k'veBq'vi (Habb-e Shabyar)	U'vet:jU
169	n'teY m'jvZxb (Habb-e Salateen)	U'vet:jU
170	n'teY g'pBK/g'ymK (Habb-e Munish/Mumsik)	U'vet:jU
171	n'teY q'v'Kv (Habb-e Yarkan)	U'vet:jU
172	n'teY w'ZbKv/I'kev (Habb-e Tinkar/Usba)	U'vet:jU
173	n'teY n'q'vZxb g'v'v'e RIq'v'tn`vi (Habb-e Hayateen)	U'vet:jU
174	n'teY ūgv (Habb-e Humma)	Zij
175	n'teY ev'Iq'v'xi `g'fx (Habb-e Bawaseer Damavi)	U'vet:jU
176	n'teY n'q'vZxb g'v'v'e (Habb-e Murrakab)	Zij
177	n'teY ev'Iq'v'xi ev`x (Habb-e Bawaseer Badi)	U'vet:jU
178	n'teY g'y'i (Habb-e Mudir)	U'vet:jU
179	n'Rt'gvj (Hazmol)	Zij
180	ging/AviK AvR'ie (Marham/Arq Ajeeb)	g'g'g
181	ging K'ev (Marham Quba)	g'g'g
182	ging/iIMb L'v'ik (Marham/Rowghan Kharish)	g'g'g
183	ging b'v'ib (Marham Naurin)	g'g'g
184	ging t'm'v'i'q'v'v'v' (Marham Soriasin)	g'g'g

ciikó-T t AZ'ek'Kxq tnvg/c"v_K JI'ai ZvjKv

List of Essential Drugs (Homoeopathic Medicine)

Potency Medicine (Potencies : 3X, 6X, 6, 12, 30, 200, 1M, 10M)

<u>SL</u>	<u>Name of Medicine</u>	<u>SL</u>	<u>Name of Medicine</u>
1	Abrotanum	45	Cannabis indica
2	Absinthium	46	Causticum
3	Aconitum nap	47	Cactus G
4	Actea Racemosa	48	Capsicum
5	Acalypha India	49	Carbo veg
6	Aesculus M	50	Carbolic acid
7	Agaricus M	51	Carbo animalis
8	Alumina	52	Calc fluor
9	Allium Cepa	53	Calc phos
10	Aloe Soc	54	Cantharis
11	Ammonium Carb	55	Caulophyllum
12	Ammonium Mur	56	Carduas mar
13	Ammonium Phos	57	Cedron
14	Angus tura vera	58	China off
15	Antimonium Crud	59	China ars
16	Antimonium Tart	60	China Sulfh
17	Anacardium	61	Chamomilla
18	Anthracinum	62	Chelidonium
19	Apis Mel	63	Cina
20	Apocynum	64	Cicuta vir
21	Arsenicum album	65	Cocculus ind
22	Arnica mont	66	Coca
23	arg. Nit	67	Coffea Crud
24	Arg. Met	68	Colchicum
25	Aur. Met	69	Conium mac
26	Bacillinum	70	Croton tig
27	Badiaga	71	Crotalus Horridus
28	Baptisia T	72	Colocynthis
29	Belladonna	73	Cundurango
30	Benzoic acid	74	Cuprum met
31	Bar. Carb	75	Digitalis
32	Baryta mur	76	Dioscorea
33	Berberis Vulgaris	77	Diphtherinum
34	Bellis per	78	Drosera
35	Bismuth	79	Dulcamara
36	Bovista	80	Equisetum
37	Borax	81	Formica rufa
38	Bryonia alb	82	Eupatorium perf
39	Bromium	83	Euphrasia
40	Bufo rana	84	Ferrum met
41	Camphora	85	Flouric acid
42	Carcinsin	86	Gelsemium
43	Calc carb	87	Glonoine
44	Calendula	88	Graphites

89	Guaiacum	140	Nyctanthes arb
90	Hamamelis vir	141	Opium
91	Helleborus	142	Oleander
92	Hepar sulph	143	Petroleum
93	Hippoz aenium	144	Phoshorus
94	Hyoscyamus	145	Phosphoric acid
95	Hydrocotyle A	146	Phytolacca
96	Hydrasitis can	147	Physostigma
97	Hypericum	148	Platina
98	Ipecacuanha	149	Plumbum met
99	Ignatia	150	Podophyllum
100	Iris ten	151	Prunus spinosa
101	Iris ver	152	Psorinum
102	Iodium	153	Pulsatilla
103	Kali bich	154	Pyrogenium
104	Kali Carb	155	Randunculus Bulb
105	Kali sulph	156	Rhatnia
106	Kali bromatum	157	Rhus-tox
107	Kali cyanatum	158	Rhododendron
108	Kali Iod	159	Robina
109	Kali Mur	160	Ruta gr.
110	Kalmia lat	161	Rumex crispus
111	Kresotum	162	Sabal Serrulata
112	Lapis albus	163	Sabina
113	Lachesis	164	Sangunaria
114	Lac Can	165	Sarsapilla
115	Lac defloratum	166	Selenium
116	Ledum pal	167	Secale corr
117	Lilium tig	168	Senecio arueus
118	Lobelia inflata	169	Sepia
119	Lycopodium	170	Silicea
120	Lyssin	171	Spongia tosta
121	Mag carb	172	Spigellia
122	Mag phos	173	Staphisagria
123	Medorrinum	174	Stramonium
124	Merc sol	175	Stannum met
125	Merc sulph	176	Sulphur
126	Mezerum	177	Sulphuric acid
127	Mercuris	178	Symphytum
128	Millefolium	179	Teucrium M.V
129	Mur. Acid	180	Tellurium
130	Murex	181	Thuja occi
131	Mygale	182	Tarentula Cub
132	Naja tri	183	Terebinthina
133	Nat mur	184	Thyroidinum
134	Nat phos	185	Trillium Pendulum
135	Nat carb	186	Trombidium
136	Nat sulph	187	Tuberculinum
137	Nat ars	188	Urtica urenus
138	Nit acid	189	Nran Nit
139	Nux vom	190	Ustilago

191 Verat alb
 192 Virat Viride
 193 Vipera tor.
 194 Viburnum op

195 Viscum alb
 196 Wyethia
 197 Zinc met

Mother Tincture

1. Abies Can
 2. Aconitum Nap
 3. Actaea Rac
 4. Aesculus Hip
 5. Agnus Cast
 6. Alfalfa (Medicago sativa)
 7. Allium Cepa
 8. Allium Sat
 9. Aloe Soc
 10. Anacardium Ori
 11. Apis Mel
 12. Aralia Race
 13. Arnica mont
 14. Asafoetida
 15. Avena sat
 16. Azadirachta Ind
 17. Baptisia Tinc
 18. Bellodonna
 19. Berberis Aqu
 20. Berberis Vul
 21. Blatta ori
 22. Bryonia Alb
 23. Buchi (Psoralea cor)
 24. Caladium Sac
 25. Calotropis G
 26. Cantharis
 27. Capsicum An
 28. Carduus Mar
 29. Caulophyllum T
 30. Ceanothus Amer
 31. Chaparro Am
 32. Chelidonium Maj
 33. China Off (Cinchona)
 34. Chionanthus
 35. Cimicifuga
 36. Cina
 37. Cinnamonum
 38. Coca
 39. Coffea Crude
 40. Colchicum A
 41. Collinsonia Can
 42. Colocynthis
 43. Condurango
 44. Crataegus Ox

45. Croton Tiglium
 46. Cyclamen
 47. Damiana (Turneva)
 48. Digitalis P
 49. Dioscorea V
 50. Dolichos P
 51. Drosera R
 52. Echinacea A
 53. Ephedra N
 54. Fraxinus A
 55. Fucus Vesi
 56. Gelsemium
 57. Ginseng
 58. Gossypium
 59. Guaiacum
 60. Gymnenma Syl
 (Mesasragi)
 61. Hamamelis Ver
 62. Helonias Dio
 63. Hydrastic can
 64. Hydrocotyle A
 65. Jaborandi
 66. Jonosia Asoka
 67. Justicia Ad.
 68. Lycopodium
 69. Millefolium
 70. Mullein Oil
 (Verbascum Thab)
 71. Myristica
 72. Nuphar Lut
 73. Nux Vomica
 74. Ocimum Canum
 75. Passiflora Inc
 76. Phytolacca D
 77. Pinus Lamb
 78. Plantago M
 79. Podophyllum
 80. Pulsatilla
 81. Quassia
 82. Rhus Tox
 83. Robinia
 84. Sabal Serr
 85. Sabina
 86. Salix Nigra

87.	Sambucus Can	95.	Tribulus T
88.	Sanguinaria Can	96.	Urtica Urens
89.	Secale Corr	97.	Viburnum Opu
90.	Senecio A	98.	Viburnum Pru
91.	Stramonium	99.	Xanthoxylum
92.	Syzygium Jamb	100.	Yohimbinum
93.	Teucrium Mv	101.	Zingiber
94.	Thuja Occ.		

Biochemic (12 Tissue Salt (Potencies 3X, 4X, 6X, 12X))

Sl. No. Name of Medicine

1.	Kali Phos	7.	Kali Mur
2.	Calc Phos	8.	Nat Mur
3.	Nat. Phos	9.	Kali Sulph
4.	Ferum Phos	10.	Nat Sulph
5.	Mag Phos	11.	Calc Sulph
6.	Silicea	12.	Calc. Fluor.

TRITURATION (Powder & Tablet)

Sl. No. Name of Medicine

1.	Acid Chryso	14.	Acetanilide
2.	Ammon Phos	15.	Ars Sulp Flav
3.	Antim Crud	16.	Ephedrine
4.	Borax	17.	Sulphur
5.	Carbo Veg	18.	Ammon Benz
6.	Cholesterinum	19.	Hecla Lava
7.	Graphites	20.	Selenium
8.	Gun Powder	21.	Glonoinum
9.	Ova Tosta	22.	Aurum Mur Nat
10.	Antim Tart	23.	Kali Bichrom
11.	Heper Sulph	24.	Uranium Nit
12.	Merc Sol	25.	Arsenic Iod
13.	Titanium		

External application only

Sl. Name of Medicine

1.	Mullen Oil	4.	Plantago Maj Q
2.	Euphrasia eye drops	5.	Kreosote Q
3.	Cineraria M succus eye drops		

Ointment /Cream

Sl. No. Name of Medicine

1.	Calendula
2.	Cantharis
3.	Rhus tox
4.	Bryonia
5.	Ledum pal
6.	Graphities

Sl. No. Name of Medicine

7.	Hamamelis
8.	Aesculus Hip
9.	Berberis
10.	Petroleum
11.	Arnica

BIOCHEMIC COMBINATION TABLETS

COMPOSITION OF THE DRUGS (each tablet contains all drugs in equal quantities)

1. No.1 : Cal Phos 3X, Ferrum Phos 3X, Nat. Mur. 3X, Kali Phos 3X
2. No. 2 : Kali Phos 3X, Mag. Phos 3X, Nat. Mur. 3X, Nat Sulf 3X
3. No. 3 : Mag. Phos 3X, Cal Phos 3X, Nat Sulf 3X, Ferrum Phos 3X
4. No. 4 : Cal Flour 3X, Kali Mur. 3X, Nat Mur 3X, Silicea 3X
5. No. 6 : Ferrum Phos 3X, Kali Mur 3X, Mag Phos 3X, Nat Mur 3X, Nat Sulf 3X
6. No. 7 : Cal Phos 3X, Ferrum Phos 3X, Kali Phos 3X, Nat Phos 3X, Nat Sulf 3X
7. No. 9 : Ferrum Phos 3X, Kali Mur 3X, Kali Phos 3X, Mag Phos 3X
8. No. 10 : Cal Phos 3X, Ferrum Phos 3X, Kali Mur 3X
9. No.12 : Ferrum Phos 3X, Nat Mur 3X, Kali Phos 3X, Mag Phos 3X
10. No.13 : Cal Phos 3X, Kali Sulf 3X, Kali Phos 3X, Nat Mur 3X
11. No.15 : Cal Phos 3X, Ferrum Phos 3X, Kali Phos 3X, Mag Phos 3X, Kali Sulf 3X
12. No.17 : Cal Flour 3X, Kali Phos 3X, Ferrum Phos 3X, Kali Mur 3X
13. No.19 : Ferrum Phos 3X, Mag Phos 3X, Kali Sulf 3X, Nat Sulf 3X
14. No. 20 : Cal Flour 3X, Cal Sulf 3X, Kali Sulf 3X, Nat Mur 3X, Nat Sulf.
15. No. 23 : Ferrum Phos 3X, Mag Phos 3X, Cal Flour 3X
16. No. 24 : Cal Phos 3X, Ferrum Phos 3X, Kali Phos 3X, Mag Phos 3X, Nat Phos 3X
17. No. 25 : Nat Phos 3X, Nat Sulf 3X, Silicea 3X
18. No. 26 : Mag Phos 3X, Cal Phos 3X, Kali Phos 3X, Cal Flour 3X
19. No. 27 : Nat Mur 3X, Kali Phos 3X, Cal Phos 3X,

ciikó-U t e'e'vcñenxb JIñai Zñjkñ (A'ññjñc'ññ_K)

List of Over-the-Counter (OTC) Drugs (Allopathic)

1. Albendazole Chewable Tablet
2. Antacid Chewable Tablet/ Suspension
3. Ascorbic Acid Chewable Tablet/ Syrup
4. Benzyl Benzoate Lotion
5. Calcium Tablet
6. Chloramphenicol Eye/Ear Ointment/Drops
7. Chlorhexidine Lotion/ Cream
8. Chloroxylonol Lotion/ Cream
9. Chlorpheniramine Maleate Tablet/ Syrup
10. Condoms
11. Diclofenac Gel
12. Dextromethorphen Syrup
13. Ferrous (Sulphate, Gluconate & Fumarate) Tablet/ Capsule/ Syrup
14. Gentian Violet
15. Glycerin Suppository
16. Low Dose Contraceptive Pills
17. Mebendazole Tablet
18. Metronidazole Tablet/ Suspension
19. Methyl Salicylate Gel
20. Milk of Magnesia Suspension
21. Mouthwash Preparations
22. Multivitamin Tablet/ Capsule/ Drops
23. Neomycin/ Gentamycin/ Bacitracin or combination Ointment/ Cream/ Dusting Powder
24. Omeprazole capsule
25. Oral Rehydration Salt (ORS) (with or without glucose or flavours) Sachets
26. Paracetamol/Acetaminophen Tablet/ Syrup/ Suspension/Suppository
27. Permethrin Ointment/ Cream
28. Potassium Permanganate Granules for Gargle
29. Povidone Iodine

30. Promethazine Theoclate Tablet
31. Ranitidin Tablet
32. Riboflavine tablet
33. Salbutamol Tablet
34. Salicylic Acid + Benzoic Acid Ointment
35. Silver Sulphadiazine Ointment
36. Sunscreen Preparations
37. Vitamin A Capsule
38. Vitamin B Complex (individual or combinations) Tablet/ Syrup/ Drops
39. Xylometazoline 0.1% Nasal Drops

ciikó-v t e'e⁻vcÍ enxb Avqje^W `K JI#ai ZvjK^v

(List of Over -the -Counter (OTC) Ayurvedic Drugs)

1. ZvjK^W `Pb
2. gnksL e^WU
3. A^WcĖšK im
4. bevqm †jšn
5. ev²x imvqb
6. mÄ^Webx imvqb
7. K^WR^W ió
8. g^WY^W K^W ió
9. Afq^W ió
10. AgZ^W ió
11. †i^WvnZK^W ió
12. AkMÜ^W ió
13. ej^W ió
14. `kg^Wy^W ió
15. gn^v `v^Wy^W ió
16. A^W†k^vK^W ió
17. m^Wie^v `i^W ió
18. †jšn^vme
19. cÎ^v½^vme
20. P^v `b^vme
21. A^Wi^We^v `v^Wme
22. n^WiZK^x LŮ
23. evZ i^vy^W ^Zj

চিকিৎসা-বিক্রেতা-বিনামূলীয়া ঔষধি (OTC) (BDDB)

List of Over-the-Counter (OTC) Drugs (Unani)

ক্রমিক সংখ্যা	Generic Name / ঔষধি নাম	Dosage Form
01	গিট্রাল ডিস্ট্রিক্ট (Etrifal Ustukhudus)	Tablet
02	গিট্রাল মুকিল (Etrifal Muqil)	Tablet
03	গিট্রাল কাশনি (Etrifal Kashnizi)	Tablet
04	গিট্রাল শাহতার (Etrifal Shahtara)	Tablet
05	গিট্রাল মুন্দি (Etrifal Mundi)	Tablet
06	গিট্রাল জামানি (Etrifal Zamani)	Tablet
07	রিওয়ারিশ কামুনি (Jowarish Kamuni)	Tablet
08	রিওয়ারিশ কুন্ডুর (Jawarish Kundur)	Tablet
09	রিওয়ারিশ জারুনি (Jawarish Zarooni)	Tablet
10	রিওয়ারিশ জালিনোস (Jawarish Jalinoos)	Tablet
11	রিওয়ারিশ মাস্তাগি (Jawarish Mastagi)	Tablet
12	মাজুন ফালাসেফা (Majoon Falasefa)	Tablet
13	মাজুন আরাদ-এ খুরমা (Majoon Arad-e Khurma)	Tablet
14	মাজুন আজারাকি (Majoon Azaraqi)	Tablet
15	মাজুন উশ্বা (Majoon Ushba)	Tablet
16	মাজুন দাবেদুল ওয়ার্ড (Majoon Dabeedul ward)	Tablet
17	মাজুন ফালাসিফা (Majoon Falasifa)	Tablet
18	মাজুন কুন্ডুর (Majoon Kundur)	Tablet
19	মাজুন পিঁয়াজ (Majoon Piyaz)	Tablet
20	মাজুন সাহাগসন্থ (Majoon Sahagsonth)	Tablet
21	মাজুন সুরান্জান (Majoon Suranjan)	Tablet
22	ল্যাক্স কটন (Laoq Katan)	Tablet
23	ল্যাক্স সপিস্তান (Laoq Sapistan)	Tablet
24	আরক বুকহার (Arq Bukhar)	Syrup
25	আরক দাশমুল (Arq Dashmool)	Syrup
26	আরক অজীব (Arq Ajeeb)	Syrup
27	আরক গুলাব (Arq Gulab)	Syrup
28	আরক কাসনি (Arq Kasni)	Syrup
29	আরক মাকো (Arq Mako)	Syrup
30	শারবাত বুজুরি (Sharbat Buzuri)	Syrup
31	শারবাত উনাব (Sharbat Unnab)	Syrup
32	শারবাত দিনার (Sharbat Deenar)	Syrup
33	শারবাত বাসাক (Sharbat Vasac)	Syrup
34	শারবাত এজাজ (Sharbat Ejaz)	Syrup
35	শারবাত নীলোফার (Sharbat Neelofar)	Syrup
36	শারবাত ফাউলাদ (Sharbat Faulad)	Syrup

ক্রমিক সংখ্যা	Generic Name / <i>জিএনআরবি</i>	Dosage Form
37	<i>kieZ gQvddx</i> (Sharbat Musaffi)	<i>Zij</i>
38	<i>kieZ nVRwgbv</i> (Sharbat Hazmina)	<i>Zij</i>
39	<i>kieZ nqvZxb gyv°ve</i> (Sharbat Hayatin Murakkab)	
40	<i>tmKvÄvxb mv`v</i> (Sikanjabeen)	<i>Zij</i>
41	<i>kieZ mVbZviv</i> (Sharbat Santara)	<i>Zij</i>
42	<i>kieZ eljtx tgvZv`j</i> (Sharbat Bazoori Motadil)	<i>Zij</i>
43	<i>kieZ tejMlx</i> (Sharbat Belgiri)	<i>Zij</i>
44	<i>kieZ KxP</i> (Sharbat Kurchi)	<i>Zij</i>
45	<i>kieZ wKklqvi</i> (Sharbat Kishwar)	<i>Zij</i>
46	<i>kieZ tme</i> (Sharbat Seb)	<i>Zij</i>
47	<i>kieZ wbmIqvb</i> (Sharbat Niswan)	<i>Zij</i>
48	<i>kieZ ZZ wmqvn</i> (Sharbat Toot Siyah)	<i>Zij</i>
49	<i>KzQ ew`k</i> (Qurs Bandish)	<i>U've+jU</i>
50	<i>KzQ MvujU've</i> (Qurs Garlitab)	<i>U've+jU</i>
51	<i>KzQ nVRtgvj</i> (Qurs Hazmol)	<i>U've+jU</i>
52	<i>KzQ cybv</i> (Qurs Pudina)	<i>U've+jU</i>
53	<i>KzQ tcvPk</i> (Qurs Pechish)	<i>U've+jU</i>
54	<i>KzQ `x`vb</i> (Qurs Deedan)	<i>U've+jU</i>
55	<i>KzQ gyvB+qb</i> (Qurs Mulayin)	<i>U've+jU</i>
56	<i>nvteY ûav</i> (Habb-e Humma)	<i>U've+jU</i>
57	<i>nvteY tkdv</i> (Habb-e Shefa)	<i>U've+jU</i>
58	<i>KzQ gkveYx LvQ</i> (Qurs Muqavvi Khas)	<i>U've+jU</i>
59	<i>KzQ Gn+Zjvg</i> (Qurs Ehtelam)	<i>U've+jU</i>
60	<i>KzQ mvjvRvZ</i> (Qurs Salajeet)	<i>U've+jU</i>
61	<i>KzQ AvQdi</i> (Qurs Asfar)	<i>U've+jU</i>
62	<i>KzQ Kev</i> (Habb-e Quba)	<i>U've+jU</i>
63	<i>KzQ Kvdi</i> (Habb-e Kafoor)	<i>U've+jU</i>
64	<i>KzQ gyvB+qb</i> (Habb-e Mulaiyin)	<i>U've+jU</i>
65	<i>KzQ G AvdmvbZxb</i> (Habb-e Afsanteen)	<i>U've+jU</i>
66	<i>nvteY tnjZvZ</i> (Habb-e Helteet)	<i>U've+jU</i>
67	<i>nvteY Kvte` tbSkv`ix</i> (Habb-e Kabid Naushadri)	<i>U've+jU</i>
68	<i>nvteY wZbKvi</i> (Habb-e Tinkar)	<i>U've+jU</i>
69	<i>nvteY nqvZxb</i> (Habb-e Hayateen)	<i>Zij</i>
70	<i>nvteY LgQy-nv`x`</i> (Habb-e Khubsul Hadeed)	<i>U've+jU</i>
71	<i>nvteY R`Iqvi</i> (Habb-e Jadwar)	<i>U've+jU</i>
72	<i>nvteY wbkvZ</i> (Habb-e Nishat)	<i>U've+jU</i>
73	<i>nvteY wRwIqvb</i> (Habb-e Jiryan)	<i>U've+jU</i>
74	<i>nvteY gpbk</i> (Habb-e Munish)	<i>U've+jU</i>
75	<i>nvteY myAvb</i> (Habb-e Suranjan)	<i>U've+jU</i>

ক্রমিক সংখ্যা	Generic Name / <i>জেনারিক নাম</i>	Dosage Form
76	<i>নবহেদ মুদীর</i> (Habb-e Mudir)	<i>উল্লেখ্য</i>
77	<i>নবহেদ অফটিমোন</i> (Habb-e Aftimon)	<i>উল্লেখ্য</i>
78	<i>নবহেদ ডাব্বা-এ-আত্ফাল</i> (Habb-e Dabba-e-Atfal)	<i>উল্লেখ্য</i>
79	<i>নবহেদ হামাল</i> (Habb-e Hamal)	<i>উল্লেখ্য</i>
80	<i>নবহেদ জাহিদ</i> (Habb-e Jawahid)	<i>উল্লেখ্য</i>
81	<i>নবহেদ জুন্ড</i> (Habb-e Jund)	<i>উল্লেখ্য</i>
82	<i>নবহেদ কারানজ্বা</i> (Habb-e Karanjwa)	<i>উল্লেখ্য</i>
83	<i>নবহেদ নাজলা</i> (Habb-e Nazla)	<i>উল্লেখ্য</i>
84	<i>নবহেদ রাআল</i> (Habb-e Raal)	<i>উল্লেখ্য</i>
85	<i>নবহেদ রাসাউত</i> (Habb-e Rasaut)	<i>উল্লেখ্য</i>
86	<i>নবহেদ সুরফা</i> (Habb-e Surfa)	<i>উল্লেখ্য</i>
87	<i>নবহেদ টাবাশির</i> (Habb-e Tabashir)	<i>উল্লেখ্য</i>
88	<i>গিংগা কুবা</i> (Marham Quba)	<i>গিংগা</i>
89	<i>গিংগা খারিশ</i> (Marham Kharish)	<i>গিংগা</i>
90	<i>ইলম্ব মল্ল</i> (Rowghan Surkh)	<i>জল</i>
91	<i>জিল্ল রব্বি</i> (Tila Jadeed)	<i>জল</i>
92	<i>মদদ সাইলান</i> (Sufoof Sailan)	<i>চন্দ্রিকা</i>
93	<i>মদদ টিন</i> (Sufoof Teen)	<i>চন্দ্রিকা</i>
94	<i>মদদ হুমুজিন</i> (Sufoof Humuzin)	<i>চন্দ্রিকা</i>
95	<i>মদদ জুরহিন</i> (Sufoof Jurhin)	<i>চন্দ্রিকা</i>
96	<i>আব-এ-নামাক শিরীন</i> (Aab-e Namak Shireen)	<i>চন্দ্রিকা</i>
97	<i>কাফুর সাইয়াল</i> (Kafoor Saiyal)	<i>চন্দ্রিকা</i>
98	<i>সানোন প্যরিন</i> (Sanoon Pyorin)	<i>চন্দ্রিকা</i>

Continental Basis Export Country List:

a) Asian: 37 Countries	b) South America: 21 Countries	c) African: 34 Countries	d) Europe: 26 Countries
1. Afghanistan 2. Azerbaijan 3. Bhutan 4. Cambodia 5. China 6. Hong Kong 7. India 8. Indonesia 9. Iraq 10. Iran 11. Jordan 12. Japan 13. Korea 14. Mongolia 15. Myanmar 16. Malaysia 17. Macau 18. Nepal 19. Pakistan 20. Philippines 21. Singapore 22. Sri Lanka 23. Tajikistan 24. Thailand 25. Turkey 26. Uzbekistan 27. Vietnam 28. Yemen 29. Taiwan 30. Maldives 31. UAE 32. Palestine 33. Lebanon 34. Kuwait 35. Qatar 36. Oman 37. Gulf Co-operative Countries (GCC)	1. Argentina 2. Belize 3. Brazil 4. Colombia 5. Costa-Rica 6. Chile 7. Ecuador 8. Guatemala 9. Guyana 10. Guam 11. Honduras 12. Kiribati 13. Morocco 14. Montenegro 15. Nicaragua 16. Panama 17. Samoa 18. Salomon Islands 19. tango 20. Venezuela 21. Vanuatu	1. Algeria 2. Burkina Faso 3. Botswana 4. Chad 5. Egypt 6. Ethiopia 7. Gambia 8. Ghana 9. Gabon 10. Kenya 11. Libya 12. Liberia 13. Lesotho 14. Mauritius 15. Nigeria 16. Malawi 17. Mali 18. Senegal 19. Somalia 20. South Africa 21. Sudan 22. Swaziland 23. Seychelles 24. Tanzania 25. Tunisia 26. Togo 27. Uganda 28. Benin 29. Burundi 30. Sierra-Leone 31. Mozambique 32. Eritrea 33. Jamaica 34. Laos	1. Austria 2. Belgium 3. Belarus 4. Denmark 5. Estonia 6. France 7. Germany 8. Hungary 9. Italy 10. Latvia 11. Lithuania 12. Moldova 13. Netherlands 14. Poland 15. Portugal 16. Russia 17. Rumania 18. Slovenia 19. Spain 20. Switzerland 21. Serbia 22. UK 23. Ukraine 24. Kyrgyzstan 25. Armenia 26. Ireland
	e) North America: 4 Countries 1. USA 2. Canada 3. Mexico 4. Republic of Dominican		
	f) Australia: 5 Countries 1. Australia 2. Fiji 3. New Zealand 4. Papua New 5. Guinea Palau		
			Total Country: 127

ciikó-Y t ASSIGNED CODE AGAINST THERAPEUTIC CLASS OF DRUG t

SI No.	Therapeutic Class	Code Number
1.	Adrenergic	001
2.	Adrenocortical Steroids-antagonists	002
3.	Amino Acids	003
4.	Anaesthetics (General)	004
5.	Anaesthetics (Local)	005
6.	Analgesics and Antipyretics	006
7.	Antacid,Adsorbent	007
8.	Anthelmintics including schistosomiasis and filaricides	008
9.	Antiarrythmics	009
10.	Anticancer	010
11.	Anticholinergic	011
12.	Anticoagulants and Fibrinolytic Drug	012
13.	Anticonvulsants	013
14.	Antidepressants	014
15.	Antidiabetes	015
16.	Antidiarrhoeal Agents	016
17.	Antidotes and Heavy Metal Antagonists	017
18.	Antiemetic	018
19.	Antifibrillants	019
20.	Antifungal Agent	020
21.	Antihistamine	021
22.	Antihypertensive	022
23.	Anti-infective	023
24.	Antimalarial Antikalazor	024
25.	Antiparkinsonism	025
26.	Antiplatelete	026
27.	Antiprotozoal	027
28.	Antipsychotic	028
29.	Antiseptic and Disinfectants	029
30.	Antitubercular and Antileprotic	030
31.	Antitussives, Expectorants and Mucolytic	031
32.	Antiviral	032
33.	Blood Coagulating	033
34.	Bulk pharmaceuticals (Raw materials)	034
35.	Cardiac Glycosides	035
36.	Cerebral Vasodilator and Drug used in stroke and Peripheral vasodialators	036
37.	Cholinergic	037
38.	Common Cold Preparations	038
39.	Contraceptives (including devices)	039
40.	Coronary Vasodilators and Antianginal drug	040
41.	Diagnostic Agents, Medical Device	041
42.	Diuretics	042
43.	Drug used for erectile dysfunction	043
44.	Drug used in Bronchial Asthma,Chronic obstructive pulmonary disease(COPD)	044

SI No.	Therapeutic Class	Code Number
45.	DRUG used in Anemia and other Blood disorder	045
46.	Drug used in Epilepsy	046
47.	Drug used in migraine	047
48.	Drug used in Osteoporosis	048
49.	Drug used in obstetrics and Genitourinary disease	049
50.	Ear and Nose Preparations	050
51.	Enzymes	051
52.	Eye Preparations	052
53.	Fertility Agents	053
54.	Galenical preparations and Prescription chemicals	054
55.	H ₂ Receptor Blocking	055
56.	Hormone	056
57.	Hypnotics, Sedatives & Anxiolytic	057
58.	Immune-suppressant	058
59.	Kidney Dialysis Fluid	059
60.	Laxatives	060
61.	Lipid Lowering	061
62.	Metals, Salts, Minerals and Calcium Preparations	062
63.	Neuromuscular Blocking	063
64.	Nonsteroidal antiinflammatory and drugs used in arthritis	064
65.	Opioid Analgesics	065
66.	Opioid Antagonists	066
67.	Proton Pump inhibitor	067
68.	Radiopharmaceuticals	068
69.	Sera, Toxins, Toxoids and Vaccines	069
70.	Skeleton Muscle Relaxant	070
71.	Skin and Mucous Membrane Preparations	071
72.	Steroidal Anti inflammatory	072
73.	Throat Preparations, Mouth Washes and Gargles	073
74.	Thyroid and Antithyroid	074
75.	Other Classification	075
76.	Uricosuric and Anti-Gout Agents	076
77.	Veterinary Drugs	077
78.	Vitamins and Combinations	078
79.	Water for Injection, Electrolytes, Blood Volume Restorers and Caloric Agents.	079

ciikó-Z t Jla ckymb Ala`Bi i AvIZxab tRjv Khvj q I ciXyMvingni VKbv t

bs	Khvjtqi bvg I VKbv	bs	Khvjtqi bvg I VKbv
XvKv efvM			
1	Jla ckymb Ala`Bi Jla feb cavb Khvj q gnvLv jx, XvKv-1212	8	Jla ZĖveavqK Jla ZĖveavq†Ki Khvj q Jla ckymb Avigivev` moK, gv`vixcy
2	Jla ckymb Ala`Bi efvMxq Khvj q 105-106 gZiSj eviYiR`K GjvKv, XvKv	9	Jla ZĖveavqK Jla ZĖveavq†Ki Khvj q Jla ckymb ikī cvK m`i tiw, gYMA
3	Jla ZĖveavqK Jla ZĖveavq†Ki Khvj q Jla ckymb knx` ZRynoK, gmbKMÄ	10	Jla ZĖveavqK Jla ZĖveavq†Ki Khvj q Jla ckymb gmR` evox tiw, bxjUyx, dli`cy
4	Jla ZĖveavqK Jla ZĖveavq†Ki Khvj q Jla ckymb 14/1, wbd Pvlvo, RvgZjv, bviqYMA	11	Jla ZĖveavqK Jla ZĖveavq†Ki Khvj q Jla ckymb Gm†K gvbvb UvIqvi, tPvivMAvjx, U½x, MvRxcy
5	Jla ZĖveavqK Jla ZĖveavq†Ki Khvj q Jla ckymb 172, tKvU tiw, ejvm`x, biims`x m`i, biims`x	12	Jla ZĖveavqK Jla ZĖveavq†Ki Khvj q Jla ckymb 142/1, e½eÜynoK, cvpov, tMvqvjMA
6	Jla ZĖveavqK Jla ZĖveavq†Ki Khvj q Jla ckymb 20/3, wzbj tiw, MvBvj, wK†kviMÄ	13	Jla ZĖveavqK Jla ZĖveavq†Ki Khvj q Jla ckymb nvmcvZvj tiw, tPšix, kvigZcy m`i, kvigZcy
7	Jla ZĖveavqK Jla ZĖveavq†Ki Khvj q Jla ckymb _vbn tiw, U½zbj		
PEMg efvM			
14	Jla ZĖveavqK Jla ZĖveavq†Ki Khvj q Jla ckymb wmiRI vev is bs-1, AvMev`, PEMg	19	Jla ZĖveavqK Jla ZĖveavq†Ki Khvj q Jla ckymb nvDvRs G†÷ U, gvBR`x †KvU, †bvqLv jx
15	Jla ZĖveavqK Jla ZĖveavq†Ki Khvj q Jla ckymb gvngy wfvj, 1099, †iBm †Kvm, Kvgjv	20	Jla ZĖveavqK Jla ZĖveavq†Ki Khvj q Jla ckymb, 366, Gg Gm †K tiw, (Gm G cviw†bi Dc†i 3q Zjv), tdbx
16	Jla ZĖveavqK Jla ZĖveavq†Ki Khvj q Jla ckymb †UKciov cavb moK, K·evRvi	21	Jla ZĖveavqK Jla ZĖveavq†Ki Khvj q Jla ckymb, nvKxg gviÄj, 353, wRvU tiw `wY, †PqvigvbnvUv, Pucy
17	Jla ZĖveavqK Jla ZĖveavq†Ki Khvj q Jla ckymb, Avqkv gviÄj, evox bs-317/5, Iqvc`v tiw, wZqviv, evpbevoxq	22	Jla ZĖveavqK Jla ZĖveavq†Ki Khvj q Jla ckymb, cU bs-48/G, †nvi s-433, KvWjZjxciov, KvWjZjx, iv½vgvU

bs	Kihvjtqi bvg I VKvb	bs	Kihvjtqi bvg I VKvb
18	Jla ZĖveavqK Jla ZĖveavq†Ki Kihvj q Jla ckymb bŷRvnb K†UR, `ŷY eŷÂvMi, ivgMŁZ WbFvimb, jŷxcŷ		
ivRkvn efM			
23	Jla ZĖveavqK Jla ZĖveavq†Ki Kihvj q Jla ckymb dŷtqRbŷtgŷgŷiqj, ŷR-216/1, KvŷRiMÄ, ivRkvn	27	Jla ZĖveavqK Jla ZĖveavq†Ki Kihvj q Jla ckymb _vbcvov, ŷmivRMÄ
24	Jla ZĖveavqK Jla ZĖveavq†Ki Kihvj q Jla ckymb ŷekvm feb, AvZvqKz†ivW, kvjMŷoqv, cvebv	28	Jla ZĖveavqK Jla ZĖveavq†Ki Kihvj q Jla ckymb nK gŷÄj, R†jkiXZjv, eMŷ
25	Jla ZĖveavqK Jla ZĖveavq†Ki Kihvj q Jla ckymb, tgBb†ivW (GŷUGg gŷVi cŷđg c†k), bIMum`i, bIMu	29	Jla ZĖveavqK Jla ZĖveavq†Ki Kihvj q Jla ckymb jv†L ivR cvov, †KvU Gŷiqv, PŷvBbeveMÄ
26	Jla ZĖveavqK Jla ZĖveavq†Ki Kihvj q Jla ckymb, Kvŷ`ŷfUv, _vbcvov, bv†Uvi	30	Jla ZĖveavqK Jla ZĖveavq†Ki Kihvj q Jla ckymb RqcŷnvU †Pavi Ae Kgvm BŰv÷ eŷvMPv gŷ`vmv †ivW, RqcŷnvU
Lŷbv efM			
31	Jla ZĖveavqK Jla ZĖveavq†Ki Kihvj q Jla ckymb 147, †mvbWvŷv Av/G, †ivW bs-8, Lŷbv	35	Jla ZĖveavqK Jla ZĖveavq†Ki Kihvj q Jla ckymb, 3184, nvRŷMŷj, cŷj k jvBb, cŷđg gRgcŷ, Kŷqv
32	Jla ZĖveavqK Jla ZĖveavq†Ki Kihvj q Jla ckymb, PŷKjvcvov, mŷvKU nvDR†ivW, nŷijvKŷyem ÷`ŷ†Űi c†k, ŷSbvB`vn	36	Jla ZĖveavqK Jla ZĖveavq†Ki Kihvj q Jla ckymb, 107, LvbRvnb Avjx†ivW, miB, ev†MinvU
33	Jla ZĖveavqK Jla ZĖveavq†Ki Kihvj q Jla ckymb, nvmcvZvj†ivW, K†jRcvov, PŷvWŷv	37	Jla ZĖveavqK Jla ZĖveavq†Ki Kihvj q Jla ckymb, †Rj†ivW, †Nvc, h†kvi
34	Jla ZĖveavqK Jla ZĖveavq†Ki Kihvj q Jla ckymb gŷnjv gŷ`vmv moK, BUvMvQv, mvZŷxiv		

eikvj efvM			
38	Jla ZĖveavqK Jla ZĖveavq†Ki Kvĥvjq Jla ckymb eòycqv dv†gm̃x feb (3q Zjv), 198/171, m`i †ivW, eikvj	41	Jla ZĖveavqK Jla ZĖveavq†Ki Kvĥvjq Jla ckymb icUAvB †ivW, meRevM †gro, cUgylvjx
39	Jla ZĖveavqK Jla ZĖveavq†Ki Kvĥvjq Jla ckymb, g̃jgvcioṽ †fvjv †cšimfv, †fvjv	42	Jla ZĖveavqK Jla ZĖveavq†Ki Kvĥvjq Jla ckymb, 175, Avgjvcioṽ †ivW, ic†ivRcȳ
40	Jla ZĖveavqK Jla ZĖveavq†Ki Kvĥvjq Jla ckymb, m. ic. Gj, feb, †ñw̃is bs-158 I IqW bs-1, PiK†jvbx icQ†bi moK, ei ,bv	43	Jla ZĖveavqK Jla ZĖveavq†Ki Kvĥvjq Jla ckymb, 175, wgjvcioṽ †ivW, ic†ivRcȳ
m†jU efvM			
44	Jla ZĖveavqK Jla ZĖveavq†Ki Kvĥvjq Jla ckymb igRv †fjv, cjex-9/ie, c†dg cvVbUỹx, g̃i`bv g†KU, m†jU	46	Jla ZĖveavqK Jla ZĖveavq†Ki Kvĥvjq Jla ckymb mȳgv-163/G, DĖi †lvjNi, m†vgMÄ
45	Jla ZĖveavqK Jla ZĖveavq†Ki Kvĥvjq Jla ckymb, †gvevki †fjv, 273/1, `iM̃n gnjv †ivW, †gšj fxeṽRvi		
iscȳ efvM			
47	Jla ZĖveavqK Jla ZĖveavq†Ki Kvĥvjq Jla ckymb ibD †mbcioṽ, iscȳ	51	Jla ZĖveavqK Jla ZĖveavq†Ki Kvĥvjq Jla ckymb evjgvoṽ ibgj Kzj i mvg†b, i`bvRcȳ
48	Jla ZĖveavqK Jla ZĖveavq†Ki Kvĥvjq Jla ckymb evox bs-123, †÷kb †ivW, Wvj c†E, bxjdvgvix	52	Jla ZĖveavqK Jla ZĖveavq†Ki Kvĥvjq Jla ckymb gȳxcioṽ, m`i, ṼiKz̃M̃ṽ
49	Jla ZĖveavqK Jla ZĖveavq†Ki Kvĥvjq Jla ckymb Avi†K †ivW (Avkv Avdm msjM) Wv 3vi cioṽ, Kv†j LijjMÄ, Kz̃M̃vg	53	Jla ZĖveavqK Jla ZĖveavq†Ki Kvĥvjq Jla ckymb Gj †R AvB †ivW, jvjgmbinU
50	Jla ZĖveavqK Jla ZĖveavq†Ki Kvĥvjq Jla ckymb kibg̃i` †ivW, M̃vBeṽÜv		

gggbmsn efvM			
54	Jla ZĖveavqK Jla ZĖveavq#Ki Kvĥvj q Jla ckymb 82, mvi`v tNvI t iW, gggbmsn	56	Jla ZĖveavqK Jla ZĖveavq#Ki Kvĥvj q Jla ckymb 166 bMv m`i, tbÎ#Kv
55	Jla ZĖveavqK Jla ZĖveavq#Ki Kvĥvj q Jla ckymb mRie w f j v, t k i c y U v D b, t k i c y-2100	57	Jla ZĖveavqK Jla ZĖveavq#Ki Kvĥvj q Jla ckymb Jla ckymb, mvi w f j v, w b D K t j R t i W, R v g j c y
cixvMi			
58	tWcy Pxd b`vkbvj KtUvj j`ve#iUix gmLv j x, XiKv	59	cviPvjK tK`xq Jla cixvMi AvMvev`, PEMvg

cikó- t Jla ckymb Aa`Bti বিভিন্ন কার্যক্রমের নির্ধারিত id t

ক্রমিক	id Gi big	cthvR` t yimgn	id (Ukv)
1	2	3	4
01	bZb Jla Drcv`b jvBtmY id	(K) G`v#jvc`v_Kt 1 ev#qvjRK`vj 2  bb-ev#qvjRK`vj (L) BDbvbx, Avqte`xK, tnvigI c`v_K I ev#qv#KigK Ges nvej	1,00,000/ 50,000/ 10,000/-
02	Jla Drcv`b jvBtmY bevqb id (2 ermi Aši)	(K) G`v#jvc`v_Kt 1 ev#qvjRK`vj 2  bb-ev#qvjRK`vj (L) BDbvbx, Avqte`xK, tnvigI c`v_K I ev#qv#KigK Ges nvej	30,000/- 15,000/- 5,000/-
03	bgbv we#kIY id	(K) G`v#jvc`v_K t 1 wec/BDGmic f`3 2  AvBGbGb/Ab`vb` (L) BDbvbx, Avqte`xK, tnvigI c`v_K I ev#qv#KigK Ges nvej	5,000/- 15,000/- 500/-
04	c` bevqb id (5 ermi Aši)	(K) G`v#jvc`v_K (L) BDbvbx, Avqte`xK, tnvigI c`v_K I ev#qv#KigK Ges nvej	10,000/- 1,000/-
05	t i m i c g j`vqb id	(K) G`v#jvc`v_K (L) BDbvbx, Avqte`xK, tnvigI c`v_K I ev#qv#KigK Ges nvej	5,000/- 500/-
06	t i m i c c b t g j`vqb id	(K) G`v#jvc`v_K (L) BDbvbx, Avqte`xK, tnvigI c`v_K I ev#qv#KigK Ges nvej	5,000/- 1,000/-
07	bZb c` Ašfj`3 id	(K) G`v#jvc`v_K (L) BDbvbx, Avqte`xK, tnvigI c`v_K I ev#qv#KigK Ges nvej	10,000/- 2,000/-
08	Drcv`b jvBtmY-Gi gmvjKvbi c i e Z b id (e`i`3 gmvjKvbi I w j w g t U W t K v a u v b x i D f q t y t I c t h v R`)	(L) G`v#jvc`v_Kt 1 ev#qvjRK`vj 2  bb-ev#qvjRK`vj (L) BDbvbx, Avqte`xK, tnvigI	2,00,000/- 1,00,000/- 50,000/-

ক্রমিক	৷d Gi big	cʰhɹʳ ʔjɪmɹ	৷d (UvK)
1	2	3	4
		cʰv_K I evʔqʔKigK Ges nveij	
09	bZb Lʔiv Wm jvBʔmY ৷d (Gʰʔjvcʰv_K)	(K) ʔcʰi GjvKvi ৷fZʔi ʔcʰi GjvKvi evnʔi	2,500/- 1,500/-
10	bZb Lʔiv Wm jvBʔmY ৷d (BDbvbx, AvqjeʰxK, ʔnwgI cʰv_K, evʔqʔKigK I nveij)	(K) ʔcʰi GjvKvi ৷fZʔi (L) ʔcʰi GjvKvi evnʔi	2,000/- 1,000/-
11	Lʔiv Wm jvBʔmY bevqb ৷d (Gʰʔjvcʰv_K)	(K) ʔcʰi GjvKvi ৷fZʔi (L) ʔcʰi GjvKvi evnʔi	1,800/- 700/-
12	Lʔiv Wm jvBʔmY bevqb ৷d (BDbvbx, AvqjeʰxK, ʔnwgI cʰv_K, evʔqʔKigK I nveij)	(K) ʔcʰi GjvKvi ৷fZʔi (L) ʔcʰi GjvKvi evnʔi	1,500/- 700/-
13	mKj cKvi bZb cvBKvix Wm jvBʔmY ৷d	mKj cvBKvix Wm jvBʔmY	10,000/-
14	cvBKvix Wm jvBʔmY bevqb ৷d		5,000/-
15	mKj cKvi Lʔiv Wm jvBʔmY gnjKvbi cvieZb ৷d	(K) ʔcʰi GjvKvi ৷fZʔi (L) ʔcʰi GjvKvi evnʔi	3,000/- 1,500/-
16	AvqʰvbiKZ.JIʔai ʔiRʔ ÷ kb ৷d	mKj cKvi JIa	35,000/-
17	AvqʰvbiKZ.JIʔai ʔiRʔ ÷ kb bevqb ৷d	mKj cKvi JIa	10,000/-
18	ʔmvm ʔfijʔWkb ʔiRʔ ÷ kb ৷d (৷Zb ermi Aʂi)	ciZ ʔmvm Gi Rbʰ	8,000/-
19	ʔmvm ʔfijʔWkb ciZ cʔʰ i Aʂfzʰ/ʔiRʔ ÷ kb ৷d (৷Zb ermi Aʂi)	ciZ cʔʰ i Rbʰ	1,000/-
20	AvqʰvbiKZ.JIʔai AbvciĒĒĒ (Gb. I. ৷m) ৷d	mKj cKvi JIa	2,000/-
21	৷ejʔ ৷d		
	(K) mKj cKvi JIa Drcvʰb jvBʔmY bevqʔbi ʔjʔĒ	1 GK ʔgqʔʰ ৷ejʔʔi Rbʰ 2 GK ʔgqʔʰ i AiaK mgq ৷ejʔʔi Rbʰ	bevqb ৷d Gi mgcʰigib bevqb ৷d ৷b, b nʔi
	(L) mKj cKvi JIʔai cvBKvix/Lʔiv jvBʔmY bevqʔbi ʔjʔĒ	1 ʔgqʰ`DIʔYi mgq 1-3 gym chʂ t	
		(K) cvBKvix jvBʔmY	200/-
		(L) Lʔiv jvBʔmY ৷gDibimcʰvj Ges ʔcʰi GjvKvi ৷fZʔi	100/-
		(M) Lʔiv jvBʔmY (ʔcʰi GjvKvi evnʔi)	50/-
		2 ʔgqʰ`DIʔYi mgq 3 gymi Dʔx 12 gym chʂt	
		(K) cvBKvix jvBʔmY	500/-
		(L) Lʔiv jvBʔmY ৷gDibimcʰvj ev ʔcʰi GjvKvi ৷fZʔi	200/-
		(M) Lʔiv jvBʔmY (ʔcʰi GjvKvi evnʔi)	100/-
		3 ʔgqʰ`DIʔYi 12 gymi Dʔx cieZx ciZ eqʔi i Rbʰ t	
		(K) cvBKvix jvBʔmY	1000/-
		(L) Lʔiv jvBʔmY ৷gDibimcʰvj ev ʔcʰi GjvKvi ৷fZʔi	500/-
		(M) Lʔiv jvBʔmY (ʔcʰi GjvKvi evnʔi)	200/-
22	mKj cKvi WzʔKU mbʰ		500/-

